alpha-hydroxy ketone - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	alpha-hydroxy ketone	go back to main search page
Accession:	CHEBI:139588	browse the term
Definition:	A ketone containing a hydroxy group on the α-carbon relative to the C=O group.
Synonyms:	related_synonym:	alpha-hydroxy-ketones; alpha-hydroxyketone; alpha-hydroxyketones
	xref:	pubmed:15326516; pubmed:19908854; pubmed:20382022; pubmed:23295224

show annotations for term's descendants Sort by:
Rat (9530 ) Mouse (9722 ) Human (10022 ) Chinchilla (0 ) Bonobo (0 ) Dog (14 ) Squirrel (0 ) Pig (4432 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (9530)

(+)-dihydromyricetin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

mitogen activated protein kinase 1

multiple interactions

EXP

ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions

EXP

ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

platelet derived growth factor subunit B

multiple interactions

EXP

ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK1 protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of MAPK3 protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PDGFRB protein]; ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PLCG1 protein]

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343

G

platelet derived growth factor receptor beta

multiple interactions

EXP

ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PDGFRB protein]

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233

G

phospholipase C, gamma 1

multiple interactions

EXP

ampelopsin analog inhibits the reaction [[PDGFB protein binds to PDGFB protein] which results in increased phosphorylation of PLCG1 protein]

NCBI chr 3:169,805,299...169,836,040
Ensembl chr 3:169,804,846...169,836,050

G

sphingosine kinase 1

decreases expression
decreases activity

ISO

ampelopsin results in decreased expression of SPHK1 protein
ampelopsin results in decreased activity of SPHK1 protein

NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

taxifolin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions
decreases activity

ISO

taxifolin inhibits the reaction [ABCC1 protein affects the export of S-(2,4-dinitrophenyl)glutathione]
taxifolin results in decreased activity of ABCC1 protein

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

acetylcholinesterase

multiple interactions

EXP

taxifolin inhibits the reaction [Rotenone results in decreased activity of ACHE protein]

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

adiponectin receptor 2

multiple interactions

ISO

taxifolin binds to and results in increased activity of ADIPOR2 protein

NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666

G

alpha-fetoprotein

affects binding
multiple interactions

EXP

taxifolin binds to AFP protein
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of AFP protein]]

PMID:23013281 PMID:25349334 PMID:33840231

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

angiotensinogen

decreases expression

ISO

taxifolin results in decreased expression of AGT protein modified form

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

aryl hydrocarbon receptor

multiple interactions

ISO

AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of CYP1A1 mRNA]; AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of UGT1A1 mRNA]

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

AKT serine/threonine kinase 1

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of AKT1 protein]; taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]]

PMID:32828744 PMID:35465754

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

apolipoprotein A1

increases expression

ISO

taxifolin results in increased expression of APOA1 protein

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein B

decreases secretion
decreases expression

ISO

taxifolin results in decreased secretion of APOB protein
taxifolin results in decreased expression of APOB protein

PMID:11108730 PMID:15380446

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of BAX protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of BAX protein]]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of BCL2 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BCL2 protein]]

PMID:32525071 PMID:35465754

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

beclin 1

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of BECN1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of BECN1 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of BECN1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of BECN1 protein]]

PMID:33840231 PMID:33882723 PMID:35465754

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

caspase 3

decreases activity
multiple interactions

EXP

taxifolin results in decreased activity of CASP3 protein
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of CASP3 protein]; taxifolin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]; taxifolin inhibits the reaction [Colistin results in increased activity of CASP3 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP3 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased activity of CASP3 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of CASP3 protein]]

PMID:24269735 PMID:32828744 PMID:33840231 PMID:33882723 PMID:35465754

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

decreases activity
multiple interactions

EXP

taxifolin results in decreased activity of CASP9 protein
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of CASP9 protein]]

PMID:24269735 PMID:33840231

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions
decreases activity

EXP
ISO

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]; taxifolin analog inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; taxifolin inhibits the reaction [Acetic Acid results in increased activity of CAT protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CAT mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CAT mRNA]; taxifolin inhibits the reaction [Rotenone results in decreased activity of CAT protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of CAT protein]]
taxifolin results in decreased activity of CAT protein
taxifolin inhibits the reaction [Hydrogen Peroxide results in increased activity of CAT protein]

PMID:30372826 PMID:32525071 PMID:33741339 PMID:35187747 PMID:35465754 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cyclin A1

decreases expression

ISO

taxifolin results in decreased expression of CCNA1 mRNA

NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300

G

cell division cycle 25A

decreases expression

ISO

taxifolin results in decreased expression of CDC25A mRNA

NCBI chr 8:118,742,824...118,761,190
Ensembl chr 8:118,742,426...118,761,188

G

carnitine palmitoyltransferase 1A

multiple interactions

EXP

taxifolin analog inhibits the reaction [Dietary Fats results in decreased expression of CPT1A mRNA]

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

cytochrome c, somatic

affects localization
multiple interactions

EXP

taxifolin affects the localization of CYCS protein
[taxifolin co-treated with dapagliflozin] inhibits the reaction [Colistin results in increased expression of CYCS protein]; taxifolin inhibits the reaction [Colistin results in increased expression of CYCS protein]

PMID:24269735 PMID:33882723

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CYP11A1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of CYP11A1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of CYP11A1 protein]

PMID:32525071 PMID:36198370

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

taxifolin results in increased expression of CYP1A1 mRNA; taxifolin results in increased expression of CYP1A1 protein
AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of CYP1A1 mRNA]

PMID:22422552 PMID:29584932

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression

ISO

taxifolin results in decreased expression of CYP2E1 mRNA

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

DCC netrin 1 receptor

increases expression

ISO

taxifolin results in increased expression of DCC mRNA

NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541

G

epidermal growth factor

decreases expression

ISO

taxifolin results in decreased expression of EGF mRNA

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

fibroblast growth factor 18

decreases expression

ISO

taxifolin results in decreased expression of FGF18 mRNA

NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933

G

fibroblast growth factor 3

decreases expression

ISO

taxifolin results in decreased expression of FGF3 mRNA

NCBI chr 1:209,430,457...209,434,832
Ensembl chr 1:209,430,457...209,434,832

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased phosphorylation of FOS protein]

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

follicle stimulating hormone subunit beta

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of FSHB protein]]

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

glucose-6-phosphate dehydrogenase

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased activity of G6PD protein]]

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

growth arrest specific 6

increases expression

ISO

taxifolin results in increased expression of GAS6 mRNA

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

growth differentiation factor 15

increases expression

ISO

taxifolin results in increased expression of GDF15 mRNA

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

glutamate-ammonia ligase

multiple interactions

EXP

taxifolin inhibits the reaction [Rotenone results in decreased activity of GLUL protein]

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

glutamic--pyruvic transaminase

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]; taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased activity of GPT protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of GPT protein]]

PMID:32828744 PMID:33840231

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of GPX1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of GPX1 protein]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione-disulfide reductase

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]; taxifolin inhibits the reaction [Colistin results in decreased expression of GSR protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of GSR protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of GSR protein]]

PMID:33882723 PMID:35465754

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase mu 1

increases expression

ISO

taxifolin results in increased expression of GSTM1 mRNA

NCBI chr 2:198,338,005...198,346,007
Ensembl chr 2:198,338,008...198,343,569

G

heme oxygenase 1

increases expression
multiple interactions
decreases expression

ISO
EXP

taxifolin results in increased expression of HMOX1 protein
Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HMOX1 protein]]
Chlorpyrifos inhibits the reaction [taxifolin results in decreased expression of HMOX1 protein]

PMID:16799064 PMID:31152760 PMID:35465754

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD17B1 protein]]

NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210

G

hydroxysteroid (17-beta) dehydrogenase 3

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of HSD17B3 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of HSD17B3 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD17B3 protein]

PMID:32525071 PMID:36198370

NCBI chr17:1,032,958...1,064,283
Ensembl chr17:1,032,958...1,064,283

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of HSD3B1 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of HSD3B1 protein]]

PMID:35465754 PMID:36198370

NCBI chr 2:188,858,574...188,864,694

G

intercellular adhesion molecule 1

multiple interactions

ISO

taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 mRNA]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]

PMID:12044887 PMID:19103272

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

ISO

taxifolin inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of STAT1 protein]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 mRNA]; taxifolin inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; taxifolin inhibits the reaction [IFNG protein results in increased phosphorylation of MAPK8 protein]
taxifolin inhibits the reaction [Chlorpyrifos results in increased secretion of IFNG protein]

PMID:12044887 PMID:19103272 PMID:31152760

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

inhibitor of nuclear factor kappa B kinase regulatory subunit gamma

multiple interactions

EXP

taxifolin inhibits the reaction [Rotenone results in increased expression of IKBKG mRNA]

NCBI chr X:157,358,279...157,397,563
Ensembl chr X:157,367,639...157,392,757

G

interleukin 15

multiple interactions

EXP

taxifolin inhibits the reaction [Colistin results in increased expression of IL15 protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of IL15 protein]]

NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348

G

interleukin 18

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of IL18 protein]]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of IL1A protein]]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

EXP
ISO

taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL1B protein]; taxifolin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
taxifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of IL1B protein]

PMID:32828744 PMID:35187747 PMID:38574953

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

EXP
ISO

taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of IL6 protein]
taxifolin inhibits the reaction [Hydrogen Peroxide results in increased expression of IL6 protein]

PMID:32828744 PMID:38574953

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin-like 3

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of INSL3 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of INSL3 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSL3 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of INSL3 protein]

PMID:32525071 PMID:36198370

NCBI chr16:18,432,668...18,434,539

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

ISO

taxifolin results in decreased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

luteinizing hormone subunit beta

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of LHB protein]]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

mitogen-activated protein kinase 8

multiple interactions

ISO
EXP

taxifolin inhibits the reaction [IFNG protein results in increased phosphorylation of MAPK8 protein]
taxifolin inhibits the reaction [Colistin results in increased activity of MAPK8 protein]

PMID:12044887 PMID:33882723

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

marker of proliferation Ki-67

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of MKI67 protein]]

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

myeloperoxidase

multiple interactions

EXP

taxifolin inhibits the reaction [Acetic Acid results in increased activity of MPO protein]; taxifolin inhibits the reaction [Rotenone results in increased activity of MPO protein]

PMID:33741339 PMID:35187747

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

mechanistic target of rapamycin kinase

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]; taxifolin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased phosphorylation of MTOR protein]]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

microsomal triglyceride transfer protein

decreases activity

ISO

taxifolin results in decreased activity of MTTP protein

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
decreases expression

ISO
EXP

taxifolin results in increased expression of NFE2L2 protein
alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]; taxifolin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]; taxifolin inhibits the reaction [Colistin results in decreased expression of NFE2L2 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of NFE2L2 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in decreased expression of NFE2L2 protein]]
taxifolin results in decreased expression of NFE2L2 protein
Chlorpyrifos inhibits the reaction [taxifolin results in decreased expression of NFE2L2 protein]

PMID:16799064 PMID:31152760 PMID:33840231 PMID:33882723 PMID:35465754

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

taxifolin inhibits the reaction [Rotenone results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nerve growth factor

multiple interactions

EXP

taxifolin inhibits the reaction [Colistin results in decreased expression of NGF protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of NGF protein]]

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834

G

NLR family, pyrin domain containing 3

multiple interactions

EXP

Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]; taxifolin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of NLRP3 protein]]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

NAD(P)H quinone dehydrogenase 1

increases activity
increases expression

ISO

taxifolin results in increased activity of NQO1 protein
taxifolin results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

O-GlcNAcase

multiple interactions

EXP

[taxifolin co-treated with dapagliflozin] inhibits the reaction [Colistin results in increased activity of OGA protein]; taxifolin inhibits the reaction [Colistin results in increased activity of OGA protein]

NCBI chr 1:254,547,311...254,589,596
Ensembl chr 1:254,547,311...254,582,855

G

proliferating cell nuclear antigen

multiple interactions

EXP

[taxifolin co-treated with [Iron-Dextran Complex results in increased abundance of Iron]] results in increased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

platelet derived growth factor subunit B

decreases expression

ISO

taxifolin results in decreased expression of PDGFB mRNA

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

EXP

taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in decreased phosphorylation of PIK3CA protein]

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

paraoxonase 1

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in decreased expression of PON1 protein]]

NCBI chr 4:34,261,312...34,292,327
Ensembl chr 4:34,261,289...34,287,924

G

peroxisome proliferator activated receptor alpha

increases phosphorylation

ISO

taxifolin results in increased phosphorylation of PPARA protein

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

PPARG coactivator 1 alpha

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of PPARGC1A protein]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

protein kinase AMP-activated catalytic subunit alpha 1

decreases phosphorylation

ISO

taxifolin results in decreased phosphorylation of PRKAA1 protein

NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450

G

protein kinase AMP-activated catalytic subunit alpha 2

decreases phosphorylation

ISO

taxifolin results in decreased phosphorylation of PRKAA2 protein

NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

taxifolin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RAS p21 protein activator 1

decreases expression

ISO

taxifolin results in decreased expression of RASA1 mRNA

NCBI chr 2:17,593,136...17,676,707
Ensembl chr 2:17,593,136...17,676,161

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP

[alogliptin co-treated with taxifolin] inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of RELA protein]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of RELA protein]; taxifolin inhibits the reaction [Colistin results in increased expression of RELA protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of RELA protein]]

PMID:33840231 PMID:33882723

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

scavenger receptor class B, member 1

multiple interactions

EXP

taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SCARB1 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SCARB1 protein]

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

sirtuin 1

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SIRT1 protein]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SIRT1 protein]

PMID:32525071 PMID:36198370

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

superoxide dismutase 1

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD1 mRNA]; taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD1 protein]

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOD2 mRNA]; taxifolin inhibits the reaction [Diethylhexyl Phthalate results in decreased expression of SOD2 mRNA]

PMID:32525071 PMID:36198370

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

SRY-box transcription factor 9

multiple interactions

EXP

taxifolin inhibits the reaction [Dibutyl Phthalate results in decreased expression of SOX9 mRNA]

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

signal transducer and activator of transcription 1

multiple interactions

ISO

taxifolin inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of STAT1 protein]

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 3

multiple interactions

EXP

taxifolin inhibits the reaction [Colistin results in decreased expression of STAT3 protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in decreased expression of STAT3 protein]]

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transforming growth factor, beta 1

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]]; Fluvastatin promotes the reaction [taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]; taxifolin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TGFB1 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TGFB1 protein]]; taxifolin promotes the reaction [Fluvastatin inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]]

PMID:33840231 PMID:33882723 PMID:35465754

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tyrosine hydroxylase

multiple interactions

EXP

taxifolin inhibits the reaction [Rotenone results in decreased activity of TH protein]

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

toll-like receptor 4

multiple interactions

EXP

alogliptin promotes the reaction [taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]]; taxifolin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TLR4 protein]; taxifolin promotes the reaction [alogliptin inhibits the reaction [[Diethylnitrosamine co-treated with Carbon Tetrachloride] results in increased expression of TLR4 protein]]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TLR4 protein]]

PMID:33840231 PMID:33882723

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions

ISO
EXP

taxifolin inhibits the reaction [Chlorpyrifos results in increased secretion of TNF protein]
taxifolin inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of TNF protein]; taxifolin inhibits the reaction [Colistin results in increased expression of TNF protein]; taxifolin promotes the reaction [dapagliflozin inhibits the reaction [Colistin results in increased expression of TNF protein]]

PMID:31152760 PMID:32828744 PMID:33882723

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

Tnf receptor-associated factor 3

increases expression

ISO

taxifolin results in increased expression of TRAF3 mRNA

NCBI chr 6:136,025,097...136,128,363
Ensembl chr 6:136,027,157...136,128,363

G

thioredoxin reductase 1

increases expression
decreases activity

ISO
EXP

taxifolin results in increased expression of TXNRD1 mRNA
taxifolin results in decreased activity of TXNRD1 protein modified form

PMID:16618767 PMID:17541156

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

uncoupling protein 1

multiple interactions

EXP

taxifolin analog inhibits the reaction [Dietary Fats results in decreased expression of UCP1 mRNA]

NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420

G

UDP glucuronosyltransferase family 1 member A1

increases expression
multiple interactions

ISO

taxifolin results in increased expression of UGT1A1 mRNA
AHR gene mutant form inhibits the reaction [taxifolin results in increased expression of UGT1A1 mRNA]

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

xanthine dehydrogenase

multiple interactions

ISO
EXP

taxifolin inhibits the reaction [XDH protein results in increased chemical synthesis of Superoxides]
taxifolin inhibits the reaction [Rotenone results in increased activity of XDH protein]

PMID:19555678 PMID:35187747

NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350

G

XPA, DNA damage recognition and repair factor

increases expression

ISO

taxifolin results in increased expression of XPA mRNA

NCBI chr 5:65,227,281...65,275,784
Ensembl chr 5:65,227,281...65,272,425

G

X-ray repair cross complementing 4

increases expression

ISO

taxifolin results in increased expression of XRCC4 mRNA

NCBI chr 2:22,686,506...22,932,929
Ensembl chr 2:22,686,508...22,933,160

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B1

increases reduction
multiple interactions

ISO

AKR1B1 protein results in increased reduction of Acetoin
[AKR1B1 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol; [AKR1B1 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1 member B10

increases reduction
multiple interactions

ISO

AKR1B10 protein results in increased reduction of Acetoin
[AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol; [AKR1B10 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

dicarbonyl and L-xylulose reductase

multiple interactions

ISO

1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]

NCBI chr10:106,504,730...106,506,619

11-dehydrocorticosterone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

hydroxysteroid 11-beta dehydrogenase 1

increases metabolic processing
increases reduction
affects abundance
multiple interactions
affects response to substance

ISO
EXP

HSD11B1 protein results in increased metabolism of 11-dehydrocorticosterone
HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone
HSD11B1 gene mutant form affects the abundance of 11-dehydrocorticosterone
[HSD11B1 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; [HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] which results in increased chemical synthesis of Corticosterone; Resveratrol inhibits the reaction [HSD11B1 protein results in increased metabolism of 11-dehydrocorticosterone]; Ziram inhibits the reaction [[HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] which results in increased chemical synthesis of Corticosterone]; Ziram inhibits the reaction [HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone]
HSD11B1 gene affects the susceptibility to 11-dehydrocorticosterone

PMID:16751407 PMID:23814014 PMID:25061560 PMID:26859423

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

EXP

[HSD11B2 protein results in increased metabolism of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; [HSD11B2 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone]

PMID:26859423 PMID:32243540

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

interleukin 6

increases expression
multiple interactions

ISO

11-dehydrocorticosterone results in increased expression of IL6 mRNA
11-dehydrocorticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of IL6 mRNA]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

serum/glucocorticoid regulated kinase 1

multiple interactions
increases expression

EXP

Carbenoxolone inhibits the reaction [11-dehydrocorticosterone results in increased expression of SGK1 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [11-dehydrocorticosterone results in increased expression of SGK1 mRNA]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

11-deoxycorticosterone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

ISO

Desoxycorticosterone results in increased expression of ACTA2 mRNA; Desoxycorticosterone results in increased expression of ACTA2 protein
Rotenone inhibits the reaction [Desoxycorticosterone results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

angiotensinogen

increases activity

EXP

Desoxycorticosterone results in increased activity of AGT protein

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

aldo-keto reductase family 1, member C3

increases metabolic processing

ISO

AKR1C18 protein results in increased metabolism of Desoxycorticosterone

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

androgen receptor

multiple interactions

ISO

Desoxycorticosterone binds to and results in increased activity of AR protein mutant form

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of BAX protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of BAX protein]; atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein]; Atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

catalase

multiple interactions

EXP

CAT protein results in increased susceptibility to [tert-Butylhydroperoxide co-treated with Desoxycorticosterone co-treated with tempol]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 2

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CCL2 mRNA; [Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CCL2 protein; Mineralocorticoid Receptor Antagonists inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CCL2 protein]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cadherin 1

decreases expression
multiple interactions

ISO

Desoxycorticosterone results in decreased expression of CDH1 mRNA; Desoxycorticosterone results in decreased expression of CDH1 protein
Rotenone inhibits the reaction [Desoxycorticosterone results in decreased expression of CDH1 protein]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cytochrome b-245 alpha chain

increases expression
multiple interactions

EXP

Desoxycorticosterone results in increased expression of CYBA mRNA; Desoxycorticosterone results in increased expression of CYBA protein
[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of CYBA protein

PMID:16271043 PMID:22431579

NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214

G

cytochrome P450, family 11, subfamily b, polypeptide 2

affects metabolic processing
multiple interactions
increases chemical synthesis

ISO
EXP

CYP11B1 protein affects the metabolism of Desoxycorticosterone
Plant Extracts inhibits the reaction [Desoxycorticosterone binds to CYP11B1 protein]
CYP11B1 protein results in increased chemical synthesis of Desoxycorticosterone

PMID:15666820 PMID:16054388 PMID:19900470

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects metabolic processing
multiple interactions
increases hydroxylation

ISO

CYP11B2 protein affects the metabolism of Desoxycorticosterone
[CYP11B2 protein results in increased hydroxylation of Desoxycorticosterone] which results in increased chemical synthesis of Corticosterone

PMID:15985365 PMID:21384875

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

endothelin 1

multiple interactions
increases expression

EXP

[Sodium Chloride, Dietary co-treated with Desoxycorticosterone] results in increased expression of EDN1 mRNA; [Sodium Chloride, Dietary co-treated with Desoxycorticosterone] results in increased expression of EDN1 protein; Clofibrate inhibits the reaction [Desoxycorticosterone results in increased expression of EDN1 protein]; Mibefradil inhibits the reaction [[Sodium Chloride, Dietary co-treated with Desoxycorticosterone] results in increased expression of EDN1 mRNA]
Desoxycorticosterone results in increased expression of EDN1; Desoxycorticosterone results in increased expression of EDN1 protein

PMID:1860718 PMID:8934362 PMID:12600921 PMID:16054168

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

multiple interactions
affects response to substance

EXP

[5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide binds to and results in decreased activity of EDNRA protein] inhibits the reaction [Desoxycorticosterone results in increased chemical synthesis of Reactive Oxygen Species]; [Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of EDNRA protein
EDNRA protein affects the susceptibility to Desoxycorticosterone

PMID:12600921 PMID:16271043 PMID:22431579

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

epidermal growth factor

multiple interactions
increases response to substance

EXP

4,5-dianilinophthalimide inhibits the reaction [EGF protein results in increased susceptibility to Desoxycorticosterone]; RTKI cpd inhibits the reaction [EGF protein results in increased susceptibility to Desoxycorticosterone]

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

E1A binding protein p300

multiple interactions

EXP

Desoxycorticosterone promotes the reaction [EP300 protein binds to SULT1A1 promoter]; Desoxycorticosterone promotes the reaction [EP300 protein binds to TAT promoter]

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

fatty acid binding protein 3

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of FABP3 protein; Mineralocorticoid Receptor Antagonists inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of FABP3 protein]

NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881

G

growth arrest specific 6

multiple interactions

EXP

GAS6 protein promotes the reaction [Desoxycorticosterone results in increased expression of IL6 protein]; GAS6 protein promotes the reaction [Desoxycorticosterone results in increased expression of TNF protein]

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

glutathione peroxidase 1

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of GPX1 protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of GPX1 protein]; atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of GPX1 protein]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

hepatitis A virus cellular receptor 1

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of HAVCR1 mRNA

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

interleukin 1 beta

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of IL1B mRNA

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

increases expression
multiple interactions

EXP

Desoxycorticosterone results in increased expression of IL6 protein
GAS6 protein promotes the reaction [Desoxycorticosterone results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

lipocalin 2

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of LCN2 mRNA; Mineralocorticoid Receptor Antagonists inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of LCN2 mRNA]

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

neutrophil cytosolic factor 1

affects localization

EXP

Desoxycorticosterone affects the localization of NCF1 protein

NCBI chr12:28,121,816...28,131,080
Ensembl chr12:28,121,366...28,131,079

G

nitric oxide synthase 3

decreases phosphorylation
multiple interactions
increases expression

EXP

Desoxycorticosterone results in decreased phosphorylation of NOS3 protein
NOS3 protein inhibits the reaction [Desoxycorticosterone results in increased expression of VCAM1 protein]
Desoxycorticosterone results in increased expression of NOS3 protein

PMID:11834524 PMID:14993198 PMID:16271043

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

NADPH oxidase 1

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of NOX1 protein

NCBI chr X:101,572,338...101,625,571
Ensembl chr X:101,572,340...101,595,520

G

natriuretic peptide A

increases expression

EXP

Desoxycorticosterone results in increased expression of NPPA protein

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

nuclear receptor subfamily 3, group C, member 1

increases phosphorylation
multiple interactions
decreases expression

ISO
EXP

Desoxycorticosterone results in increased phosphorylation of NR3C1 protein
Desoxycorticosterone promotes the reaction [NR3C1 protein binds to TAT promoter]
Desoxycorticosterone results in decreased expression of NR3C1 mRNA
Desoxycorticosterone binds to and results in increased activity of NR3C1 protein

PMID:8969928 PMID:11956172 PMID:18483179 PMID:22465009

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

decreases expression

EXP

Desoxycorticosterone results in decreased expression of NR3C2 mRNA

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

platelet derived growth factor subunit A

multiple interactions

EXP

[PDGFA protein binds to PDGFB protein] which results in increased susceptibility to Desoxycorticosterone

NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322

G

platelet derived growth factor subunit B

multiple interactions

EXP

[PDGFA protein binds to PDGFB protein] which results in increased susceptibility to Desoxycorticosterone

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343

G

proopiomelanocortin

increases abundance

ISO

POMC protein results in increased abundance of Desoxycorticosterone

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

PPARA protein affects the susceptibility to [Sodium Chloride, Dietary co-treated with Desoxycorticosterone]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

PPARG coactivator 1 alpha

increases expression

ISO

Desoxycorticosterone results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

prostaglandin-endoperoxide synthase 2

increases expression

EXP

Desoxycorticosterone results in increased expression of PTGS2 protein

PMID:15834289 PMID:16271043

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

Rac family small GTPase 1

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of RAC1 protein

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109

G

renin

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of REN protein

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

solute carrier family 22 member 2

multiple interactions

EXP

Desoxycorticosterone inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 22 member 3

multiple interactions

EXP

Desoxycorticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353

G

solute carrier organic anion transporter family, member 1a1

multiple interactions
decreases activity

EXP

Desoxycorticosterone inhibits the reaction [SLCO1A1 protein results in increased uptake of estradiol-17 beta-glucuronide]
Desoxycorticosterone results in decreased activity of SLCO1A1 protein

NCBI chr 4:176,606,924...176,682,027
Ensembl chr 4:176,607,687...176,681,992

G

superoxide dismutase 1

decreases expression
multiple interactions

EXP

Desoxycorticosterone results in decreased expression of SOD1 protein
[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD1 protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD1 protein]; atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD1 protein]; tempol inhibits the reaction [Desoxycorticosterone results in decreased expression of SOD1 protein]

PMID:12646410 PMID:22431579

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions
decreases expression

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD2 protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD2 protein]; Atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in decreased expression of SOD2 protein]; SOD2 protein inhibits the reaction [Desoxycorticosterone results in increased expression of VCAM1 protein]
Desoxycorticosterone results in decreased expression of SOD2 protein

PMID:11834524 PMID:22431579

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

secreted phosphoprotein 1

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of SPP1 mRNA; [Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of SPP1 protein; Mineralocorticoid Receptor Antagonists inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of SPP1 mRNA]

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

sulfotransferase family 1A member 1

multiple interactions

EXP

Desoxycorticosterone promotes the reaction [EP300 protein binds to SULT1A1 promoter]

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

tyrosine aminotransferase

multiple interactions

EXP

Desoxycorticosterone promotes the reaction [EP300 protein binds to TAT promoter]; Desoxycorticosterone promotes the reaction [NR3C1 protein binds to TAT promoter]

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

tenascin C

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNC mRNA; Mineralocorticoid Receptor Antagonists inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNC mRNA]; Spironolactone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNC mRNA]

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131

G

tumor necrosis factor

multiple interactions
increases expression

EXP

GAS6 protein promotes the reaction [Desoxycorticosterone results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

multiple interactions

EXP

[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein; acetovanillone inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein]; atrasentan inhibits the reaction [[Desoxycorticosterone co-treated with Sodium Chloride] results in increased expression of TP53 protein]

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

vascular cell adhesion molecule 1

multiple interactions
increases expression

EXP

NOS3 protein inhibits the reaction [Desoxycorticosterone results in increased expression of VCAM1 protein]; SOD2 protein inhibits the reaction [Desoxycorticosterone results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

xanthine dehydrogenase

increases activity
multiple interactions

EXP

Desoxycorticosterone results in increased activity of XDH protein
Desoxycorticosterone promotes the reaction [XDH protein results in increased chemical synthesis of Reactive Oxygen Species]

NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350

11-deoxycortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

androgen receptor

multiple interactions

ISO

Cortodoxone binds to and results in increased activity of AR protein mutant form

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases metabolic processing
affects metabolic processing

ISO

CYP11B1 protein results in increased metabolism of Cortodoxone
CYP11B1 protein affects the metabolism of Cortodoxone

PMID:15522937 PMID:15780661 PMID:15985365 PMID:16030167 PMID:16054388 More...

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases metabolic processing
affects metabolic processing

ISO

CYP11B2 protein results in increased metabolism of Cortodoxone
CYP11B2 protein affects the metabolism of Cortodoxone

PMID:15743198 PMID:19900470

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

nuclear receptor subfamily 3, group C, member 1

affects binding

ISO

Cortodoxone binds to NR3C1 protein

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Cortodoxone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

17alpha-hydroxypregnenolone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects chemical synthesis
increases metabolic processing
multiple interactions
decreases acetylation
affects metabolic processing

ISO

CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxypregnenolone
CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]
CYP17A1 protein results in decreased acetylation of 17-alpha-Hydroxypregnenolone
CYP17A1 protein affects the metabolism of 17-alpha-Hydroxypregnenolone

PMID:15562394 PMID:16030167 PMID:17194026 PMID:29100959

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

17alpha-hydroxyprogesterone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

androgen receptor

increases activity
multiple interactions

ISO

17-alpha-Hydroxyprogesterone results in increased activity of AR protein
17-alpha-Hydroxyprogesterone inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]

PMID:21543282 PMID:33049310

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

EXP

[Diethylstilbestrol results in decreased expression of CYP11A1 protein] which results in decreased abundance of 17-alpha-Hydroxyprogesterone

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 17, subfamily a, polypeptide 1

affects abundance
increases metabolic processing
multiple interactions
affects metabolic processing
affects chemical synthesis

ISO

CYP17A1 protein affects the abundance of 17-alpha-Hydroxyprogesterone
CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]; TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone]
CYP17A1 protein affects the chemical synthesis of 17-alpha-Hydroxyprogesterone

PMID:16030167 PMID:17194026 PMID:21427057 PMID:29100959

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

estrogen receptor 1

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

fatty acid binding protein 4

multiple interactions

ISO

[17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

insulin 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; [17-alpha-Hydroxyprogesterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone binds to and results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO

17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of NR3C1 protein

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

progesterone receptor

multiple interactions

ISO

17-alpha-Hydroxyprogesterone analog binds to and results in increased activity of PGR protein

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

solute carrier family 22 member 2

multiple interactions

ISO

17-alpha-Hydroxyprogesterone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

tumor necrosis factor

multiple interactions

ISO

TNF protein inhibits the reaction [CYP17A1 protein affects the metabolism of 17-alpha-Hydroxyprogesterone]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

18-hydroxycortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily b, polypeptide 2

affects chemical synthesis

ISO

CYP11B1 protein affects the chemical synthesis of 18-hydroxycortisol

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects chemical synthesis

ISO

CYP11B2 protein affects the chemical synthesis of 18-hydroxycortisol

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

proopiomelanocortin

increases abundance

ISO

POMC protein results in increased abundance of 18-hydroxycortisol

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects chemical synthesis

ISO

CYP11B2 protein affects the chemical synthesis of 18-oxocortisol

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

21-dehydrocortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B15

multiple interactions

EXP

[AKR1B8 protein co-treated with NADP] affects the reduction of 21-dehydrocortisol

NCBI chr 4:63,964,421...63,976,995
Ensembl chr 4:63,960,880...63,978,349

3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

DNA topoisomerase I

increases activity

ISO

3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin results in increased activity of TOP1 protein

NCBI chr 3:169,713,195...169,796,330
Ensembl chr 3:169,713,130...169,796,327

3-hydroxypyruvic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldehyde dehydrogenase 2 family member

multiple interactions

EXP

[Disulfiram results in decreased activity of ALDH2 protein] which results in increased susceptibility to hydroxypyruvic acid

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

catalase

decreases response to substance

EXP

CAT protein results in decreased susceptibility to hydroxypyruvic acid

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

4'-epidoxorubicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression

ISO
EXP

3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of ABCB1 mRNA; [Epirubicin co-treated with chrysophsin] results in increased expression of ABCB1 mRNA; ABCB1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCB1 mRNA]
[Diethylnitrosamine co-treated with Epirubicin] results in increased expression of ABCB1 protein
Epirubicin analog results in increased expression of ABCB1 mRNA; Epirubicin results in increased expression of ABCB1 mRNA

PMID:11818250 PMID:12576456 PMID:22914566 PMID:23867903 PMID:26335193

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions
increases expression
decreases response to substance

ISO

3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA]; ABCC1 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC1 mRNA]
Epirubicin analog results in increased expression of ABCC1 mRNA; Epirubicin results in increased expression of ABCC1 mRNA
ABCC1 protein results in decreased susceptibility to Epirubicin

PMID:7954421 PMID:12576456 PMID:12657726 PMID:22914566 PMID:23867903 More...

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 2

multiple interactions
increases expression

ISO

3',4',7-trihydroxyisoflavone inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA]; formononetin inhibits the reaction [Epirubicin results in increased expression of ABCC2 mRNA]
Epirubicin analog results in increased expression of ABCC2 mRNA; Epirubicin results in increased expression of ABCC2 mRNA

PMID:22914566 PMID:23867903 PMID:26335193

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases response to substance

ISO

ABCG2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]
ABCG2 protein results in decreased susceptibility to Epirubicin

PMID:10606239 PMID:12576456

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation

ISO
EXP

paeonol inhibits the reaction [Epirubicin results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]; paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of AKT1 protein]

PMID:26646421 PMID:29505745

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

androgen receptor

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of AR protein; Epirubicin binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

autophagy related 5

decreases expression
multiple interactions

EXP

Epirubicin results in decreased expression of ATG5 protein
paeonol inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of ATG5 protein]

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

autophagy related 7

multiple interactions

ISO

[baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of ATG7 mRNA

NCBI chr 4:149,390,000...149,597,534
Ensembl chr 4:149,391,390...149,598,319

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

ISO

3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of BAX mRNA]; [baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of BAX protein; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of BAX mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of BAX mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of BAX mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of BAX mRNA]; formononetin promotes the reaction [Epirubicin results in increased expression of BAX mRNA]
paeonol inhibits the reaction [Epirubicin results in increased expression of BAX protein]

PMID:22914566 PMID:23867903 PMID:26335193 PMID:26646421 PMID:29505745 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

increases expression
multiple interactions
decreases expression

ISO

Epirubicin analog results in increased expression of BCL2 mRNA; Epirubicin results in increased expression of BCL2 mRNA
paeonol inhibits the reaction [Epirubicin results in decreased expression of BCL2 protein]
[Epirubicin analog co-treated with chrysophsin analog] results in increased expression of BCL2 mRNA; [Epirubicin co-treated with chrysophsin] results in increased expression of BCL2 mRNA

PMID:14503796 PMID:23867903 PMID:26335193 PMID:26646421 PMID:29505745

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

beclin 1

decreases expression
multiple interactions

EXP
ISO

Epirubicin results in decreased expression of BECN1 protein
[baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in increased expression of BECN1 protein
paeonol inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]; Sirolimus inhibits the reaction [Epirubicin results in decreased expression of BECN1 protein]

PMID:29505745 PMID:38040128

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

baculoviral IAP repeat-containing 5

decreases response to substance
multiple interactions
increases expression

ISO

BIRC5 protein results in decreased susceptibility to Epirubicin
[Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]

PMID:16188142 PMID:35872041

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

baculoviral IAP repeat-containing 6

decreases response to substance

ISO

BIRC6 results in decreased susceptibility to Epirubicin

NCBI chr 6:26,474,843...26,668,275
Ensembl chr 6:26,474,843...26,668,507

G

caspase 1

increases response to substance

ISO

CASP1 results in increased susceptibility to Epirubicin

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

multiple interactions
increases cleavage
increases expression
increases activity

ISO

3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of CASP3 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of CASP3 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP3 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP3 mRNA]; Epirubicin results in increased activity of and affects the localization of CASP3 protein; formononetin promotes the reaction [Epirubicin results in increased activity of CASP3 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP3 mRNA]
paeonol inhibits the reaction [Epirubicin results in increased cleavage of CASP3 protein]

PMID:14503796 PMID:15996160 PMID:22914566 PMID:23867903 PMID:26335193 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

multiple interactions

ISO

Epirubicin promotes the reaction [formononetin results in increased activity of CASP8 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP8 mRNA]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions
increases expression
increases activity

ISO

3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of CASP9 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of CASP9 mRNA]; Epirubicin promotes the reaction [formononetin results in increased activity of CASP9 protein]; Epirubicin promotes the reaction [formononetin results in increased expression of CASP9 mRNA]; formononetin promotes the reaction [Epirubicin results in increased activity of CASP9 protein]; formononetin promotes the reaction [Epirubicin results in increased expression of CASP9 mRNA]

PMID:22914566 PMID:23867903 PMID:26335193

Ensembl chr 5:159,391,188...159,409,648

G

catalase

decreases activity
multiple interactions

ISO
EXP

Epirubicin results in decreased activity of CAT protein
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased activity of CAT protein]
paeonol inhibits the reaction [Epirubicin results in decreased activity of CAT protein]

PMID:26646421 PMID:36822302

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cellular communication network factor 2

increases expression
multiple interactions

ISO

Epirubicin results in increased expression of CCN2 mRNA
Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA]

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

dihydropyrimidine dehydrogenase

multiple interactions

ISO

DPYD protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin]

NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778

G

epidermal growth factor receptor

multiple interactions

ISO

EGFR protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions
increases phosphorylation

ISO

[Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of EIF4EBP1 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased phosphorylation of EIF4EBP1 protein]

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

ERBB2 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]; ERBB2 protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]

PMID:16446318 PMID:16682728 PMID:18768436

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

ISO

ERBB3 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

estrogen receptor 1

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of ESR2 protein

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

Fas cell surface death receptor

increases expression

EXP

Epirubicin results in increased expression of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

increases expression

EXP

Epirubicin results in increased expression of FASLG protein; Epirubicin results in increased expression of FASLG protein modified form

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

FKBP prolyl isomerase like

increases expression

ISO

Epirubicin results in increased expression of FKBPL mRNA

NCBI chr20:4,104,457...4,105,927
Ensembl chr20:4,104,019...4,105,615

G

follicle stimulating hormone subunit beta

decreases expression
multiple interactions

EXP

Epirubicin results in decreased expression of FSHB protein
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased expression of FSHB protein]

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

interleukin 2

increases expression
multiple interactions

ISO

Epirubicin results in increased expression of IL2 mRNA; Epirubicin results in increased expression of IL2 protein
paeonol inhibits the reaction [Epirubicin results in increased expression of IL2 mRNA]; paeonol inhibits the reaction [Epirubicin results in increased expression of IL2 protein]

PMID:26646421 PMID:29505745

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 6

increases expression
multiple interactions

ISO

Epirubicin results in increased expression of IL6 protein
Epirubicin results in increased expression of IL6 mRNA
paeonol inhibits the reaction [Epirubicin results in increased expression of IL6 mRNA]

PMID:17914082 PMID:19060235 PMID:26646421

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

increases expression

ISO

Epirubicin results in increased expression of IL6R protein

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO

Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MARVEL domain containing 1

increases response to substance

ISO

MARVELD1 protein results in increased susceptibility to Epirubicin

NCBI chr 1:250,903,342...250,907,393
Ensembl chr 1:250,903,342...250,907,393

G

microRNA 1

decreases expression
multiple interactions

EXP

Epirubicin results in decreased expression of MIR1 mRNA
paeonol inhibits the reaction [Epirubicin results in decreased expression of MIR1 mRNA]

NCBI chr18:2,160,327...2,160,413

G

myeloperoxidase

increases activity
multiple interactions

EXP

Epirubicin results in increased activity of MPO protein
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased activity of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

mechanistic target of rapamycin kinase

increases phosphorylation
multiple interactions

EXP

Epirubicin results in increased phosphorylation of MTOR protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Epirubicin results in increased phosphorylation of MTOR protein]; paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

nuclear receptor coactivator 2

multiple interactions

ISO

Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]

NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776

G

NFKB inhibitor alpha

multiple interactions

EXP

Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein; paeonol inhibits the reaction [Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein]; prolinedithiocarbamate inhibits the reaction [Epirubicin results in decreased expression of and results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

natriuretic peptide A

increases expression

ISO

Epirubicin results in increased expression of NPPA protein

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ISO

Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Epirubicin inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein]

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

ISO

Epirubicin results in increased cleavage of PARP1 protein
[Gossypol co-treated with Epirubicin] results in increased cleavage of PARP1 protein
paeonol inhibits the reaction [Epirubicin results in increased cleavage of PARP1 protein]

PMID:26646421 PMID:35872041

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

progesterone receptor

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of PGR protein

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

pleckstrin homology-like domain, family A, member 2

increases response to substance

ISO

PHLDA2 results in increased susceptibility to Epirubicin

NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920

G

PML nuclear body scaffold

affects mutagenesis

ISO

Epirubicin affects the mutagenesis of PML gene

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

prolactin

increases expression
multiple interactions

EXP

Epirubicin results in increased expression of PRL protein
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased expression of PRL protein]

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

retinoic acid receptor, alpha

affects mutagenesis

ISO

Epirubicin affects the mutagenesis of RARA gene

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:84,389,622...84,425,160

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases phosphorylation

EXP

paeonol inhibits the reaction [Epirubicin results in increased phosphorylation of RELA protein]; prolinedithiocarbamate inhibits the reaction [Epirubicin results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ribosomal protein S6 kinase B1

multiple interactions
increases phosphorylation

ISO

Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of RPS6KB1 protein]; MK 2206 inhibits the reaction [Epirubicin results in increased phosphorylation of RPS6KB1 protein]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

superoxide dismutase 2

affects response to substance

ISO

SOD2 protein affects the susceptibility to Epirubicin

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

sequestosome 1

multiple interactions
increases expression

EXP

paeonol inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]; Sirolimus inhibits the reaction [Epirubicin results in increased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

transforming growth factor, beta 1

multiple interactions

ISO

[baicalein 5,6,7-trimethyl ether co-treated with Epirubicin] results in decreased expression of TGFB1 mRNA

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

thyroid hormone receptor alpha

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of THRA protein

NCBI chr10:84,198,141...84,225,659
Ensembl chr10:84,197,011...84,225,657

G

thyroid hormone receptor beta

multiple interactions

ISO

Epirubicin binds to and results in decreased activity of THRB protein

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680

G

tumor necrosis factor

increases expression
multiple interactions

ISO

Epirubicin results in increased expression of TNF mRNA; Epirubicin results in increased expression of TNF protein
paeonol inhibits the reaction [Epirubicin results in increased expression of TNF mRNA]; paeonol inhibits the reaction [Epirubicin results in increased expression of TNF protein]

PMID:26646421 PMID:29505745

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

DNA topoisomerase II alpha

multiple interactions

ISO

TOP2A protein affects the susceptibility to [Cyclophosphamide co-treated with Epirubicin co-treated with Fluorouracil]; TOP2A protein affects the susceptibility to [Fluorouracil co-treated with Epirubicin co-treated with Cyclophosphamide]

PMID:16682728 PMID:18465341

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tumor protein p53

multiple interactions
increases expression

ISO

3',4',7-trihydroxyisoflavone promotes the reaction [Epirubicin results in increased expression of TP53 mRNA]; [Epirubicin analog co-treated with chrysophsin analog] results in increased expression of TP53 mRNA; chrysophsin promotes the reaction [Epirubicin results in increased expression of TP53 mRNA]; Epirubicin promotes the reaction [3',4',7-trihydroxyisoflavone results in increased expression of TP53 mRNA]; Epirubicin promotes the reaction [chrysophsin results in increased expression of TP53 mRNA]

PMID:22914566 PMID:26335193

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

thyroid stimulating hormone subunit beta

multiple interactions
decreases expression

EXP

3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in decreased expression of TSHB protein]

NCBI chr 2:192,913,171...192,918,054
Ensembl chr 2:192,913,171...192,942,984

G

thymidine phosphorylase

multiple interactions

ISO

[Epirubicin co-treated with Cyclophosphamide] results in increased expression of TYMP protein

NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003

G

vascular endothelial growth factor C

multiple interactions

ISO

VEGFC mRNA results in increased susceptibility to [Paclitaxel co-treated with Epirubicin co-treated with CMF regimen]

NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887

G

xanthine dehydrogenase

increases activity
multiple interactions

EXP

Epirubicin results in increased activity of XDH protein
3-(indol-3-yl)propionic acid inhibits the reaction [Epirubicin results in increased activity of XDH protein]

NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350

5Z-7-oxozeaenol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 3

decreases expression

ISO

(5Z)-7-oxozeaenol decreases expression of BIRC3 protein in esophageal adenocarcinoma cells

RGD

NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590

G

mitogen activated protein kinase kinase kinase 7

decreases phosphorylation

ISO

5Z-7-oxozeaenol decreases phosphorylation of Map3k7 protein in hypertrophic heart

RGD

NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012

6alpha-methylprednisolone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
increases secretion

ISO

ABCB1 gene polymorphism affects the susceptibility to [Methotrexate co-treated with Methylprednisolone]; ABCB1 protein results in increased susceptibility to [Methotrexate co-treated with Methylprednisolone]; Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Methylprednisolone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Methylprednisolone]
Methylprednisolone results in increased expression of ABCB1 mRNA; Methylprednisolone results in increased expression of ABCB1 protein

PMID:16932953 PMID:22079615 PMID:22464980

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

Methylprednisolone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

atypical chemokine receptor 3

decreases expression

ISO

Methylprednisolone results in decreased expression of ACKR3 mRNA

NCBI chr 9:98,247,300...98,258,877
Ensembl chr 9:98,246,605...98,260,214

G

adenosine A2a receptor

decreases expression

ISO

Methylprednisolone results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,270...13,332,802
Ensembl chr20:13,315,270...13,332,802

G

AKT serine/threonine kinase 1

decreases phosphorylation
multiple interactions

EXP

Methylprednisolone results in decreased phosphorylation of AKT1 protein
naringin inhibits the reaction [Methylprednisolone results in decreased phosphorylation of AKT1 protein]

PMID:15187100 PMID:30878453

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases secretion

EXP

Alendronate inhibits the reaction [Methylprednisolone results in increased secretion of ALPL protein]; Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in increased secretion of ALPL protein]]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

adhesion molecule with Ig like domain 2

decreases expression

ISO

Methylprednisolone results in decreased expression of AMIGO2 mRNA

NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218

G

ANTXR cell adhesion molecule 1

increases expression

ISO

Methylprednisolone results in increased expression of ANTXR1 mRNA

NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892

G

aldehyde oxidase 1

increases expression

ISO

Methylprednisolone results in increased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

androgen receptor

multiple interactions

ISO

Methylprednisolone binds to and results in decreased activity of AR protein; Methylprednisolone binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

Methylprednisolone results in decreased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of BAX mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BAX mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BAX protein]

PMID:17570061 PMID:26093215

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 mRNA]; Methylprednisolone inhibits the reaction [Hydrogen Peroxide affects the expression of BCL2 protein]

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

BCL2-related protein A1

decreases expression

ISO

Methylprednisolone results in decreased expression of BCL2A1 mRNA

NCBI chr 8:98,596,806...98,604,890
Ensembl chr 8:98,596,650...98,604,890

G

bone gamma-carboxyglutamate protein

decreases secretion
decreases expression
multiple interactions

EXP

Methylprednisolone results in decreased secretion of BGLAP protein
Methylprednisolone results in decreased expression of BGLAP mRNA; Methylprednisolone results in decreased expression of BGLAP protein
[Nebivolol co-treated with Alendronate] inhibits the reaction [Methylprednisolone results in decreased secretion of BGLAP protein]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of BGLAP protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of BGLAP protein]

PMID:30291735 PMID:37659742

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

bone marrow stromal cell antigen 2

decreases expression

ISO

Methylprednisolone results in decreased expression of BST2 mRNA

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

calpain 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide results in increased expression of CAPN2 protein]

NCBI chr13:96,681,902...96,732,625
Ensembl chr13:96,681,848...96,732,625

G

caspase 3

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Hydrogen Peroxide results in increased cleavage of and results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

multiple interactions
decreases activity
increases activity

EXP

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of CAT protein; Alendronate inhibits the reaction [Methylprednisolone results in decreased activity of CAT protein]; Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in decreased activity of CAT protein]]
Methylprednisolone results in increased activity of CAT protein

PMID:1942778 PMID:30291735

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 20

decreases expression

ISO

Methylprednisolone results in decreased expression of CCL20 mRNA; Methylprednisolone results in decreased expression of CCL20 protein

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

cellular communication network factor 1

increases expression

ISO

Methylprednisolone results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression

ISO

Methylprednisolone results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 5

increases expression

ISO

Methylprednisolone results in increased expression of CCN5 mRNA

NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062

G

calmegin

decreases expression

ISO

Methylprednisolone results in decreased expression of CLGN mRNA

NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325

G

collagen type I alpha 1 chain

multiple interactions
increases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]
Methylprednisolone results in increased expression of COL1A1 mRNA

PMID:19192274 PMID:26093215

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type IV alpha 1 chain

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA]

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

cathepsin D

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Isoproterenol results in increased expression of CTSD mRNA]

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

C-X-C motif chemokine ligand 1

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL1 mRNA

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 2

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL2 mRNA

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCL1 mRNA

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine receptor 4

decreases expression

ISO

Methylprednisolone results in decreased expression of CXCR4 mRNA

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
increases activity

ISO

Methylprednisolone results in decreased expression of CYP3A4 mRNA
Methylprednisolone results in increased activity of CYP3A4 protein

PMID:15964336 PMID:16837568

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

DNA-damage-inducible transcript 4

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of DDIT4 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of DDIT4 protein]

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

iodothyronine deiodinase 2

increases expression

ISO

Methylprednisolone results in increased expression of DIO2 mRNA

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

dystrophin

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form]; Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA]

NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835

G

endothelin 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type B

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDNRB mRNA]

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

EGF containing fibulin extracellular matrix protein 1

increases expression

ISO

Methylprednisolone results in increased expression of EFEMP1 mRNA

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808

G

estrogen receptor 1

multiple interactions

ISO

Methylprednisolone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

coagulation factor VIII

increases expression

ISO

Methylprednisolone results in increased expression of F8 protein

NCBI chr18:155,237...187,186
Ensembl chr18:155,309...186,683

G

fatty acid binding protein 4

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FABP4 mRNA
bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fibulin 1

increases expression

ISO

Methylprednisolone results in increased expression of FBLN1 mRNA

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

F-box protein 32

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FBXO32 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of FBXO32 protein]

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

Fc epsilon receptor II

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 protein]

NCBI chr12:6,540,697...6,552,364
Ensembl chr12:6,540,703...6,549,374

G

forkhead box O1

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of FOXO1 protein
echinacoside inhibits the reaction [Methylprednisolone results in increased expression of FOXO1 protein]; Testosterone inhibits the reaction [Methylprednisolone results in increased expression of FOXO1 protein]

PMID:21931329 PMID:38336255

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

guanylate binding protein 1

decreases expression

ISO

Methylprednisolone results in decreased expression of GBP1 mRNA

NCBI chr 2:234,071,366...234,106,012
Ensembl chr 2:234,190,708...234,206,802
Ensembl chr 2:234,190,708...234,206,802

G

glial fibrillary acidic protein

decreases expression

ISO

Methylprednisolone results in decreased expression of GFAP protein

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

gastric inhibitory polypeptide

increases secretion

EXP

Methylprednisolone results in increased secretion of GIP protein

NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216

G

glycoprotein m6b

increases expression

ISO

Methylprednisolone results in increased expression of GPM6B mRNA

NCBI chr X:31,689,485...31,836,199
Ensembl chr X:31,690,359...31,733,272

G

glutamic--pyruvic transaminase

multiple interactions

ISO

[Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

multiple interactions
increases activity

EXP

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of GPX1 protein
Methylprednisolone results in increased activity of GPX1 protein

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

gasdermin E

decreases expression

ISO

Methylprednisolone results in decreased expression of GSDME mRNA

NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 6

decreases expression

ISO

Methylprednisolone results in decreased expression of HERC6 mRNA

NCBI chr 4:88,854,612...88,897,043
Ensembl chr 4:88,854,640...88,896,993

G

hypoxia inducible lipid droplet-associated

decreases expression

ISO

Methylprednisolone results in decreased expression of HILPDA mRNA

NCBI chr 4:58,836,463...58,839,423
Ensembl chr 4:58,836,463...58,839,423

G

heme oxygenase 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

hydroxysteroid 11-beta dehydrogenase 1

decreases expression

ISO

Methylprednisolone results in decreased expression of HSD11B1 mRNA

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

5-hydroxytryptamine receptor 3A

multiple interactions
decreases activity

ISO

[Methylprednisolone co-treated with Metoclopramide] results in decreased activity of HTR3A protein; [Methylprednisolone co-treated with ramosetron] results in decreased activity of HTR3A protein
Methylprednisolone results in decreased activity of HTR3A protein

NCBI chr 8:58,138,514...58,150,960
Ensembl chr 8:58,138,226...58,150,884

G

inhibitor of DNA binding 3

increases expression

ISO

Methylprednisolone results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

interferon, alpha-inducible protein 27

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI27 mRNA

NCBI chr 6:128,355,312...128,361,783
Ensembl chr 6:128,355,079...128,361,781

G

interferon-induced protein 35

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI35 mRNA

NCBI chr10:86,881,270...86,889,523
Ensembl chr10:86,887,122...86,889,750

G

interferon-induced protein 44

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon-induced protein 44-like

decreases expression

ISO

Methylprednisolone results in decreased expression of IFI44L mRNA

NCBI chr 2:243,328,629...243,366,404
Ensembl chr 2:243,328,723...243,366,404

G

interferon induced with helicase C domain 1

decreases expression

ISO

Methylprednisolone results in decreased expression of IFIH1 mRNA

NCBI chr 3:67,635,924...67,683,968
Ensembl chr 3:67,637,545...67,683,968

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

ISO

Methylprednisolone results in decreased expression of IFIT3 mRNA

NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521

G

interleukin 10

increases expression

ISO

Methylprednisolone results in increased expression of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 1 beta

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor antagonist

decreases expression

ISO

Methylprednisolone results in decreased expression of IL1RN mRNA

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 23 subunit alpha

decreases expression

ISO

Methylprednisolone results in decreased expression of IL23A mRNA

NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434

G

interleukin 4

multiple interactions
decreases expression

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased activity of and results in increased phosphorylation of STAT6 protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of FCER2 protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of JAK1 protein]
Methylprednisolone results in decreased expression of IL4 protein

PMID:7988651 PMID:11997017

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 4 receptor

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R mRNA]; Methylprednisolone inhibits the reaction [IL4 protein results in increased expression of IL4R protein]; Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of IL4R protein]

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 5

decreases expression

ISO

Methylprednisolone results in decreased expression of IL5 protein

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of IL6 mRNA]
Methylprednisolone results in decreased expression of IL6 mRNA; Methylprednisolone results in decreased expression of IL6 protein

PMID:19192274 PMID:26093215

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

ISO

cobaltiprotoporphyrin inhibits the reaction [Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]]; Methylprednisolone inhibits the reaction [Glucose results in increased secretion of INS1 protein]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

interferon regulatory factor 7

decreases expression

ISO

Methylprednisolone results in decreased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

ISG15 ubiquitin-like modifier

decreases expression

ISO

Methylprednisolone results in decreased expression of ISG15 mRNA

NCBI chr 5:172,066,369...172,067,656
Ensembl chr 5:172,066,369...172,067,656

G

interferon stimulated exonuclease gene 20

decreases expression

ISO

Methylprednisolone results in decreased expression of ISG20 mRNA

NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:142,236,137...142,246,401

G

Janus kinase 1

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein results in increased phosphorylation of JAK1 protein]

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

laminin subunit beta 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA]

NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760

G

laminin subunit beta 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA]

NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090

G

laminin subunit beta 3

decreases expression

ISO

Methylprednisolone results in decreased expression of LAMB3 mRNA

NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081

G

lymphocyte antigen 6 family member E

decreases expression

ISO

Methylprednisolone results in decreased expression of LY6E mRNA

NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443

G

mitogen activated protein kinase 1

multiple interactions
decreases expression
decreases phosphorylation

EXP

cobaltous chloride inhibits the reaction [Methylprednisolone results in decreased expression of MAPK1 protein modified form]; cobaltous chloride inhibits the reaction [Methylprednisolone results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

myristoylated alanine rich protein kinase C substrate

decreases expression

ISO

Methylprednisolone results in decreased expression of MARCKS mRNA

NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882

G

myelin basic protein

decreases expression

ISO

Methylprednisolone results in decreased expression of MBP protein

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

MET proto-oncogene, receptor tyrosine kinase

decreases expression

ISO

Methylprednisolone results in decreased expression of MET mRNA

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

matrix metallopeptidase 10

decreases expression

ISO

Methylprednisolone results in decreased expression of MMP10 mRNA

NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613

G

matrix metallopeptidase 12

decreases expression

ISO

Methylprednisolone results in decreased expression of MMP12 mRNA

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478

G

myeloperoxidase

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MPO protein]
[Polymyxin B co-treated with Methylprednisolone] inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]; Methylprednisolone inhibits the reaction [Alpha-Amanitin results in increased activity of MPO protein]
Methylprednisolone results in decreased expression of MPO protein

PMID:26093215 PMID:28557239 PMID:30891624

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

mucin 5AC, oligomeric mucus/gel-forming

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of MUC5AC mRNA]

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

MX dynamin like GTPase 1

decreases expression

ISO

Methylprednisolone results in decreased expression of MX1 mRNA

NCBI chr11:50,269,056...50,294,699
Ensembl chr11:50,269,057...50,292,904

G

NDUFA4, mitochondrial complex associated like 2

decreases expression

ISO

Methylprednisolone results in decreased expression of COXFA4L2 mRNA

NCBI chr 7:65,242,169...65,244,296
Ensembl chr 7:65,242,135...65,244,277

G

NFE2 like bZIP transcription factor 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in decreased expression of NFE2L2 mRNA]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of NFKB1 mRNA]

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

nidogen 2

increases expression

ISO

Methylprednisolone results in increased expression of NID2 mRNA

NCBI chr15:4,507,224...4,562,949
Ensembl chr15:4,506,756...4,562,949

G

neuromedin B

decreases expression

ISO

Methylprednisolone results in decreased expression of NMB mRNA

NCBI chr 1:144,278,678...144,290,523
Ensembl chr 1:144,278,453...144,281,422

G

nitric oxide synthase 2

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nuclear receptor subfamily 4, group A, member 3

decreases expression

ISO

Methylprednisolone results in decreased expression of NR4A3 mRNA

NCBI chr 5:67,157,141...67,198,287
Ensembl chr 5:67,157,375...67,198,285

G

2'-5' oligoadenylate synthetase 1A

decreases expression

ISO

Methylprednisolone results in decreased expression of OAS1 mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

2'-5'-oligoadenylate synthetase 3

decreases expression

ISO

Methylprednisolone results in decreased expression of OAS3 mRNA

NCBI chr12:41,439,645...41,463,392
Ensembl chr12:41,439,643...41,464,420

G

2'-5'-oligoadenylate synthetase-like

decreases expression

ISO

Methylprednisolone results in decreased expression of OASL mRNA

NCBI chr12:47,343,551...47,356,509
Ensembl chr12:47,343,551...47,356,483

G

phosphoglycerate dehydrogenase

decreases expression

ISO

Methylprednisolone results in decreased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

phospholipase A1 member A

multiple interactions

ISO

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA1A mRNA]

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

phospholipase A2 group 4A

multiple interactions

ISO

Methylprednisolone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

phospholipid phosphatase 3

decreases expression

ISO

Methylprednisolone results in decreased expression of PLPP3 mRNA

NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

EXP

bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in increased expression of PPARG protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG mRNA]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in decreased expression of PPARG protein]
Methylprednisolone results in increased expression of PPARG mRNA; Methylprednisolone results in increased expression of PPARG protein

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

proline and arginine rich end leucine rich repeat protein

increases expression

ISO

Methylprednisolone results in increased expression of PRELP mRNA

NCBI chr13:47,920,480...47,943,547
Ensembl chr13:47,922,590...47,932,324

G

prostaglandin-endoperoxide synthase 2

decreases expression

ISO

Methylprednisolone results in decreased expression of PTGS2 mRNA

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of RELA protein modified form]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

increases activity
multiple interactions

EXP

Methylprednisolone results in increased activity of REN protein
Sodium Chloride inhibits the reaction [Methylprednisolone results in increased activity of REN protein]

PMID:235222 PMID:6277579

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

regulator of G-protein signaling 4

decreases expression

ISO

Methylprednisolone results in decreased expression of RGS4 mRNA

NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884

G

RNA sensor RIG-1

decreases expression

ISO

Methylprednisolone results in decreased expression of RIGI mRNA

NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:60,117,398...60,165,995

G

receptor-interacting serine-threonine kinase 2

decreases expression

ISO

Methylprednisolone results in decreased expression of RIPK2 mRNA

NCBI chr 5:34,428,573...34,459,808
Ensembl chr 5:34,428,573...34,459,663

G

ring finger protein 19B

decreases expression

ISO

Methylprednisolone results in decreased expression of RNF19B mRNA

NCBI chr 5:146,690,453...146,715,729
Ensembl chr 5:146,690,577...146,714,394

G

radical S-adenosyl methionine domain containing 2

decreases expression

ISO

Methylprednisolone results in decreased expression of RSAD2 mRNA

NCBI chr 6:48,774,985...48,788,245
Ensembl chr 6:48,774,985...48,788,320

G

RUNX family transcription factor 2

multiple interactions
decreases expression

EXP

bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 mRNA]; bisphenol A diglycidyl ether inhibits the reaction [Methylprednisolone results in decreased expression of RUNX2 protein]; Methylprednisolone inhibits the reaction [bisphenol A diglycidyl ether results in increased expression of RUNX2 protein]
Methylprednisolone results in decreased expression of RUNX2 mRNA; Methylprednisolone results in decreased expression of RUNX2 protein

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

sirtuin 1

multiple interactions

ISO

Methylprednisolone inhibits the reaction [DMD gene mutant form results in increased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

solute carrier family 43, member 3

decreases expression

ISO

Methylprednisolone results in decreased expression of SLC43A3 mRNA

NCBI chr 3:90,414,822...90,450,654
Ensembl chr 3:90,415,977...90,436,976

G

solute carrier family 7 member 11

decreases expression

ISO

Methylprednisolone results in decreased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

spermine synthase

decreases expression

ISO

Methylprednisolone results in decreased expression of SMS mRNA

NCBI chr X:41,331,693...41,387,713
Ensembl chr X:41,331,799...41,387,712

G

superoxide dismutase 2

multiple interactions
decreases expression
increases activity

EXP
ISO

[Methylprednisolone co-treated with Puromycin Aminonucleoside] results in increased activity of SOD2 protein
Methylprednisolone results in decreased expression of SOD2 mRNA
Methylprednisolone results in increased activity of SOD2 protein

PMID:1942778 PMID:19192274

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

signal transducer and activator of transcription 1

decreases expression

ISO

Methylprednisolone results in decreased expression of STAT1 mRNA

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 4

decreases expression

ISO

Methylprednisolone results in decreased expression of STAT4 mRNA

NCBI chr 9:56,964,617...57,080,523
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 6

multiple interactions

ISO

Methylprednisolone inhibits the reaction [IL4 protein promotes the reaction [STAT6 protein binds to FCER2 promoter]]; Methylprednisolone inhibits the reaction [IL4 protein results in increased activity of and results in increased phosphorylation of STAT6 protein]

NCBI chr 7:65,365,505...65,382,825
Ensembl chr 7:65,365,306...65,383,795

G

steroid sulfatase

increases expression

ISO

Methylprednisolone results in increased expression of STS mRNA

NCBI chr X:46,102,524...46,110,868
Ensembl chr X:46,102,548...46,111,104

G

transforming growth factor, beta 1

multiple interactions

EXP

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

thrombospondin 1

increases expression

ISO

Methylprednisolone results in increased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

toll-like receptor 2

decreases expression

ISO

Methylprednisolone results in decreased expression of TLR2 mRNA

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

tumor necrosis factor

multiple interactions
decreases expression

EXP
ISO

Methylprednisolone inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Methylprednisolone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of TNF mRNA]
[Cyclophosphamide co-treated with Methylprednisolone] inhibits the reaction [Paraquat results in increased expression of TNF protein]
Methylprednisolone results in decreased expression of TNF protein

PMID:8384958 PMID:26093215 PMID:28557239 PMID:33737140

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 2

decreases expression

ISO

Methylprednisolone results in decreased expression of TNFAIP2 mRNA

NCBI chr 6:136,297,388...136,311,106
Ensembl chr 6:136,298,082...136,311,106

G

tripartite motif containing 63

increases expression
multiple interactions

EXP

Methylprednisolone results in increased expression of TRIM63 protein
Testosterone inhibits the reaction [Methylprednisolone results in increased expression of TRIM63 protein]

NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:151,817,225...151,831,058

G

thioredoxin interacting protein

increases expression

ISO

Methylprednisolone results in increased expression of TXNIP mRNA

NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731

G

von Willebrand factor

decreases expression
increases expression

ISO

Methylprednisolone results in decreased expression of VWF protein
Methylprednisolone results in increased expression of VWF protein

PMID:7491699 PMID:20405515

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757

6beta-hydroxycortisol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects chemical synthesis

ISO

CYP3A4 protein affects the chemical synthesis of 6 beta-hydroxycortisol

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B1

increases reduction
multiple interactions

ISO

AKR1B1 protein results in increased reduction of Acetoin
[AKR1B1 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol; [AKR1B1 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1 member B10

increases reduction
multiple interactions

ISO

AKR1B10 protein results in increased reduction of Acetoin
[AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2,3-butylene glycol; [AKR1B10 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

G

dicarbonyl and L-xylulose reductase

multiple interactions

ISO

1,2-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 1,4-naphthoquinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; 9,10-phenanthrenequinone inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]; [[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin; [DCXR protein co-treated with NAD] results in increased chemical synthesis of Acetoin; Vitamin K 3 inhibits the reaction [[[DCXR protein co-treated with NAD] results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin]

NCBI chr10:106,504,730...106,506,619

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases secretion
increases expression
multiple interactions

ISO

ABCB1 protein results in increased secretion of Aldosterone
Aldosterone results in increased expression of ABCB1 mRNA
Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Aldosterone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Aldosterone]

PMID:12387747 PMID:22464980

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

angiotensin I converting enzyme

increases activity
increases expression
multiple interactions

EXP

Aldosterone results in increased activity of ACE protein
Aldosterone results in increased expression of ACE mRNA
AG 1879 inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]; Dactinomycin inhibits the reaction [Aldosterone results in increased activity of ACE protein]; Dactinomycin inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]; Genistein inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]; RTKI cpd inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased activity of ACE protein]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of ACE mRNA]

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

actin alpha 2, smooth muscle

increases expression
multiple interactions

ISO
EXP

Aldosterone results in increased expression of ACTA2 mRNA; Aldosterone results in increased expression of ACTA2 protein
Spironolactone inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]; tempol inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]
eplerenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 mRNA]; eplerenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]; Rotenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 mRNA]; Rotenone inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]; U 0126 inhibits the reaction [Aldosterone results in increased expression of ACTA2 mRNA]; U 0126 inhibits the reaction [Aldosterone results in increased expression of ACTA2 protein]

PMID:17596522 PMID:25204689

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

angiotensinogen

increases abundance
multiple interactions
increases secretion
increases expression

ISO
EXP

AGT protein modified form results in increased abundance of Aldosterone; AGT protein results in increased abundance of Aldosterone
AGT protein affects the reaction [SLC9A3 gene mutant form results in increased abundance of Aldosterone]
AGT protein results in increased secretion of Aldosterone
Aldosterone results in increased expression of AGT protein alternative form
AGT protein affects the reaction [DAB2 protein results in increased secretion of Aldosterone]; AGT protein alternative form promotes the reaction [Aldosterone results in increased expression of IL18 mRNA]
[AGT co-treated with REN] results in increased abundance of Aldosterone; [Valsartan co-treated with benidipine] inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; benidipine inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]; Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]; efonidipine inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; Enalapril inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]; KCNJ5 protein inhibits the reaction [AGT protein results in increased secretion of Aldosterone]; Losartan inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; Mibefradil inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; naringin inhibits the reaction [AGT protein results in increased secretion of Aldosterone]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Valsartan inhibits the reaction [AGT protein results in increased abundance of Aldosterone]

PMID:6257467 PMID:7588239 PMID:8952583 PMID:11549694 PMID:16788141 More...

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

angiotensin II receptor, type 1a

multiple interactions
increases expression

ISO
EXP

[Losartan results in decreased activity of AGTR1 protein] which results in decreased abundance of Aldosterone
Aldosterone results in increased expression of AGTR1A mRNA

PMID:9087624 PMID:9124547 PMID:15302841

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

angiotensin II receptor, type 2

increases expression

EXP

Aldosterone results in increased expression of AGTR2 mRNA

NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745

G

aldo-keto reductase family 1, member D1

multiple interactions

ISO

[AKR1D1 protein co-treated with NADP] results in increased reduction of Aldosterone

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

albumin

multiple interactions

ISO

ALB protein inhibits the reaction [Acetaminophen results in increased abundance of Aldosterone]

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases expression

ISO

acephate inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; alachlor inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Atrazine metabolite inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; bifenthrin inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; cypermethrin inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; DDT inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Dimethoate inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; fenvalerate inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; fipronil inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Methoxychlor inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; o,p'-DDT inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Permethrin inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; terbutylazine inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]; Zineb inhibits the reaction [Aldosterone results in increased expression of ALPL mRNA]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

aquaporin 2

multiple interactions

EXP

[Aldosterone co-treated with Lithium] affects the expression of AQP2 protein

NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319

G

caspase 3

multiple interactions

EXP

Aldosterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

cellular communication network factor 2

increases expression
multiple interactions

EXP
ISO

Aldosterone results in increased expression of CCN2 protein
Aldosterone results in increased expression of CCN2 mRNA
Spironolactone inhibits the reaction [Aldosterone results in increased expression of CCN2 protein]

PMID:17278980 PMID:30809271

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

Cd80 molecule

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CD80 mRNA; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of CD80 mRNA]

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

cadherin 1

decreases expression
multiple interactions

ISO

Aldosterone results in decreased expression of CDH1 mRNA; Aldosterone results in decreased expression of CDH1 protein
eplerenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 mRNA]; eplerenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 protein]; Rotenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 mRNA]; Rotenone inhibits the reaction [Aldosterone results in decreased expression of CDH1 protein]; U 0126 inhibits the reaction [Aldosterone results in decreased expression of CDH1 mRNA]; U 0126 inhibits the reaction [Aldosterone results in decreased expression of CDH1 protein]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

collagen type I alpha 1 chain

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL1A1 mRNA; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL1A1 mRNA]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

increases expression

ISO

Aldosterone results in increased expression of COL1A2 mRNA

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

collagen type III alpha 1 chain

increases expression
multiple interactions

ISO
EXP

Aldosterone results in increased expression of COL3A1 mRNA
[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL3A1 mRNA; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of COL3A1 mRNA]

PMID:27773435 PMID:30809271

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 1 chain

multiple interactions

EXP

[Eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; Eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

CREB binding protein

multiple interactions

EXP

Aldosterone promotes the reaction [NR3C2 protein binds to CREBBP protein]; Aldosterone results in increased expression of and results in increased localization of CREBBP protein

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

citrate synthase

multiple interactions

EXP

[[Aldosterone co-treated with Mifepristone] results in increased abundance of Mineralocorticoids] which results in increased activity of CS protein

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases chemical synthesis
affects chemical synthesis
multiple interactions

ISO
EXP

CYP11B2 protein polymorphism results in increased chemical synthesis of Aldosterone; CYP11B2 protein results in increased chemical synthesis of Aldosterone
CYP11B2 protein affects the chemical synthesis of Aldosterone
[CYP11B2 protein results in increased hydroxylation of Corticosterone] which results in increased chemical synthesis of Aldosterone

PMID:12525251 PMID:12783697 PMID:15731365 PMID:16043663 PMID:16054388 More...

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

DAB adaptor protein 2

multiple interactions

EXP

AGT protein affects the reaction [DAB2 protein results in increased secretion of Aldosterone]

NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888

G

dehydrogenase/reductase 3

multiple interactions

ISO

Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]

NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653

G

endothelin 1

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of EDN1 protein
[EDN1 protein binds to and results in increased activity of EDNRA protein] promotes the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

multiple interactions

EXP

[cyclo(Trp-Asp-Pro-Val-Leu) binds to and results in decreased activity of EDNRA protein] inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; [EDN1 protein binds to and results in increased activity of EDNRA protein] promotes the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

epidermal growth factor receptor

increases expression

EXP

Aldosterone results in increased expression of EGFR mRNA

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

coagulation factor II (thrombin) receptor

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of F2R mRNA

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579

G

Fas ligand

increases expression

EXP

Aldosterone results in increased expression of FASLG protein

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

growth arrest specific 6

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of GAS6 protein
NR3C2 protein promotes the reaction [Aldosterone results in increased expression of GAS6 protein]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of GAS6 protein]

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

GATA binding protein 4

increases expression

EXP

Aldosterone results in increased expression of GATA4 protein

NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of GCLC protein
Spironolactone inhibits the reaction [Aldosterone results in increased expression of GCLC protein]; tempol inhibits the reaction [Aldosterone results in increased expression of GCLC protein]

PMID:24512358 PMID:25204689

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutathione S-transferase pi 1

increases expression

EXP

Aldosterone results in increased expression of GSTP1 protein

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

heme oxygenase 1

increases expression

EXP

Aldosterone results in increased expression of HMOX1 protein

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein A2/B1

increases expression

EXP

Aldosterone results in increased expression of HNRNPA2B1 mRNA; Aldosterone results in increased expression of HNRNPA2B1 protein

NCBI chr 4:81,867,354...81,875,886
Ensembl chr 4:81,869,661...81,877,572

G

heparanase

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of HPSE mRNA; Aldosterone results in increased expression of HPSE protein
Spironolactone inhibits the reaction [Aldosterone results in increased expression of HPSE mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of HPSE protein]

NCBI chr14:9,200,971...9,241,377
Ensembl chr14:9,188,275...9,241,754

G

interleukin 18

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of IL18 mRNA; Aldosterone results in increased expression of IL18 protein
[cyclo(Trp-Asp-Pro-Val-Leu) binds to and results in decreased activity of EDNRA protein] inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; [EDN1 protein binds to and results in increased activity of EDNRA protein] promotes the reaction [Aldosterone results in increased expression of IL18 mRNA]; AGT protein alternative form promotes the reaction [Aldosterone results in increased expression of IL18 mRNA]; Bezafibrate inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Eplerenone inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; exoenzyme C3, Clostridium botulinum inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; fasudil inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; olmesartan inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Pioglitazone inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; prolinedithiocarbamate inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; SN50 peptide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 6

increases expression

ISO

Aldosterone results in increased expression of IL6 protein

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

Janus kinase 2

increases phosphorylation
multiple interactions

EXP

Aldosterone results in increased phosphorylation of JAK2 protein
Dactinomycin inhibits the reaction [Aldosterone results in increased phosphorylation of JAK2 protein]; Spironolactone inhibits the reaction [Aldosterone results in increased phosphorylation of JAK2 protein]

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

potassium inwardly-rectifying channel, subfamily J, member 5

multiple interactions
decreases secretion

ISO

KCNJ5 protein inhibits the reaction [AGT protein results in increased secretion of Aldosterone]
KCNJ5 protein results in decreased secretion of Aldosterone

NCBI chr 8:38,981,598...39,011,197
Ensembl chr 8:38,983,034...39,011,101

G

mitogen activated protein kinase 1

multiple interactions

ISO

Acetylcysteine inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Aldosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein; eplerenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Rotenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK1 protein]

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

affects chemical synthesis

ISO

MAPK14 protein affects the chemical synthesis of Aldosterone

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions

ISO

Acetylcysteine inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Aldosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein; eplerenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rotenone inhibits the reaction [Aldosterone results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

metallothionein 1A

multiple interactions
increases expression

EXP

[Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in increased expression of MT1A protein; Amlodipine inhibits the reaction [Aldosterone results in increased expression of MT1A mRNA]; Spironolactone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in increased expression of MT1A protein]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of MT1A mRNA]

PMID:17616752 PMID:19333130

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

metal-regulatory transcription factor 1

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of MTF1 mRNA; Aldosterone results in increased expression of MTF1 protein
Amlodipine inhibits the reaction [Aldosterone results in increased expression of MTF1 mRNA]; Amlodipine inhibits the reaction [Aldosterone results in increased expression of MTF1 protein]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of MTF1 mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of MTF1 protein]

NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions

ISO

Aldosterone inhibits the reaction [NEDD4L gene mutant form results in decreased cleavage of SCNN1A protein]

NCBI chr18:60,663,918...60,996,824
Ensembl chr18:60,663,970...60,996,824

G

NFE2 like bZIP transcription factor 2

increases activity
multiple interactions

EXP

Aldosterone results in increased activity of NFE2L2 protein
Spironolactone inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]; tempol inhibits the reaction [Aldosterone results in increased activity of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nucleolar protein 3

decreases phosphorylation

EXP

Aldosterone results in decreased phosphorylation of NOL3 protein

NCBI chr19:50,066,493...50,068,175
Ensembl chr19:50,063,986...50,068,722

G

natriuretic peptide A

multiple interactions
decreases secretion
increases expression

EXP
ISO

Aldosterone promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of NPPA mRNA]
NPPA protein results in decreased secretion of Aldosterone

PMID:2434734 PMID:2931268 PMID:19966502

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

natriuretic peptide B

decreases abundance
affects abundance

ISO

NPPB protein results in decreased abundance of Aldosterone
NPPB affects the abundance of Aldosterone

PMID:16333235 PMID:20339970

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects binding
increases activity
decreases expression

ISO
EXP

Aldosterone binds to and results in increased activity of NR3C1 protein
NR3C1 protein binds to Aldosterone
Aldosterone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]
Aldosterone results in increased activity of NR3C1 protein
Aldosterone results in decreased expression of NR3C1 mRNA
Aldosterone binds to NR3C1 protein mutant form

PMID:1597467 PMID:8969928 PMID:11861974 PMID:15362971 PMID:15774500 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions
increases activity
increases phosphorylation
decreases expression
affects localization
increases expression
affects binding

ISO
EXP

acephate inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; acephate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; alachlor inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; alachlor inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Aldosterone binds to and results in increased activity of NR3C2 protein; Aldosterone inhibits the reaction [TSG101 protein binds to NR3C2 protein]; Aldosterone results in decreased expression of and affects the ubiquitination of NR3C2 protein; Atrazine metabolite inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Atrazine metabolite inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; bifenthrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; bifenthrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; bisphenol A inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; bisphenol AF inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; bisphenol B inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; cypermethrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; cypermethrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; DDT inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; DDT inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Dihydrotestosterone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Dimethoate inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Dimethoate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; fenvalerate inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; fipronil inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Methoxychlor inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Methoxychlor inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Metribolone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; o,p'-DDT inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; o,p'-DDT inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Permethrin inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Permethrin inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Pesticides inhibits the reaction [Aldosterone results in increased expression of NR3C2 mRNA]; Soil Pollutants inhibits the reaction [Aldosterone results in increased expression of NR3C2 mRNA]; Spironolactone inhibits the reaction [Aldosterone affects the ubiquitination of NR3C2 protein]; Spironolactone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; terbutylazine inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; terbutylazine inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Testosterone inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]; Zineb inhibits the reaction [Aldosterone affects the localization of NR3C2 protein]; Zineb inhibits the reaction [Aldosterone results in increased activity of NR3C2 protein]
Aldosterone results in increased phosphorylation of NR3C2 protein
Aldosterone results in decreased expression of NR3C2 protein
Aldosterone inhibits the reaction [TSG101 protein binds to NR3C2 protein]; FR 180204 inhibits the reaction [Aldosterone results in increased phosphorylation of NR3C2 protein]
Aldosterone results in increased expression of NR3C2 mRNA; Aldosterone results in increased expression of NR3C2 protein
Aldosterone binds to NR3C2 protein
Aldosterone results in decreased expression of NR3C2 mRNA
Aldosterone promotes the reaction [NR3C2 protein binds to CREBBP protein]; Aldosterone results in increased expression of and results in increased localization of NR3C2 protein; NR3C2 protein promotes the reaction [Aldosterone results in increased expression of GAS6 protein]; torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein]

PMID:7954537 PMID:8798622 PMID:8969928 PMID:15362971 PMID:15780662 More...

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

oxidized low density lipoprotein receptor 1

multiple interactions
increases expression

ISO

Spironolactone inhibits the reaction [Aldosterone results in increased expression of OLR1 mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of OLR1 protein]
Aldosterone results in increased expression of OLR1 mRNA; Aldosterone results in increased expression of OLR1 protein

NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598

G

plasminogen activator, tissue type

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of PLAT mRNA

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased activity of PLG protein modified form

NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320

G

proopiomelanocortin

multiple interactions
increases secretion
increases abundance
decreases abundance

ISO
EXP

Dexamethasone inhibits the reaction [POMC protein results in increased abundance of Aldosterone]
POMC results in increased secretion of Aldosterone
POMC protein results in decreased abundance of Aldosterone

PMID:1659878 PMID:2551692 PMID:3015796

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

peroxisome proliferator-activated receptor gamma

affects abundance

ISO

PPARG protein affects the abundance of Aldosterone

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

increases expression

EXP

Aldosterone results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

RELA proto-oncogene, NF-kB subunit

increases activity
multiple interactions

EXP

Aldosterone results in increased activity of RELA protein
Bezafibrate inhibits the reaction [Aldosterone results in increased activity of RELA protein]; pioglitazone inhibits the reaction [Aldosterone results in increased activity of RELA protein]; prolinedithiocarbamate inhibits the reaction [Aldosterone results in increased activity of RELA protein]; SN50 peptide inhibits the reaction [Aldosterone results in increased activity of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

multiple interactions

ISO

[AGT co-treated with REN] results in increased abundance of Aldosterone; candesartan inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]; Enalapril inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone]

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

sodium channel epithelial 1 subunit alpha

increases expression
multiple interactions
affects expression

ISO

Aldosterone results in increased expression of SCNN1A mRNA; Aldosterone results in increased expression of SCNN1A protein
Aldosterone inhibits the reaction [NEDD4L gene mutant form results in decreased cleavage of SCNN1A protein]
Aldosterone affects the expression of SCNN1A mRNA

PMID:16555725 PMID:18665318 PMID:23348737

NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405

G

sodium channel epithelial 1 subunit beta

increases expression

ISO

Aldosterone results in increased expression of SCNN1B mRNA; Aldosterone results in increased expression of SCNN1B protein

NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049

G

sodium channel epithelial 1 subunit gamma

increases expression

ISO

Aldosterone results in increased expression of SCNN1G mRNA; Aldosterone results in increased expression of SCNN1G protein

NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097

G

serpin family E member 1

multiple interactions
increases expression

EXP
ISO

[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA; [Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein; [Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of SERPINE1 mRNA; [Eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; [Eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]
Aldosterone results in increased expression of SERPINE1 mRNA

PMID:18682491 PMID:27773435 PMID:30809271

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

serum/glucocorticoid regulated kinase 1

multiple interactions
decreases expression
increases expression

EXP
ISO

Spironolactone inhibits the reaction [Aldosterone results in increased expression of SGK1 mRNA]
Aldosterone results in decreased expression of SGK1 protein
TSG101 mutant form inhibits the reaction [Aldosterone results in decreased expression of SGK1 protein]

PMID:15130897 PMID:19429930 PMID:22798426

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

solute carrier family 12 member 2

multiple interactions

EXP

Spironolactone inhibits the reaction [Aldosterone results in increased activity of SLC12A2 protein]

NCBI chr18:53,546,263...53,614,478
Ensembl chr18:53,546,333...53,614,470

G

solute carrier family 30 member 1

multiple interactions
increases expression

EXP

Spironolactone inhibits the reaction [Aldosterone results in increased expression of SLC30A1 mRNA]

NCBI chr13:106,022,019...106,025,892
Ensembl chr13:106,022,019...106,025,892

G

solute carrier family 39 member 1

multiple interactions
increases expression

EXP

Spironolactone inhibits the reaction [Aldosterone results in increased expression of SLC39A1 mRNA]

NCBI chr 2:178,001,052...178,006,689
Ensembl chr 2:178,001,119...178,006,689

G

solute carrier family 9 member A1

increases expression
multiple interactions

EXP

Aldosterone results in increased expression of SLC9A1 mRNA
eplerenone inhibits the reaction [Aldosterone results in increased expression of SLC9A1 mRNA]

NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517

G

solute carrier family 9 member A3

multiple interactions
increases abundance

ISO

AGT protein affects the reaction [SLC9A3 gene mutant form results in increased abundance of Aldosterone]

NCBI chr 1:30,953,215...30,996,209
Ensembl chr 1:30,953,216...30,996,002

G

snail family transcriptional repressor 1

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [Aldosterone results in increased expression of SNAI1 mRNA]; eplerenone inhibits the reaction [Aldosterone results in increased expression of SNAI1 mRNA]; Rotenone inhibits the reaction [Aldosterone results in increased expression of SNAI1 mRNA]; U 0126 inhibits the reaction [Aldosterone results in increased expression of SNAI1 mRNA]

NCBI chr 3:176,667,476...176,671,965

G

superoxide dismutase 1

multiple interactions
increases activity

EXP

[Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in decreased activity of SOD1 protein; [Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in increased activity of SOD1 protein; Amlodipine inhibits the reaction [Aldosterone results in increased activity of SOD1 protein]; Spironolactone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in decreased activity of SOD1 protein]; Spironolactone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride co-treated with Potassium Chloride] results in increased activity of SOD1 protein]; Spironolactone inhibits the reaction [Aldosterone results in increased activity of SOD1 protein]

PMID:17616752 PMID:19333130

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

tyrosine aminotransferase

multiple interactions

EXP

Aldosterone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

transforming growth factor, beta 1

increases secretion
multiple interactions
increases expression

EXP

Aldosterone results in increased secretion of TGFB1 protein
[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein; [Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TGFB1 mRNA; [Eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; [Eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TGFB1 mRNA]; Eplerenone inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; Spironolactone inhibits the reaction [Aldosterone results in increased expression of TGFB1 mRNA]; Spironolactone inhibits the reaction [Aldosterone results in increased secretion of TGFB1 protein]; tempol inhibits the reaction [Aldosterone results in increased expression of TGFB1 mRNA]

PMID:15130897 PMID:18682491 PMID:25204689 PMID:27773435

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions

EXP

[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNF mRNA; Eplerenone inhibits the reaction [[Aldosterone co-treated with Sodium Chloride, Dietary] results in increased expression of TNF mRNA]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

transient receptor potential cation channel, subfamily M, member 4

increases expression

ISO

Aldosterone results in increased expression of TRPM4 protein

NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653

G

tumor susceptibility 101

multiple interactions

ISO

Aldosterone inhibits the reaction [TSG101 protein binds to NR3C2 protein]; TSG101 mutant form inhibits the reaction [Aldosterone results in decreased expression of SGK1 protein]

NCBI chr 1:106,549,035...106,578,859
Ensembl chr 1:106,535,021...106,578,775

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions
increases glucuronidation

ISO

alclofenac inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Anti-Inflammatory Agents, Non-Steroidal inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; cicloprofen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Diclofenac inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Diflunisal inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Fenoprofen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Ibuprofen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Indomethacin inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Ketoprofen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Ketorolac inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Meclofenamic Acid inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Mefenamic Acid inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; Naproxen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; pirprofen inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]; tiaprofenic acid inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Aldosterone]

NCBI chr14:21,251,535...21,274,451
Ensembl chr14:21,251,535...21,274,451

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
increases secretion

ISO

Beclomethasone inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; Beclomethasone inhibits the reaction [ABCB1 protein results in increased export of fluorexon]; Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Beclomethasone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Beclomethasone]
Beclomethasone results in increased expression of ABCB1 mRNA; Beclomethasone results in increased expression of ABCB1 protein

PMID:15370884 PMID:16442095 PMID:22464980

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

increases expression

ISO

Beclomethasone results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily C member 1

increases expression

ISO

Beclomethasone results in increased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily G member 2

multiple interactions
increases activity

ISO

Beclomethasone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Beclomethasone inhibits the reaction [ABCG2 protein results in increased export of Mitoxantrone]
Beclomethasone results in increased activity of ABCG2 protein

PMID:15365089 PMID:16442095

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

acid phosphatase 5, tartrate resistant

decreases activity

ISO

Beclomethasone results in decreased activity of ACP5 protein

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

adrenoceptor beta 2

increases expression

ISO

Beclomethasone results in increased expression of ADRB2 mRNA

PMID:9032216 PMID:15679717

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

bradykinin receptor B1

decreases expression

ISO

Beclomethasone results in decreased expression of BDKRB1 mRNA

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

bone gamma-carboxyglutamate protein

decreases expression

ISO

Beclomethasone results in decreased expression of BGLAP protein

PMID:7746775 PMID:9232087 PMID:9544892

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

caspase 9

increases activity

ISO

Beclomethasone results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

catalase

increases expression

ISO

Beclomethasone results in increased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 11

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 2

decreases expression

ISO

Beclomethasone results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Beclomethasone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Beclomethasone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

multiple interactions
decreases expression

ISO

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CCL5 protein; [Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CCL5 protein; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]
Beclomethasone results in decreased expression of CCL5 mRNA; Beclomethasone results in decreased expression of CCL5 protein

PMID:8534483 PMID:10903220 PMID:14643170 PMID:15679717

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

CD44 molecule

multiple interactions

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]; Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

colony stimulating factor 2

multiple interactions
decreases secretion
increases activity

ISO

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CSF2 protein; [Beclomethasone co-treated with Formoterol Fumarate] results in decreased secretion of CSF2 protein; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CSF2 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of CSF2 protein]; Beclomethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
Beclomethasone results in decreased secretion of CSF2 protein
Beclomethasone results in increased activity of CSF2 protein

PMID:7545059 PMID:10460758 PMID:10868704 PMID:11167953 PMID:11730731 More...

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

C-X-C motif chemokine ligand 10

decreases secretion

ISO

Beclomethasone results in decreased secretion of CXCL10 protein

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression

ISO

Beclomethasone results in decreased expression of CYP2S1 mRNA

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
increases expression

ISO

1-aminobenzotriazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Ketoconazole inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Mifepristone inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Paraoxon inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]; Physostigmine inhibits the reaction [Beclomethasone results in increased expression of CYP3A5 mRNA]

PMID:12538830 PMID:23512537 PMID:24555085

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

eosinophil peroxidase

multiple interactions

EXP

Beclomethasone inhibits the reaction [sephadex results in increased expression of EPX protein]

NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180

G

Fc epsilon receptor Ig

decreases expression

EXP

Beclomethasone results in decreased expression of FCER1G protein

NCBI chr13:86,181,908...86,186,766
Ensembl chr13:86,181,908...86,186,859

G

fibroblast growth factor 2

multiple interactions
decreases activity

ISO

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; [Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Formoterol Fumarate promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibronectin 1

multiple interactions

ISO

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; [Beclomethasone co-treated with Formoterol Fumarate] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

Fos proto-oncogene, AP-1 transcription factor subunit

decreases expression

ISO

Beclomethasone results in decreased expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

gamma-glutamyltransferase 5

increases activity
increases expression
multiple interactions

ISO

Beclomethasone results in increased activity of GGT5 protein
Beclomethasone results in increased expression of GGT5 mRNA
[Beclomethasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4

NCBI chr20:13,042,694...13,070,960
Ensembl chr20:13,042,696...13,070,892

G

hydroxysteroid 11-beta dehydrogenase 2

increases metabolic processing

ISO

HSD11B2 protein results in increased metabolism of Beclomethasone

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

intercellular adhesion molecule 1

multiple interactions

ISO

Beclomethasone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interleukin 10

decreases secretion

ISO

Beclomethasone results in decreased secretion of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 13

multiple interactions
increases activity

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 protein]
Beclomethasone results in increased activity of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 1 beta

multiple interactions
decreases secretion
decreases expression

ISO

Beclomethasone inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]; Beclomethasone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]
Beclomethasone results in decreased secretion of IL1B protein
Beclomethasone results in decreased expression of IL1B protein

PMID:7545059 PMID:9176529 PMID:9371735 PMID:10460758 PMID:15337628

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor antagonist

decreases expression

ISO

Beclomethasone results in decreased expression of IL1RN protein

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Beclomethasone results in decreased expression of IL2RA protein

PMID:8111605 PMID:9314351

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 3

multiple interactions

ISO

Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL3 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of IL3 protein]

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810

G

interleukin 4

multiple interactions
decreases expression

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]; Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]
Beclomethasone results in decreased expression of IL4 protein

PMID:7988651 PMID:18076728

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

multiple interactions
decreases expression

ISO

Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL5 mRNA]; Beclomethasone inhibits the reaction [Antigens, Dermatophagoides results in increased secretion of IL5 protein]
Beclomethasone results in decreased expression of IL5 protein

PMID:7988651 PMID:10813552 PMID:11167953

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Beclomethasone inhibits the reaction [IL13 protein results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

kallikrein 1-related peptidase C10

increases expression

ISO

Beclomethasone results in increased expression of KLK3 mRNA

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

lactotransferrin

multiple interactions
decreases secretion

ISO

Beclomethasone inhibits the reaction [methylcholine results in increased secretion of LTF protein]
Beclomethasone results in decreased secretion of LTF protein

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

MEFV innate immunity regulator, pyrin

increases response to substance

ISO

MEFV mutant form results in increased susceptibility to Beclomethasone

NCBI chr10:12,288,514...12,303,337
Ensembl chr10:12,293,782...12,303,333

G

matrix metallopeptidase 2

multiple interactions

ISO

Beclomethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

multiple interactions
decreases expression

ISO

Beclomethasone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]
Beclomethasone results in decreased expression of MMP9 protein

PMID:10452757 PMID:10455257

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

nitric oxide synthase 2

decreases expression

ISO

Beclomethasone results in decreased expression of NOS2 protein

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Beclomethasone results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 3, group C, member 1

affects localization
increases expression
affects binding
multiple interactions
increases activity

ISO
EXP

Beclomethasone affects the localization of NR3C1 protein
Beclomethasone results in increased expression of NR3C1 mRNA
Beclomethasone binds to NR3C1 protein
[Beclomethasone co-treated with Albuterol] affects the localization of NR3C1 protein; [Beclomethasone co-treated with Formoterol Fumarate] affects the localization of NR3C1 protein; Beclomethasone affects the localization of and results in increased activity of NR3C1 protein; Beclomethasone binds to and results in increased activity of NR3C1 protein
Beclomethasone results in increased activity of NR3C1 protein

PMID:16814 PMID:2207292 PMID:15362971 PMID:15679717 PMID:15860753 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Beclomethasone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

phospholipase A1 member A

multiple interactions

ISO

Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA1A mRNA]

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

phospholipase A2 group 4A

decreases activity
multiple interactions

ISO

Beclomethasone results in decreased activity of PLA2G4A protein
Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G4A mRNA]

PMID:15337628 PMID:20573295

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

multiple interactions

EXP

Beclomethasone inhibits the reaction [Acetylcholine results in increased phosphorylation of PPP1R14A protein]

NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:93,708,218...93,719,147

G

ras homolog family member A

multiple interactions

EXP

Beclomethasone inhibits the reaction [[[Antigens, Bacterial co-treated with Allergens] results in increased expression of and results in increased activity of RHOA protein] which results in increased susceptibility to Acetylcholine]; Beclomethasone inhibits the reaction [[Antigens, Bacterial co-treated with Allergens] results in increased expression of and results in increased activity of RHOA protein]; Beclomethasone inhibits the reaction [[Antigens, Bacterial co-treated with Allergens] results in increased expression of RHOA mRNA]

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302

G

ribonuclease A family member 2

decreases expression

ISO

Beclomethasone results in decreased expression of RNASE2 protein

NCBI chr15:26,923,125...26,923,934
Ensembl chr15:26,923,134...26,923,955

G

ribonuclease A family member 3

multiple interactions
decreases expression

ISO

[Salmeterol Xinafoate co-treated with Beclomethasone] affects the reaction [Allergens results in increased expression of RNASE3 protein]; Beclomethasone affects the reaction [Allergens results in increased expression of RNASE3 protein]
Beclomethasone results in decreased expression of RNASE3 protein

PMID:1443864 PMID:10513351 PMID:10573242 PMID:12166584 PMID:12587966 More...

NCBI chr15:26,985,399...26,986,269
Ensembl chr15:26,985,271...26,986,400

G

selectin E

multiple interactions

ISO

Beclomethasone inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903

G

solute carrier family 22 member 2

multiple interactions

ISO

Beclomethasone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

Thy-1 cell surface antigen

multiple interactions

ISO

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]; Formoterol Fumarate promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]

NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540

G

TIMP metallopeptidase inhibitor 1

increases expression

ISO

Beclomethasone results in increased expression of TIMP1 protein

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tumor necrosis factor

multiple interactions
decreases secretion

ISO

Beclomethasone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Beclomethasone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]; Beclomethasone inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]
Beclomethasone results in decreased secretion of TNF protein

PMID:8937731 PMID:9150321 PMID:9819297 PMID:10100995 PMID:10903220 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

vascular cell adhesion molecule 1

multiple interactions

ISO

Beclomethasone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

decreases expression

ISO

Beclomethasone results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aquaporin 4

increases expression

EXP

Betamethasone results in increased expression of AQP4 mRNA

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

androgen receptor

multiple interactions

ISO

Betamethasone binds to and results in increased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

C-C motif chemokine ligand 2

decreases expression

ISO

Betamethasone results in decreased expression of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Betamethasone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Betamethasone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

early growth response 1

affects expression

ISO

Betamethasone affects the expression of EGR1 mRNA

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

follicle stimulating hormone subunit beta

decreases expression

EXP

Betamethasone results in decreased expression of FSHB protein

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

frataxin

increases expression

ISO

Betamethasone results in increased expression of FXN mRNA

NCBI chr 1:231,300,457...231,323,989
Ensembl chr 1:231,300,150...231,323,989

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

ISO

Betamethasone results in increased expression of and results in increased activity of HPGD protein

NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions
increases metabolic processing

EXP
ISO

Betamethasone inhibits the reaction [HSD11B2 protein affects the metabolism of Corticosterone]
HSD11B2 protein results in increased metabolism of Betamethasone

PMID:16549198 PMID:19490994

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

hydroxysteroid (17-beta) dehydrogenase 4

increases expression

ISO

Betamethasone results in increased expression of HSD17B4 mRNA

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

luteinizing hormone subunit beta

increases expression

EXP

Betamethasone results in increased expression of LHB protein

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases activity
affects binding

ISO

NR3C1 protein alternative form inhibits the reaction [Betamethasone results in increased activity of NR3C1 protein alternative form]
Betamethasone binds to NR3C1 protein

PMID:15362971 PMID:15755863 PMID:16507850 PMID:21543282

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Betamethasone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

vascular endothelial growth factor A

decreases expression

ISO

Betamethasone results in decreased expression of VEGFA protein

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

betamethasone valerate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CD40 molecule

decreases expression

ISO

Betamethasone Valerate results in decreased expression of CD40 protein

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

CD83 molecule

decreases expression

ISO

Betamethasone Valerate results in decreased expression of CD83 protein

NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047

G

CD86 molecule

decreases expression

ISO

Betamethasone Valerate results in decreased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

colony stimulating factor 2

decreases expression

ISO

Betamethasone Valerate results in decreased expression of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

interferon gamma

decreases expression

ISO

Betamethasone Valerate results in decreased expression of IFNG protein

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interleukin 2

decreases expression

ISO

Betamethasone Valerate results in decreased expression of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 3

decreases expression

ISO

Betamethasone Valerate results in decreased expression of IL3 protein

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810

G

interleukin 4

decreases expression

ISO

Betamethasone Valerate results in decreased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

decreases expression

ISO

Betamethasone Valerate results in decreased expression of IL5 protein

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

BCAR1 scaffold protein, Cas family member

decreases phosphorylation

ISO

blebbistatin results in decreased phosphorylation of BCAR1 protein

NCBI chr19:56,588,500...56,623,190
Ensembl chr19:56,588,500...56,623,190

G

cadherin 1

affects localization
decreases activity

ISO

blebbistatin affects the localization of CDH1 protein
blebbistatin results in decreased activity of CDH1 protein

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases expression

ISO

[blebbistatin results in decreased activity of MYH9 protein] promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
blebbistatin results in increased expression of CYP1A1 mRNA

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

integrin subunit beta 1

decreases activity

ISO

blebbistatin results in decreased activity of ITGB1 protein

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

myosin heavy chain 2

decreases activity

ISO

blebbistatin results in decreased activity of MYH2 protein

NCBI chr10:52,355,739...52,382,235
Ensembl chr10:52,355,739...52,382,235

G

myosin, heavy chain 9

decreases activity
multiple interactions

ISO

blebbistatin results in decreased activity of MYH9 protein
[blebbistatin results in decreased activity of MYH9 protein] promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

protein tyrosine kinase 2

decreases phosphorylation

ISO

blebbistatin results in decreased phosphorylation of PTK2 protein

NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catenin beta 1

decreases expression
multiple interactions

ISO

bruceine D results in decreased expression of CTNNB1 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of CTNNB1 protein]]; bruceine D affects the reaction [Oxygen deficiency affects the expression of CTNNB1 protein]; bruceine D inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

catenin, beta-interacting protein 1

decreases expression
multiple interactions
affects binding

ISO

bruceine D results in decreased expression of CTNNBIP1 protein
bruceine D inhibits the reaction [CTNNB1 protein binds to CTNNBIP1 protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of HK2 protein]]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of LDHA protein]]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of PKM protein]]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC16A3 protein]]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A1 protein]]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A3 protein]]; CTNNBIP1 protein affects the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]
bruceine D binds to CTNNBIP1 protein

NCBI chr 5:165,245,019...165,293,994
Ensembl chr 5:165,245,098...165,293,991

G

cytochrome c, somatic

multiple interactions
decreases expression

ISO

bruceine D affects the reaction [Oxygen deficiency affects the expression of CYCS protein]
bruceine D results in decreased expression of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

hypoxia inducible factor 1 subunit alpha

multiple interactions
decreases expression

ISO

bruceine D inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; CTNNBIP1 protein affects the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]
bruceine D results in decreased expression of HIF1A protein

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

hexokinase 2

multiple interactions

ISO

bruceine D affects the reaction [Oxygen deficiency affects the expression of HK2 protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of HK2 protein]]

NCBI chr 4:116,792,258...116,841,275
Ensembl chr 4:116,792,258...116,841,275

G

lactate dehydrogenase A

decreases expression
multiple interactions

ISO

bruceine D results in decreased expression of LDHA protein
bruceine D affects the reaction [Oxygen deficiency affects the expression of LDHA protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of LDHA protein]]

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

pyruvate kinase M1/2

multiple interactions

ISO

bruceine D affects the reaction [Oxygen deficiency affects the expression of PKM protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of PKM protein]]

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

solute carrier family 16 member 3

multiple interactions

ISO

bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC16A3 protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC16A3 protein]]

NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,714,466...106,720,903

G

solute carrier family 2 member 1

decreases expression
multiple interactions

ISO

bruceine D results in decreased expression of SLC2A1 protein
bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A1 protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A1 protein]]

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 3

decreases expression
multiple interactions

ISO

bruceine D results in decreased expression of SLC2A3 protein
bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A3 protein]; CTNNBIP1 protein affects the reaction [bruceine D affects the reaction [Oxygen deficiency affects the expression of SLC2A3 protein]]

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

ISO

Budesonide inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Budesonide results in decreased activity of ABCB11 protein

NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581

G

ATP binding cassette subfamily B member 1A

increases expression

ISO

Budesonide results in increased expression of ABCB1 protein

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

adrenoceptor beta 2

increases expression

ISO

Budesonide results in increased expression of ADRB2 protein

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

androgen receptor

multiple interactions

ISO

Budesonide binds to and results in decreased activity of AR protein; Budesonide inhibits the reaction [Metribolone results in increased activity of AR protein]

PMID:18324785 PMID:25752796

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

BCL2, apoptosis regulator

decreases expression

ISO

Budesonide results in decreased expression of BCL2 protein

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

bone gamma-carboxyglutamate protein

decreases expression

ISO

Budesonide results in decreased expression of BGLAP protein

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

Budesonide results in decreased expression of BIRC5 mRNA

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

caspase 3

decreases expression

ISO

Budesonide results in decreased expression of CASP3 mRNA

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 9

increases activity

ISO

Budesonide results in increased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

C-C motif chemokine ligand 11

multiple interactions

ISO

Budesonide inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 17

decreases expression

ISO

Budesonide results in decreased expression of CCL17 protein

NCBI chr19:10,208,120...10,218,340
Ensembl chr19:10,208,120...10,209,895

G

C-C motif chemokine ligand 2

decreases expression
multiple interactions

ISO
EXP

Budesonide results in decreased expression of CCL2 protein
Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL2 mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL2 protein]

PMID:15734790 PMID:20116850

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Budesonide results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Budesonide results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

multiple interactions

ISO

Budesonide inhibits the reaction [TNF protein results in increased secretion of CCL5 mRNA]; Budesonide inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]

PMID:10903220 PMID:14643170

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cyclin B2

decreases expression

ISO

Budesonide results in decreased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin E1

decreases expression

ISO

Budesonide results in decreased expression of CCNE1 mRNA

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO

Budesonide inhibits the reaction [vinyl carbamate results in decreased expression of CDKN1A protein]
Budesonide results in increased expression of CDKN1A mRNA

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

ISO

Budesonide inhibits the reaction [vinyl carbamate results in decreased expression of CDKN1B protein]

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

CREB binding protein

increases expression

ISO

Budesonide results in increased expression of CREBBP protein

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

colony stimulating factor 2

multiple interactions
increases activity
decreases secretion

ISO

Budesonide inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]
Budesonide results in increased activity of CSF2 protein
Budesonide results in decreased secretion of CSF2 protein

PMID:7621058 PMID:10460758 PMID:10868704 PMID:11730731

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 2 alpha 1

increases expression

ISO

Budesonide results in increased expression of CSNK2A1 mRNA

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

C-X-C motif chemokine ligand 1

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL1 mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL1 protein]

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 2

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL2 mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL2 protein]

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL3 mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CXCL3 protein]

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
increases expression
multiple interactions

EXP
ISO

Budesonide results in decreased expression of CYP3A2 mRNA
Budesonide results in increased expression of CYP3A4 mRNA
[Budesonide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

PMID:19562681 PMID:20888898 PMID:25455453

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression
multiple interactions

EXP
ISO

Budesonide results in increased expression of CYP3A9 mRNA
Ketoconazole inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA]; Mifepristone inhibits the reaction [Budesonide results in increased expression of CYP3A5 mRNA]

PMID:12538830 PMID:19562681 PMID:20888898 PMID:24555085

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

eosinophil peroxidase

multiple interactions

EXP

Budesonide inhibits the reaction [sephadex results in increased expression of EPX protein]

NCBI chr10:73,164,096...73,175,180
Ensembl chr10:73,164,096...73,175,180

G

glucagon

decreases expression
multiple interactions

EXP

Budesonide results in decreased expression of GCG mRNA
[Fatty Acids co-treated with Budesonide] results in increased expression of GCG mRNA

PMID:12524409 PMID:14705828

NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533

G

interferon gamma

decreases secretion
multiple interactions

ISO
EXP

Budesonide results in decreased secretion of IFNG protein
Budesonide inhibits the reaction [Tobacco Smoke Pollution results in decreased secretion of IFNG protein]
[zafirlukast co-treated with Prednisone co-treated with Budesonide] inhibits the reaction [Antigens results in increased secretion of IFNG protein]

PMID:7621058 PMID:15569474 PMID:16160912

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 2

multiple interactions

ISO

Budesonide inhibits the reaction [vinyl carbamate results in decreased methylation of IGF2 protein]

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

interleukin 13

multiple interactions
increases activity

ISO

Budesonide inhibits the reaction [IL13 protein results in increased expression of CCL11 protein]; Budesonide inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Budesonide inhibits the reaction [IL13 protein results in increased expression of IL6 protein]
Budesonide results in increased activity of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 17A

multiple interactions

ISO

Budesonide inhibits the reaction [Ozone results in increased expression of IL17A protein]; Progesterone promotes the reaction [Budesonide inhibits the reaction [Ozone results in increased expression of IL17A protein]]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 1 beta

decreases secretion
multiple interactions

ISO
EXP

Budesonide results in decreased secretion of IL1B protein
Budesonide inhibits the reaction [IL1B protein results in increased acetylation of H4C16 protein]; Budesonide inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]; Budesonide inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Budesonide inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Hydrogen Peroxide inhibits the reaction [Budesonide inhibits the reaction [IL1B protein results in increased acetylation of H4C16 protein]]; Theophylline inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Budesonide inhibits the reaction [IL1B protein results in increased acetylation of H4C16 protein]]]
Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B protein]
Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Salmeterol Xinafoate]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Terbutaline]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in increased expression of PTGS2 mRNA]; Budesonide inhibits the reaction [Ozone results in increased expression of IL1B protein]

PMID:7621058 PMID:9371735 PMID:10460758 PMID:15337628 PMID:15734790 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 4

decreases expression
multiple interactions

ISO
EXP

Budesonide results in decreased expression of IL4 protein
Budesonide inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of IL4 protein]

PMID:7988651 PMID:12406821 PMID:15086961 PMID:15569474

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 4 receptor

decreases expression

ISO

Budesonide results in decreased expression of IL4R protein

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 5

decreases expression

ISO

Budesonide results in decreased expression of IL5 protein

PMID:7988651 PMID:12406821 PMID:15086961

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions

EXP
ISO

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]
Budesonide inhibits the reaction [Ozone results in increased expression of IL6 protein]; Progesterone promotes the reaction [Budesonide inhibits the reaction [Ozone results in increased expression of IL6 protein]]
Budesonide inhibits the reaction [IL13 protein results in increased expression of IL6 mRNA]; Budesonide inhibits the reaction [IL13 protein results in increased expression of IL6 protein]

PMID:15734790 PMID:17988555 PMID:28279894

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

EXP

Budesonide inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]; Budesonide inhibits the reaction [Glucose results in increased secretion of INS1 protein]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

EXP

Budesonide results in decreased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

lactotransferrin

multiple interactions
decreases secretion

ISO

Budesonide inhibits the reaction [methylcholine results in increased secretion of LTF protein]
Budesonide results in decreased secretion of LTF protein

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

mitogen activated protein kinase 14

multiple interactions

ISO

Budesonide inhibits the reaction [Ozone results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

matrix metallopeptidase 12

multiple interactions

EXP

Budesonide inhibits the reaction [Tobacco Smoke Pollution results in increased secretion of MMP12 protein]

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478

G

matrix metallopeptidase 9

multiple interactions

EXP

Budesonide inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MMP9 mRNA]; Budesonide promotes the reaction [Formoterol Fumarate inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]; Formoterol Fumarate promotes the reaction [Budesonide inhibits the reaction [Cadmium Chloride results in increased activity of MMP9 protein]]

PMID:15734790 PMID:25313925

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

myeloperoxidase

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MPO protein]

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

metallothionein 2

increases expression
multiple interactions

ISO

Budesonide results in increased expression of MT2A mRNA
Terbutaline affects the reaction [Budesonide results in increased expression of MT2A mRNA]

NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO

Budesonide inhibits the reaction [Benzo(a)pyrene results in increased expression of MYC mRNA]

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

nitric oxide synthase 2

decreases expression
multiple interactions

ISO
EXP

Budesonide results in decreased expression of NOS2 mRNA
Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]

PMID:15734790 PMID:17163412

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nuclear receptor subfamily 1, group I, member 2

increases expression
multiple interactions
increases activity

EXP
ISO

Budesonide results in increased expression of NR1I2 mRNA
[Budesonide results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

PMID:19562681 PMID:25455453

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects binding
increases activity
decreases expression

ISO
EXP

2,2',3,5',6-pentachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,3',4,4',5-pentachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,4,2',4'-tetrachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,4,4'-trichlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,4,5,2',4',5'-hexachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,4,5,2',5'-pentachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; 2,5,2',5'-tetrachlorobiphenyl inhibits the reaction [Budesonide results in increased activity of NR3C1 protein]; Budesonide affects the reaction [Terbutaline results in increased expression of NR3C1 mRNA]
[Budesonide binds to NR3C1 protein] which results in increased expression of SLC51A mRNA; [Budesonide binds to NR3C1 protein] which results in increased expression of SLC51B mRNA
Budesonide results in decreased expression of NR3C1 mRNA

PMID:8977508 PMID:9973176 PMID:10335001 PMID:15362971 PMID:16507850 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Budesonide results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

proliferating cell nuclear antigen

decreases expression

ISO

Budesonide results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

progesterone receptor

multiple interactions

ISO

Budesonide binds to and results in increased activity of PGR protein

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

phospholipase A2 group 4A

decreases activity

ISO

Budesonide results in decreased activity of PLA2G4A protein

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Budesonide co-treated with Glucose] binds to PPARA protein; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

protein phosphatase, Mg2+/Mn2+ dependent, 1L

increases expression

ISO

Budesonide results in increased expression of PPM1L protein

NCBI chr 2:155,876,605...156,149,371
Ensembl chr 2:155,876,605...156,149,371

G

patched 2

decreases expression

ISO

Budesonide results in decreased expression of PTCH2 mRNA

NCBI chr 5:135,808,856...135,829,087
Ensembl chr 5:135,808,895...135,828,986

G

prostaglandin E synthase 2

multiple interactions

EXP

Budesonide promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGES2 protein]

NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:36,088,246...36,097,694

G

prostaglandin-endoperoxide synthase 1

multiple interactions

EXP

Budesonide promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS1 mRNA]

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO
EXP

Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in increased expression of PTGS2 mRNA]
Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]

PMID:15734790 PMID:20061444

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

ribonuclease A family member 3

decreases expression

ISO

Budesonide results in decreased expression of RNASE3 protein

NCBI chr15:26,985,399...26,986,269
Ensembl chr15:26,985,271...26,986,400

G

selectin E

multiple interactions

EXP
ISO

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE mRNA]
Budesonide inhibits the reaction [IL1B protein results in increased expression of SELE mRNA]

PMID:9371735 PMID:15734790

NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903

G

selectin L

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELL mRNA]

NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600

G

selectin P

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELP mRNA]

NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987

G

solute carrier family 22 member 2

multiple interactions

ISO

Budesonide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 22 member 3

multiple interactions

ISO

Budesonide inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]; SLC22A3 protein results in increased susceptibility to [Budesonide results in decreased transport of Formoterol Fumarate]

PMID:17920670 PMID:21914487

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353

G

solute carrier family 51 member A

increases expression
multiple interactions

ISO
EXP

Budesonide results in increased expression of SLC51A mRNA
[Budesonide binds to NR3C1 protein] which results in increased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

SLC51 subunit beta

increases expression
multiple interactions

ISO
EXP

Budesonide results in increased expression of SLC51B mRNA
[Budesonide binds to NR3C1 protein] which results in increased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ISO

Budesonide inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Budesonide inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 4:176,282,577...176,355,557
Ensembl chr 4:176,282,584...176,351,083

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

ISO

Budesonide inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Budesonide inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]

NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:163,371,410...163,419,279

G

secreted phosphoprotein 1

increases expression

ISO

Budesonide results in increased expression of SPP1 protein

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

steroidogenic acute regulatory protein

multiple interactions

ISO

Budesonide promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR mRNA]]; Budesonide promotes the reaction [LG 100268 promotes the reaction [T0901317 results in increased expression of STAR protein]]; Budesonide promotes the reaction [T0901317 promotes the reaction [LG 100268 results in increased expression of STAR protein]]

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

transforming growth factor, beta 1

multiple interactions

ISO

Budesonide inhibits the reaction [Ozone results in increased expression of TGFB1 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta receptor 2

increases expression

ISO

Budesonide results in increased expression of TGFBR2 protein

NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469

G

transglutaminase 2

increases expression

ISO

Budesonide results in increased expression of TGM2 protein

NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240

G

TIMP metallopeptidase inhibitor 1

multiple interactions

EXP

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TIMP1 mRNA]

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

tumor necrosis factor

decreases expression
multiple interactions
decreases secretion

ISO
EXP

Budesonide results in decreased expression of TNF protein
Budesonide inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Budesonide inhibits the reaction [TNF protein results in increased secretion of CCL5 mRNA]; Budesonide inhibits the reaction [TNF protein results in increased secretion of CCL5 protein]; Budesonide inhibits the reaction [TNF protein results in increased secretion of CXCL8 mRNA]; Budesonide inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]
Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF protein]
Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Formoterol Fumarate]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Salmeterol Xinafoate]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in decreased susceptibility to Terbutaline]; Budesonide inhibits the reaction [[TNF protein co-treated with IL1B protein] results in increased expression of PTGS2 mRNA]; Budesonide inhibits the reaction [Ozone results in increased expression of TNF protein]
Budesonide results in decreased secretion of TNF protein

PMID:7621058 PMID:10100995 PMID:10903220 PMID:14643170 PMID:15589479 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

decreases expression

ISO

Budesonide results in decreased expression of TP53 protein

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

ubiquitin C

decreases expression

ISO

Budesonide results in decreased expression of UBC mRNA

NCBI chr12:36,899,673...36,905,275
Ensembl chr12:36,900,127...36,905,275

G

vascular cell adhesion molecule 1

multiple interactions

EXP
ISO

Budesonide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of VCAM1 mRNA]
Budesonide inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

PMID:10100995 PMID:15734790

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

decreases expression
multiple interactions

ISO

Budesonide results in decreased expression of VEGFA protein
Budesonide inhibits the reaction [Benzo(a)pyrene results in increased expression of VEGFA mRNA]; Budesonide inhibits the reaction [Benzo(a)pyrene results in increased expression of VEGFA protein]

PMID:15969944 PMID:20116850

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

chaetoglobosin A

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

EXP

chaetoglobosins results in increased phosphorylation of AKT1 protein
wortmannin inhibits the reaction [chaetoglobosins results in increased phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

gap junction protein, alpha 1

multiple interactions

EXP

chaetoglobosins inhibits the reaction [Dieldrin results in decreased phosphorylation of GJA1 protein]; chaetoglobosins inhibits the reaction [Hexachlorocyclohexane results in decreased phosphorylation of GJA1 protein]

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

EXP

chaetoglobosins results in increased phosphorylation of GSK3B protein
wortmannin inhibits the reaction [chaetoglobosins results in increased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

interferon beta 1

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]

NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487

G

interleukin 1 beta

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interferon regulatory factor 7

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of IRF7 mRNA]

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

EXP
ISO

chaetoglobosins results in increased phosphorylation of MAPK1 protein
chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

PMID:18040759 PMID:33285210

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

EXP
ISO

chaetoglobosins results in increased phosphorylation of MAPK3 protein
chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]

PMID:18040759 PMID:33285210

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MYD88, innate immune signal transduction adaptor

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of MYD88 mRNA]

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

nitric oxide synthase 2

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases phosphorylation

EXP

chaetoglobosins results in decreased phosphorylation of RAF1 protein

NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

toll-like receptor 4

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

tumor necrosis factor

multiple interactions

ISO

chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; chaetoglobosins inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; chaetoglobosins results in increased expression of and results in increased secretion of TNF protein

PMID:28535995 PMID:33285210

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

chlortetracycline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

catalase

decreases activity

ISO

Chlortetracycline results in decreased activity of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

glutathione S-transferase pi 1

multiple interactions

ISO

Chlortetracycline inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate]

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetoacetyl-CoA synthetase

increases expression

ISO

Clobetasol results in increased expression of AACS mRNA

NCBI chr12:36,774,471...36,817,835
Ensembl chr12:36,774,471...36,822,543

G

ATP binding cassette subfamily A member 1

increases expression

ISO

Clobetasol results in increased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily A member 2

decreases expression

ISO

Clobetasol results in decreased expression of ABCA2 mRNA

NCBI chr 3:28,642,660...28,662,689
Ensembl chr 3:28,642,758...28,662,681

G

ATP binding cassette subfamily B member 6

increases expression

ISO

Clobetasol results in increased expression of ABCB6 mRNA

NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 1

decreases expression

ISO

Clobetasol results in decreased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily F member 1

decreases expression

ISO

Clobetasol results in decreased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

acetyl-CoA acyltransferase 1A

increases expression

ISO

Clobetasol results in increased expression of ACAA1A mRNA

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-CoA acyltransferase 2

increases expression

ISO

Clobetasol results in increased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

increases expression

ISO

Clobetasol results in increased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acyl-CoA thioesterase 11

increases expression

ISO

Clobetasol results in increased expression of ACOT11 mRNA

NCBI chr 5:126,756,255...126,804,526
Ensembl chr 5:126,756,255...126,804,507

G

acyl-CoA synthetase bubblegum family member 1

increases expression

ISO

Clobetasol results in increased expression of ACSBG1 mRNA

NCBI chr 8:63,887,433...63,943,486
Ensembl chr 8:63,887,435...63,984,178

G

acyl-CoA synthetase short-chain family member 2

increases expression

ISO

Clobetasol results in increased expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin alpha 2, smooth muscle

increases expression

ISO

Clobetasol results in increased expression of ACTA2 mRNA

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, beta

increases expression

ISO

Clobetasol results in increased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, gamma 1

increases expression

ISO

Clobetasol results in increased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

actin related protein 1B

increases expression

ISO

Clobetasol results in increased expression of ACTR1B mRNA

NCBI chr 9:46,424,677...46,434,341
Ensembl chr 9:46,424,678...46,434,341

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

ISO

Clobetasol results in increased expression of ADAMTS1 mRNA

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

ADP-ribosylarginine hydrolase

increases expression

ISO

Clobetasol results in increased expression of ADPRH mRNA

NCBI chr11:75,805,347...75,811,686
Ensembl chr11:75,805,310...75,812,452

G

1-acylglycerol-3-phosphate O-acyltransferase 1

increases expression

ISO

Clobetasol results in increased expression of AGPAT1 mRNA

NCBI chr20:4,140,565...4,149,531
Ensembl chr20:4,140,565...4,150,445

G

adenosylhomocysteinase-like 1

increases expression

ISO

Clobetasol results in increased expression of AHCYL1 mRNA

NCBI chr 2:197,982,335...198,016,770
Ensembl chr 2:197,982,344...198,033,930

G

AHNAK nucleoprotein

decreases expression

ISO

Clobetasol results in decreased expression of AHNAK mRNA

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675

G

adenylate kinase 3

increases expression

ISO

Clobetasol results in increased expression of AK3 mRNA

NCBI chr 1:236,151,012...236,178,689
Ensembl chr 1:236,151,012...236,178,183

G

adenylate kinase 5

decreases expression

ISO

Clobetasol results in decreased expression of AK5 mRNA

NCBI chr 2:244,057,240...244,241,372
Ensembl chr 2:244,057,240...244,241,366

G

A-kinase anchoring protein 13

decreases expression

ISO

Clobetasol results in decreased expression of AKAP13 mRNA

NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:138,724,150...139,029,401

G

aldo-keto reductase family 1 member B1

increases expression

ISO

Clobetasol results in increased expression of AKR1B1 mRNA

NCBI chr 4:63,899,222...63,913,315
Ensembl chr 4:63,899,222...63,913,315

G

activated leukocyte cell adhesion molecule

decreases expression

ISO

Clobetasol results in decreased expression of ALCAM mRNA

NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876

G

aldehyde dehydrogenase 1 family, member A1

increases expression

ISO

Clobetasol results in increased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member L2

decreases expression

ISO

Clobetasol results in decreased expression of ALDH1L2 mRNA

NCBI chr 7:22,141,872...22,193,403
Ensembl chr 7:22,141,842...22,193,398

G

ALMS1, centrosome and basal body associated protein

decreases expression

ISO

Clobetasol results in decreased expression of ALMS1 mRNA

NCBI chr 4:119,683,085...119,783,471
Ensembl chr 4:119,683,076...119,783,471

G

autocrine motility factor receptor

increases expression

ISO

Clobetasol results in increased expression of AMFR mRNA

NCBI chr19:11,002,451...11,038,182
Ensembl chr19:11,002,101...11,038,364

G

ankyrin repeat and KH domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ANKHD1 mRNA

NCBI chr18:28,436,296...28,534,954
Ensembl chr18:28,436,394...28,534,954

G

ankyrin repeat domain containing 11

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD11 mRNA

NCBI chr19:67,848,836...68,007,491
Ensembl chr19:67,848,844...68,007,491

G

ankyrin repeat domain 12

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD12 mRNA

NCBI chr 9:113,030,127...113,134,816
Ensembl chr 9:113,030,919...113,134,762

G

ankyrin repeat domain 46

increases expression

ISO

Clobetasol results in increased expression of ANKRD46 mRNA

NCBI chr 7:69,532,303...69,553,311
Ensembl chr 7:69,532,304...69,545,421

G

ankyrin repeat domain 52

decreases expression

ISO

Clobetasol results in decreased expression of ANKRD52 mRNA

NCBI chr 7:1,390,730...1,410,139
Ensembl chr 7:1,391,325...1,407,410

G

aldehyde oxidase 1

increases expression

ISO

Clobetasol results in increased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

adaptor related protein complex 1 subunit mu 1

increases expression

ISO

Clobetasol results in increased expression of AP1M1 mRNA

NCBI chr16:17,620,910...17,636,431
Ensembl chr16:17,616,187...17,636,462

G

adaptor related protein complex 3 subunit delta 1

decreases expression

ISO

Clobetasol results in decreased expression of AP3D1 mRNA

NCBI chr 7:9,620,909...9,656,350
Ensembl chr 7:9,620,968...9,656,342

G

APC regulator of WNT signaling pathway

decreases expression

ISO

Clobetasol results in decreased expression of APC mRNA

NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022

G

APC regulator of WNT signaling pathway 2

decreases expression

ISO

Clobetasol results in decreased expression of APC2 mRNA

NCBI chr 7:10,043,010...10,065,037
Ensembl chr 7:10,043,010...10,065,210

G

APC down-regulated 1

decreases expression

ISO

Clobetasol results in decreased expression of APCDD1 mRNA

NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356

G

apelin

decreases expression

ISO

Clobetasol results in decreased expression of APLN mRNA

NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246

G

ARF GTPase 3

increases expression

ISO

Clobetasol results in increased expression of ARF3 mRNA

NCBI chr 7:131,765,039...131,792,075
Ensembl chr 7:131,750,672...131,770,123

G

ARF GTPase 4

increases expression

ISO

Clobetasol results in increased expression of ARF4 mRNA

NCBI chr16:1,903,238...1,920,012
Ensembl chr16:1,903,371...1,920,011

G

ARF GTPase 5

increases expression

ISO

Clobetasol results in increased expression of ARF5 mRNA

NCBI chr 4:58,003,919...58,006,898
Ensembl chr 4:58,003,932...58,006,835

G

ARF guanine nucleotide exchange factor 1

decreases expression

ISO

Clobetasol results in decreased expression of ARFGEF1 mRNA

NCBI chr 5:13,764,507...13,859,237
Ensembl chr 5:13,764,975...13,859,237

G

ARF guanine nucleotide exchange factor 2

decreases expression

ISO

Clobetasol results in decreased expression of ARFGEF2 mRNA

NCBI chr 3:175,966,575...176,052,715
Ensembl chr 3:175,966,579...176,052,713

G

Rho GTPase activating protein 23

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP23 mRNA

NCBI chr10:82,891,021...82,993,230
Ensembl chr10:82,890,853...82,993,228

G

Rho GTPase activating protein 31

affects expression

ISO

Clobetasol affects the expression of ARHGAP31 mRNA

NCBI chr11:75,544,176...75,657,087
Ensembl chr11:75,544,040...75,661,076

G

Rho GTPase activating protein 35

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP35 mRNA

NCBI chr 1:86,330,566...86,447,414
Ensembl chr 1:86,330,566...86,447,414

G

Rho GTPase activating protein 5

decreases expression

ISO

Clobetasol results in decreased expression of ARHGAP5 mRNA

NCBI chr 6:75,711,199...75,774,636
Ensembl chr 6:75,711,515...75,774,636

G

Rho guanine nucleotide exchange factor 26

decreases expression

ISO

Clobetasol results in decreased expression of ARHGEF26 mRNA

NCBI chr 2:148,889,405...149,000,538
Ensembl chr 2:148,889,423...149,000,538

G

Rho guanine nucleotide exchange factor 4

decreases expression

ISO

Clobetasol results in decreased expression of ARHGEF4 mRNA

NCBI chr 9:44,357,716...44,500,959
Ensembl chr 9:44,357,736...44,501,550

G

AT-rich interaction domain 1B

decreases expression

ISO

Clobetasol results in decreased expression of ARID1B mRNA

NCBI chr 1:47,973,199...48,328,793
Ensembl chr 1:47,973,997...48,328,793

G

AT-rich interaction domain 2

decreases expression

ISO

Clobetasol results in decreased expression of ARID2 mRNA

NCBI chr 7:129,326,371...129,443,813
Ensembl chr 7:129,324,137...129,443,187

G

ARF like GTPase 1

increases expression

ISO

Clobetasol results in increased expression of ARL1 mRNA

NCBI chr 7:25,007,401...25,018,572
Ensembl chr 7:25,006,981...25,019,319

G

ARF like GTPase 2

increases expression

ISO

Clobetasol results in increased expression of ARL2 mRNA

NCBI chr 1:212,863,422...212,875,425
Ensembl chr 1:212,863,423...212,875,373

G

ARF like GTPase 2 binding protein

decreases expression

ISO

Clobetasol results in decreased expression of ARL2BP mRNA

NCBI chr19:10,342,895...10,352,529
Ensembl chr19:10,342,895...10,352,514

G

ARF like GTPase 4A

decreases expression

ISO

Clobetasol results in decreased expression of ARL4A mRNA

NCBI chr 6:62,809,287...62,811,297
Ensembl chr 6:62,804,548...62,820,760

G

ARL6 interacting reticulophagy regulator 1

increases expression

ISO

Clobetasol results in increased expression of ARL6IP1 mRNA

NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232

G

armadillo repeat containing, X-linked 4

decreases expression

ISO

Clobetasol results in decreased expression of ARMCX4 mRNA

NCBI chr X:102,153,743...102,164,173
Ensembl chr X:102,153,800...102,164,633

G

ASH1 like histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of ASH1L mRNA

NCBI chr 2:176,644,393...176,780,848
Ensembl chr 2:176,644,924...176,780,847

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

ISO

Clobetasol results in increased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

aspartate beta-hydroxylase domain containing 2

increases expression

ISO

Clobetasol results in increased expression of ASPHD2 mRNA

NCBI chr12:49,908,539...49,919,060
Ensembl chr12:49,908,241...49,925,254

G

ASXL transcriptional regulator 3

decreases expression

ISO

Clobetasol results in decreased expression of ASXL3 mRNA

NCBI chr18:13,868,223...14,040,867
Ensembl chr18:13,868,674...14,037,373

G

autophagy related 13

increases expression

ISO

Clobetasol results in increased expression of ATG13 mRNA

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

autophagy related 4B, cysteine peptidase

increases expression

ISO

Clobetasol results in increased expression of ATG4B mRNA

NCBI chr 9:101,729,772...101,761,456
Ensembl chr 9:101,726,782...101,761,622

G

antioxidant 1 copper chaperone

increases expression

ISO

Clobetasol results in increased expression of ATOX1 mRNA

NCBI chr10:40,065,525...40,080,627
Ensembl chr10:40,065,527...40,080,585

G

ATPase phospholipid transporting 10B

decreases expression

ISO

Clobetasol results in decreased expression of ATP10B mRNA

NCBI chr10:27,996,729...28,252,801
Ensembl chr10:27,910,295...28,251,450

G

ATPase Na+/K+ transporting subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of ATP1A1 mRNA

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase Na+/K+ transporting subunit beta 2

increases expression

ISO

Clobetasol results in increased expression of ATP1B2 mRNA

NCBI chr10:54,817,473...54,823,708
Ensembl chr10:54,817,476...54,823,708

G

ATP synthase F1 subunit alpha

increases expression

ISO

Clobetasol results in increased expression of ATP5F1A mRNA

NCBI chr18:73,567,537...73,575,473
Ensembl chr18:73,567,526...73,575,922

G

ATP synthase F1 subunit beta

increases expression

ISO

Clobetasol results in increased expression of ATP5F1B mRNA

NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462

G

ATP synthase membrane subunit c locus 2

increases expression

ISO

Clobetasol results in increased expression of ATP5MC2 mRNA

NCBI chr 7:135,669,847...135,680,839
Ensembl chr 7:135,669,848...135,678,231

G

ATP synthase membrane subunit f

increases expression

ISO

Clobetasol results in increased expression of ATP5MF mRNA

NCBI chr12:14,535,435...14,542,007
Ensembl chr12:14,522,832...14,542,709

G

ATP synthase membrane subunit j

increases expression

ISO

Clobetasol results in increased expression of ATP5MJ mRNA

NCBI chr 6:136,839,890...136,845,640
Ensembl chr 1:177,906,475...177,907,045
Ensembl chr 1:177,906,475...177,907,045

G

ATP synthase peripheral stalk subunit d

increases expression

ISO

Clobetasol results in increased expression of ATP5PD mRNA

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATP synthase peripheral stalk subunit OSCP

increases expression

ISO

Clobetasol results in increased expression of ATP5PO mRNA

NCBI chr11:44,651,171...44,657,483
Ensembl chr11:44,651,173...44,657,520

G

ATPase H+ transporting V0 subunit B

increases expression

ISO

Clobetasol results in increased expression of ATP6V0B mRNA

NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:136,708,823...136,716,828

G

ATPase H+ transporting V0 subunit C

increases expression

ISO

Clobetasol results in increased expression of ATP6V0C mRNA

NCBI chr10:13,700,764...13,707,147
Ensembl chr10:13,700,764...13,706,245

G

ATPase, H+ transporting V0 subunit e2

increases expression

ISO

Clobetasol results in increased expression of ATP6V0E2 mRNA

NCBI chr 4:78,815,771...78,818,919
Ensembl chr 4:78,813,129...78,819,680

G

ATRX, chromatin remodeler

decreases expression

ISO

Clobetasol results in decreased expression of ATRX mRNA

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

ataxin 2

decreases expression

ISO

Clobetasol results in decreased expression of ATXN2 mRNA

NCBI chr12:40,413,657...40,509,895
Ensembl chr12:40,414,904...40,510,473

G

ataxin 7-like 3B

increases expression

ISO

Clobetasol results in increased expression of ATXN7L3B mRNA

NCBI chr 7:50,208,666...50,212,190
Ensembl chr 7:50,208,676...50,212,190

G

aurora kinase B

increases expression

ISO

Clobetasol results in increased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

beta-1,3-glucuronyltransferase 1

decreases expression

ISO

Clobetasol results in decreased expression of B3GAT1 mRNA

NCBI chr 8:33,362,791...33,390,446
Ensembl chr 8:33,363,048...33,390,443

G

beta-1,3-glucuronyltransferase 2

decreases expression

ISO

Clobetasol results in decreased expression of B3GAT2 mRNA

NCBI chr 9:33,663,482...33,746,466
Ensembl chr 9:33,663,482...33,746,466

G

BTB domain and CNC homolog 2

decreases expression

ISO

Clobetasol results in decreased expression of BACH2 mRNA

NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234

G

brain abundant, membrane attached signal protein 1

decreases expression

ISO

Clobetasol results in decreased expression of BASP1 mRNA

NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178

G

BCL2 associated X, apoptosis regulator

increases expression

ISO

Clobetasol results in increased expression of BAX mRNA

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

branched chain ketoacid dehydrogenase kinase

increases expression

ISO

Clobetasol results in increased expression of BCKDK mRNA

NCBI chr 1:191,945,809...191,950,480
Ensembl chr 1:191,946,471...191,953,453

G

BCL6, transcription repressor

increases expression

ISO

Clobetasol results in increased expression of BCL6 mRNA

NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047

G

BAF chromatin remodeling complex subunit BCL7A

decreases expression

ISO

Clobetasol results in decreased expression of BCL7A mRNA

NCBI chr12:38,872,851...38,904,770
Ensembl chr12:38,872,851...38,904,770

G

BCL9, transcription coactivator

decreases expression

ISO

Clobetasol results in decreased expression of BCL9 mRNA

NCBI chr 2:187,449,425...187,475,241
Ensembl chr 2:187,449,425...187,475,241

G

BCL6 co-repressor-like 1

decreases expression

ISO

Clobetasol results in decreased expression of BCORL1 mRNA

NCBI chr X:132,394,703...132,462,414
Ensembl chr X:132,397,069...132,461,976

G

BCR activator of RhoGEF and GTPase

decreases expression

ISO

Clobetasol results in decreased expression of BCR mRNA

NCBI chr20:13,468,732...13,596,333
Ensembl chr20:13,468,732...13,596,333

G

BDP1 general transcription factor IIIB subunit

decreases expression

ISO

Clobetasol results in decreased expression of BDP1 mRNA

NCBI chr 2:33,112,518...33,204,270
Ensembl chr 2:33,112,518...33,204,241

G

basic helix-loop-helix family, member e40

increases expression

ISO

Clobetasol results in increased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

baculoviral IAP repeat-containing 6

decreases expression

ISO

Clobetasol results in decreased expression of BIRC6 mRNA

NCBI chr 6:26,474,843...26,668,275
Ensembl chr 6:26,474,843...26,668,507

G

bridge-like lipid transfer protein family member 3A

decreases expression

ISO

Clobetasol results in decreased expression of BLTP3A mRNA

NCBI chr20:5,912,033...5,956,404
Ensembl chr20:5,912,106...5,956,403

G

bone morphogenetic protein 7

increases expression

ISO

Clobetasol results in increased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

bone morphogenetic protein receptor type 2

decreases expression

ISO

Clobetasol results in decreased expression of BMPR2 mRNA

NCBI chr 9:68,685,942...68,801,353
Ensembl chr 9:68,685,988...68,801,350

G

BCL2 family apoptosis regulator BOK

increases expression

ISO

Clobetasol results in increased expression of BOK mRNA

NCBI chr 9:101,670,729...101,681,834
Ensembl chr 9:101,670,625...101,681,833

G

BOP1 ribosomal biogenesis factor

increases expression

ISO

Clobetasol results in increased expression of BOP1 mRNA

NCBI chr 7:110,052,716...110,076,529
Ensembl chr 7:110,052,720...110,076,529

G

bora, aurora kinase A activator

decreases expression

ISO

Clobetasol results in decreased expression of BORA mRNA

NCBI chr15:82,205,467...82,243,499
Ensembl chr15:82,205,697...82,244,052

G

bromodomain containing 7

decreases expression

ISO

Clobetasol results in decreased expression of BRD7 mRNA

NCBI chr19:34,882,238...34,910,944
Ensembl chr19:34,882,304...34,910,944

G

BRICK1 subunit of SCAR/WAVE actin nucleating complex

increases expression

ISO

Clobetasol results in increased expression of BRK1 mRNA

NCBI chr 4:148,306,436...148,321,668
Ensembl chr 4:148,306,398...148,321,984

G

bromodomain and WD repeat domain containing 1

increases expression

ISO

Clobetasol results in increased expression of BRWD1 mRNA

NCBI chr11:48,756,174...48,853,692
Ensembl chr11:48,756,811...48,848,256

G

bassoon (presynaptic cytomatrix protein)

decreases expression

ISO

Clobetasol results in decreased expression of BSN mRNA

NCBI chr 8:117,663,447...117,754,412
Ensembl chr 8:117,670,334...117,754,412

G

BTB domain containing 2

increases expression

ISO

Clobetasol results in increased expression of BTBD2 mRNA

NCBI chr 7:9,710,392...9,726,032
Ensembl chr 7:9,712,269...9,726,032

G

BUB3 mitotic checkpoint protein

increases expression

ISO

Clobetasol results in increased expression of BUB3 mRNA

NCBI chr 1:195,760,532...195,771,140
Ensembl chr 1:195,758,105...195,791,028

G

complement C2

increases expression

ISO

Clobetasol results in increased expression of C2 mRNA

NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740

G

carbonic anhydrase 8

decreases expression

ISO

Clobetasol results in decreased expression of CAR8 mRNA

NCBI chr 5:26,102,767...26,199,819
Ensembl chr 5:26,102,813...26,199,796

G

calcineurin binding protein 1

decreases expression

ISO

Clobetasol results in decreased expression of CABIN1 mRNA

NCBI chr20:12,892,750...13,014,801
Ensembl chr20:12,892,771...13,014,800

G

calreticulin

increases expression

ISO

Clobetasol results in increased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

cullin-associated and neddylation-dissociated 2 (putative)

decreases expression

ISO

Clobetasol results in decreased expression of CAND2 mRNA

NCBI chr 4:150,507,659...150,535,755
Ensembl chr 4:150,507,657...150,541,293

G

calpain 10

increases expression

ISO

Clobetasol results in increased expression of CAPN10 mRNA

NCBI chr 9:100,943,665...100,957,910
Ensembl chr 9:100,945,551...100,957,912

G

calpain 6

decreases expression

ISO

Clobetasol results in decreased expression of CAPN6 mRNA

NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178

G

capping actin protein of muscle Z-line subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of CAPZA1 mRNA

NCBI chr 2:195,008,035...195,053,100
Ensembl chr 2:195,008,039...195,053,100

G

cask-interacting protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CASKIN2 mRNA

NCBI chr10:101,526,131...101,540,362
Ensembl chr10:101,526,195...101,540,349

G

caspase 3

increases activity

ISO

Clobetasol results in increased activity of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

increases expression

ISO

Clobetasol results in increased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

carbonyl reductase 3

increases expression

ISO

Clobetasol results in increased expression of CBR3 mRNA

NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558

G

coiled-coil and C2 domain containing 1A

decreases expression

ISO

Clobetasol results in decreased expression of CC2D1A mRNA

NCBI chr19:40,916,587...40,931,702
Ensembl chr19:40,916,532...40,931,701

G

coiled-coil and C2 domain containing 2A

decreases expression

ISO

Clobetasol results in decreased expression of CC2D2A mRNA

NCBI chr14:71,563,835...71,648,352
Ensembl chr14:71,563,835...71,648,331

G

coiled coil domain containing 88A

decreases expression

ISO

Clobetasol results in decreased expression of CCDC88A mRNA

NCBI chr14:107,304,654...107,456,104
Ensembl chr14:107,305,199...107,453,285

G

coiled-coil domain containing 88C

decreases expression

ISO

Clobetasol results in decreased expression of CCDC88C mRNA

NCBI chr 6:125,899,337...126,019,162
Ensembl chr 6:125,899,526...126,018,865

G

cellular communication network factor 2

increases expression

ISO

Clobetasol results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

copper chaperone for superoxide dismutase

increases expression

ISO

Clobetasol results in increased expression of CCS mRNA

NCBI chr 1:211,543,192...211,564,354
Ensembl chr 1:211,542,701...211,564,260

G

chaperonin containing TCP1 subunit 2

increases expression

ISO

Clobetasol results in increased expression of CCT2 mRNA

NCBI chr 7:54,578,654...54,591,428
Ensembl chr 7:54,578,663...54,592,977

G

chaperonin containing TCP1 subunit 3

increases expression

ISO

Clobetasol results in increased expression of CCT3 mRNA

NCBI chr 2:176,063,529...176,088,180
Ensembl chr 2:176,063,526...176,089,925

G

chaperonin containing TCP1 subunit 7

increases expression

ISO

Clobetasol results in increased expression of CCT7 mRNA

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973

G

CD109 molecule

increases expression

ISO

Clobetasol results in increased expression of CD109 mRNA

NCBI chr 8:88,334,736...88,449,463
Ensembl chr 8:88,334,736...88,449,462

G

CD40 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD40 protein

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

Cd80 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD80 protein

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

Cd81 molecule

increases expression

ISO

Clobetasol results in increased expression of CD81 mRNA

NCBI chr 1:207,665,274...207,681,094
Ensembl chr 1:207,664,885...207,681,092

G

CD86 molecule

decreases expression

ISO

Clobetasol results in decreased expression of CD86 protein

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

CDC42 binding protein kinase beta

decreases expression

ISO

Clobetasol results in decreased expression of CDC42BPB mRNA

NCBI chr 6:136,154,905...136,241,259
Ensembl chr 6:136,154,905...136,237,570

G

CDC42 effector protein 1

increases expression

ISO

Clobetasol results in increased expression of CDC42EP1 mRNA

NCBI chr 7:112,275,759...112,283,665
Ensembl chr 7:112,275,792...112,283,664

G

cell division cycle associated 7

increases expression

ISO

Clobetasol results in increased expression of CDCA7 mRNA

NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947

G

cadherin 13

increases expression

ISO

Clobetasol results in increased expression of CDH13 mRNA

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 4

decreases expression

ISO

Clobetasol results in decreased expression of CDH4 mRNA

NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020

G

cyclin-dependent kinase 5

increases expression

ISO

Clobetasol results in increased expression of CDK5 mRNA

NCBI chr 4:11,647,098...11,651,606
Ensembl chr 4:11,647,141...11,652,777

G

cyclin-dependent kinase-like 5

increases expression

ISO

Clobetasol results in increased expression of CDKL5 mRNA

NCBI chr X:37,566,320...37,796,766
Ensembl chr X:37,566,378...37,796,760

G

CDKN2A interacting protein N-terminal like

increases expression

ISO

Clobetasol results in increased expression of CDKN2AIPNL mRNA

NCBI chr10:36,731,983...36,741,500
Ensembl chr10:36,732,013...36,741,495

G

cerebellar degeneration-related protein 2

increases expression

ISO

Clobetasol results in increased expression of CDR2 mRNA

NCBI chr 1:184,934,128...184,959,036
Ensembl chr 1:184,934,129...184,968,863

G

CECR2, histone acetyl-lysine reader

decreases expression

ISO

Clobetasol results in decreased expression of CECR2 mRNA

NCBI chr 4:155,562,576...155,670,253
Ensembl chr 4:155,562,727...155,666,741

G

cadherin, EGF LAG seven-pass G-type receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of CELSR1 mRNA

NCBI chr 7:118,867,450...119,004,859
Ensembl chr 7:118,867,450...119,004,856

G

centromere protein E

decreases expression

ISO

Clobetasol results in decreased expression of CENPE mRNA

NCBI chr 2:226,310,970...226,369,636
Ensembl chr 2:226,300,798...226,369,636

G

centromere protein F

decreases expression

ISO

Clobetasol results in decreased expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

centrosomal protein 131

decreases expression

ISO

Clobetasol results in decreased expression of CEP131 mRNA

NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797

G

centrosomal protein 350

decreases expression

ISO

Clobetasol results in decreased expression of CEP350 mRNA

NCBI chr13:70,573,597...70,714,673
Ensembl chr13:70,573,597...70,714,673

G

cofilin 1

increases expression

ISO

Clobetasol results in increased expression of CFL1 mRNA

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353

G

CF transmembrane conductance regulator

increases expression

ISO

Clobetasol results in increased expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

coiled-coil-helix-coiled-coil-helix domain containing 2

increases expression

ISO

Clobetasol results in increased expression of CHCHD2 mRNA

NCBI chr12:32,464,847...32,470,871
Ensembl chr12:32,464,824...32,470,871

G

chromodomain helicase DNA binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CHD2 mRNA

NCBI chr 1:136,597,993...136,726,874
Ensembl chr 1:136,599,900...136,710,335

G

chromodomain helicase DNA binding protein 3

decreases expression

ISO

Clobetasol results in decreased expression of CHD3 mRNA

NCBI chr10:54,562,437...54,588,842
Ensembl chr10:54,562,437...54,588,810

G

chromodomain helicase DNA binding protein 7

decreases expression

ISO

Clobetasol results in decreased expression of CHD7 mRNA

NCBI chr 5:26,609,245...26,792,736
Ensembl chr 5:26,609,407...26,792,734

G

chromodomain helicase DNA binding protein 8

decreases expression

ISO

Clobetasol results in decreased expression of CHD8 mRNA

NCBI chr15:27,379,285...27,438,959
Ensembl chr15:27,379,285...27,417,851

G

charged multivesicular body protein 7

increases expression

ISO

Clobetasol results in increased expression of CHMP7 mRNA

NCBI chr15:51,200,759...51,215,992
Ensembl chr15:51,201,298...51,215,992

G

carbohydrate sulfotransferase 2

increases expression

ISO

Clobetasol results in increased expression of CHST2 mRNA

NCBI chr 8:104,839,716...104,845,961
Ensembl chr 8:104,831,292...104,860,301

G

carbohydrate sulfotransferase 3

decreases expression

ISO

Clobetasol results in decreased expression of CHST3 mRNA

NCBI chr20:28,657,308...28,694,976
Ensembl chr20:28,657,308...28,694,526

G

cytosolic iron-sulfur assembly component 2B

increases expression

ISO

Clobetasol results in increased expression of CIAO2B mRNA

NCBI chr19:350,644...352,518
Ensembl chr19:350,653...352,518

G

cytokine induced apoptosis inhibitor 1

increases expression

ISO

Clobetasol results in increased expression of CIAPIN1 mRNA

NCBI chr19:10,185,955...10,199,120
Ensembl chr19:10,182,088...10,201,495

G

CDGSH iron sulfur domain 1

increases expression

ISO

Clobetasol results in increased expression of CISD1 mRNA

NCBI chr20:17,254,462...17,267,843
Ensembl chr20:17,254,187...17,271,042

G

creatine kinase B

increases expression

ISO

Clobetasol results in increased expression of CKB mRNA

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

CDC28 protein kinase regulatory subunit 1B

increases expression

ISO

Clobetasol results in increased expression of CKS1B mRNA

NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365

G

cytoplasmic linker associated protein 2

decreases expression

ISO

Clobetasol results in decreased expression of CLASP2 mRNA

NCBI chr 8:122,555,532...122,736,934
Ensembl chr 8:122,555,524...122,737,587

G

CAP-GLY domain containing linker protein 3

decreases expression

ISO

Clobetasol results in decreased expression of CLIP3 mRNA

NCBI chr 1:94,674,492...94,690,643
Ensembl chr 1:94,674,661...94,690,642

G

caseinolytic mitochondrial matrix peptidase proteolytic subunit

increases expression

ISO

Clobetasol results in increased expression of CLPP mRNA

NCBI chr 9:1,917,305...1,924,706
Ensembl chr 9:1,918,682...1,924,705

G

CLPTM1 regulator of GABA type A receptor forward trafficking

increases expression

ISO

Clobetasol results in increased expression of CLPTM1 mRNA

NCBI chr 1:88,417,447...88,449,047
Ensembl chr 1:88,417,447...88,449,446

G

CLPTM1-like

increases expression

ISO

Clobetasol results in increased expression of CLPTM1L mRNA

NCBI chr 1:31,496,094...31,512,148
Ensembl chr 1:31,496,094...31,512,077

G

citramalyl-CoA lyase

increases expression

ISO

Clobetasol results in increased expression of CLYBL mRNA

NCBI chr15:105,690,283...105,912,347
Ensembl chr15:105,690,295...105,912,345

G

cms1 ribosomal small subunit homolog

increases expression

ISO

Clobetasol results in increased expression of CMSS1 mRNA

NCBI chr11:56,403,620...56,701,751
Ensembl chr11:56,403,499...56,701,755

G

cytochrome C oxidase assembly factor 3

increases expression

ISO

Clobetasol results in increased expression of COA3 mRNA

NCBI chr10:86,720,454...86,721,435
Ensembl chr10:86,720,456...86,721,440

G

collagen type XI alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264

G

collagen type XII alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL12A1 mRNA

NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:89,427,834...89,545,711

G

collagen type III alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type IV alpha 2 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL4A2 mRNA

NCBI chr16:84,749,672...84,885,520
Ensembl chr16:84,749,672...84,885,520

G

collagen type V alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type IX alpha 1 chain

decreases expression

ISO

Clobetasol results in decreased expression of COL9A1 mRNA

NCBI chr 9:34,081,364...34,164,552
Ensembl chr 9:34,003,905...34,164,543

G

COPI coat complex subunit beta 1

increases expression

ISO

Clobetasol results in increased expression of COPB1 mRNA

NCBI chr 1:177,838,751...177,876,688
Ensembl chr 1:177,838,752...177,872,840

G

COPI coat complex subunit epsilon

increases expression

ISO

Clobetasol results in increased expression of COPE mRNA

NCBI chr16:19,148,832...19,159,052
Ensembl chr16:19,148,832...19,159,212

G

COP9 signalosome subunit 8

increases expression

ISO

Clobetasol results in increased expression of COPS8 mRNA

NCBI chr 9:98,655,031...98,664,861
Ensembl chr 9:98,654,870...98,665,381

G

coactosin-like F-actin binding protein 1

increases expression

ISO

Clobetasol results in increased expression of COTL1 mRNA

NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840

G

cytochrome c oxidase assembly factor COX14

increases expression

ISO

Clobetasol results in increased expression of COX14 mRNA

NCBI chr 7:132,731,069...132,733,159
Ensembl chr 7:132,731,069...132,733,159

G

cytochrome c oxidase copper chaperone COX17

increases expression

ISO

Clobetasol results in increased expression of COX17 mRNA

NCBI chr11:75,906,245...75,912,036
Ensembl chr11:75,906,248...75,912,019

G

cytochrome c oxidase assembly factor COX19

increases expression

ISO

Clobetasol results in increased expression of COX19 mRNA

NCBI chr12:20,417,389...20,426,868
Ensembl chr12:20,417,341...20,426,868

G

cytochrome c oxidase subunit 5A

increases expression

ISO

Clobetasol results in increased expression of COX5A mRNA

NCBI chr 8:66,818,284...66,829,691
Ensembl chr 8:66,818,196...66,830,279

G

cytochrome c oxidase subunit 6A1

increases expression

ISO

Clobetasol results in increased expression of COX6A1 mRNA

NCBI chr12:46,922,709...46,925,762
Ensembl chr12:46,912,648...46,925,768

G

cytochrome c oxidase subunit 8A

increases expression

ISO

Clobetasol results in increased expression of COX8A mRNA

NCBI chr 1:213,831,302...213,833,623
Ensembl chr 1:213,831,298...213,833,623

G

carboxypeptidase E

increases expression

ISO

Clobetasol results in increased expression of CPE mRNA

NCBI chr16:29,796,707...29,908,647
Ensembl chr16:29,796,689...29,909,524

G

ciliogenesis and planar polarity effector complex subunit 1

decreases expression

ISO

Clobetasol results in decreased expression of CPLANE1 mRNA

NCBI chr 2:58,996,119...59,096,817
Ensembl chr 2:58,996,130...59,096,817

G

crumbs cell polarity complex component 2

decreases expression

ISO

Clobetasol results in decreased expression of CRB2 mRNA

NCBI chr 3:41,946,694...41,974,629
Ensembl chr 3:41,947,325...41,974,629

G

cAMP responsive element binding protein 3

increases expression

ISO

Clobetasol results in increased expression of CREB3 mRNA

NCBI chr 5:62,613,652...62,619,019
Ensembl chr 5:62,613,638...62,619,500

G

CREB binding protein

decreases expression

ISO

Clobetasol results in decreased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

cysteine-rich with EGF-like domains 1

increases expression

ISO

Clobetasol results in increased expression of CRELD1 mRNA

NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116

G

cysteine-rich with EGF-like domains 2

increases expression

ISO

Clobetasol results in increased expression of CRELD2 mRNA

NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:121,788,745...121,796,228

G

CREB regulated transcription coactivator 3

decreases expression

ISO

Clobetasol results in decreased expression of CRTC3 mRNA

NCBI chr 1:143,962,038...144,064,324
Ensembl chr 1:143,962,038...144,064,288

G

cryptochrome circadian regulator 1

increases expression

ISO

Clobetasol results in increased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

citrate synthase

increases expression

ISO

Clobetasol results in increased expression of CS mRNA

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine sulfinic acid decarboxylase

increases expression

ISO

Clobetasol results in increased expression of CSAD mRNA

NCBI chr 7:135,187,175...135,216,495
Ensembl chr 7:135,187,175...135,215,581

G

cold shock domain containing C2

increases expression

ISO

Clobetasol results in increased expression of CSDC2 mRNA

NCBI chr 7:115,332,134...115,346,599
Ensembl chr 7:115,332,128...115,346,596

G

colony stimulating factor 2

decreases secretion

ISO

Clobetasol results in decreased secretion of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 2 alpha 1

increases expression

ISO

Clobetasol results in increased expression of CSNK2A1 mRNA

NCBI chr 3:161,170,295...161,217,073
Ensembl chr 3:161,170,405...161,215,698

G

cysteine and glycine-rich protein 1

increases expression

ISO

Clobetasol results in increased expression of CSRP1 mRNA

NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139

G

cysteine and glycine-rich protein 2

increases expression

ISO

Clobetasol results in increased expression of CSRP2 mRNA

NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238

G

catenin alpha-like 1

decreases expression

ISO

Clobetasol results in decreased expression of CTNNAL1 mRNA

NCBI chr 5:76,309,546...76,375,869
Ensembl chr 5:76,309,546...76,364,637

G

cathepsin B

increases expression

ISO

Clobetasol results in increased expression of CTSB mRNA

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cathepsin O

increases expression

ISO

Clobetasol results in increased expression of CTSO mRNA

NCBI chr 2:169,528,468...169,551,975
Ensembl chr 2:169,528,511...169,554,995

G

CUE domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of CUEDC1 mRNA

NCBI chr10:73,389,798...73,484,914
Ensembl chr10:73,389,841...73,483,749

G

cut-like homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of CUX2 mRNA

NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528

G

C-X-C motif chemokine ligand 12

increases expression

ISO

Clobetasol results in increased expression of CXCL12 mRNA

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

cytochrome c, somatic

increases expression

ISO

Clobetasol results in increased expression of CYCS mRNA

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

Clobetasol results in increased expression of CYP1A1 mRNA
Tretinoin inhibits the reaction [Clobetasol results in increased expression of CYP1A1 mRNA]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ISO

[Clobetasol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

ISO

Clobetasol results in increased expression of CYP3A5 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 51

increases expression

ISO

Clobetasol results in increased expression of CYP51 mRNA

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

dishevelled associated activator of morphogenesis 2

decreases expression

ISO

Clobetasol results in decreased expression of DAAM2 mRNA

NCBI chr 9:18,926,620...19,044,672
Ensembl chr 9:18,926,623...19,044,671

G

defender against cell death 1

increases expression

ISO

Clobetasol results in increased expression of DAD1 mRNA

NCBI chr15:31,647,326...31,667,159
Ensembl chr15:31,647,326...31,667,287

G

DAZ associated protein 2

increases expression

ISO

Clobetasol results in increased expression of DAZAP2 mRNA

NCBI chr 7:133,593,503...133,599,044
Ensembl chr 7:133,593,512...133,599,047

G

DDB1 and CUL4 associated factor 12

increases expression

ISO

Clobetasol results in increased expression of DCAF12 mRNA

NCBI chr 5:61,256,353...61,278,155
Ensembl chr 5:61,256,353...61,278,119

G

doublecortin domain containing 2

decreases expression

ISO

Clobetasol results in decreased expression of DCDC2A mRNA

NCBI chr17:40,274,009...40,459,757
Ensembl chr17:40,274,009...40,458,790

G

dachsous cadherin-related 1

decreases expression

ISO

Clobetasol results in decreased expression of DCHS1 mRNA

NCBI chr 1:169,516,758...169,550,789
Ensembl chr 1:169,516,762...169,536,639

G

deoxycytidine kinase

increases expression

ISO

Clobetasol results in increased expression of DCK mRNA

NCBI chr14:19,589,298...19,610,326
Ensembl chr14:19,589,298...19,610,326

G

damage-specific DNA binding protein 1

increases expression

ISO

Clobetasol results in increased expression of DDB1 mRNA

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

D-dopachrome tautomerase

increases expression

ISO

Clobetasol results in increased expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121

G

delta(4)-desaturase, sphingolipid 1

increases expression

ISO

Clobetasol results in increased expression of DEGS1 mRNA

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

derlin 1

increases expression

ISO

Clobetasol results in increased expression of DERL1 mRNA

NCBI chr 7:91,293,963...91,316,639
Ensembl chr 7:91,258,382...91,316,678

G

diacylglycerol kinase kappa

decreases expression

ISO

Clobetasol results in decreased expression of DGKK mRNA

NCBI chr X:18,253,849...18,385,805
Ensembl chr X:18,256,463...18,385,640

G

24-dehydrocholesterol reductase

increases expression

ISO

Clobetasol results in increased expression of DHCR24 mRNA

NCBI chr 5:126,573,366...126,599,940
Ensembl chr 5:126,573,338...126,599,936

G

7-dehydrocholesterol reductase

increases expression

ISO

Clobetasol results in increased expression of DHCR7 mRNA

NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382

G

dihydrofolate reductase

decreases expression

ISO

Clobetasol results in decreased expression of DHFR mRNA

NCBI chr 2:25,320,895...25,346,004

G

diablo, IAP-binding mitochondrial protein

decreases expression

ISO

Clobetasol results in decreased expression of DIABLO mRNA

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

death inducer-obliterator 1

decreases expression

ISO

Clobetasol results in decreased expression of DIDO1 mRNA

NCBI chr 3:188,150,100...188,203,445
Ensembl chr 3:188,150,100...188,194,823

G

DLG associated protein 4

decreases expression

ISO

Clobetasol results in decreased expression of DLGAP4 mRNA

NCBI chr 3:165,584,271...165,731,868
Ensembl chr 3:165,584,360...165,730,604

G

delta like canonical Notch ligand 3

increases expression

ISO

Clobetasol results in increased expression of DLL3 mRNA

NCBI chr 1:92,689,577...92,698,125
Ensembl chr 1:92,689,577...92,697,406

G

dynein, axonemal, assembly factor 3

increases expression

ISO

Clobetasol results in increased expression of DNAAF3 mRNA

NCBI chr 1:78,333,985...78,342,034
Ensembl chr 1:78,333,971...78,342,685

G

DnaJ heat shock protein family (Hsp40) member B11

increases expression

ISO

Clobetasol results in increased expression of DNAJB11 mRNA

NCBI chr11:91,656,334...91,672,800
Ensembl chr11:91,656,335...91,672,800

G

DnaJ heat shock protein family (Hsp40) member C3

increases expression

ISO

Clobetasol results in increased expression of DNAJC3 mRNA

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643

G

dynamin 3

decreases expression

ISO

Clobetasol results in decreased expression of DNM3 mRNA

NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350

G

2'-deoxynucleoside 5'-phosphate N-hydrolase 1

increases expression

ISO

Clobetasol results in increased expression of DNPH1 mRNA

NCBI chr 9:21,978,894...21,981,631
Ensembl chr 9:21,978,894...21,981,631

G

dihydropyrimidinase-like 2

increases expression

ISO

Clobetasol results in increased expression of DPYSL2 mRNA

NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065

G

dihydropyrimidinase-like 4

decreases expression

ISO

Clobetasol results in decreased expression of DPYSL4 mRNA

NCBI chr 1:203,312,646...203,328,523
Ensembl chr 1:203,311,694...203,328,523

G

dorsal inhibitory axon guidance protein

decreases expression

ISO

Clobetasol results in decreased expression of DRAXIN mRNA

NCBI chr 5:163,813,308...163,846,609
Ensembl chr 5:163,816,502...163,855,174

G

DS cell adhesion molecule

decreases expression

ISO

Clobetasol results in decreased expression of DSCAM mRNA

NCBI chr11:49,391,385...49,976,861
Ensembl chr11:49,347,531...49,976,238

G

dual specificity phosphatase 6

increases expression

ISO

Clobetasol results in increased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dishevelled segment polarity protein 3

decreases expression

ISO

Clobetasol results in decreased expression of DVL3 mRNA

NCBI chr11:93,869,834...93,887,013
Ensembl chr11:93,869,834...93,886,903

G

dynein cytoplasmic 1 heavy chain 1

decreases expression

ISO

Clobetasol results in decreased expression of DYNC1H1 mRNA

NCBI chr 6:135,436,375...135,502,117
Ensembl chr 6:135,430,750...135,502,116

G

dynein light chain Tctex-type 1

increases expression

ISO

Clobetasol results in increased expression of DYNLT1B mRNA

NCBI chr 1:49,292,093...49,299,051
Ensembl chr 1:49,282,243...49,298,951

G

EBP, cholestenol delta-isomerase

increases expression

ISO

Clobetasol results in increased expression of EBP mRNA

NCBI chr X:16,971,372...16,977,782
Ensembl chr X:16,971,405...16,977,781

G

endothelial differentiation-related factor 1

increases expression

ISO

Clobetasol results in increased expression of EDF1 mRNA

NCBI chr 3:28,764,906...28,779,499

G

early endosome antigen 1

decreases expression

ISO

Clobetasol results in decreased expression of EEA1 mRNA

NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476

G

eukaryotic translation elongation factor 2

increases expression

ISO

Clobetasol results in increased expression of EEF2 mRNA

NCBI chr 7:9,183,836...9,196,255
Ensembl chr 7:9,183,961...9,189,544

G

eukaryotic translation initiation factor 2B subunit beta

increases expression

ISO

Clobetasol results in increased expression of EIF2B2 mRNA

NCBI chr 6:110,597,979...110,604,403
Ensembl chr 6:110,597,729...110,604,403

G

eukaryotic translation initiation factor 3, subunit G

increases expression

ISO

Clobetasol results in increased expression of EIF3G mRNA

NCBI chr 8:27,705,914...27,709,946
Ensembl chr 8:27,705,915...27,709,987

G

eukaryotic translation initiation factor 3, subunit I

increases expression

ISO

Clobetasol results in increased expression of EIF3I mRNA

NCBI chr 5:147,219,457...147,226,910
Ensembl chr 5:147,219,366...147,241,232

G

eukaryotic translation initiation factor 4A3

increases expression

ISO

Clobetasol results in increased expression of EIF4A3 mRNA

NCBI chr10:105,047,567...105,057,561
Ensembl chr10:105,047,568...105,058,207

G

eukaryotic translation initiation factor 4E binding protein 1

increases expression

ISO

Clobetasol results in increased expression of EIF4EBP1 mRNA

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 5B

decreases expression

ISO

Clobetasol results in decreased expression of EIF5B mRNA

NCBI chr 9:47,718,706...47,773,289
Ensembl chr 9:47,718,706...47,778,583

G

eukaryotic translation initiation factor 6

increases expression

ISO

Clobetasol results in increased expression of EIF6 mRNA

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

ELAV like RNA binding protein 3

decreases expression

ISO

Clobetasol results in decreased expression of ELAVL3 mRNA

NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659

G

extracellular leucine-rich repeat and fibronectin type III domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ELFN1 mRNA

NCBI chr12:19,773,911...19,839,375
Ensembl chr12:19,772,908...19,841,961

G

ELOVL fatty acid elongase 5

increases expression

ISO

Clobetasol results in increased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ER membrane protein complex subunit 4

increases expression

ISO

Clobetasol results in increased expression of EMC4 mRNA

NCBI chr 3:119,624,100...119,633,170
Ensembl chr 3:119,624,100...119,629,118

G

ER membrane protein complex subunit 7

increases expression

ISO

Clobetasol results in increased expression of EMC7 mRNA

NCBI chr 3:119,714,617...119,728,748
Ensembl chr 3:119,718,357...119,730,486

G

EMG1 N1-specific pseudouridine methyltransferase

increases expression

ISO

Clobetasol results in increased expression of EMG1 mRNA

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

ectonucleoside triphosphate diphosphohydrolase 6

increases expression

ISO

Clobetasol results in increased expression of ENTPD6 mRNA

NCBI chr 3:160,036,055...160,058,580
Ensembl chr 3:160,036,121...160,059,451

G

E1A binding protein p300

decreases expression

ISO

Clobetasol results in decreased expression of EP300 mRNA

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

erythrocyte membrane protein band 4.1

decreases expression

ISO

Clobetasol results in decreased expression of EPB41 mRNA

NCBI chr 5:149,394,080...149,548,178
Ensembl chr 5:149,394,096...149,543,540

G

ergosterol biosynthesis 28 homolog

increases expression

ISO

Clobetasol results in increased expression of ERG28 mRNA

NCBI chr 6:111,205,102...111,214,068
Ensembl chr 6:111,205,103...111,214,068

G

envoplakin

decreases expression

ISO

Clobetasol results in decreased expression of EVPL mRNA

NCBI chr10:101,957,107...101,973,656
Ensembl chr10:101,941,064...101,973,656

G

FA core complex associated protein 24

increases expression

ISO

Clobetasol results in increased expression of FAAP24 mRNA

NCBI chr 1:97,188,678...97,194,899
Ensembl chr 1:97,188,678...97,194,882

G

fatty acid binding protein 7

increases expression

ISO

Clobetasol results in increased expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

fatty acid desaturase 1

increases expression

ISO

Clobetasol results in increased expression of FADS1 mRNA

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615

G

fatty acid desaturase 2

increases expression

ISO

Clobetasol results in increased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

family with sequence similarity 184, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM184A mRNA

NCBI chr20:33,477,089...33,599,296
Ensembl chr20:33,477,089...33,599,293

G

family with sequence similarity 185, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM185A mRNA

NCBI chr 4:14,469,165...14,555,167
Ensembl chr 4:14,499,869...14,555,167

G

family with sequence similarity 193, member A

decreases expression

ISO

Clobetasol results in decreased expression of FAM193A mRNA

NCBI chr14:80,480,742...80,607,086
Ensembl chr14:80,480,742...80,607,024

G

Fas cell surface death receptor

increases expression

ISO

Clobetasol results in increased expression of FAS protein

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

fatty acid synthase

increases expression

ISO

Clobetasol results in increased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAT atypical cadherin 1

decreases expression

ISO

Clobetasol results in decreased expression of FAT1 mRNA

NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609

G

FAT atypical cadherin 3

decreases expression

ISO

Clobetasol results in decreased expression of FAT3 mRNA

NCBI chr 8:20,972,840...21,555,679
Ensembl chr 8:20,972,840...21,555,240

G

fibrillarin

increases expression

ISO

Clobetasol results in increased expression of FBL mRNA

NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506

G

F-box and leucine-rich repeat protein 18

decreases expression

ISO

Clobetasol results in decreased expression of FBXL18 mRNA

NCBI chr12:16,781,901...16,812,728
Ensembl chr12:16,789,665...16,814,240

G

farnesyl diphosphate farnesyl transferase 1

increases expression

ISO

Clobetasol results in increased expression of FDFT1 mRNA

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168

G

fasciculation and elongation protein zeta 1

decreases expression

ISO

Clobetasol results in decreased expression of FEZ1 mRNA

NCBI chr 8:44,733,288...44,778,519
Ensembl chr 8:44,733,300...44,784,097

G

fibronectin leucine rich transmembrane protein 2

decreases expression

ISO

Clobetasol results in decreased expression of FLRT2 mRNA

NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004

G

FLVCR choline and putative heme transporter 2

decreases expression

ISO

Clobetasol results in decreased expression of FLVCR2 mRNA

NCBI chr 6:111,139,352...111,203,345
Ensembl chr 6:111,139,295...111,203,345

G

formation of mitochondrial complex V assembly factor 1

increases expression

ISO

Clobetasol results in increased expression of FMC1 mRNA

NCBI chr 4:68,241,009...68,249,045
Ensembl chr 4:68,241,009...68,268,534

G

formin-like 2

decreases expression

ISO

Clobetasol results in decreased expression of FMNL2 mRNA

NCBI chr 3:57,758,236...58,033,832
Ensembl chr 3:57,758,191...58,033,831

G

formin binding protein 4

decreases expression

ISO

Clobetasol results in decreased expression of FNBP4 mRNA

NCBI chr 3:97,188,852...97,218,916
Ensembl chr 3:97,188,884...97,219,435

G

fibronectin type III domain containing 10

increases expression

ISO

Clobetasol results in increased expression of FNDC10 mRNA

NCBI chr 5:171,581,960...171,584,519
Ensembl chr 5:171,580,033...171,595,399

G

forkhead box K1

decreases expression

ISO

Clobetasol results in decreased expression of FOXK1 mRNA

NCBI chr12:17,223,599...17,288,564
Ensembl chr12:17,229,430...17,288,564

G

FAD-dependent oxidoreductase domain containing 1

increases expression

ISO

Clobetasol results in increased expression of FOXRED1 mRNA

NCBI chr 8:41,789,557...41,818,064
Ensembl chr 8:41,808,843...41,817,980

G

FERM domain containing 8

increases expression

ISO

Clobetasol results in increased expression of FRMD8 mRNA

NCBI chr 1:212,572,534...212,593,181
Ensembl chr 1:212,572,537...212,592,695

G

FERM and PDZ domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of FRMPD1 mRNA

NCBI chr 5:64,238,730...64,340,778
Ensembl chr 5:64,238,768...64,340,776

G

FRY microtubule binding protein

increases expression

ISO

Clobetasol results in increased expression of FRY mRNA

NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603

G

frizzled-related protein

increases expression

ISO

Clobetasol results in increased expression of FRZB mRNA

NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096

G

ferritin heavy chain 1

increases expression

ISO

Clobetasol results in increased expression of FTH1 mRNA

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

GABA type A receptor associated protein like 2

increases expression

ISO

Clobetasol results in increased expression of GABARAPL2 mRNA

NCBI chr19:56,819,826...56,830,662
Ensembl chr19:56,819,791...56,830,660

G

gamma-aminobutyric acid type B receptor subunit 2

decreases expression

ISO

Clobetasol results in decreased expression of GABBR2 mRNA

NCBI chr 5:65,743,073...66,083,695
Ensembl chr 5:65,743,073...66,083,695

G

galactokinase 1

increases expression

ISO

Clobetasol results in increased expression of GALK1 mRNA

NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,735,061...101,746,258

G

growth associated protein 43

decreases expression

ISO

Clobetasol results in decreased expression of GAP43 mRNA

NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797

G

glycyl-tRNA synthetase 1

increases expression

ISO

Clobetasol results in increased expression of GARS1 mRNA

NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876

G

glutamate-cysteine ligase, catalytic subunit

decreases expression

ISO

Clobetasol results in decreased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

GCN1 activator of EIF2AK4

decreases expression

ISO

Clobetasol results in decreased expression of GCN1 mRNA

NCBI chr12:46,652,273...46,715,119
Ensembl chr12:46,652,273...46,713,488

G

glycine cleavage system protein H

increases expression

ISO

Clobetasol results in increased expression of GCSH mRNA

NCBI chr19:61,944,850...61,955,607
Ensembl chr19:61,944,850...61,955,607

G

growth differentiation factor 11

decreases expression

ISO

Clobetasol results in decreased expression of GDF11 mRNA

NCBI chr 7:1,896,229...1,909,147
Ensembl chr 7:1,896,229...1,905,222

G

GDP dissociation inhibitor 1

increases expression

ISO

Clobetasol results in increased expression of GDI1 mRNA

NCBI chr X:157,238,900...157,245,562
Ensembl chr X:157,238,892...157,245,560

G

glycerophosphodiester phosphodiesterase domain containing 3

increases expression

ISO

Clobetasol results in increased expression of GDPD3 mRNA

NCBI chr 1:190,804,053...190,813,609
Ensembl chr 1:190,803,993...190,813,606

G

guided entry of tail-anchored proteins factor 3, ATPase

increases expression

ISO

Clobetasol results in increased expression of GET3 mRNA

NCBI chr19:40,034,675...40,043,064
Ensembl chr19:40,034,967...40,043,061

G

glutamine-fructose-6-phosphate transaminase 2

increases expression

ISO

Clobetasol results in increased expression of GFPT2 mRNA

NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419

G

glycosylated lysosomal membrane protein

increases expression

ISO

Clobetasol results in increased expression of GLMP mRNA

NCBI chr 2:176,092,098...176,095,688
Ensembl chr 2:176,091,839...176,097,208

G

glyoxalase 1

increases expression

ISO

Clobetasol results in increased expression of GLO1 mRNA

NCBI chr20:8,665,061...8,683,095
Ensembl chr20:8,665,061...8,683,191

G

glutaredoxin 3

increases expression

ISO

Clobetasol results in increased expression of GLRX3 mRNA

NCBI chr 1:201,671,410...201,701,722
Ensembl chr 1:201,671,481...201,701,717

G

glutaredoxin 5

increases expression

ISO

Clobetasol results in increased expression of GLRX5 mRNA

NCBI chr 6:129,752,902...129,763,278
Ensembl chr 6:129,752,840...129,763,278

G

glutamate-ammonia ligase

increases expression

ISO

Clobetasol results in increased expression of GLUL mRNA

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

ganglioside GM2 activator

increases expression

ISO

Clobetasol results in increased expression of GM2A mRNA

NCBI chr10:39,719,919...39,732,452
Ensembl chr10:39,719,938...39,732,451

G

germ cell-less 1, spermatogenesis associated

increases expression

ISO

Clobetasol results in increased expression of GMCL1 mRNA

NCBI chr 4:120,697,976...120,737,267
Ensembl chr 4:120,697,976...120,737,257

G

G protein subunit alpha 13

increases expression

ISO

Clobetasol results in increased expression of GNA13 mRNA

NCBI chr10:94,837,271...94,870,290
Ensembl chr10:94,836,444...94,874,968

G

G protein subunit alpha i3

increases expression

ISO

Clobetasol results in increased expression of GNAI3 mRNA

NCBI chr 2:198,430,920...198,468,874

G

G protein subunit beta 2

increases expression

ISO

Clobetasol results in increased expression of GNB2 mRNA

NCBI chr12:24,795,505...24,800,796
Ensembl chr12:24,795,827...24,800,796

G

golgin B1

decreases expression

ISO

Clobetasol results in decreased expression of GOLGB1 mRNA

NCBI chr11:77,348,573...77,406,165
Ensembl chr11:77,348,961...77,406,006

G

glutamic-oxaloacetic transaminase 1

increases expression

ISO

Clobetasol results in increased expression of GOT1 mRNA

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glycerol-3-phosphate dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of GPD1 mRNA

NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368

G

G protein-coupled estrogen receptor 1

increases expression

ISO

Clobetasol results in increased expression of GPER1 mRNA

NCBI chr12:20,331,073...20,336,527
Ensembl chr12:20,327,679...20,337,144

G

glucose-6-phosphate isomerase

increases expression

ISO

Clobetasol results in increased expression of GPI1 mRNA

NCBI chr 1:95,965,389...95,996,932
Ensembl chr 1:95,965,396...95,993,261

G

G protein-coupled receptor 17

decreases expression

ISO

Clobetasol results in decreased expression of GPR17 mRNA

NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702

G

G protein-coupled receptor, class C, group 5, member B

increases expression

ISO

Clobetasol results in increased expression of GPRC5B mRNA

NCBI chr 1:182,748,247...182,772,711
Ensembl chr 1:182,748,247...182,772,757

G

glutathione peroxidase 1

increases expression

ISO

Clobetasol results in increased expression of GPX1 mRNA

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glyoxylate and hydroxypyruvate reductase

increases expression

ISO

Clobetasol results in increased expression of GRHPR mRNA

NCBI chr 5:64,029,856...64,039,287
Ensembl chr 5:64,022,368...64,039,276

G

glutamate ionotropic receptor kainate type subunit 3

decreases expression

ISO

Clobetasol results in decreased expression of GRIK3 mRNA

NCBI chr 5:143,052,442...143,268,873
Ensembl chr 5:143,052,442...143,268,873

G

glutamate ionotropic receptor NMDA type subunit associated protein 1

increases expression

ISO

Clobetasol results in increased expression of GRINA mRNA

NCBI chr 7:109,842,870...109,846,048
Ensembl chr 7:109,843,196...109,846,042

G

glutamate metabotropic receptor 3

decreases expression

ISO

Clobetasol results in decreased expression of GRM3 mRNA

NCBI chr 4:25,319,218...25,600,721
Ensembl chr 4:25,319,942...25,564,764

G

glycogen synthase kinase 3 alpha

increases expression

ISO

Clobetasol results in increased expression of GSK3A mRNA

NCBI chr 1:89,943,669...89,953,514
Ensembl chr 1:89,943,669...89,953,593

G

glutathione-disulfide reductase

increases expression

ISO

Clobetasol results in increased expression of GSR mRNA

NCBI chr16:65,185,574...65,228,742
Ensembl chr16:65,185,574...65,228,394

G

glutathione S-transferase mu 2

increases expression

ISO

Clobetasol results in increased expression of GSTM5 mRNA

NCBI chr 2:198,312,179...198,316,962

G

glutathione S-transferase pi 1

increases expression

ISO

Clobetasol results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

GTP binding protein 1

increases expression

ISO

Clobetasol results in increased expression of GTPBP1 mRNA

NCBI chr 7:113,128,645...113,153,094
Ensembl chr 7:113,128,670...113,154,621

G

guanylate cyclase 1 soluble subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of GUCY1A1 mRNA

NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737

G

H1.0 linker histone

increases expression

ISO

Clobetasol results in increased expression of H1F0 mRNA

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H2A.J histone

increases expression

ISO

Clobetasol results in increased expression of H2AJ mRNA

NCBI chr 4:171,406,922...171,407,406
Ensembl chr 4:171,406,177...171,408,845

G

histidyl-tRNA synthetase 1

increases expression

ISO

Clobetasol results in increased expression of HARS1 mRNA

NCBI chr18:28,655,669...28,672,712
Ensembl chr18:28,655,671...28,672,712

G

heparin-binding EGF-like growth factor

decreases expression

ISO

Clobetasol results in decreased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

host cell factor C1

decreases expression

ISO

Clobetasol results in decreased expression of HCFC1 mRNA

NCBI chr X:156,839,100...156,864,132
Ensembl chr X:156,839,100...156,863,813

G

histone deacetylase 3

increases expression

ISO

Clobetasol results in increased expression of HDAC3 mRNA

NCBI chr18:30,021,847...30,041,061
Ensembl chr18:30,021,941...30,041,025

G

HECT domain E3 ubiquitin protein ligase 4

decreases expression

ISO

Clobetasol results in decreased expression of HECTD4 mRNA

NCBI chr12:40,800,232...40,991,584
Ensembl chr12:40,843,770...40,991,798

G

hepatic and glial cell adhesion molecule

increases expression

ISO

Clobetasol results in increased expression of HEPACAM mRNA

NCBI chr 8:45,276,594...45,294,006
Ensembl chr 8:45,276,683...45,295,548

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

decreases expression

ISO

Clobetasol results in decreased expression of HERC1 mRNA

NCBI chr 8:75,796,347...75,965,347
Ensembl chr 8:75,796,357...75,965,347

G

huntingtin interacting protein 1 related

decreases expression

ISO

Clobetasol results in decreased expression of HIP1R mRNA

NCBI chr12:38,251,085...38,279,756
Ensembl chr12:38,251,086...38,279,654

G

HIVEP zinc finger 1

decreases expression

ISO

Clobetasol results in decreased expression of HIVEP1 mRNA

NCBI chr17:22,790,855...22,920,359
Ensembl chr17:22,790,855...22,917,196

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

ISO

Clobetasol results in increased expression of HMGCR mRNA

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

hook microtubule-tethering protein 3

decreases expression

ISO

Clobetasol results in decreased expression of HOOK3 mRNA

NCBI chr16:72,656,929...72,751,696
Ensembl chr16:72,657,019...72,764,071

G

homeo box A5

decreases expression

ISO

Clobetasol results in decreased expression of HOXA5 mRNA

NCBI chr 4:82,632,958...82,636,851
Ensembl chr 4:82,632,306...82,639,038

G

HR, lysine demethylase and nuclear receptor corepressor

decreases expression

ISO

Clobetasol results in decreased expression of HR mRNA

NCBI chr15:52,036,540...52,056,019
Ensembl chr15:52,036,540...52,056,015

G

heparan sulfate-glucosamine 3-sulfotransferase 1

increases expression

ISO

Clobetasol results in increased expression of HS3ST1 mRNA

NCBI chr14:75,398,101...75,429,628
Ensembl chr14:75,398,026...75,436,848

G

hydroxysteroid (17-beta) dehydrogenase 4

increases expression

ISO

Clobetasol results in increased expression of HSD17B4 mRNA

NCBI chr18:45,515,427...45,604,467
Ensembl chr18:45,515,373...45,604,467

G

hydroxysteroid (17-beta) dehydrogenase 7

increases expression

ISO

Clobetasol results in increased expression of HSD17B7 mRNA

NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754

G

heat shock protein family E (Hsp10) member 1

increases expression

ISO

Clobetasol results in increased expression of HSPE1 mRNA

NCBI chr 9:64,084,327...64,087,415
Ensembl chr 9:64,085,068...64,087,502

G

heparan sulfate proteoglycan 2

decreases expression

ISO

Clobetasol results in decreased expression of HSPG2 mRNA

NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:154,960,846...155,061,971

G

Huntingtin interacting protein K

increases expression

ISO

Clobetasol results in increased expression of HYPK mRNA

NCBI chr 3:128,888,709...128,890,089
Ensembl chr 3:128,888,717...128,891,405

G

intercellular adhesion molecule 1

decreases expression

ISO

Clobetasol results in decreased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

inhibitor of DNA binding 1

increases expression

ISO

Clobetasol results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 3

increases expression

ISO

Clobetasol results in increased expression of ID3 mRNA

NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856

G

isocitrate dehydrogenase (NADP(+)) 2

increases expression

ISO

Clobetasol results in increased expression of IDH2 mRNA

NCBI chr 1:143,447,925...143,467,248
Ensembl chr 1:143,439,323...143,467,248

G

isopentenyl-diphosphate delta isomerase 1

increases expression

ISO

Clobetasol results in increased expression of IDI1 mRNA

NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524

G

immediate early response 3 interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of IER3IP1 mRNA

NCBI chr18:72,749,976...72,761,060
Ensembl chr18:72,749,976...72,801,679

G

insulin-like growth factor binding protein 2

increases expression

ISO

Clobetasol results in increased expression of IGFBP2 mRNA

NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171

G

insulin-like growth factor binding protein 3

increases expression

ISO

Clobetasol results in increased expression of IGFBP3 mRNA

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

insulin-like growth factor binding protein 5

decreases expression

ISO

Clobetasol results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

immunoglobulin superfamily, member 10

decreases expression

ISO

Clobetasol results in decreased expression of IGSF10 mRNA

NCBI chr 2:145,725,868...145,754,850
Ensembl chr 2:145,725,878...145,754,579

G

immunoglobulin superfamily, member 9B

decreases expression

ISO

Clobetasol results in decreased expression of IGSF9B mRNA

NCBI chr 8:33,971,779...34,027,390
Ensembl chr 8:33,971,779...34,018,128

G

interleukin 1 alpha

decreases secretion

ISO

Clobetasol results in decreased secretion of IL1A protein

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Clobetasol results in decreased expression of IL2RA protein

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin enhancer binding factor 2

decreases expression

ISO

Clobetasol results in decreased expression of ILF2 mRNA

NCBI chr 2:178,256,927...178,268,773
Ensembl chr 2:178,248,585...178,268,920

G

IMP U3 small nucleolar ribonucleoprotein 3

increases expression

ISO

Clobetasol results in increased expression of IMP3 mRNA

NCBI chr 8:66,235,498...66,236,386

G

impact RWD domain protein

increases expression

ISO

Clobetasol results in increased expression of IMPACT mRNA

NCBI chr18:4,383,546...4,422,280
Ensembl chr18:4,383,575...4,422,278

G

inosine monophosphate dehydrogenase 2

increases expression

ISO

Clobetasol results in increased expression of IMPDH2 mRNA

NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873

G

INO80 complex ATPase subunit

decreases expression

ISO

Clobetasol results in decreased expression of INO80 mRNA

NCBI chr 3:126,822,280...126,919,532
Ensembl chr 3:126,822,280...126,919,532

G

insulin induced gene 1

increases expression

ISO

Clobetasol results in increased expression of INSIG1 mRNA

NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778

G

integrator complex subunit 11

increases expression

ISO

Clobetasol results in increased expression of INTS11 mRNA

NCBI chr 5:171,761,370...171,779,883
Ensembl chr 5:171,761,371...171,779,883

G

integrator complex subunit 5

increases expression

ISO

Clobetasol results in increased expression of INTS5 mRNA

NCBI chr 1:215,218,012...215,222,790
Ensembl chr 1:215,218,017...215,223,240

G

IQ motif containing GTPase activating protein 2

decreases expression

ISO

Clobetasol results in decreased expression of IQGAP2 mRNA

NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:28,629,558...28,904,649

G

IQ motif and Sec7 domain ArfGEF 1

decreases expression

ISO

Clobetasol results in decreased expression of IQSEC1 mRNA

NCBI chr 4:124,725,917...125,045,351
Ensembl chr 4:124,725,917...125,045,550

G

insulin receptor substrate 2

decreases expression

ISO

Clobetasol results in decreased expression of IRS2 mRNA

NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543

G

inosine triphosphatase

increases expression

ISO

Clobetasol results in increased expression of ITPA mRNA

NCBI chr 3:138,338,549...138,350,329
Ensembl chr 3:138,338,349...138,350,329

G

intersectin 1

decreases expression

ISO

Clobetasol results in decreased expression of ITSN1 mRNA

NCBI chr11:44,464,515...44,646,598
Ensembl chr11:44,513,186...44,646,598

G

isovaleryl-CoA dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of IVD mRNA

NCBI chr 3:126,305,584...126,326,016
Ensembl chr 3:126,305,364...126,328,160

G

interacts with SUPT6H, CTD assembly factor 1

decreases expression

ISO

Clobetasol results in decreased expression of IWS1 mRNA

NCBI chr18:23,969,352...24,011,560
Ensembl chr18:23,969,733...24,010,415

G

Janus kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of JAK1 mRNA

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

junctional adhesion molecule 3

increases expression

ISO

Clobetasol results in increased expression of JAM3 mRNA

NCBI chr 8:33,767,606...33,828,451
Ensembl chr 8:33,767,607...33,828,623

G

jumonji domain containing 1C

decreases expression

ISO

Clobetasol results in decreased expression of JMJD1C mRNA

NCBI chr20:21,330,990...21,508,580
Ensembl chr20:21,330,990...21,461,916

G

jumonji domain containing 8

increases expression

ISO

Clobetasol results in increased expression of JMJD8 mRNA

NCBI chr10:15,353,460...15,356,392
Ensembl chr10:15,353,475...15,356,393

G

junction mediating and regulatory protein, p53 cofactor

decreases expression

ISO

Clobetasol results in decreased expression of JMY mRNA

NCBI chr 2:26,401,047...26,465,959
Ensembl chr 2:26,409,969...26,465,649

G

Jupiter microtubule associated homolog 1

increases expression

ISO

Clobetasol results in increased expression of JPT1 mRNA

NCBI chr10:101,243,428...101,261,464
Ensembl chr10:101,243,424...101,261,469

G

KN motif and ankyrin repeat domains 4

decreases expression

ISO

Clobetasol results in decreased expression of KANK4 mRNA

NCBI chr 5:118,516,994...118,581,024
Ensembl chr 5:118,517,971...118,581,002

G

kazrin, periplakin interacting protein

decreases expression

ISO

Clobetasol results in decreased expression of KAZN mRNA

NCBI chr 5:159,675,803...160,666,084
Ensembl chr 5:159,675,803...160,664,154

G

potassium voltage-gated channel subfamily A member 2

decreases expression

ISO

Clobetasol results in decreased expression of KCNA2 mRNA

NCBI chr 2:197,392,746...197,406,606
Ensembl chr 2:197,392,698...197,407,519

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

increases expression

ISO

Clobetasol results in increased expression of KCNMB4 mRNA

NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281

G

potassium sodium-activated channel subfamily T member 1

increases expression

ISO

Clobetasol results in increased expression of KCNT1 mRNA

NCBI chr 3:29,081,071...29,136,902
Ensembl chr 3:29,081,321...29,134,768

G

potassium channel tetramerization domain containing 5

increases expression

ISO

Clobetasol results in increased expression of KCTD5 mRNA

NCBI chr10:13,583,781...13,609,762
Ensembl chr10:13,583,781...13,610,062

G

KDEL endoplasmic reticulum protein retention receptor 2

increases expression

ISO

Clobetasol results in increased expression of KDELR2 mRNA

NCBI chr12:16,252,424...16,270,737
Ensembl chr12:16,252,424...16,270,719

G

lysine demethylase 6B

decreases expression

ISO

Clobetasol results in decreased expression of KDM6B mRNA

NCBI chr10:54,619,520...54,641,014
Ensembl chr10:54,619,544...54,629,610

G

KH RNA binding domain containing, signal transduction associated 1

decreases expression

ISO

Clobetasol results in decreased expression of KHDRBS1 mRNA

NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:147,347,904...147,373,448

G

kinesin family member 13A

decreases expression

ISO

Clobetasol results in decreased expression of KIF13A mRNA

NCBI chr17:17,972,227...18,154,763
Ensembl chr17:17,972,325...18,154,760

G

kinesin family member 5A

decreases expression

ISO

Clobetasol results in decreased expression of KIF5A mRNA

NCBI chr 7:64,937,210...64,974,339
Ensembl chr 7:64,934,740...64,978,272

G

kirre like nephrin family adhesion molecule 2

increases expression

ISO

Clobetasol results in increased expression of KIRREL2 mRNA

NCBI chr 1:94,836,243...94,846,119
Ensembl chr 1:94,836,243...94,846,119

G

KLF transcription factor 9

increases expression

ISO

Clobetasol results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

lysine methyltransferase 2C

decreases expression

ISO

Clobetasol results in decreased expression of KMT2C mRNA

NCBI chr 4:10,353,698...10,755,965
Ensembl chr 4:10,353,735...10,568,620

G

lysine methyltransferase 2D

decreases expression

ISO

Clobetasol results in decreased expression of KMT2D mRNA

NCBI chr 7:131,859,696...131,901,032
Ensembl chr 7:131,859,696...131,900,072

G

lysine methyltransferase 2E

decreases expression

ISO

Clobetasol results in decreased expression of KMT2E mRNA

NCBI chr 4:12,550,570...12,655,329
Ensembl chr 4:12,550,570...12,619,721

G

kinetochore scaffold 1

decreases expression

ISO

Clobetasol results in decreased expression of KNL1 mRNA

NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774

G

keratinocyte associated protein 2

increases expression

ISO

Clobetasol results in increased expression of KRTCAP2 mRNA

NCBI chr 2:176,952,167...176,956,163
Ensembl chr 2:176,949,809...176,956,163

G

KTI12 chromatin associated

increases expression

ISO

Clobetasol results in increased expression of KTI12 mRNA

NCBI chr 5:128,829,751...128,831,273
Ensembl chr 5:128,826,844...128,834,910

G

laminin subunit alpha 1

decreases expression

ISO

Clobetasol results in decreased expression of LAMA1 mRNA

NCBI chr 9:115,139,548...115,263,620
Ensembl chr 9:115,139,548...115,264,251

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 1

increases expression

ISO

Clobetasol results in increased expression of LAMTOR1 mRNA

NCBI chr 1:165,684,001...165,689,698
Ensembl chr 1:165,684,091...165,703,178

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 5

increases expression

ISO

Clobetasol results in increased expression of LAMTOR5 mRNA

NCBI chr 2:197,588,242...197,593,598
Ensembl chr 2:197,588,242...197,593,598

G

lysosomal protein transmembrane 4 beta

increases expression

ISO

Clobetasol results in increased expression of LAPTM4B mRNA

NCBI chr 7:67,319,438...67,362,547
Ensembl chr 7:67,319,542...67,363,258

G

La ribonucleoprotein 1, translational regulator

decreases expression

ISO

Clobetasol results in decreased expression of LARP1 mRNA

NCBI chr10:42,691,833...42,746,816
Ensembl chr10:42,691,600...42,746,816

G

LBH regulator of WNT signaling pathway

increases expression

ISO

Clobetasol results in increased expression of LBH mRNA

NCBI chr 6:28,321,040...28,344,855
Ensembl chr 6:28,321,040...28,370,238

G

leukocyte receptor cluster member 8

decreases expression

ISO

Clobetasol results in decreased expression of LENG8 mRNA

NCBI chr 1:79,113,038...79,124,868
Ensembl chr 1:79,113,038...79,124,738

G

LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

increases expression

ISO

Clobetasol results in increased expression of LFNG mRNA

NCBI chr12:19,144,474...19,152,951
Ensembl chr12:19,124,662...19,152,918

G

galectin 1

increases expression

ISO

Clobetasol results in increased expression of LGALS1 mRNA

NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800

G

galectin-like

increases expression

ISO

Clobetasol results in increased expression of LGALSL mRNA

NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487

G

lin-52 DREAM MuvB core complex component

increases expression

ISO

Clobetasol results in increased expression of LIN52 mRNA

NCBI chr 6:109,829,896...109,927,122
Ensembl chr 6:109,830,131...109,925,310

G

lipopolysaccharide-induced TNF factor

increases expression

ISO

Clobetasol results in increased expression of LITAF mRNA

NCBI chr10:5,163,258...5,199,930
Ensembl chr10:5,163,242...5,199,930

G

lectin, mannose-binding 2

increases expression

ISO

Clobetasol results in increased expression of LMAN2 mRNA

NCBI chr17:9,274,362...9,294,950
Ensembl chr17:9,274,136...9,292,370

G

LIM and cysteine-rich domains 1

increases expression

ISO

Clobetasol results in increased expression of LMCD1 mRNA

NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875

G

lactoperoxidase

increases expression

ISO

Clobetasol results in increased expression of LPO mRNA

NCBI chr10:73,104,170...73,124,683
Ensembl chr10:73,104,188...73,123,456

G

LDL receptor related protein 1

decreases expression

ISO

Clobetasol results in decreased expression of LRP1 mRNA

NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196

G

LDL receptor related protein 2

increases expression

ISO

Clobetasol results in increased expression of LRP2 mRNA

NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535

G

leucine rich repeat containing 4B

decreases expression

ISO

Clobetasol results in decreased expression of LRRC4B mRNA

NCBI chr 1:104,058,558...104,092,831
Ensembl chr 1:104,072,128...104,093,298

G

leucine rich repeat transmembrane neuronal 2

decreases expression

ISO

Clobetasol results in decreased expression of LRRTM2 mRNA

NCBI chr18:27,091,919...27,096,967
Ensembl chr18:27,091,919...27,096,967

G

LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

ISO

Clobetasol results in increased expression of LSM4 mRNA

NCBI chr16:18,789,466...18,795,164
Ensembl chr16:18,789,467...18,794,886

G

LSM8 homolog, U6 small nuclear RNA associated

increases expression

ISO

Clobetasol results in increased expression of LSM8 mRNA

NCBI chr 4:48,272,128...48,277,994
Ensembl chr 4:48,272,164...48,280,162

G

lymphocyte antigen 75

decreases expression

ISO

Clobetasol results in decreased expression of LY75 protein

NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878

G

mono-ADP ribosylhydrolase 1

increases expression

ISO

Clobetasol results in increased expression of MACROD1 mRNA

NCBI chr 1:213,675,413...213,831,571
Ensembl chr 1:213,675,406...213,816,348

G

MAF bZIP transcription factor K

increases expression

ISO

Clobetasol results in increased expression of MAFK mRNA

NCBI chr12:19,948,473...19,970,351
Ensembl chr12:19,948,476...19,959,192

G

MAGE family member E1

decreases expression

ISO

Clobetasol results in decreased expression of MAGEE1 mRNA

NCBI chr X:74,254,848...74,258,395
Ensembl chr X:74,254,958...74,258,371

G

MAGE family member H1

increases expression

ISO

Clobetasol results in increased expression of MAGEH1 mRNA

NCBI chr X:21,725,709...21,726,965
Ensembl chr X:21,718,669...21,727,219

G

mannosidase beta like

increases expression

ISO

Clobetasol results in increased expression of MANBAL mRNA

NCBI chr 3:166,455,067...166,484,652
Ensembl chr 3:166,455,066...166,487,431

G

mesencephalic astrocyte-derived neurotrophic factor

increases expression

ISO

Clobetasol results in increased expression of MANF mRNA

NCBI chr 8:116,427,053...116,430,259
Ensembl chr 8:116,427,048...116,429,910

G

microtubule-associated protein 1B

decreases expression

ISO

Clobetasol results in decreased expression of MAP1B mRNA

NCBI chr 2:32,551,423...32,644,471
Ensembl chr 2:32,551,423...32,657,094

G

microtubule-associated protein 1 light chain 3 beta

increases expression

ISO

Clobetasol results in increased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

microtubule-associated protein 2

decreases expression

ISO

Clobetasol results in decreased expression of MAP2 mRNA

NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459

G

mitogen activated protein kinase kinase 1

increases expression

ISO

Clobetasol results in increased expression of MAP2K1 mRNA

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen-activated protein kinase 8 interacting protein 2

increases expression

ISO

Clobetasol results in increased expression of MAPK8IP2 mRNA

NCBI chr 7:122,406,350...122,416,602
Ensembl chr 7:122,406,350...122,416,602

G

meiosis regulator and mRNA stability factor 1

decreases expression

ISO

Clobetasol results in decreased expression of MARF1 mRNA

NCBI chr10:1,395,271...1,439,974
Ensembl chr10:1,395,282...1,439,974

G

microtubule associated serine/threonine kinase family member 4

decreases expression

ISO

Clobetasol results in decreased expression of MAST4 mRNA

NCBI chr 2:35,627,190...36,219,090
Ensembl chr 2:35,627,190...36,218,832

G

minichromosome maintenance complex component 3 associated protein

decreases expression

ISO

Clobetasol results in decreased expression of MCM3AP mRNA

NCBI chr20:12,127,060...12,164,651
Ensembl chr20:12,127,060...12,164,651

G

mediator of DNA damage checkpoint 1

decreases expression

ISO

Clobetasol results in decreased expression of MDC1 mRNA

NCBI chr20:2,898,496...2,914,960
Ensembl chr20:2,900,308...2,914,960

G

malate dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of MDH1 mRNA

NCBI chr14:99,831,934...99,847,227
Ensembl chr14:99,831,615...99,847,232

G

malate dehydrogenase 2

increases expression

ISO

Clobetasol results in increased expression of MDH2 mRNA

NCBI chr12:26,530,886...26,543,841
Ensembl chr12:26,530,881...26,543,841

G

midasin AAA ATPase 1

decreases expression

ISO

Clobetasol results in decreased expression of MDN1 mRNA

NCBI chr 5:51,851,785...51,982,688
Ensembl chr 5:51,851,809...51,982,688

G

mitochondrial trans-2-enoyl-CoA reductase

increases expression

ISO

Clobetasol results in increased expression of MECR mRNA

NCBI chr 5:149,313,765...149,339,964
Ensembl chr 5:149,313,774...149,342,825

G

multiple EGF-like-domains 9

increases expression

ISO

Clobetasol results in increased expression of MEGF9 mRNA

NCBI chr 5:89,008,679...89,120,731
Ensembl chr 5:89,008,679...89,120,731

G

MER proto-oncogene, tyrosine kinase

increases expression

ISO

Clobetasol results in increased expression of MERTK mRNA

NCBI chr 3:136,391,936...136,498,366
Ensembl chr 3:136,383,560...136,500,192

G

mesoderm development LRP chaperone

increases expression

ISO

Clobetasol results in increased expression of MESD mRNA

NCBI chr 1:147,275,904...147,289,134
Ensembl chr 1:147,275,396...147,289,134

G

methionyl aminopeptidase 1

increases expression

ISO

Clobetasol results in increased expression of METAP1 mRNA

NCBI chr 2:229,664,677...229,697,730
Ensembl chr 2:229,664,677...229,719,084

G

meteorin, glial cell differentiation regulator

increases expression

ISO

Clobetasol results in increased expression of METRN mRNA

NCBI chr10:15,321,200...15,323,218
Ensembl chr10:15,321,200...15,323,642

G

mex-3 RNA binding family member A

decreases expression

ISO

Clobetasol results in decreased expression of MEX3A mRNA

NCBI chr 2:176,287,900...176,297,369
Ensembl chr 2:176,287,900...176,297,369

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

ISO

Clobetasol results in increased expression of MFSD2A mRNA

NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916

G

MIA SH3 domain ER export factor 3

decreases expression

ISO

Clobetasol results in decreased expression of MIA3 mRNA

NCBI chr13:97,502,040...97,547,155
Ensembl chr13:97,494,275...97,543,587

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

decreases expression

ISO

Clobetasol results in decreased expression of MICAL3 mRNA

NCBI chr 4:155,824,941...156,025,003
Ensembl chr 4:155,824,946...156,005,238

G

marker of proliferation Ki-67

decreases expression

ISO

Clobetasol results in decreased expression of MKI67 mRNA

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

makorin, ring finger protein, 3

increases expression

ISO

Clobetasol results in increased expression of MKRN3 mRNA

NCBI chr 1:125,338,664...125,341,178
Ensembl chr 1:125,338,564...125,341,164

G

malectin

increases expression

ISO

Clobetasol results in increased expression of MLEC mRNA

NCBI chr12:47,118,918...47,133,598
Ensembl chr12:47,118,855...47,130,064

G

MLLT1, super elongation complex subunit

decreases expression

ISO

Clobetasol results in decreased expression of MLLT1 mRNA

NCBI chr 9:1,818,204...1,863,091
Ensembl chr 9:1,818,204...1,863,089

G

metabolism of cobalamin associated D

increases expression

ISO

Clobetasol results in increased expression of MMADHC mRNA

NCBI chr 3:55,117,832...55,135,735
Ensembl chr 3:55,117,833...55,135,851

G

mitochondrial pyruvate carrier 2

increases expression

ISO

Clobetasol results in increased expression of MPC2 mRNA

NCBI chr13:80,261,143...80,280,668
Ensembl chr13:80,259,727...80,280,668

G

mitochondrial ribosomal protein L14

increases expression

ISO

Clobetasol results in increased expression of MRPL14 mRNA

NCBI chr 9:22,800,286...22,812,711
Ensembl chr 9:22,795,744...22,812,855

G

mitochondrial ribosomal protein L34

increases expression

ISO

Clobetasol results in increased expression of MRPL34 mRNA

NCBI chr16:18,186,447...18,187,182
Ensembl chr16:18,185,306...18,187,181

G

mitochondrial ribosomal protein L46

increases expression

ISO

Clobetasol results in increased expression of MRPL46 mRNA

NCBI chr 1:142,108,266...142,117,030
Ensembl chr 1:142,106,531...142,117,030

G

mitochondrial ribosomal protein S14

increases expression

ISO

Clobetasol results in increased expression of MRPS14 mRNA

NCBI chr13:74,962,597...74,968,344
Ensembl chr13:74,962,515...74,970,975

G

mitochondrial ribosomal protein S26

increases expression

ISO

Clobetasol results in increased expression of MRPS26 mRNA

NCBI chr 3:138,222,324...138,223,987
Ensembl chr 3:138,222,165...138,223,987

G

mitochondrial ribosomal protein S27

increases expression

ISO

Clobetasol results in increased expression of MRPS27 mRNA

NCBI chr 2:32,474,178...32,542,741
Ensembl chr 2:32,473,965...32,542,738

G

methylsterol monooxygenase 1

increases expression

ISO

Clobetasol results in increased expression of MSMO1 mRNA

NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445

G

moesin

increases expression

ISO

Clobetasol results in increased expression of MSN mRNA

NCBI chr X:65,005,546...65,073,512
Ensembl chr X:65,005,458...65,075,129

G

microtubule crosslinking factor 2

decreases expression

ISO

Clobetasol results in decreased expression of MTCL2 mRNA

NCBI chr 3:166,089,141...166,161,043
Ensembl chr 3:166,095,480...166,161,102

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases expression

ISO

Clobetasol results in increased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

mechanistic target of rapamycin kinase

decreases expression

ISO

Clobetasol results in decreased expression of MTOR mRNA

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

multivesicular body subunit 12B

decreases expression

ISO

Clobetasol results in decreased expression of MVB12B mRNA

NCBI chr 3:37,431,636...37,590,276
Ensembl chr 3:37,431,636...37,615,407

G

Max dimerization protein 3

increases expression

ISO

Clobetasol results in increased expression of MXD3 mRNA

NCBI chr17:9,306,552...9,310,278
Ensembl chr17:9,302,321...9,310,278

G

MYC binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of MYCBP2 mRNA

NCBI chr15:86,352,061...86,590,126
Ensembl chr15:86,352,061...86,590,325

G

myosin, heavy chain 9

decreases expression

ISO

Clobetasol results in decreased expression of MYH9 mRNA

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

myosin IXA

decreases expression

ISO

Clobetasol results in decreased expression of MYO9A mRNA

NCBI chr 8:69,044,853...69,248,094
Ensembl chr 8:69,044,885...69,245,231

G

nucleic acid binding protein 2

increases expression

ISO

Clobetasol results in increased expression of NABP2 mRNA

NCBI chr 7:1,415,491...1,421,113
Ensembl chr 7:1,415,492...1,422,682

G

neuron navigator 3

decreases expression

ISO

Clobetasol results in decreased expression of NAV3 mRNA

NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893

G

neural cell adhesion molecule 2

decreases expression

ISO

Clobetasol results in decreased expression of NCAM2 mRNA

NCBI chr11:33,591,748...34,078,788
Ensembl chr11:33,591,713...34,078,788

G

NCK-associated protein 5-like

decreases expression

ISO

Clobetasol results in decreased expression of NCKAP5L mRNA

NCBI chr 7:132,433,569...132,470,638
Ensembl chr 7:132,433,574...132,470,836

G

nucleolin

decreases expression

ISO

Clobetasol results in decreased expression of NCL mRNA

NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:94,446,682...94,456,083

G

nicalin

increases expression

ISO

Clobetasol results in increased expression of NCLN mRNA

NCBI chr 7:8,862,324...8,872,699
Ensembl chr 7:8,862,751...8,872,698

G

NDC1 transmembrane nucleoporin

increases expression

ISO

Clobetasol results in increased expression of NDC1 mRNA

NCBI chr 5:127,384,172...127,431,093
Ensembl chr 5:127,384,665...127,431,090

G

Nedd4 family interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of NDFIP1 mRNA

NCBI chr18:30,516,931...30,567,199
Ensembl chr18:30,516,981...30,568,471

G

NADH:ubiquinone oxidoreductase subunit A2

increases expression

ISO

Clobetasol results in increased expression of NDUFA2 mRNA

NCBI chr18:28,629,795...28,631,884
Ensembl chr18:28,629,795...28,631,884

G

NADH:ubiquinone oxidoreductase subunit A8

increases expression

ISO

Clobetasol results in increased expression of NDUFA8 mRNA

NCBI chr 3:39,783,479...39,799,507
Ensembl chr 3:39,783,479...39,799,507

G

NADH:ubiquinone oxidoreductase subunit A9

increases expression

ISO

Clobetasol results in increased expression of NDUFA9 mRNA

NCBI chr 4:161,345,398...161,374,188
Ensembl chr 4:161,345,400...161,375,025

G

NADH:ubiquinone oxidoreductase subunit B10

increases expression

ISO

Clobetasol results in increased expression of NDUFB10 mRNA

NCBI chr10:14,253,805...14,255,966
Ensembl chr10:14,253,805...14,255,966

G

NADH:ubiquinone oxidoreductase subunit B3

increases expression

ISO

Clobetasol results in increased expression of NDUFB3 mRNA

NCBI chr 9:67,623,417...67,633,629
Ensembl chr 9:67,623,614...67,633,613

G

NADH:ubiquinone oxidoreductase subunit B5

increases expression

ISO

Clobetasol results in increased expression of NDUFB5 mRNA

NCBI chr 2:117,447,605...117,461,943
Ensembl chr 2:117,447,035...117,461,590

G

NADH:ubiquinone oxidoreductase subunit B6

increases expression

ISO

Clobetasol results in increased expression of NDUFB6 mRNA

NCBI chr 5:60,196,585...60,206,152
Ensembl chr 5:60,196,585...60,206,055

G

NADH:ubiquinone oxidoreductase subunit C1

increases expression

ISO

Clobetasol results in increased expression of NDUFC1 mRNA

NCBI chr 2:137,597,944...137,601,819
Ensembl chr 2:137,600,156...137,601,735

G

NADH:ubiquinone oxidoreductase subunit C2

increases expression

ISO

Clobetasol results in increased expression of NDUFC2 mRNA

NCBI chr 1:161,122,370...161,129,413
Ensembl chr 1:161,123,150...161,129,419

G

NADH:ubiquinone oxidoreductase core subunit S7

increases expression

ISO

Clobetasol results in increased expression of NDUFS7 mRNA

NCBI chr 7:10,103,226...10,110,862
Ensembl chr 7:10,103,227...10,110,691

G

NADH:ubiquinone oxidoreductase core subunit V1

increases expression

ISO

Clobetasol results in increased expression of NDUFV1 mRNA

NCBI chr 1:210,729,856...210,735,103
Ensembl chr 1:210,729,858...210,734,949

G

neural EGFL like 2

increases expression

ISO

Clobetasol results in increased expression of NELL2 mRNA

NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917

G

neuraminidase 1

increases expression

ISO

Clobetasol results in increased expression of NEU1 mRNA

NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383

G

neurofascin

decreases expression

ISO

Clobetasol results in decreased expression of NFASC mRNA

NCBI chr13:46,549,369...46,735,989
Ensembl chr13:46,549,369...46,736,139

G

neuroguidin

increases expression

ISO

Clobetasol results in increased expression of NGDN mRNA

NCBI chr15:32,459,898...32,467,260
Ensembl chr15:32,399,109...32,467,260

G

NHP2 ribonucleoprotein

increases expression

ISO

Clobetasol results in increased expression of NHP2 mRNA

NCBI chr10:36,378,020...36,381,362
Ensembl chr10:36,377,997...36,381,354

G

ninjurin 1

increases expression

ISO

Clobetasol results in increased expression of NINJ1 mRNA

NCBI chr17:15,659,208...15,668,115
Ensembl chr17:15,659,200...15,668,063

G

ninein-like

decreases expression

ISO

Clobetasol results in decreased expression of NINL mRNA

NCBI chr 3:160,208,757...160,275,077
Ensembl chr 3:160,196,883...160,275,108

G

notchless homolog 1

increases expression

ISO

Clobetasol results in increased expression of NLE1 mRNA

NCBI chr10:68,331,609...68,342,562
Ensembl chr10:68,331,609...68,340,386

G

neuroligin 2

decreases expression

ISO

Clobetasol results in decreased expression of NLGN2 mRNA

NCBI chr10:55,042,175...55,056,578
Ensembl chr10:55,043,185...55,056,578

G

NME/NM23 nucleoside diphosphate kinase 1

increases expression

ISO

Clobetasol results in increased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310

G

NME/NM23 nucleoside diphosphate kinase 4

increases expression

ISO

Clobetasol results in increased expression of NME4 mRNA

NCBI chr10:15,619,106...15,622,961
Ensembl chr10:15,619,106...15,623,098

G

NOP10 ribonucleoprotein

increases expression

ISO

Clobetasol results in increased expression of NOP10 mRNA

NCBI chr 3:119,521,255...119,522,340
Ensembl chr 3:119,521,255...119,522,340

G

NOP protein chaperone 1

increases expression

ISO

Clobetasol results in increased expression of NOPCHAP1 mRNA

NCBI chr 7:22,241,236...22,247,150
Ensembl chr 7:22,241,236...22,247,150

G

notch receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of NOTCH1 mRNA

NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613

G

notch receptor 2

decreases expression

ISO

Clobetasol results in decreased expression of NOTCH2 mRNA

NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823

G

NOVA alternative splicing regulator 1

decreases expression

ISO

Clobetasol results in decreased expression of NOVA1 mRNA

NCBI chr 6:69,506,983...69,632,437
Ensembl chr 6:69,506,983...69,632,437

G

NPC intracellular cholesterol transporter 1

increases expression

ISO

Clobetasol results in increased expression of NPC1 mRNA

NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800

G

NPC intracellular cholesterol transporter 2

increases expression

ISO

Clobetasol results in increased expression of NPC2 mRNA

NCBI chr 6:110,128,325...110,149,245
Ensembl chr 6:110,128,325...110,150,004

G

nucleophosmin/nucleoplasmin, 3

increases expression

ISO

Clobetasol results in increased expression of NPM3 mRNA

NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:254,544,664...254,546,649

G

NAD(P)H quinone dehydrogenase 1

increases expression

ISO

Clobetasol results in increased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 1, group D, member 2

decreases expression

ISO

Clobetasol results in decreased expression of NR1D2 mRNA

NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

ISO

Clobetasol results in increased activity of NR1I2 protein
[Clobetasol results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 2, group F, member 1

decreases expression

ISO

Clobetasol results in decreased expression of NR2F1 mRNA

NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

increases expression

ISO

Clobetasol results in increased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220

G

neuronal vesicle trafficking associated 1

increases expression

ISO

Clobetasol results in increased expression of NSG1 mRNA

NCBI chr14:76,861,079...76,882,822
Ensembl chr14:76,860,746...76,883,390

G

NSE3 homolog, SMC5-SMC6 complex component

increases expression

ISO

Clobetasol results in increased expression of NSMCE3 mRNA

NCBI chr 1:127,812,572...127,813,899

G

5'-nucleotidase domain containing 2

increases expression

ISO

Clobetasol results in increased expression of NT5DC2 mRNA

NCBI chr16:6,328,925...6,336,978
Ensembl chr16:6,328,523...6,336,980

G

netrin 1

decreases expression

ISO

Clobetasol results in decreased expression of NTN1 mRNA

NCBI chr10:53,398,852...53,597,595
Ensembl chr10:53,398,852...53,584,060

G

NUBP iron-sulfur cluster assembly factor 2

increases expression

ISO

Clobetasol results in increased expression of NUBP2 mRNA

NCBI chr10:14,407,743...14,411,428
Ensembl chr10:14,407,745...14,411,600

G

nudix hydrolase 9

increases expression

ISO

Clobetasol results in increased expression of NUDT9 mRNA

NCBI chr14:5,980,042...5,997,998
Ensembl chr14:5,980,043...6,005,783

G

nucleoredoxin

increases expression

ISO

Clobetasol results in increased expression of NXN mRNA

NCBI chr10:61,607,557...61,745,807
Ensembl chr10:61,607,568...61,745,807

G

ornithine decarboxylase 1

increases expression

ISO

Clobetasol results in increased expression of ODC1 mRNA

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

olfactomedin 2

increases expression

ISO

Clobetasol results in increased expression of OLFM2 mRNA

NCBI chr 8:27,480,703...27,558,416
Ensembl chr 8:27,480,711...27,558,460

G

oligodendrocyte transcription factor 1

increases expression

ISO

Clobetasol results in increased expression of OLIG1 mRNA

NCBI chr11:44,000,450...44,002,592
Ensembl chr11:44,000,281...44,002,592

G

one cut homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of ONECUT2 mRNA

NCBI chr18:60,101,967...60,161,095
Ensembl chr18:60,102,126...60,107,668

G

prolyl 4-hydroxylase subunit beta

increases expression

ISO

Clobetasol results in increased expression of P4HB mRNA

NCBI chr10:106,335,300...106,346,911
Ensembl chr10:106,335,300...106,346,911

G

prolyl 4-hydroxylase, transmembrane

increases expression

ISO

Clobetasol results in increased expression of P4HTM mRNA

NCBI chr 8:118,153,158...118,172,199
Ensembl chr 8:118,153,158...118,171,002

G

poly(A) binding protein, cytoplasmic 1

decreases expression

ISO

Clobetasol results in decreased expression of PABPC1 mRNA

NCBI chr 7:69,662,513...69,674,806
Ensembl chr 7:69,663,068...69,675,050

G

presenilin associated, rhomboid-like

increases expression

ISO

Clobetasol results in increased expression of PARL mRNA

NCBI chr11:94,097,559...94,124,915
Ensembl chr11:94,097,934...94,148,287

G

poly (ADP-ribose) polymerase 1

decreases expression

ISO

Clobetasol results in decreased expression of PARP1 mRNA

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

PBX homeobox interacting protein 1

decreases expression

ISO

Clobetasol results in decreased expression of PBXIP1 mRNA

NCBI chr 2:177,154,056...177,167,810
Ensembl chr 2:177,154,101...177,167,328

G

protocadherin 10

decreases expression

ISO

Clobetasol results in decreased expression of PCDH10 mRNA

NCBI chr 2:130,553,432...130,619,591
Ensembl chr 2:130,553,425...130,613,407

G

protocadherin 17

decreases expression

ISO

Clobetasol results in decreased expression of PCDH17 mRNA

NCBI chr15:66,631,549...66,725,007
Ensembl chr15:66,633,142...66,722,105

G

protocadherin gamma subfamily A, 2

decreases expression

ISO

Clobetasol results in decreased expression of PCDHGA2 mRNA

NCBI chr18:29,745,189...29,919,095

G

protocadherin gamma subfamily C, 3

decreases expression

ISO

Clobetasol results in decreased expression of PCDHGC3 mRNA

NCBI chr18:29,884,245...29,919,095

G

PCF11 cleavage and polyadenylation factor subunit

increases expression

ISO

Clobetasol results in increased expression of PCF11 mRNA

NCBI chr 1:156,109,724...156,136,950
Ensembl chr 1:156,109,724...156,136,435

G

procollagen C-endopeptidase enhancer

increases expression

ISO

Clobetasol results in increased expression of PCOLCE mRNA

NCBI chr12:24,720,972...24,727,287
Ensembl chr12:24,720,936...24,727,287

G

prenylcysteine oxidase 1 like

increases expression

ISO

Clobetasol results in increased expression of PCYOX1L mRNA

NCBI chr18:57,420,971...57,431,632
Ensembl chr18:57,420,977...57,431,632

G

phosducin-like 3

increases expression

ISO

Clobetasol results in increased expression of PDCL3 mRNA

NCBI chr 9:48,730,083...48,738,554
Ensembl chr 9:48,723,767...48,739,529

G

protein disulfide isomerase family A, member 4

increases expression

ISO

Clobetasol results in increased expression of PDIA4 mRNA

NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191

G

protein disulfide isomerase family A, member 6

increases expression

ISO

Clobetasol results in increased expression of PDIA6 mRNA

NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091

G

pseudopodium-enriched atypical kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of PEAK1 mRNA

NCBI chr 8:65,501,068...65,715,768
Ensembl chr 8:65,505,043...65,715,111

G

phosphatidylethanolamine binding protein 1

increases expression

ISO

Clobetasol results in increased expression of PEBP1 mRNA

NCBI chr12:44,946,307...44,967,890
Ensembl chr12:44,963,675...44,971,780

G

prefoldin subunit 6

increases expression

ISO

Clobetasol results in increased expression of PFDN6 mRNA

NCBI chr20:4,947,844...4,949,318
Ensembl chr20:4,947,844...4,949,318

G

profilin 1

increases expression

ISO

Clobetasol results in increased expression of PFN1 mRNA

NCBI chr10:55,863,882...55,866,587
Ensembl chr10:55,863,881...55,868,611

G

phosphoglycerate mutase 1

increases expression

ISO

Clobetasol results in increased expression of PGAM1 mRNA

NCBI chr 1:250,673,152...250,680,762
Ensembl chr 1:250,673,049...250,690,203

G

phosphogluconate dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of PGD mRNA

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

phosphoglycerate kinase 1

increases expression

ISO

Clobetasol results in increased expression of PGK1 mRNA

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959

G

prohibitin 1

increases expression

ISO

Clobetasol results in increased expression of PHB1 mRNA

NCBI chr10:81,102,043...81,114,815
Ensembl chr10:81,102,028...81,116,233

G

PHD finger protein 3

decreases expression

ISO

Clobetasol results in decreased expression of PHF3 mRNA

NCBI chr 9:40,559,929...40,632,096
Ensembl chr 9:40,559,929...40,632,056

G

PHD finger protein 5A

increases expression

ISO

Clobetasol results in increased expression of PHF5A mRNA

NCBI chr 7:115,258,609...115,265,174
Ensembl chr 7:115,258,609...115,265,174

G

phosphoglycerate dehydrogenase

increases expression

ISO

Clobetasol results in increased expression of PHGDH mRNA

NCBI chr 2:188,595,700...188,624,789
Ensembl chr 2:188,595,700...188,624,789

G

PHD and ring finger domains 1

decreases expression

ISO

Clobetasol results in decreased expression of PHRF1 mRNA

NCBI chr 1:205,763,264...205,796,478
Ensembl chr 1:205,763,549...205,801,557

G

phosphatidylinositol glycan anchor biosynthesis, class S

increases expression

ISO

Clobetasol results in increased expression of PIGS mRNA

NCBI chr10:63,720,568...63,735,255
Ensembl chr10:63,720,661...63,735,253

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta

decreases expression

ISO

Clobetasol results in decreased expression of PIK3C2B mRNA

NCBI chr13:47,046,866...47,107,733
Ensembl chr13:47,047,127...47,107,725

G

phosphoinositide-3-kinase regulatory subunit 1

increases expression

ISO

Clobetasol results in increased expression of PIK3R1 mRNA

NCBI chr 2:34,612,946...34,697,660
Ensembl chr 2:34,612,946...34,626,347

G

Pim-3 proto-oncogene, serine/threonine kinase

increases expression

ISO

Clobetasol results in increased expression of PIM3 mRNA

NCBI chr 7:121,822,076...121,836,257
Ensembl chr 7:121,832,742...121,836,259

G

phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

increases expression

ISO

Clobetasol results in increased expression of PIP4K2A mRNA

NCBI chr17:86,405,080...86,576,597
Ensembl chr17:86,405,081...86,576,430

G

phosphatidylinositol-4,5-bisphosphate 4-phosphatase 2

increases expression

ISO

Clobetasol results in increased expression of PIP4P2 mRNA

NCBI chr 5:33,057,046...33,104,448
Ensembl chr 5:33,056,684...33,104,451

G

pyruvate kinase M1/2

increases expression

ISO

Clobetasol results in increased expression of PKM mRNA

NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396

G

phospholipase C, gamma 2

decreases expression

ISO

Clobetasol results in decreased expression of PLCG2 mRNA

NCBI chr19:62,456,196...62,592,684
Ensembl chr19:62,453,259...62,592,684

G

polo-like kinase 2

increases expression

ISO

Clobetasol results in increased expression of PLK2 mRNA

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1

increases expression

ISO

Clobetasol results in increased expression of PLOD1 mRNA

NCBI chr 5:163,623,847...163,650,737
Ensembl chr 5:163,623,848...163,651,110

G

procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3

increases expression

ISO

Clobetasol results in increased expression of PLOD3 mRNA

NCBI chr12:25,313,070...25,323,631
Ensembl chr12:25,313,072...25,323,631

G

phospholipid transfer protein

increases expression

ISO

Clobetasol results in increased expression of PLTP mRNA

NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:173,994,162...174,012,505

G

plexin A1

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA1 mRNA

NCBI chr 4:123,295,165...123,340,132
Ensembl chr 4:123,297,244...123,340,428

G

plexin A2

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA2 mRNA

NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453

G

plexin A4

decreases expression

ISO

Clobetasol results in decreased expression of PLXNA4 mRNA

NCBI chr 4:61,687,483...62,129,467
Ensembl chr 4:61,687,510...62,129,445

G

plexin C1

decreases expression

ISO

Clobetasol results in decreased expression of PLXNC1 mRNA

NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:31,276,978...31,431,092

G

plexin D1

decreases expression

ISO

Clobetasol results in decreased expression of PLXND1 mRNA

NCBI chr 4:150,675,377...150,715,706
Ensembl chr 4:150,675,377...150,715,566

G

RNA polymerase I and III subunit C

increases expression

ISO

Clobetasol results in increased expression of POLR1C mRNA

NCBI chr 9:22,233,318...22,237,430
Ensembl chr 9:22,233,305...22,237,428

G

RNA polymerase I and III subunit D

increases expression

ISO

Clobetasol results in increased expression of POLR1D mRNA

NCBI chr12:13,084,505...13,118,069
Ensembl chr12:13,084,512...13,095,627

G

RNA polymerase II subunit A

decreases expression

ISO

Clobetasol results in decreased expression of POLR2A mRNA

NCBI chr10:54,951,162...54,977,179
Ensembl chr10:54,951,162...54,977,179

G

RNA polymerase II subunit I

increases expression

ISO

Clobetasol results in increased expression of POLR2I mRNA

NCBI chr 1:94,610,976...94,612,413
Ensembl chr 1:94,610,942...94,613,000

G

RNA polymerase II, I and III subunit L

increases expression

ISO

Clobetasol results in increased expression of POLR2L mRNA

NCBI chr 1:205,999,607...206,001,615
Ensembl chr19:8,341,868...8,342,071

G

RNA polymerase III subunit H

increases expression

ISO

Clobetasol results in increased expression of POLR3H mRNA

NCBI chr 7:115,309,571...115,319,881
Ensembl chr 7:115,309,589...115,319,915

G

RNA polymerase III subunit K

increases expression

ISO

Clobetasol results in increased expression of POLR3K mRNA

NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:189,360,171...189,366,697

G

peptidylprolyl isomerase E

increases expression

ISO

Clobetasol results in increased expression of PPIE mRNA

NCBI chr 5:140,691,285...140,704,347
Ensembl chr 5:140,683,801...140,740,767

G

peptidylprolyl isomerase like 1

increases expression

ISO

Clobetasol results in increased expression of PPIL1 mRNA

NCBI chr20:7,303,919...7,323,962
Ensembl chr20:7,303,922...7,318,781

G

protein phosphatase, Mg2+/Mn2+ dependent, 1K

increases expression

ISO

Clobetasol results in increased expression of PPM1K mRNA

NCBI chr 4:88,942,226...88,969,139
Ensembl chr 4:88,942,386...88,969,136

G

protein phosphatase methylesterase 1

increases expression

ISO

Clobetasol results in increased expression of PPME1 mRNA

NCBI chr 1:164,080,242...164,127,261
Ensembl chr 1:164,080,242...164,127,220

G

protein phosphatase 1 catalytic subunit alpha

increases expression

ISO

Clobetasol results in increased expression of PPP1CA mRNA

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193

G

protein phosphatase 1 catalytic subunit beta

increases expression

ISO

Clobetasol results in increased expression of PPP1CB mRNA

NCBI chr 6:29,681,099...29,712,835
Ensembl chr 6:29,681,100...29,712,924

G

protein phosphatase 1, regulatory (inhibitor) subunit 14B

increases expression

ISO

Clobetasol results in increased expression of PPP1R14B mRNA

NCBI chr 1:213,594,416...213,596,527
Ensembl chr12:21,088,517...21,101,431
Ensembl chr 1:21,088,517...21,101,431

G

protein phosphatase 1, regulatory subunit 26

decreases expression

ISO

Clobetasol results in decreased expression of PPP1R26 mRNA

NCBI chr 3:32,179,686...32,188,069
Ensembl chr 3:32,177,235...32,188,264

G

protein phosphatase 1, regulatory subunit 35

increases expression

ISO

Clobetasol results in increased expression of PPP1R35 mRNA

NCBI chr12:24,552,709...24,556,040

G

protein phosphatase 1, regulatory subunit 3C

increases expression

ISO

Clobetasol results in increased expression of PPP1R3C mRNA

NCBI chr 1:243,873,524...243,878,527
Ensembl chr 1:243,871,704...243,878,835

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

ISO

Clobetasol results in increased expression of PPP2R1A mRNA

NCBI chr 1:69,213,198...69,232,441
Ensembl chr 1:69,213,038...69,238,242

G

protein phosphatase 4, catalytic subunit

increases expression

ISO

Clobetasol results in increased expression of PPP4C mRNA

NCBI chr 1:190,823,447...190,830,247
Ensembl chr 1:190,823,486...190,830,168

G

protein phosphatase 5, catalytic subunit

increases expression

ISO

Clobetasol results in increased expression of PPP5C mRNA

NCBI chr 1:86,818,297...86,842,505
Ensembl chr 1:86,818,297...86,842,950

G

PEAK1 related kinase activating pseudokinase 1

decreases expression

ISO

Clobetasol results in decreased expression of PRAG1 mRNA

NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532

G

peroxiredoxin 1

increases expression

ISO

Clobetasol results in increased expression of PRDX1 mRNA

NCBI chr 5:135,383,906...135,399,504
Ensembl chr 5:135,383,906...135,399,504

G

peroxiredoxin 2

increases expression

ISO

Clobetasol results in increased expression of PRDX2 mRNA

NCBI chr19:40,085,788...40,091,083
Ensembl chr19:40,084,430...40,091,006

G

peroxiredoxin 3

increases expression

ISO

Clobetasol results in increased expression of PRDX3 mRNA

NCBI chr 1:269,987,691...270,000,111
Ensembl chr 1:269,987,685...270,000,300

G

peroxiredoxin 5

increases expression

ISO

Clobetasol results in increased expression of PRDX5 mRNA

NCBI chr 1:213,529,042...213,532,787
Ensembl chr 1:213,529,035...213,533,020

G

protein kinase C, alpha

decreases expression

ISO

Clobetasol results in decreased expression of PRKCA mRNA

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

protein kinase C, beta

decreases expression

ISO

Clobetasol results in decreased expression of PRKCB mRNA

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

proline-rich basic protein 1

decreases expression

ISO

Clobetasol results in decreased expression of PROB1 mRNA

NCBI chr18:27,516,599...27,521,443
Ensembl chr18:27,516,332...27,523,808

G

phosphoribosyl pyrophosphate synthetase 2

increases expression

ISO

Clobetasol results in increased expression of PRPS2 mRNA

NCBI chr X:30,592,845...30,630,127
Ensembl chr X:30,593,019...30,630,126

G

proline rich 12

decreases expression

ISO

Clobetasol results in decreased expression of PRR12 mRNA

NCBI chr 1:104,646,492...104,670,454
Ensembl chr 1:104,646,492...104,670,454

G

proline-rich coiled-coil 2B

decreases expression

ISO

Clobetasol results in decreased expression of PRRC2B mRNA

NCBI chr 3:35,831,017...35,916,854
Ensembl chr 3:35,863,046...35,916,854

G

proline-rich coiled-coil 2C

decreases expression

ISO

Clobetasol results in decreased expression of PRRC2C mRNA

NCBI chr13:77,537,226...77,606,926
Ensembl chr13:77,537,814...77,607,001

G

prune homolog 2 with BCH domain

increases expression

ISO

Clobetasol results in increased expression of PRUNE2 mRNA

NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592

G

proteasome 20S subunit alpha 2

increases expression

ISO

Clobetasol results in increased expression of PSMA2 mRNA

NCBI chr17:55,250,054...55,260,441
Ensembl chr17:55,247,442...55,339,673

G

proteasome 20S subunit alpha 5

increases expression

ISO

Clobetasol results in increased expression of PSMA5 mRNA

NCBI chr 2:198,584,502...198,607,867
Ensembl chr 2:198,584,505...198,607,867

G

proteasome 20S subunit alpha 6

increases expression

ISO

Clobetasol results in increased expression of PSMA6 mRNA

NCBI chr 6:78,500,676...78,531,693
Ensembl chr 6:78,500,736...78,531,717

G

proteasome 20S subunit beta 3

increases expression

ISO

Clobetasol results in increased expression of PSMB3 mRNA

NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883

G

proteasome 20S subunit beta 4

increases expression

ISO

Clobetasol results in increased expression of PSMB4 mRNA

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

proteasome 20S subunit beta 5

increases expression

ISO

Clobetasol results in increased expression of PSMB5 mRNA

NCBI chr15:32,042,784...32,047,379
Ensembl chr15:32,042,787...32,047,379

G

proteasome 20S subunit beta 7

increases expression

ISO

Clobetasol results in increased expression of PSMB7 mRNA

NCBI chr 3:42,767,500...42,827,470
Ensembl chr 3:42,767,501...42,827,601

G

proteasome 26S subunit, ATPase 5

increases expression

ISO

Clobetasol results in increased expression of PSMC5 mRNA

NCBI chr10:91,687,553...91,693,487
Ensembl chr10:91,686,295...91,695,921

G

proteasome 26S subunit, non-ATPase 13

increases expression

ISO

Clobetasol results in increased expression of PSMD13 mRNA

NCBI chr 1:205,394,248...205,406,525
Ensembl chr 1:205,393,746...205,411,651

G

proteasome 26S subunit, non-ATPase 6

increases expression

ISO

Clobetasol results in increased expression of PSMD6 mRNA

NCBI chr15:13,532,675...13,542,682
Ensembl chr15:13,532,675...13,542,682

G

phosphoserine phosphatase

increases expression

ISO

Clobetasol results in increased expression of PSPH mRNA

NCBI chr12:32,527,091...32,541,182
Ensembl chr12:32,519,269...32,541,180

G

polypyrimidine tract binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of PTBP2 mRNA

NCBI chr 2:210,497,610...210,558,497
Ensembl chr 2:210,497,706...210,558,291

G

pentatricopeptide repeat domain 2

increases expression

ISO

Clobetasol results in increased expression of PTCD2 mRNA

NCBI chr 2:32,446,441...32,474,114
Ensembl chr 2:32,446,182...32,474,285

G

phosphatidylserine synthase 2

increases expression

ISO

Clobetasol results in increased expression of PTDSS2 mRNA

NCBI chr 1:205,671,024...205,695,556
Ensembl chr 1:205,671,041...205,695,553

G

prostaglandin E synthase 2

increases expression

ISO

Clobetasol results in increased expression of PTGES2 mRNA

NCBI chr 3:36,088,246...36,095,430
Ensembl chr 3:36,088,246...36,097,694

G

prostaglandin F2 receptor inhibitor

increases expression

ISO

Clobetasol results in increased expression of PTGFRN mRNA

NCBI chr 2:191,158,166...191,233,432
Ensembl chr 2:191,158,166...191,234,115

G

protein phosphatase 2 phosphatase activator

increases expression

ISO

Clobetasol results in increased expression of PTPA mRNA

NCBI chr 3:34,087,637...34,118,100
Ensembl chr 3:34,087,575...34,162,772

G

protein tyrosine phosphatase, receptor type, F

decreases expression

ISO

Clobetasol results in decreased expression of PTPRF mRNA

NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426

G

protein tyrosine phosphatase, receptor type, S

decreases expression

ISO

Clobetasol results in decreased expression of PTPRS mRNA

NCBI chr 9:1,332,558...1,394,161
Ensembl chr 9:1,332,559...1,394,093

G

PTTG1 interacting protein

increases expression

ISO

Clobetasol results in increased expression of PTTG1IP mRNA

NCBI chr20:11,029,608...11,047,395
Ensembl chr20:11,029,608...11,046,909

G

peroxisomal membrane protein 2

increases expression

ISO

Clobetasol results in increased expression of PXMP2 mRNA

NCBI chr12:52,053,951...52,064,283
Ensembl chr12:52,053,788...52,064,283

G

pyrroline-5-carboxylate reductase 2

increases expression

ISO

Clobetasol results in increased expression of PYCR2 mRNA

NCBI chr13:95,158,236...95,162,030
Ensembl chr13:95,158,183...95,162,029

G

quinoid dihydropteridine reductase

increases expression

ISO

Clobetasol results in increased expression of QDPR mRNA

NCBI chr14:69,882,776...69,896,378
Ensembl chr14:69,882,612...69,896,379

G

glutamine and serine rich 1

decreases expression

ISO

Clobetasol results in decreased expression of QSER1 mRNA

NCBI chr 3:111,592,377...111,658,825
Ensembl chr 3:111,595,171...111,657,103

G

R3H domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of R3HDM1 mRNA

NCBI chr13:42,148,281...42,286,311
Ensembl chr13:42,148,290...42,286,311

G

RAB1A, member RAS oncogene family

increases expression

ISO

Clobetasol results in increased expression of RAB1A mRNA

NCBI chr14:98,623,582...98,648,766
Ensembl chr14:98,623,635...98,661,582

G

RAB, member RAS oncogene family-like 6

decreases expression

ISO

Clobetasol results in decreased expression of RABL6 mRNA

NCBI chr 3:28,800,802...28,826,722
Ensembl chr 3:28,800,802...28,826,722

G

Ras association (RalGDS/AF-6) and pleckstrin homology domains 1

decreases expression

ISO

Clobetasol results in decreased expression of RAPH1 mRNA

NCBI chr 9:69,397,272...69,484,174
Ensembl chr 9:69,401,517...69,484,019

G

ribonucleoprotein, PTB-binding 2

increases expression

ISO

Clobetasol results in increased expression of RAVER2 mRNA

NCBI chr 5:120,796,807...120,898,281
Ensembl chr 5:120,800,126...120,895,825

G

RB binding protein 4, chromatin remodeling factor

increases expression

ISO

Clobetasol results in increased expression of RBBP4 mRNA

NCBI chr 5:146,940,207...146,959,501
Ensembl chr 5:146,922,611...146,959,501

G

RB binding protein 6, ubiquitin ligase

decreases expression

ISO

Clobetasol results in decreased expression of RBBP6 mRNA

NCBI chr 1:186,934,563...186,966,852
Ensembl chr 1:186,934,938...186,966,852

G

RNA binding motif protein 15B

decreases expression

ISO

Clobetasol results in decreased expression of RBM15B mRNA

NCBI chr 8:116,422,309...116,425,374
Ensembl chr 8:116,421,540...116,425,940

G

regulator of chromosome condensation 2

increases expression

ISO

Clobetasol results in increased expression of RCC2 mRNA

NCBI chr 5:158,277,476...158,300,294
Ensembl chr 5:158,277,476...158,300,294

G

receptor accessory protein 5

increases expression

ISO

Clobetasol results in increased expression of REEP5 mRNA

NCBI chr18:26,219,528...26,257,505
Ensembl chr18:26,219,530...26,250,660

G

arginine-glutamic acid dipeptide repeats

decreases expression

ISO

Clobetasol results in decreased expression of RERE mRNA

NCBI chr 5:166,048,770...166,380,559
Ensembl chr 5:166,048,844...166,380,558

G

REV3 like, DNA directed polymerase zeta catalytic subunit

decreases expression

ISO

Clobetasol results in decreased expression of REV3L mRNA

NCBI chr20:44,686,482...44,844,668
Ensembl chr20:44,686,940...44,844,668

G

required for excision 1-B domain containing

increases expression

ISO

Clobetasol results in increased expression of REX1BD mRNA

NCBI chr16:18,956,023...18,958,494
Ensembl chr16:18,955,969...18,958,494

G

refilin B

increases expression

ISO

Clobetasol results in increased expression of RFLNB mRNA

NCBI chr10:61,391,947...61,398,224
Ensembl chr10:61,390,659...61,398,224

G

regulatory factor X, 7

decreases expression

ISO

Clobetasol results in decreased expression of RFX7 mRNA

NCBI chr 8:82,134,747...82,219,898
Ensembl chr 8:82,134,747...82,219,898

G

Ras homolog, mTORC1 binding

increases expression

ISO

Clobetasol results in increased expression of RHEB mRNA

NCBI chr 4:11,012,173...11,053,860
Ensembl chr 4:11,012,643...11,053,931

G

ras homolog family member T2

increases expression

ISO

Clobetasol results in increased expression of RHOT2 mRNA

NCBI chr10:15,363,467...15,369,263
Ensembl chr10:15,361,726...15,369,006

G

ring finger protein 145

increases expression

ISO

Clobetasol results in increased expression of RNF145 mRNA

NCBI chr10:29,507,779...29,552,153
Ensembl chr10:29,507,772...29,552,151

G

ring finger protein 168

decreases expression

ISO

Clobetasol results in decreased expression of RNF168 mRNA

NCBI chr11:81,991,352...82,013,306
Ensembl chr11:81,991,360...82,013,306

G

ring finger protein 187

increases expression

ISO

Clobetasol results in increased expression of RNF187 mRNA

NCBI chr10:44,209,080...44,214,979
Ensembl chr10:44,202,332...44,215,470

G

ring finger protein 5

increases expression

ISO

Clobetasol results in increased expression of RNF5 mRNA

NCBI chr20:4,150,032...4,152,593
Ensembl chr20:4,150,138...4,152,591

G

Ro60, Y RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of RO60 mRNA

NCBI chr13:58,049,838...58,070,828
Ensembl chr13:58,049,858...58,076,264

G

roundabout guidance receptor 1

decreases expression

ISO

Clobetasol results in decreased expression of ROBO1 mRNA

NCBI chr11:24,067,869...25,108,694
Ensembl chr11:24,067,878...25,108,694

G

Rho-associated coiled-coil containing protein kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of ROCK1 mRNA

NCBI chr18:1,387,360...1,509,218
Ensembl chr18:1,387,360...1,509,147

G

ribosomal protein L12

increases expression

ISO

Clobetasol results in increased expression of RPL12 mRNA

NCBI chr 3:36,661,940...36,664,314
Ensembl chr 3:36,661,939...36,664,306

G

ribosomal protein L13

increases expression

ISO

Clobetasol results in increased expression of RPL13 mRNA

NCBI chr19:68,062,442...68,065,065
Ensembl chr19:68,062,493...68,065,059

G

ribosomal protein L13A

decreases expression

ISO

Clobetasol results in decreased expression of RPL13A mRNA

NCBI chr 1:104,746,223...104,748,975
Ensembl chr 1:104,746,223...104,748,914

G

ribosomal protein L14

increases expression

ISO

Clobetasol results in increased expression of RPL14 mRNA

NCBI chr 8:129,163,620...129,166,745
Ensembl chr 8:129,163,317...129,167,459

G

ribosomal protein L18

increases expression

ISO

Clobetasol results in increased expression of RPL18 mRNA

NCBI chr 1:105,325,269...105,327,911
Ensembl chr 1:105,325,250...105,327,910

G

ribosomal protein L24

increases expression

ISO

Clobetasol results in increased expression of RPL24 mRNA

NCBI chr11:58,122,997...58,128,405
Ensembl chr11:58,122,997...58,128,405

G

ribosomal protein L27

increases expression

ISO

Clobetasol results in increased expression of RPL27 mRNA

NCBI chr10:86,875,758...86,879,457
Ensembl chr10:86,876,024...86,879,441

G

ribosomal protein L37A

increases expression

ISO

Clobetasol results in increased expression of RPL37A mRNA

NCBI chr 9:81,748,091...81,750,174
Ensembl chr 9:81,748,103...81,751,975

G

ribosomal protein L39

increases expression

ISO

Clobetasol results in increased expression of RPL39 mRNA

NCBI chr X:121,192,901...121,195,896
Ensembl chr 7:31,721,884...31,722,039
Ensembl chr15:31,721,884...31,722,039
Ensembl chr X:31,721,884...31,722,039

G

ribosomal protein L8

increases expression

ISO

Clobetasol results in increased expression of RPL8 mRNA

NCBI chr 7:110,506,815...110,509,106
Ensembl chr 7:110,506,800...110,509,103
Ensembl chr 3:110,506,800...110,509,103

G

ribosomal protein L9

increases expression

ISO

Clobetasol results in increased expression of RPL9 mRNA

NCBI chr14:43,247,536...43,250,784
Ensembl chr14:43,247,588...43,250,782
Ensembl chr 1:43,247,588...43,250,782

G

ribosomal protein lateral stalk subunit P0

increases expression

ISO

Clobetasol results in increased expression of RPLP0 mRNA

NCBI chr12:46,715,121...46,718,390
Ensembl chr12:46,715,124...46,718,422

G

ribophorin II

increases expression

ISO

Clobetasol results in increased expression of RPN2 mRNA

NCBI chr 3:166,361,955...166,409,272
Ensembl chr 3:166,362,049...166,409,922

G

ribonuclease P/MRP subunit p25 like

increases expression

ISO

Clobetasol results in increased expression of RPP25L mRNA

NCBI chr 5:61,674,299...61,675,844
Ensembl chr 5:61,672,199...61,675,168

G

ribosomal protein S11

increases expression

ISO

Clobetasol results in increased expression of RPS11 mRNA

NCBI chr 1:104,742,153...104,744,261
Ensembl chr 1:104,742,155...104,744,337

G

ribosomal protein S14

affects expression

ISO

Clobetasol affects the expression of RPS14 mRNA

NCBI chr18:56,492,010...56,503,092
Ensembl chr18:56,498,245...56,503,091

G

ribosomal protein S15a

increases expression

ISO

Clobetasol results in increased expression of RPS15A mRNA

NCBI chr 1:181,854,396...181,861,330
Ensembl chr 1:181,854,396...181,861,201

G

ribosomal protein S18

increases expression

ISO

Clobetasol results in increased expression of RPS18 mRNA

NCBI chr20:4,933,741...4,937,423
Ensembl chr20:4,917,095...4,937,423

G

ribosomal protein S27-like

increases expression

ISO

Clobetasol results in increased expression of RPS27L mRNA

NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130
Ensembl chr 8:33,713,661...33,714,130

G

ribosomal protein S5

increases expression

ISO

Clobetasol results in increased expression of RPS5 mRNA

NCBI chr 1:82,610,965...82,615,262
Ensembl chr 1:82,610,965...82,615,262

G

ribosomal protein S8

increases expression

ISO

Clobetasol results in increased expression of RPS8 mRNA

NCBI chr 5:135,866,941...135,869,511
Ensembl chr 5:135,866,941...135,869,548

G

remodeling and spacing factor 1

decreases expression

ISO

Clobetasol results in decreased expression of RSF1 mRNA

NCBI chr 1:161,303,596...161,426,326
Ensembl chr 1:161,303,660...161,420,290

G

ribosomal L24 domain containing 1

increases expression

ISO

Clobetasol results in increased expression of RSL24D1 mRNA

NCBI chr 8:82,733,627...82,742,632
Ensembl chr 8:82,733,649...82,744,497

G

RT1 class II, locus DMa

increases expression

ISO

Clobetasol results in increased expression of H2-DMA mRNA

NCBI chr20:4,708,932...4,712,335
Ensembl chr20:4,708,933...4,712,335

G

RNA 2',3'-cyclic phosphate and 5'-OH ligase

increases expression

ISO

Clobetasol results in increased expression of RTCB mRNA

NCBI chr 7:19,795,393...19,814,875
Ensembl chr 7:19,795,393...19,814,875

G

retrotransposon Gag like 5

decreases expression

ISO

Clobetasol results in decreased expression of RTL5 mRNA

NCBI chr X:71,223,914...71,228,713
Ensembl chr X:71,221,371...71,232,653

G

reticulon 4 interacting protein 1

increases expression

ISO

Clobetasol results in increased expression of RTN4IP1 mRNA

NCBI chr20:48,964,903...49,004,235
Ensembl chr20:48,964,816...49,006,456

G

RuvB-like AAA ATPase 2

increases expression

ISO

Clobetasol results in increased expression of RUVBL2 mRNA

NCBI chr 1:105,038,487...105,051,851
Ensembl chr 1:105,038,174...105,051,720

G

ryanodine receptor 3

decreases expression

ISO

Clobetasol results in decreased expression of RYR3 mRNA

NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677

G

S100 calcium binding protein A10

increases expression

ISO

Clobetasol results in increased expression of S100A10 mRNA

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103

G

SAC3 domain containing 1

increases expression

ISO

Clobetasol results in increased expression of SAC3D1 mRNA

NCBI chr 1:212,843,463...212,845,842
Ensembl chr 1:212,843,463...212,845,883

G

spalt-like transcription factor 1

decreases expression

ISO

Clobetasol results in decreased expression of SALL1 mRNA

NCBI chr19:34,179,316...34,196,278
Ensembl chr19:34,181,078...34,196,278

G

sterile alpha motif domain containing 4B

decreases expression

ISO

Clobetasol results in decreased expression of SAMD4B mRNA

NCBI chr 1:92,816,955...92,855,243
Ensembl chr 1:92,809,800...92,841,393

G

SAMM50 sorting and assembly machinery component

increases expression

ISO

Clobetasol results in increased expression of SAMM50 mRNA

NCBI chr 7:117,197,460...117,221,668
Ensembl chr 7:117,197,381...117,224,581

G

S-adenosylmethionine sensor upstream of mTORC1

increases expression

ISO

Clobetasol results in increased expression of SAMTOR mRNA

NCBI chr 4:42,847,720...42,911,546
Ensembl chr 4:42,836,172...42,917,567

G

Sin3A associated protein 18

increases expression

ISO

Clobetasol results in increased expression of SAP18 mRNA

NCBI chr15:36,058,784...36,063,089
Ensembl chr10:87,156,914...87,158,257
Ensembl chr15:87,156,914...87,158,257

G

Sin3A associated protein 30

increases expression

ISO

Clobetasol results in increased expression of SAP30 mRNA

NCBI chr16:37,758,494...37,763,825
Ensembl chr16:37,757,656...37,763,823

G

secretion associated, Ras related GTPase 1A

increases expression

ISO

Clobetasol results in increased expression of SAR1A mRNA

NCBI chr20:30,166,310...30,178,718
Ensembl chr20:30,166,334...30,178,710

G

secretion associated, Ras related GTPase 1B

increases expression

ISO

Clobetasol results in increased expression of SAR1B mRNA

NCBI chr10:36,525,365...36,555,009
Ensembl chr10:36,519,384...36,555,005

G

store-operated calcium entry-associated regulatory factor

increases expression

ISO

Clobetasol results in increased expression of SARAF mRNA

NCBI chr16:64,720,404...64,738,653
Ensembl chr16:64,720,418...64,738,653

G

SAM and SH3 domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of SASH1 mRNA

NCBI chr 1:4,940,207...5,238,777
Ensembl chr 1:4,940,207...5,238,530

G

strawberry notch homolog 2

decreases expression

ISO

Clobetasol results in decreased expression of SBNO2 mRNA

NCBI chr 7:10,256,221...10,300,175
Ensembl chr 7:10,253,248...10,300,176

G

SR-related CTD-associated factor 11

decreases expression

ISO

Clobetasol results in decreased expression of SCAF11 mRNA

NCBI chr 7:129,450,872...129,503,280
Ensembl chr 7:129,417,955...129,503,280

G

stearoyl-CoA desaturase

increases expression

ISO

Clobetasol results in increased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

stimulator of chondrogenesis 1

increases expression

ISO

Clobetasol results in increased expression of SCRG1 mRNA

NCBI chr16:37,770,739...37,799,010
Ensembl chr16:37,770,739...37,799,010

G

syndecan 4

increases expression

ISO

Clobetasol results in increased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670

G

stromal cell derived factor 2

increases expression

ISO

Clobetasol results in increased expression of SDF2 mRNA

NCBI chr10:63,638,634...63,649,109
Ensembl chr10:63,638,634...63,649,108

G

stromal cell-derived factor 2-like 1

increases expression

ISO

Clobetasol results in increased expression of SDF2L1 mRNA

NCBI chr11:97,376,878...97,379,120
Ensembl chr11:97,376,878...97,379,120

G

succinate dehydrogenase complex flavoprotein subunit A

increases expression

ISO

Clobetasol results in increased expression of SDHA mRNA

NCBI chr 1:30,764,553...30,789,523
Ensembl chr 1:30,764,590...30,790,121

G

succinate dehydrogenase complex subunit C

increases expression

ISO

Clobetasol results in increased expression of SDHC mRNA

NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044

G

sidekick cell adhesion molecule 2

decreases expression

ISO

Clobetasol results in decreased expression of SDK2 mRNA

NCBI chr10:99,324,047...99,601,683
Ensembl chr10:99,324,047...99,601,683

G

SEC11 homolog A, signal peptidase complex subunit

increases expression

ISO

Clobetasol results in increased expression of SEC11A mRNA

NCBI chr 1:144,290,680...144,318,658
Ensembl chr 1:144,284,497...144,324,009

G

SEC13 homolog, nuclear pore and COPII coat complex component

increases expression

ISO

Clobetasol results in increased expression of SEC13 mRNA

NCBI chr 4:148,433,344...148,446,735
Ensembl chr 4:148,433,349...148,446,755

G

SEC61 translocon subunit alpha 1

increases expression

ISO

Clobetasol results in increased expression of SEC61A1 mRNA

NCBI chr 4:122,530,785...122,545,141
Ensembl chr 4:122,530,789...122,545,141

G

SEC61 translocon subunit beta

increases expression

ISO

Clobetasol results in increased expression of SEC61B mRNA

NCBI chr 5:66,569,184...66,577,394
Ensembl chr 5:66,569,196...66,580,028

G

SEL1L family member 3

increases expression

ISO

Clobetasol results in increased expression of SEL1L3 mRNA

NCBI chr14:61,988,350...62,095,542
Ensembl chr14:61,988,346...62,095,542

G

selenium binding protein 1

increases expression

ISO

Clobetasol results in increased expression of SELENBP1 mRNA

NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:185,183,004...185,194,295

G

selenoprotein K

increases expression

ISO

Clobetasol results in increased expression of SELENOK mRNA

NCBI chr16:5,158,601...5,167,183
Ensembl chr16:5,158,621...5,168,512

G

serine incorporator 5

increases expression

ISO

Clobetasol results in increased expression of SERINC5 mRNA

NCBI chr 2:25,581,952...25,685,403
Ensembl chr 2:25,581,951...25,685,403

G

serpin family E member 2

increases expression

ISO

Clobetasol results in increased expression of SERPINE2 mRNA

NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202

G

SET binding protein 1

decreases expression

ISO

Clobetasol results in decreased expression of SETBP1 mRNA

NCBI chr18:74,465,616...74,827,455
Ensembl chr18:74,465,616...74,827,455

G

SET domain containing 1A, histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of SETD1A mRNA

NCBI chr 1:191,818,752...191,842,167
Ensembl chr 1:191,818,752...191,842,160

G

SET domain containing 2, histone lysine methyltransferase

decreases expression

ISO

Clobetasol results in decreased expression of SETD2 mRNA

NCBI chr 8:119,390,207...119,475,863
Ensembl chr 8:119,390,207...119,475,863

G

splicing factor 3b, subunit 3

increases expression

ISO

Clobetasol results in increased expression of SF3B3 mRNA

NCBI chr19:55,692,124...55,729,640
Ensembl chr19:55,692,126...55,729,621

G

small G protein signaling modulator 2

decreases expression

ISO

Clobetasol results in decreased expression of SGSM2 mRNA

NCBI chr10:60,216,556...60,258,199
Ensembl chr10:60,216,556...60,257,817

G

SH3 domain binding glutamate-rich protein like 3

increases expression

ISO

Clobetasol results in increased expression of SH3BGRL3 mRNA

NCBI chr 5:151,637,897...151,639,270
Ensembl chr 5:151,637,674...151,639,395

G

SH3-domain binding protein 4

decreases expression

ISO

Clobetasol results in decreased expression of SH3BP4 mRNA

NCBI chr 9:97,107,877...97,186,878
Ensembl chr 9:97,107,877...97,186,878

G

SH3 domain containing 19

decreases expression

ISO

Clobetasol results in decreased expression of SH3D19 mRNA

NCBI chr 2:173,654,234...173,814,030
Ensembl chr 2:173,654,420...173,814,025

G

shisa family member 3

increases expression

ISO

Clobetasol results in increased expression of SHISA3 mRNA

NCBI chr14:40,917,563...40,922,135
Ensembl chr14:40,917,564...40,922,135

G

solute carrier family 10 member 6

increases expression

ISO

Clobetasol results in increased expression of SLC10A6 mRNA

NCBI chr14:6,385,348...6,407,532
Ensembl chr14:6,385,537...6,408,894

G

solute carrier family 11 member 2

increases expression

ISO

Clobetasol results in increased expression of SLC11A2 mRNA

NCBI chr 7:133,381,878...133,429,921
Ensembl chr 7:133,381,878...133,418,941

G

solute carrier family 12, member 9

increases expression

ISO

Clobetasol results in increased expression of SLC12A9 mRNA

NCBI chr12:25,005,741...25,022,628
Ensembl chr12:25,005,738...25,022,607

G

solute carrier family 25 member 11

increases expression

ISO

Clobetasol results in increased expression of SLC25A11 mRNA

NCBI chr10:55,856,209...55,859,060
Ensembl chr10:55,855,979...55,859,060

G

solute carrier family 25 member 18

increases expression

ISO

Clobetasol results in increased expression of SLC25A18 mRNA

NCBI chr 4:155,672,939...155,693,549
Ensembl chr 4:155,673,169...155,693,548

G

solute carrier family 25 member 29

increases expression

ISO

Clobetasol results in increased expression of SLC25A29 mRNA

NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:133,506,331...133,517,827

G

solute carrier family 25 member 3

increases expression

ISO

Clobetasol results in increased expression of SLC25A3 mRNA

NCBI chr 7:27,499,164...27,506,685
Ensembl chr 7:27,499,165...27,506,309

G

solute carrier family 25 member 33

increases expression

ISO

Clobetasol results in increased expression of SLC25A33 mRNA

NCBI chr 5:165,478,070...165,518,186
Ensembl chr 5:165,478,072...165,502,973

G

solute carrier family 25, member 39

increases expression

ISO

Clobetasol results in increased expression of SLC25A39 mRNA

NCBI chr10:87,862,630...87,867,626
Ensembl chr10:87,862,631...87,866,973

G

solute carrier family 25 member 4

increases expression

ISO

Clobetasol results in increased expression of SLC25A4 mRNA

NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700

G

solute carrier family 25 member 5

increases expression

ISO

Clobetasol results in increased expression of SLC25A5 mRNA

NCBI chr X:120,897,616...120,900,683
Ensembl chr X:120,897,563...120,900,688

G

solute carrier family 2 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 35 member A1

increases expression

ISO

Clobetasol results in increased expression of SLC35A1 mRNA

NCBI chr 5:54,021,896...54,044,677
Ensembl chr 5:54,021,896...54,044,677

G

solute carrier family 38, member 2

increases expression

ISO

Clobetasol results in increased expression of SLC38A2 mRNA

NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619

G

solute carrier family 39 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC39A1 mRNA

NCBI chr 2:178,001,052...178,006,689
Ensembl chr 2:178,001,119...178,006,689

G

solute carrier family 44, member 5

increases expression

ISO

Clobetasol results in increased expression of SLC44A5 mRNA

NCBI chr 2:245,570,875...245,866,369
Ensembl chr 2:245,570,829...245,867,780

G

solute carrier family 48 member 1

increases expression

ISO

Clobetasol results in increased expression of SLC48A1 mRNA

NCBI chr 7:130,794,233...130,802,119
Ensembl chr 7:130,794,245...130,803,022

G

solute carrier family 6 member 1

decreases expression

ISO

Clobetasol results in decreased expression of SLC6A1 mRNA

NCBI chr 4:149,004,447...149,037,840
Ensembl chr 4:149,004,635...149,037,839

G

solute carrier family 6 member 9

increases expression

ISO

Clobetasol results in increased expression of SLC6A9 mRNA

NCBI chr 5:136,660,022...136,694,173
Ensembl chr 5:136,659,948...136,694,172

G

solute carrier family 7 member 5

increases expression

ISO

Clobetasol results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

slit guidance ligand 3

increases expression

ISO

Clobetasol results in increased expression of SLIT3 mRNA

NCBI chr10:20,075,929...20,660,704
Ensembl chr10:20,076,021...20,660,704

G

SLX4 structure-specific endonuclease subunit

decreases expression

ISO

Clobetasol results in decreased expression of SLX4 mRNA

NCBI chr10:12,032,131...12,055,685
Ensembl chr10:12,033,048...12,055,650

G

small integral membrane protein 7

increases expression

ISO

Clobetasol results in increased expression of SMIM7 mRNA

NCBI chr16:17,308,466...17,312,384
Ensembl chr16:17,308,395...17,312,371

G

staphylococcal nuclease and tudor domain containing 1

increases expression

ISO

Clobetasol results in increased expression of SND1 mRNA

NCBI chr 4:58,060,689...58,459,926
Ensembl chr 4:58,060,640...58,459,925

G

sushi, nidogen and EGF-like domains 1

decreases expression

ISO

Clobetasol results in decreased expression of SNED1 mRNA

NCBI chr 9:101,221,497...101,281,401
Ensembl chr 9:101,221,530...101,281,401

G

small nuclear ribonucleoprotein U11/U12 subunit 25

increases expression

ISO

Clobetasol results in increased expression of SNRNP25 mRNA

NCBI chr10:15,924,932...15,928,279
Ensembl chr10:15,924,940...15,928,252

G

small nuclear ribonucleoprotein U5 subunit 40

increases expression

ISO

Clobetasol results in increased expression of SNRNP40 mRNA

NCBI chr 5:147,984,758...148,017,932
Ensembl chr 5:147,984,656...148,018,725

G

small nuclear ribonucleoprotein polypeptides B and B1

increases expression

ISO

Clobetasol results in increased expression of SNRPB mRNA

NCBI chr 3:137,824,870...137,832,479
Ensembl chr 3:137,824,683...137,832,515

G

small nuclear ribonucleoprotein D2 polypeptide

increases expression

ISO

Clobetasol results in increased expression of SNRPD2 mRNA

NCBI chr 1:87,926,030...87,929,259
Ensembl chr 1:87,926,048...87,933,339
Ensembl chr20:87,926,048...87,933,339

G

sorting nexin 17

increases expression

ISO

Clobetasol results in increased expression of SNX17 mRNA

NCBI chr 6:30,897,500...30,902,972
Ensembl chr 6:30,897,501...30,902,972

G

sine oculis binding protein homolog

decreases expression

ISO

Clobetasol results in decreased expression of SOBP mRNA

NCBI chr20:48,064,445...48,243,607
Ensembl chr20:48,064,445...48,243,607

G

SON DNA and RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of SON mRNA

NCBI chr11:44,336,818...44,409,127
Ensembl chr11:44,377,976...44,409,127

G

SRY-box transcription factor 11

decreases expression

ISO

Clobetasol results in decreased expression of SOX11 mRNA

NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691

G

SRY-box transcription factor 4

decreases expression

ISO

Clobetasol results in decreased expression of SOX4 mRNA

NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024

G

SRY-box transcription factor 6

decreases expression

ISO

Clobetasol results in decreased expression of SOX6 mRNA

NCBI chr 1:179,157,678...179,769,243
Ensembl chr 1:179,163,566...179,711,727

G

SRY-box transcription factor 9

decreases expression

ISO

Clobetasol results in decreased expression of SOX9 mRNA

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

signal peptidase complex subunit 2

increases expression

ISO

Clobetasol results in increased expression of SPCS2 mRNA

NCBI chr 1:163,575,842...163,595,269
Ensembl chr 1:163,575,842...163,595,271

G

sperm antigen with calponin homology and coiled-coil domains 1

decreases expression

ISO

Clobetasol results in decreased expression of SPECC1 mRNA

NCBI chr10:47,138,351...47,412,311
Ensembl chr10:47,138,398...47,412,319

G

SPARC/osteonectin, cwcv and kazal like domains proteoglycan 2

increases expression

ISO

Clobetasol results in increased expression of SPOCK2 mRNA

NCBI chr20:28,580,262...28,607,198
Ensembl chr20:28,580,226...28,608,409

G

sprouty RTK signaling antagonist 4

increases expression

ISO

Clobetasol results in increased expression of SPRY4 mRNA

NCBI chr18:30,687,633...30,702,546
Ensembl chr18:30,687,039...30,704,173

G

SPRY domain containing 4

increases expression

ISO

Clobetasol results in increased expression of SPRYD4 mRNA

NCBI chr 7:1,217,984...1,222,231
Ensembl chr 7:1,218,122...1,219,942

G

spectrin, beta, non-erythrocytic 1

decreases expression

ISO

Clobetasol results in decreased expression of SPTBN1 mRNA

NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836

G

spectrin, beta, non-erythrocytic 2

decreases expression

ISO

Clobetasol results in decreased expression of SPTBN2 mRNA

NCBI chr 1:211,432,373...211,473,016
Ensembl chr 1:211,432,373...211,473,306

G

serine palmitoyltransferase, small subunit A

increases expression

ISO

Clobetasol results in increased expression of SPTSSA mRNA

NCBI chr 6:77,879,931...77,891,344
Ensembl chr 6:77,879,941...77,891,403

G

Snf2-related CREBBP activator protein

decreases expression

ISO

Clobetasol results in decreased expression of SRCAP mRNA

NCBI chr 1:191,554,043...191,607,096
Ensembl chr 1:191,554,043...191,604,265

G

SRC kinase signaling inhibitor 1

decreases expression

ISO

Clobetasol results in decreased expression of SRCIN1 mRNA

NCBI chr10:82,999,295...83,066,359
Ensembl chr10:82,991,033...83,067,419

G

SLIT-ROBO Rho GTPase activating protein 3

decreases expression

ISO

Clobetasol results in decreased expression of SRGAP3 mRNA

NCBI chr 4:147,391,082...147,626,407
Ensembl chr 4:147,395,880...147,625,713

G

spermidine synthase

increases expression

ISO

Clobetasol results in increased expression of SRM mRNA

NCBI chr 5:164,309,002...164,312,203
Ensembl chr 5:164,308,991...164,332,705

G

SRP receptor subunit alpha

increases expression

ISO

Clobetasol results in increased expression of SRPRA mRNA

NCBI chr 8:41,818,199...41,824,292
Ensembl chr 8:41,818,229...41,824,280

G

sulfiredoxin 1

increases expression

ISO

Clobetasol results in increased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

SS18 like 2

increases expression

ISO

Clobetasol results in increased expression of SS18L2 mRNA

NCBI chr 8:130,252,774...130,255,388
Ensembl chr 8:130,252,782...130,257,367

G

signal sequence receptor subunit 3

increases expression

ISO

Clobetasol results in increased expression of SSR3 mRNA

NCBI chr 2:151,915,101...151,935,162
Ensembl chr 2:151,906,149...151,935,170

G

steroidogenic acute regulatory protein

decreases expression

ISO

Clobetasol results in decreased expression of STAR mRNA

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

StAR-related lipid transfer domain containing 4

increases expression

ISO

Clobetasol results in increased expression of STARD4 mRNA

NCBI chr18:25,088,831...25,104,172
Ensembl chr18:25,091,255...25,104,172

G

StAR-related lipid transfer domain containing 9

decreases expression

ISO

Clobetasol results in decreased expression of STARD9 mRNA

NCBI chr 3:128,034,866...128,150,493
Ensembl chr 3:128,034,908...128,127,402

G

stathmin 3

increases expression

ISO

Clobetasol results in increased expression of STMN3 mRNA

NCBI chr 3:188,794,358...188,802,494
Ensembl chr 3:188,794,358...188,802,873

G

stonin 2

decreases expression

ISO

Clobetasol results in decreased expression of STON2 mRNA

NCBI chr 6:116,291,898...116,441,391
Ensembl chr 6:116,298,198...116,407,092

G

STIP1 homology and U-box containing protein 1

increases expression

ISO

Clobetasol results in increased expression of STUB1 mRNA

NCBI chr10:15,355,278...15,357,559
Ensembl chr10:15,355,279...15,357,559

G

SUB1 regulator of transcription

increases expression

ISO

Clobetasol results in increased expression of SUB1 mRNA

NCBI chr 2:62,735,379...62,747,545
Ensembl chr 2:62,732,736...62,747,679

G

SUN domain containing ossification factor

decreases expression

ISO

Clobetasol results in decreased expression of SUCO mRNA

NCBI chr13:76,726,095...76,791,174
Ensembl chr13:76,726,859...76,791,174

G

SPT6 homolog, histone chaperone and transcription elongation factor

decreases expression

ISO

Clobetasol results in decreased expression of SUPT6 mRNA

NCBI chr10:63,601,990...63,638,851
Ensembl chr10:63,601,993...63,638,851

G

surfeit 4

increases expression

ISO

Clobetasol results in increased expression of SURF4 mRNA

NCBI chr 3:30,646,435...30,659,641
Ensembl chr 3:30,638,299...30,661,390

G

spectrin repeat containing nuclear envelope protein 1

decreases expression

ISO

Clobetasol results in decreased expression of SYNE1 mRNA

NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721

G

spectrin repeat containing nuclear envelope protein 2

decreases expression

ISO

Clobetasol results in decreased expression of SYNE2 mRNA

NCBI chr 6:100,272,729...100,586,364
Ensembl chr 6:100,272,729...100,583,723

G

synergin, gamma

decreases expression

ISO

Clobetasol results in decreased expression of SYNRG mRNA

NCBI chr10:69,346,154...69,428,714
Ensembl chr10:69,322,114...69,428,714

G

TGF-beta activated kinase 1/MAP3K7 binding protein 2

decreases expression

ISO

Clobetasol results in decreased expression of TAB2 mRNA

NCBI chr 1:4,195,400...4,245,485
Ensembl chr 1:4,195,400...4,245,485

G

transgelin 2

increases expression

ISO

Clobetasol results in increased expression of TAGLN2 mRNA

NCBI chr13:87,499,350...87,506,328
Ensembl chr13:87,499,394...87,506,330

G

TAO kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of TAOK1 mRNA

NCBI chr10:62,871,198...62,989,049
Ensembl chr10:62,871,198...62,957,595

G

transcription activation suppressor family member 2

decreases expression

ISO

Clobetasol results in decreased expression of TASOR2 mRNA

NCBI chr17:71,504,656...71,559,878
Ensembl chr17:71,504,822...71,559,035

G

tubulin folding cofactor C

increases expression

ISO

Clobetasol results in increased expression of TBCC mRNA

NCBI chr 9:21,596,472...21,597,660
Ensembl chr 9:21,595,615...21,597,842

G

tubulin folding cofactor D

increases expression

ISO

Clobetasol results in increased expression of TBCD mRNA

NCBI chr10:107,215,626...107,372,398
Ensembl chr10:107,215,633...107,372,402

G

transcriptional and immune response regulator

increases expression

ISO

Clobetasol results in increased expression of TCIM mRNA

NCBI chr16:74,298,344...74,299,637
Ensembl chr16:74,298,344...74,299,636

G

TEF transcription factor, PAR bZIP family member

decreases expression

ISO

Clobetasol results in decreased expression of TEF mRNA

NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:115,193,282...115,221,928

G

TEN1 subunit of CST complex

increases expression

ISO

Clobetasol results in increased expression of TEN1 mRNA

NCBI chr10:101,930,212...101,951,932
Ensembl chr10:101,930,222...101,953,979

G

TIA1 cytotoxic granule-associated RNA binding protein

decreases expression

ISO

Clobetasol results in decreased expression of TIA1 mRNA

NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665

G

translocase of inner mitochondrial membrane 10

increases expression

ISO

Clobetasol results in increased expression of TIMM10 mRNA

NCBI chr 3:90,315,048...90,318,613
Ensembl chr 3:90,315,092...90,318,614

G

translocase of inner mitochondrial membrane 13

increases expression

ISO

Clobetasol results in increased expression of TIMM13 mRNA

NCBI chr 7:9,459,490...9,460,849
Ensembl chr 7:9,459,582...9,460,862

G

translocase of inner mitochondrial membrane 8A1

increases expression

ISO

Clobetasol results in increased expression of TIMM8A1 mRNA

NCBI chr X:102,011,206...102,015,444
Ensembl chr X:102,011,206...102,015,444

G

TIMP metallopeptidase inhibitor 4

increases expression

ISO

Clobetasol results in increased expression of TIMP4 mRNA

NCBI chr 4:149,978,667...149,985,350
Ensembl chr 4:149,978,685...149,985,452

G

talin 1

decreases expression

ISO

Clobetasol results in decreased expression of TLN1 mRNA

NCBI chr 5:62,583,730...62,613,687
Ensembl chr 5:62,583,731...62,613,687

G

TM2 domain containing 2

increases expression

ISO

Clobetasol results in increased expression of TM2D2 mRNA

NCBI chr16:73,719,331...73,724,853
Ensembl chr16:73,719,332...73,724,981

G

transmembrane p24 trafficking protein 3

increases expression

ISO

Clobetasol results in increased expression of TMED3 mRNA

NCBI chr 8:99,121,361...99,129,653
Ensembl chr 8:99,121,361...99,129,215

G

transmembrane p24 trafficking protein 4

increases expression

ISO

Clobetasol results in increased expression of TMED4 mRNA

NCBI chr14:85,338,980...85,343,577
Ensembl chr14:85,338,980...85,343,577

G

transmembrane protein 101

increases expression

ISO

Clobetasol results in increased expression of TMEM101 mRNA

NCBI chr10:87,605,300...87,609,053
Ensembl chr10:87,605,300...87,608,999

G

transmembrane protein 109

increases expression

ISO

Clobetasol results in increased expression of TMEM109 mRNA

NCBI chr 1:216,944,516...216,955,091
Ensembl chr 1:216,944,519...216,955,138

G

transmembrane protein 128

increases expression

ISO

Clobetasol results in increased expression of TMEM128 mRNA

NCBI chr14:76,751,848...76,761,576
Ensembl chr14:76,752,603...76,772,217

G

transmembrane protein 131

decreases expression

ISO

Clobetasol results in decreased expression of TMEM131 mRNA

NCBI chr 9:46,512,328...46,658,624
Ensembl chr 9:46,512,328...46,658,481

G

transmembrane protein 135

increases expression

ISO

Clobetasol results in increased expression of TMEM135 mRNA

NCBI chr 1:152,418,929...152,692,405
Ensembl chr 1:152,418,930...152,633,717

G

transmembrane protein 151B

decreases expression

ISO

Clobetasol results in decreased expression of TMEM151B mRNA

NCBI chr 9:22,953,881...22,961,726
Ensembl chr 9:22,953,881...22,961,726

G

transmembrane protein 160

increases expression

ISO

Clobetasol results in increased expression of TMEM160 mRNA

NCBI chr 1:86,292,582...86,295,290
Ensembl chr 1:86,292,753...86,297,780

G

transmembrane protein 179

increases expression

ISO

Clobetasol results in increased expression of TMEM179 mRNA

NCBI chr 6:137,390,422...137,401,438
Ensembl chr 6:137,390,423...137,401,438

G

transmembrane protein 208

increases expression

ISO

Clobetasol results in increased expression of TMEM208 mRNA

NCBI chr19:50,113,494...50,116,210
Ensembl chr19:50,113,510...50,124,153

G

transmembrane protein 229A

increases expression

ISO

Clobetasol results in increased expression of TMEM229A mRNA

NCBI chr 4:54,405,822...54,410,802
Ensembl chr 4:54,399,867...54,412,225

G

transmembrane protein 256

increases expression

ISO

Clobetasol results in increased expression of TMEM256 mRNA

NCBI chr10:55,056,959...55,058,869
Ensembl chr10:55,056,760...55,058,862

G

transmembrane protein 35A

increases expression

ISO

Clobetasol results in increased expression of TMEM35A mRNA

NCBI chr X:101,796,623...101,807,471
Ensembl chr X:101,796,623...101,807,470

G

transmembrane protein 43

increases expression

ISO

Clobetasol results in increased expression of TMEM43 mRNA

NCBI chr 4:125,534,844...125,549,986
Ensembl chr 4:125,534,813...125,549,988

G

transmembrane protein 50B

increases expression

ISO

Clobetasol results in increased expression of TMEM50B mRNA

NCBI chr11:44,290,805...44,323,650
Ensembl chr11:44,290,807...44,323,607

G

transmembrane protein 59

increases expression

ISO

Clobetasol results in increased expression of TMEM59 mRNA

NCBI chr 5:127,191,320...127,212,436
Ensembl chr 5:127,191,030...127,217,531

G

transmembrane protein 97

increases expression

ISO

Clobetasol results in increased expression of TMEM97 mRNA

NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818

G

tumor necrosis factor

decreases secretion

ISO

Clobetasol results in decreased secretion of TNF protein

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 1A

increases expression

ISO

Clobetasol results in increased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

tenascin R

decreases expression

ISO

Clobetasol results in decreased expression of TNR mRNA

NCBI chr13:74,285,141...74,706,174
Ensembl chr13:74,507,366...74,701,115

G

trinucleotide repeat containing 18

decreases expression

ISO

Clobetasol results in decreased expression of TNRC18 mRNA

NCBI chr12:16,868,930...16,965,224
Ensembl chr12:16,868,978...16,965,217

G

transducer of ERBB2, 2

increases expression

ISO

Clobetasol results in increased expression of TOB2 mRNA

NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:115,239,895...115,258,155

G

toll interacting protein

increases expression

ISO

Clobetasol results in increased expression of TOLLIP mRNA

NCBI chr 1:206,391,120...206,413,809
Ensembl chr 1:206,380,308...206,411,988

G

triosephosphate isomerase 1

increases expression

ISO

Clobetasol results in increased expression of TPI1 mRNA

NCBI chr 4:159,301,558...159,305,088
Ensembl chr 4:159,301,562...159,305,413

G

translocated promoter region, nuclear basket protein

decreases expression

ISO

Clobetasol results in decreased expression of TPR mRNA

NCBI chr13:64,974,419...65,037,604
Ensembl chr13:64,974,419...65,037,602

G

taperin

increases expression

ISO

Clobetasol results in increased expression of TPRN mRNA

NCBI chr 3:28,474,322...28,481,800
Ensembl chr 3:28,473,620...28,482,117

G

transformer 2 alpha

decreases expression

ISO

Clobetasol results in decreased expression of TRA2A mRNA

NCBI chr 4:79,551,699...79,570,621
Ensembl chr 4:79,551,542...79,570,619

G

TP53 regulated inhibitor of apoptosis 1

increases expression

ISO

Clobetasol results in increased expression of TRIAP1 mRNA

NCBI chr12:46,928,273...46,930,766
Ensembl chr12:46,928,273...46,930,766

G

TLR4 interactor with leucine-rich repeats

decreases expression

ISO

Clobetasol results in decreased expression of TRIL mRNA

NCBI chr 4:84,252,781...84,257,626
Ensembl chr 4:84,239,028...84,260,209

G

tripartite motif-containing 35

increases expression

ISO

Clobetasol results in increased expression of TRIM35 mRNA

NCBI chr15:44,669,222...44,685,766
Ensembl chr15:44,656,322...44,685,765

G

tripartite motif-containing 67

decreases expression

ISO

Clobetasol results in decreased expression of TRIM67 mRNA

NCBI chr19:69,659,857...69,703,290
Ensembl chr19:69,661,777...69,698,805

G

trio Rho guanine nucleotide exchange factor

decreases expression

ISO

Clobetasol results in decreased expression of TRIO mRNA

NCBI chr 2:80,235,485...80,531,824
Ensembl chr 2:80,235,485...80,531,612

G

tRNA methyltransferase 10B

increases expression

ISO

Clobetasol results in increased expression of TRMT10B mRNA

NCBI chr 5:64,344,491...64,368,175
Ensembl chr 5:64,344,545...64,368,172

G

transformation/transcription domain-associated protein

decreases expression

ISO

Clobetasol results in decreased expression of TRRAP mRNA

NCBI chr12:14,851,758...14,941,444
Ensembl chr12:14,851,758...14,941,407

G

TSC22 domain family, member 1

decreases expression

ISO

Clobetasol results in decreased expression of TSC22D1 mRNA

NCBI chr15:58,159,612...58,260,244
Ensembl chr15:58,159,952...58,183,322

G

TSC22 domain family, member 3

increases expression

ISO

Clobetasol results in increased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

TSC22 domain family, member 4

increases expression

ISO

Clobetasol results in increased expression of TSC22D4 mRNA

NCBI chr12:24,575,948...24,588,806
Ensembl chr12:24,567,176...24,587,894

G

translin

increases expression

ISO

Clobetasol results in increased expression of TSN mRNA

NCBI chr13:31,917,133...31,930,069
Ensembl chr13:31,919,231...31,930,417

G

tetraspanin 13

increases expression

ISO

Clobetasol results in increased expression of TSPAN13 mRNA

NCBI chr 6:58,466,051...58,492,804
Ensembl chr 6:58,465,684...58,492,819

G

tetraspanin 3

increases expression

ISO

Clobetasol results in increased expression of TSPAN3 mRNA

NCBI chr 8:65,442,100...65,465,961
Ensembl chr 8:65,442,101...65,465,844

G

tetraspanin 31

increases expression

ISO

Clobetasol results in increased expression of TSPAN31 mRNA

NCBI chr 7:64,774,881...64,783,534
Ensembl chr 7:64,774,910...64,777,726

G

tau tubulin kinase 1

decreases expression

ISO

Clobetasol results in decreased expression of TTBK1 mRNA

NCBI chr 9:21,990,973...22,035,961
Ensembl chr 9:21,990,973...22,035,961

G

tetratricopeptide repeat domain 17

decreases expression

ISO

Clobetasol results in decreased expression of TTC17 mRNA

NCBI chr 3:100,718,820...100,829,464
Ensembl chr 3:100,718,827...100,829,129

G

tetratricopeptide repeat domain 28

decreases expression

ISO

Clobetasol results in decreased expression of TTC28 mRNA

NCBI chr12:51,002,816...51,443,461
Ensembl chr12:51,005,089...51,443,531

G

tubulin tyrosine ligase like 12

increases expression

ISO

Clobetasol results in increased expression of TTLL12 mRNA

NCBI chr 7:116,612,609...116,631,244
Ensembl chr 7:116,612,609...116,631,577

G

TUB bipartite transcription factor

decreases expression

ISO

Clobetasol results in decreased expression of TUB mRNA

NCBI chr 1:172,386,772...172,465,791
Ensembl chr 1:172,382,197...172,465,790

G

tubulin, alpha 1A

increases expression

ISO

Clobetasol results in increased expression of TUBA1A mRNA

NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035

G

tubulin, alpha 1B

increases expression

ISO

Clobetasol results in increased expression of TUBA1B mRNA

NCBI chr 7:131,969,606...131,972,587
Ensembl chr 7:131,968,770...131,996,035

G

tubulin, alpha 1C

increases expression

ISO

Clobetasol results in increased expression of TUBA1C mRNA

NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311

G

tubulin, beta 2A class IIa

increases expression

ISO

Clobetasol results in increased expression of TUBB2A mRNA

NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838

G

tubulin, beta 5 class I

increases expression

ISO

Clobetasol results in increased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

taxilin beta

decreases expression

ISO

Clobetasol results in decreased expression of TXLNB mRNA

NCBI chr 1:14,224,647...14,269,837
Ensembl chr 1:14,195,329...14,269,835

G

thioredoxin-like 1

increases expression

ISO

Clobetasol results in increased expression of TXNL1 mRNA

NCBI chr18:59,397,275...59,428,072
Ensembl chr18:59,398,535...59,435,518

G

tRNA-yW synthesizing protein 5

increases expression

ISO

Clobetasol results in increased expression of TYW5 mRNA

NCBI chr 9:66,455,364...66,473,446
Ensembl chr 9:66,455,370...66,473,446

G

UBA domain containing 2

increases expression

ISO

Clobetasol results in increased expression of UBAC2 mRNA

NCBI chr15:105,366,776...105,514,435
Ensembl chr15:105,366,697...105,514,444

G

UBA-like domain containing 2

increases expression

ISO

Clobetasol results in increased expression of UBALD2 mRNA

NCBI chr10:102,161,370...102,165,952
Ensembl chr10:102,160,866...102,168,041

G

ubiquitin-conjugating enzyme E2G 2

increases expression

ISO

Clobetasol results in increased expression of UBE2G2 mRNA

NCBI chr20:10,983,322...11,005,060
Ensembl chr20:10,983,325...11,005,187

G

ubiquitin family domain containing 1

increases expression

ISO

Clobetasol results in increased expression of UBFD1 mRNA

NCBI chr 1:186,057,267...186,068,832
Ensembl chr 1:186,057,123...186,066,103

G

ubiquitin-like 5

increases expression

ISO

Clobetasol results in increased expression of UBL5 mRNA

NCBI chr 8:27,457,738...27,461,458

G

ubiquitin protein ligase E3 component n-recognin 4

decreases expression

ISO

Clobetasol results in decreased expression of UBR4 mRNA

NCBI chr 5:156,919,029...157,027,127
Ensembl chr 5:156,919,085...157,027,127

G

ubiquitin protein ligase E3 component n-recognin 7

increases expression

ISO

Clobetasol results in increased expression of UBR7 mRNA

NCBI chr 6:127,663,454...127,683,302
Ensembl chr 6:127,663,447...127,694,390

G

UBX domain protein 4

decreases expression

ISO

Clobetasol results in decreased expression of UBXN4 mRNA

NCBI chr13:42,292,346...42,324,928
Ensembl chr13:42,292,528...42,326,143

G

uncoupling protein 2

increases expression

ISO

Clobetasol results in increased expression of UCP2 mRNA

NCBI chr 1:164,251,373...164,257,742
Ensembl chr 1:164,251,373...164,257,743

G

unc-80 homolog, NALCN channel complex subunit

decreases expression

ISO

Clobetasol results in decreased expression of UNC80 mRNA

NCBI chr 9:75,461,618...75,639,849
Ensembl chr 9:75,461,599...75,639,842

G

ubiquinol-cytochrome c reductase complex assembly factor 2

increases expression

ISO

Clobetasol results in increased expression of UQCC2 mRNA

NCBI chr20:5,204,682...5,217,080
Ensembl chr17:12,088,037...12,088,606
Ensembl chr20:12,088,037...12,088,606

G

ubiquinol-cytochrome c reductase, complex III subunit X

increases expression

ISO

Clobetasol results in increased expression of UQCR10 mRNA

NCBI chr14:83,789,657...83,791,914
Ensembl chr14:83,789,658...83,791,914

G

ubiquinol-cytochrome c reductase core protein 1

increases expression

ISO

Clobetasol results in increased expression of UQCRC1 mRNA

NCBI chr 8:118,468,223...118,479,968
Ensembl chr 8:118,468,200...118,479,964

G

ubiquitin specific peptidase 34

decreases expression

ISO

Clobetasol results in decreased expression of USP34 mRNA

NCBI chr14:101,487,110...101,677,519
Ensembl chr14:101,487,153...101,678,632

G

ubiquitin specific peptidase 54

increases expression

ISO

Clobetasol results in increased expression of USP54 mRNA

NCBI chr15:3,706,013...3,806,935
Ensembl chr15:3,741,311...3,806,932

G

UTP14A small subunit processome component

decreases expression

ISO

Clobetasol results in decreased expression of UTP14A mRNA

NCBI chr X:132,317,163...132,342,524
Ensembl chr X:132,317,159...132,342,523

G

utrophin

decreases expression

ISO

Clobetasol results in decreased expression of UTRN mRNA

NCBI chr 1:8,541,061...9,044,487
Ensembl chr 1:8,542,798...9,044,487

G

vasohibin 1

increases expression

ISO

Clobetasol results in increased expression of VASH1 mRNA

NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689

G

vascular cell adhesion molecule 1

decreases expression

ISO

Clobetasol results in decreased expression of VCAM1 mRNA

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

voltage-dependent anion channel 1

increases expression

ISO

Clobetasol results in increased expression of VDAC1 mRNA

NCBI chr10:37,029,377...37,060,542
Ensembl chr10:37,023,145...37,060,541

G

voltage-dependent anion channel 2

increases expression

ISO

Clobetasol results in increased expression of VDAC2 mRNA

NCBI chr15:2,512,214...2,526,105
Ensembl chr15:2,512,216...2,532,229

G

vimentin

increases expression

ISO

Clobetasol results in increased expression of VIM mRNA

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vitamin K epoxide reductase complex, subunit 1

increases expression

ISO

Clobetasol results in increased expression of VKORC1 mRNA

NCBI chr 1:191,932,969...191,935,490

G

vacuolar protein sorting 13 homolog B

decreases expression

ISO

Clobetasol results in decreased expression of VPS13B mRNA

NCBI chr 7:68,436,996...69,013,574
Ensembl chr 7:68,443,655...69,013,574

G

VPS37B subunit of ESCRT-I

decreases expression

ISO

Clobetasol results in decreased expression of VPS37B mRNA

NCBI chr12:38,220,973...38,249,935
Ensembl chr12:38,220,959...38,249,935

G

vexin

decreases expression

ISO

Clobetasol results in decreased expression of VXN mRNA

NCBI chr 5:14,442,040...14,467,500
Ensembl chr 5:14,442,040...14,467,500

G

WASP family member 1

decreases expression

ISO

Clobetasol results in decreased expression of WASF1 mRNA

NCBI chr20:45,908,458...45,956,118
Ensembl chr20:45,908,750...45,955,640

G

WW domain binding protein 2

increases expression

ISO

Clobetasol results in increased expression of WBP2 mRNA

NCBI chr10:101,811,308...101,819,766
Ensembl chr10:101,812,321...101,819,770

G

WD repeat and FYVE domain containing 3

decreases expression

ISO

Clobetasol results in decreased expression of WDFY3 mRNA

NCBI chr14:7,873,946...8,115,002
Ensembl chr14:7,911,151...8,114,993

G

WD repeat domain 26

decreases expression

ISO

Clobetasol results in decreased expression of WDR26 mRNA

NCBI chr13:95,462,017...95,503,826
Ensembl chr13:95,462,020...95,503,738

G

WD repeat domain 46

increases expression

ISO

Clobetasol results in increased expression of WDR46 mRNA

NCBI chr20:4,939,721...4,947,619
Ensembl chr20:4,939,732...4,947,741

G

wolframin ER transmembrane glycoprotein

increases expression

ISO

Clobetasol results in increased expression of WFS1 mRNA

NCBI chr14:78,035,205...78,059,718
Ensembl chr14:78,034,864...78,060,459

G

WAS/WASL interacting protein family, member 2

decreases expression

ISO

Clobetasol results in decreased expression of WIPF2 mRNA

NCBI chr10:84,317,305...84,357,862
Ensembl chr10:84,317,334...84,356,123

G

Wnt family member 7A

decreases expression

ISO

Clobetasol results in decreased expression of WNT7A mRNA

NCBI chr 4:125,420,276...125,466,149
Ensembl chr 4:125,420,276...125,466,149

G

WSC domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of WSCD1 mRNA

NCBI chr10:56,884,404...56,924,013
Ensembl chr10:56,884,583...56,924,013

G

WT1 associated protein

decreases expression

ISO

Clobetasol results in decreased expression of WTAP mRNA

NCBI chr 1:50,070,973...50,096,074
Ensembl chr 1:50,070,769...50,096,072

G

WW and C2 domain containing 2

decreases expression

ISO

Clobetasol results in decreased expression of WWC2 mRNA

NCBI chr16:50,991,096...51,154,529
Ensembl chr16:50,991,096...51,154,526

G

Yip1 interacting factor homolog A, membrane trafficking protein

increases expression

ISO

Clobetasol results in increased expression of YIF1A mRNA

NCBI chr 1:211,823,921...211,828,437
Ensembl chr 1:211,824,273...211,828,802

G

Yip1 domain family, member 3

increases expression

ISO

Clobetasol results in increased expression of YIPF3 mRNA

NCBI chr 9:22,227,867...22,233,177
Ensembl chr 9:22,227,871...22,233,177

G

YLP motif containing 1

decreases expression

ISO

Clobetasol results in decreased expression of YLPM1 mRNA

NCBI chr 6:110,373,371...110,449,578
Ensembl chr 6:110,373,686...110,449,578

G

yippee-like 4

decreases expression

ISO

Clobetasol results in decreased expression of YPEL4 mRNA

NCBI chr 3:90,222,060...90,227,395
Ensembl chr 3:90,222,803...90,227,381

G

YTH N6-methyladenosine RNA binding protein C1

decreases expression

ISO

Clobetasol results in decreased expression of YTHDC1 mRNA

NCBI chr14:21,540,276...21,570,724
Ensembl chr14:21,540,278...21,570,769

G

YY1 transcription factor

decreases expression

ISO

Clobetasol results in decreased expression of YY1 mRNA

NCBI chr 6:133,471,615...133,500,875
Ensembl chr 6:133,471,562...133,497,257

G

zinc finger, BED-type containing 6

decreases expression

ISO

Clobetasol results in decreased expression of ZBED6 mRNA

NCBI chr13:47,659,269...47,665,540
Ensembl chr13:47,658,667...47,668,221

G

zinc finger CCCH-type containing 7B

decreases expression

ISO

Clobetasol results in decreased expression of ZC3H7B mRNA

NCBI chr 7:115,142,245...115,190,513
Ensembl chr 7:115,142,420...115,190,513

G

zinc finger CCHC-type containing 14

decreases expression

ISO

Clobetasol results in decreased expression of ZCCHC14 mRNA

NCBI chr19:66,582,800...66,627,136
Ensembl chr19:66,582,800...66,627,136

G

zinc finger, C3H1-type containing

decreases expression

ISO

Clobetasol results in decreased expression of ZFC3H1 mRNA

NCBI chr 7:52,894,417...52,950,755
Ensembl chr 7:52,894,172...52,950,758

G

zinc finger homeobox 2

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX2 mRNA

NCBI chr15:32,501,755...32,541,720
Ensembl chr15:32,503,115...32,535,085

G

zinc finger homeobox 3

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX3 mRNA

NCBI chr19:52,789,146...53,795,664
Ensembl chr19:53,551,488...53,795,664

G

zinc finger homeobox 4

decreases expression

ISO

Clobetasol results in decreased expression of ZFHX4 mRNA

NCBI chr 2:98,131,996...98,321,070
Ensembl chr 2:98,131,996...98,315,469

G

zinc finger protein 282

decreases expression

ISO

Clobetasol results in decreased expression of ZFP282 mRNA

NCBI chr 4:78,215,940...78,241,193
Ensembl chr 4:78,215,898...78,241,192

G

zinc finger protein 316

decreases expression

ISO

Clobetasol results in decreased expression of ZFP316 mRNA

NCBI chr12:16,408,032...16,427,427
Ensembl chr12:16,408,464...16,427,427

G

zinc finger protein 334

decreases expression

ISO

Clobetasol results in decreased expression of ZFP334 mRNA

NCBI chr 3:174,531,835...174,544,374
Ensembl chr 3:174,533,517...174,544,400

G

zinc finger protein 423

decreases expression

ISO

Clobetasol results in decreased expression of ZFP423 mRNA

NCBI chr19:35,282,149...35,580,775
Ensembl chr19:35,282,110...35,580,773

G

zinc finger protein 462

decreases expression

ISO

Clobetasol results in decreased expression of ZFP462 mRNA

NCBI chr 5:74,465,383...74,606,020
Ensembl chr 5:74,468,643...74,606,020

G

zinc finger protein 488

decreases expression

ISO

Clobetasol results in decreased expression of ZFP488 mRNA

NCBI chr16:9,289,286...9,299,928
Ensembl chr16:9,280,322...9,300,400

G

zinc finger protein 57

increases expression

ISO

Clobetasol results in increased expression of ZFP57 mRNA

NCBI chr20:1,526,565...1,546,480
Ensembl chr20:1,527,961...1,535,041

G

zinc finger protein 592

decreases expression

ISO

Clobetasol results in decreased expression of ZFP592 mRNA

NCBI chr 1:144,355,227...144,411,686
Ensembl chr 1:144,361,654...144,411,684

G

zinc finger protein 609

decreases expression

ISO

Clobetasol results in decreased expression of ZFP609 mRNA

NCBI chr 8:75,109,676...75,243,045
Ensembl chr 8:75,109,676...75,213,086

G

zinc finger protein 638

decreases expression

ISO

Clobetasol results in decreased expression of ZFP638 mRNA

NCBI chr 4:117,913,528...118,032,644
Ensembl chr 4:117,913,545...118,032,643

G

zinc finger protein 706

increases expression

ISO

Clobetasol results in increased expression of ZFP706 mRNA

NCBI chr 7:70,050,960...70,059,588
Ensembl chr 7:70,052,534...70,059,159

G

zinc finger with KRAB and SCAN domains 3

decreases expression

ISO

Clobetasol results in decreased expression of ZKSCAN3 mRNA

NCBI chr17:47,912,816...47,928,553
Ensembl chr17:47,912,912...47,928,551

G

zinc finger ZZ-type and EF-hand domain containing 1

decreases expression

ISO

Clobetasol results in decreased expression of ZZEF1 mRNA

NCBI chr10:57,911,728...58,049,412
Ensembl chr10:57,911,728...58,049,412

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B10

decreases activity

ISO

cohumulone results in decreased activity of AKR1B10 protein

NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

EXP

Corticosterone results in increased expression of A2M mRNA

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

ATP binding cassette subfamily G member 2

decreases activity

ISO

Corticosterone results in decreased activity of ABCG2 protein

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

acetyl-CoA carboxylase alpha

multiple interactions

EXP

[Corticosterone co-treated with oleoyl-estrone] affects the expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

aggrecan

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of ACAN mRNA; Corticosterone results in decreased expression of ACAN protein
3-methyladenine promotes the reaction [Corticosterone results in decreased expression of ACAN protein]; bafilomycin A1 promotes the reaction [Corticosterone results in decreased expression of ACAN protein]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of ACAN mRNA]; MIR421 affects the reaction [Corticosterone results in decreased expression of ACAN protein]; Sirolimus inhibits the reaction [Corticosterone results in decreased expression of ACAN protein]

PMID:29660438 PMID:29966748 PMID:32663519 PMID:38759937

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779

G

angiotensin I converting enzyme

increases expression
multiple interactions
decreases methylation

EXP

Corticosterone results in increased expression of ACE mRNA
Mifepristone inhibits the reaction [Corticosterone results in increased expression of ACE mRNA]
Corticosterone results in decreased methylation of ACE promoter

PMID:15755911 PMID:30423288

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

acetylcholinesterase

multiple interactions

ISO

[Corticosterone co-treated with Physostigmine] results in decreased activity of ACHE protein; ACHE protein inhibits the reaction [Paraoxon results in increased abundance of Corticosterone]; Corticosterone inhibits the reaction [Isoflurophate results in decreased activity of ACHE protein]; Corticosterone inhibits the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased activity of ACHE protein]

PMID:17005312 PMID:28500787

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

ATP citrate lyase

multiple interactions

EXP

[Corticosterone co-treated with oleoyl-estrone] affects the expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

actin, alpha 1, skeletal muscle

increases expression

EXP

Corticosterone results in increased expression of ACTA1 mRNA

NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178

G

actin gamma 2, smooth muscle

increases expression

EXP

Corticosterone results in increased expression of ACTG2 mRNA

NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

increases expression

EXP

Corticosterone results in increased expression of ADAMTS1 mRNA

NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression

ISO

[Corticosterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein
Corticosterone results in increased expression of ADIPOQ mRNA

PMID:29782964 PMID:34801515

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

adrenomedullin

increases expression

EXP

Corticosterone results in increased expression of ADM mRNA

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

adenosine A1 receptor

multiple interactions
decreases expression

ISO

Edaravone inhibits the reaction [Corticosterone results in decreased expression of ADORA1 mRNA]

NCBI chr13:48,210,922...48,247,826
Ensembl chr13:48,213,273...48,247,190

G

adrenoceptor beta 2

increases expression

EXP

Corticosterone results in increased expression of ADRB2 mRNA

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

angiotensinogen

increases secretion

ISO

AGT protein results in increased secretion of Corticosterone

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

angiotensin II receptor, type 1a

multiple interactions
decreases expression

EXP

Mifepristone inhibits the reaction [Corticosterone results in increased expression of AGTR1A mRNA]
Corticosterone results in decreased expression of AGTR1A mRNA

NCBI chr17:34,383,397...34,435,523
Ensembl chr17:34,381,467...34,435,660

G

angiotensin II receptor, type 2

multiple interactions
decreases expression

EXP

Mifepristone inhibits the reaction [Corticosterone results in decreased expression of AGTR2 mRNA]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of AGTR2 protein]; Mifepristone inhibits the reaction [Corticosterone results in increased expression of AGTR2 mRNA]
Corticosterone results in decreased expression of AGTR2 mRNA; Corticosterone results in decreased expression of AGTR2 protein

PMID:30423288 PMID:37972751

NCBI chr X:116,914,320...116,918,504
Ensembl chr X:116,913,656...116,918,745

G

aldo-keto reductase family 1, member D1

multiple interactions

ISO

[AKR1D1 protein co-treated with NADP] results in increased reduction of Corticosterone

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

AKT serine/threonine kinase 1

decreases expression

EXP

Corticosterone results in decreased expression of AKT1 mRNA

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 18 family, member A1

decreases expression

EXP

Corticosterone results in decreased expression of ALDH18A1 mRNA

NCBI chr 1:249,325,082...249,357,383
Ensembl chr 1:249,325,082...249,357,383

G

alkaline phosphatase, biomineralization associated

multiple interactions
decreases expression

EXP

Enalapril inhibits the reaction [Corticosterone results in decreased expression of ALPL mRNA]

NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167

G

angiopoietin-like 2

decreases expression

EXP

Corticosterone results in decreased expression of ANGPTL2 mRNA

NCBI chr 3:36,914,876...36,944,715
Ensembl chr 3:36,914,745...36,945,876

G

apurinic/apyrimidinic endodeoxyribonuclease 1

affects localization
multiple interactions

EXP

Corticosterone affects the localization of APEX1 protein
[Corticosterone co-treated with Ethanol] affects the localization of APEX1 protein

NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329

G

aquaporin 1

increases expression

EXP

Corticosterone results in increased expression of AQP1 mRNA

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

androgen receptor

multiple interactions
increases activity
affects binding

ISO
EXP

[Testosterone co-treated with Estradiol co-treated with Corticosterone] promotes the reaction [AR protein binds to TRAF6 protein]; Corticosterone binds to and results in increased activity of AR protein mutant form; Corticosterone inhibits the reaction [Metribolone results in increased activity of AR protein]; Corticosterone inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein]
Corticosterone results in increased activity of AR protein
Corticosterone binds to AR protein

PMID:11956172 PMID:14565775 PMID:18324785 PMID:21543282 PMID:29162470 More...

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arrestin, beta 1

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of ARRB1 mRNA
Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of ARRB1 mRNA]

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859

G

arrestin, beta 2

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of ARRB2 mRNA
Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of ARRB2 mRNA]

NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,645,357...55,653,487

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

EXP

Corticosterone results in decreased expression of ASNS mRNA

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

ATPase Na+/K+ transporting subunit alpha 3

decreases expression

EXP

Corticosterone results in decreased expression of ATP1A3 mRNA

NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:89,700,649...89,729,825

G

ATPase H+ transporting V1 subunit G1

decreases expression

EXP

Corticosterone results in decreased expression of ATP6V1G1 mRNA

NCBI chr 5:81,976,959...81,983,139
Ensembl chr 5:81,977,015...81,985,930

G

aurora kinase B

decreases expression

EXP

Corticosterone results in decreased expression of AURKB mRNA

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

arginine vasopressin

decreases expression

EXP

Corticosterone results in decreased expression of AVP mRNA

NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522

G

BCL2 associated X, apoptosis regulator

increases expression
affects expression
multiple interactions

EXP

Corticosterone results in increased expression of BAX protein
Corticosterone affects the expression of BAX mRNA
Estradiol inhibits the reaction [Corticosterone results in increased expression of BAX protein]; Estradiol promotes the reaction [Testosterone inhibits the reaction [Corticosterone results in increased expression of BAX protein]]; so-ochim-tang-gamibang affects the reaction [Corticosterone affects the expression of BAX mRNA]; Testosterone inhibits the reaction [Corticosterone results in increased expression of BAX protein]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in increased expression of BAX protein]]

PMID:27988398 PMID:29625166

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions
affects expression
decreases expression

EXP

Estradiol inhibits the reaction [Corticosterone results in decreased expression of BCL2 protein]; Estradiol promotes the reaction [Testosterone inhibits the reaction [Corticosterone results in decreased expression of BCL2 protein]]; so-ochim-tang-gamibang affects the reaction [Corticosterone affects the expression of BCL2 mRNA]; Testosterone inhibits the reaction [Corticosterone results in decreased expression of BCL2 protein]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in decreased expression of BCL2 protein]]

PMID:27988398 PMID:29625166

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions
increases expression

EXP

[Corticosterone results in increased expression of BCL2L1 protein] which results in decreased susceptibility to Doxorubicin; BCL2L1 protein affects the reaction [Corticosterone results in decreased susceptibility to Doxorubicin]; JUN protein affects the reaction [Corticosterone results in increased expression of BCL2L1 mRNA]; Mifepristone inhibits the reaction [Corticosterone results in increased expression of BCL2L1 protein]
Corticosterone results in increased expression of BCL2L1 mRNA; Corticosterone results in increased expression of BCL2L1 protein

PMID:15755911 PMID:24480152 PMID:26915917

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

brain-derived neurotrophic factor

decreases expression
affects expression
multiple interactions

ISO
EXP

Corticosterone results in decreased expression of BDNF protein
Corticosterone affects the expression of BDNF protein
O-1602 compound affects the reaction [Corticosterone affects the expression of BDNF protein]; so-ochim-tang-gamibang inhibits the reaction [Corticosterone results in decreased expression of BDNF mRNA]
2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in decreased expression of BDNF protein]; KT 5823 inhibits the reaction [2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in decreased expression of BDNF protein]]

PMID:22244747 PMID:22850435 PMID:27988398 PMID:32733244

NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657

G

brain expressed X-linked 2

decreases expression

EXP

Corticosterone results in decreased expression of BEX1 mRNA

NCBI chr X:103,811,458...103,812,986
Ensembl chr X:103,808,935...103,812,092

G

bone gamma-carboxyglutamate protein

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of BGLAP mRNA
Enalapril inhibits the reaction [Corticosterone results in decreased expression of BGLAP mRNA]

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

bone morphogenetic protein 2

increases expression

EXP

Corticosterone results in increased expression of BMP2 mRNA

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

bone morphogenetic protein 6

increases expression

EXP

Corticosterone results in increased expression of BMP6 mRNA

NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261

G

BTG anti-proliferation factor 2

increases expression

EXP

Corticosterone results in increased expression of BTG2 mRNA

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690

G

complement C3

affects expression

EXP

Corticosterone affects the expression of C3 mRNA

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

calcitonin-related polypeptide alpha

increases abundance
increases expression
multiple interactions

EXP

CALCA protein results in increased abundance of Corticosterone
Corticosterone results in increased expression of CALCA protein
O-1602 compound inhibits the reaction [Corticosterone results in increased expression of CALCA protein]

PMID:12639925 PMID:32733244

NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529

G

calpain 6

decreases expression

EXP

Corticosterone results in decreased expression of CAPN6 mRNA

NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178

G

cysteinyl-tRNA synthetase 1

decreases expression

EXP

Corticosterone results in decreased expression of CARS1 mRNA

NCBI chr 1:208,183,092...208,225,425
Ensembl chr 1:208,182,788...208,225,407

G

CART prepropeptide

increases abundance
multiple interactions

EXP

CARTPT protein results in increased abundance of Corticosterone
astressin B inhibits the reaction [CARTPT protein results in increased abundance of Corticosterone]

NCBI chr 2:32,989,215...32,991,794
Ensembl chr 2:32,989,215...32,999,712

G

caspase 12

decreases expression

EXP

Corticosterone results in decreased expression of CASP12 mRNA

NCBI chr 8:10,927,188...10,954,442
Ensembl chr 8:10,926,994...10,954,442

G

caspase 3

multiple interactions
increases expression
increases cleavage

EXP

Corticosterone inhibits the reaction [Deoxyglucose results in increased activity of CASP3 protein]; Corticosterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Corticosterone inhibits the reaction [Palmitates results in increased activity of CASP3 protein]; Estradiol inhibits the reaction [Corticosterone results in increased cleavage of CASP3 protein]; Estradiol promotes the reaction [Testosterone inhibits the reaction [Corticosterone results in increased cleavage of CASP3 protein]]; Mifepristone inhibits the reaction [Corticosterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; so-ochim-tang-gamibang inhibits the reaction [Corticosterone results in increased expression of CASP3 mRNA]; Testosterone inhibits the reaction [Corticosterone results in increased cleavage of CASP3 protein]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in increased cleavage of CASP3 protein]]

PMID:15755911 PMID:26915917 PMID:27988398 PMID:29625166

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

decreases expression

EXP

Corticosterone results in decreased expression of CASP4 mRNA

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 8

multiple interactions
increases cleavage

EXP

Estradiol inhibits the reaction [Corticosterone results in increased cleavage of CASP8 protein]; Estradiol promotes the reaction [Testosterone inhibits the reaction [Corticosterone results in increased cleavage of CASP8 protein]]; Testosterone inhibits the reaction [Corticosterone results in increased cleavage of CASP8 protein]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in increased cleavage of CASP8 protein]]

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

catalase

increases activity
multiple interactions

ISO

Corticosterone results in increased activity of CAT protein
Clozapine inhibits the reaction [Corticosterone results in increased activity of CAT protein]; Clozapine inhibits the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]]; Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]; Sulpiride promotes the reaction [Lipopolysaccharides inhibits the reaction [Corticosterone results in increased activity of CAT protein]]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 2

decreases expression
multiple interactions

EXP
ISO

Corticosterone results in decreased expression of CCL2 mRNA
Corticosterone promotes the reaction [Isoflurophate results in increased expression of CCL2 mRNA]
[Corticosterone co-treated with Isoflurophate] results in increased expression of CCL2 mRNA; [Corticosterone co-treated with O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate] results in increased expression of CCL2 mRNA; [Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of CCL2 mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of CCL2 mRNA]; Corticosterone promotes the reaction [Isoflurophate results in increased expression of CCL2 mRNA]; Corticosterone promotes the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased expression of CCL2 mRNA]; Physostigmine inhibits the reaction [Corticosterone results in decreased expression of CCL2 mRNA]

PMID:15755911 PMID:28500787 PMID:28782715 PMID:29751049 PMID:29846716

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cellular communication network factor 3

increases expression

EXP

Corticosterone results in increased expression of CCN3 mRNA

NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581

G

cyclin B1

decreases expression

EXP

Corticosterone results in decreased expression of CCNB1 mRNA; Corticosterone results in decreased expression of CCNB1 protein

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of CCND1 protein
Ethanol affects the reaction [Corticosterone results in decreased expression of CCND1 protein]

PMID:12807724 PMID:38259729

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D2

decreases expression

EXP

Corticosterone results in decreased expression of CCND2 mRNA; Corticosterone results in decreased expression of CCND2 protein

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

cyclin E1

decreases expression

EXP

Corticosterone results in decreased expression of CCNE1 protein

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

Cd200 molecule

decreases expression

EXP

Corticosterone results in decreased expression of CD200 mRNA

NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569

G

CD36 molecule

increases expression

EXP

Corticosterone results in increased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

CD59b molecule

increases expression

EXP

Corticosterone results in increased expression of CD59 mRNA

NCBI chr 3:110,914,008...110,932,489
Ensembl chr 3:110,914,091...110,935,310

G

Cd68 molecule

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of CD68 mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of CD68 mRNA]

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

cell division cycle 20

decreases expression

EXP

Corticosterone results in decreased expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cell division cycle associated 3 like 1

decreases expression

EXP

Corticosterone results in decreased expression of CDCA3L1 mRNA

NCBI chr 9:53,998,610...53,999,608

G

cadherin 2

multiple interactions

ISO

[Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CDH2 protein

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cyclin-dependent kinase 1

decreases expression

EXP

Corticosterone results in decreased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin dependent kinase 2

multiple interactions
decreases activity
decreases expression

EXP

Corticosterone promotes the reaction [CDKN1A protein binds to CDK2 protein]
Corticosterone results in decreased activity of CDK2 protein
Corticosterone results in decreased expression of CDK2 protein

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase 4

multiple interactions
decreases expression
decreases activity

EXP

Corticosterone inhibits the reaction [CDKN1A protein binds to CDK4 protein]; Corticosterone promotes the reaction [CDKN1B protein binds to CDK4 protein]
Corticosterone results in decreased expression of CDK4 protein
Corticosterone results in decreased activity of CDK4 protein

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase inhibitor 1A

affects expression
multiple interactions

EXP

Corticosterone affects the expression of CDKN1A protein
Corticosterone inhibits the reaction [CDKN1A protein binds to CDK4 protein]; Corticosterone promotes the reaction [CDKN1A protein binds to CDK2 protein]

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

EXP

Corticosterone promotes the reaction [CDKN1B protein binds to CDK4 protein]
Corticosterone results in increased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 2A

decreases expression

EXP

Corticosterone results in decreased expression of CDKN2A mRNA

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

cysteine dioxygenase type 1

increases expression

EXP

Corticosterone results in increased expression of CDO1 mRNA

NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891

G

CEA cell adhesion molecule 4

increases expression

EXP

Corticosterone results in increased expression of CEACAM10 mRNA

NCBI chr 1:89,504,555...89,510,831
Ensembl chr 1:89,504,555...89,510,831

G

CCAAT/enhancer binding protein alpha

increases expression

EXP

Corticosterone results in increased expression of CEBPA mRNA

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of CEBPB mRNA
CEBPB protein affects the reaction [Corticosterone results in increased expression of PTGS2 mRNA]; CEBPB protein affects the reaction [Corticosterone results in increased expression of PTGS2 protein]; Corticosterone promotes the reaction [CEBPB protein binds to PTGS2 promoter]

PMID:15755911 PMID:18650268

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

CCAAT/enhancer binding protein delta

increases expression

EXP
ISO

Corticosterone results in increased expression of CEBPD mRNA

PMID:15755911 PMID:34801515

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

complement factor D

decreases expression

ISO

Corticosterone results in decreased expression of CFD mRNA; Corticosterone results in decreased expression of CFD protein

NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:10,463,775...10,465,572

G

CDC28 protein kinase regulatory subunit 2

decreases expression

EXP

Corticosterone results in decreased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519
Ensembl chr17:13,722,361...13,727,519

G

claudin 2

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of CLDN2 protein

NCBI chr X:108,248,383...108,258,847
Ensembl chr X:108,237,676...108,262,377

G

cannabinoid receptor 1

increases abundance

ISO

CNR1 gene mutant form results in increased abundance of Corticosterone

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

collagen type II alpha 1 chain

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of COL2A1 mRNA; Corticosterone results in decreased expression of COL2A1 protein
Mifepristone inhibits the reaction [Corticosterone results in decreased expression of COL2A1 mRNA]

PMID:29660438 PMID:29966748 PMID:32663519

NCBI chr 7:130,977,561...131,006,627
Ensembl chr 7:130,977,561...131,006,627

G

catechol-O-methyltransferase

multiple interactions
decreases expression

ISO

Edaravone inhibits the reaction [Corticosterone results in decreased expression of COMT mRNA]

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

ceruloplasmin

increases expression

EXP

Corticosterone results in increased expression of CP mRNA

NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087

G

carnitine palmitoyltransferase 1A

increases expression

EXP

Corticosterone results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

cAMP responsive element binding protein 1

decreases phosphorylation

ISO

Corticosterone results in decreased phosphorylation of CREB1 protein

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CREB binding protein

multiple interactions
decreases expression

ISO

2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in decreased expression of CREBBP protein]; KT 5823 inhibits the reaction [2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in decreased expression of CREBBP protein]]

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

corticotropin releasing hormone

multiple interactions
decreases expression
increases expression
affects expression
increases abundance

EXP
ISO

Astemizole inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]; Corticosterone affects the reaction [Nitroprusside results in increased secretion of CRH protein]; Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]; E 4031 inhibits the reaction [Corticosterone inhibits the reaction [CRH protein results in increased secretion of Adrenocorticotropic Hormone]]; O-1602 compound inhibits the reaction [Corticosterone results in increased expression of CRH protein]
CRH protein affects the reaction [[DUSP8 protein affects the susceptibility to Dietary Fats] which affects the abundance of Corticosterone]
Corticosterone results in decreased expression of CRH mRNA
Corticosterone results in increased expression of CRH mRNA; Corticosterone results in increased expression of CRH protein
Corticosterone affects the expression of CRH mRNA
CRH protein results in increased abundance of Corticosterone

PMID:3015567 PMID:7816204 PMID:18835572 PMID:21359208 PMID:26821211 More...

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

corticotropin releasing hormone receptor 1

decreases expression

EXP

Corticosterone results in decreased expression of CRHR1 mRNA

NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466

G

cysteine-rich secretory protein LCCL domain containing 2

increases expression

EXP

Corticosterone results in increased expression of CRISPLD2 mRNA

NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349

G

citrate synthase

decreases activity

EXP

Corticosterone results in decreased activity of CS protein

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

cysteine and glycine-rich protein 2

increases expression

EXP

Corticosterone results in increased expression of CSRP2 mRNA

NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238

G

cysteine and glycine rich protein 3

increases expression

EXP

Corticosterone results in increased expression of CSRP3 mRNA

NCBI chr 1:107,664,338...107,682,916
Ensembl chr 1:107,664,338...107,682,916

G

catenin alpha 1

multiple interactions

ISO

[Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CTNNA1 protein

NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007

G

catenin beta 1

multiple interactions

ISO

[Corticosterone results in increased phosphorylation of NDRG1 protein] promotes the reaction [NDRG1 protein binds to CTNNB1 protein]; [Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CTNNB1 protein

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin S

increases expression

EXP

Corticosterone results in increased expression of CTSS mRNA

NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:185,775,296...185,803,440

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases chemical synthesis

ISO

CYP11B1 protein results in increased chemical synthesis of Corticosterone

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

affects metabolic processing
multiple interactions
increases hydroxylation
increases chemical synthesis

ISO

CYP11B2 protein affects the metabolism of Corticosterone
[CYP11B2 protein results in increased hydroxylation of Corticosterone] which results in increased chemical synthesis of Aldosterone; [CYP11B2 protein results in increased hydroxylation of Desoxycorticosterone] which results in increased chemical synthesis of Corticosterone
CYP11B2 protein results in increased chemical synthesis of Corticosterone

PMID:16054388 PMID:21384875

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

EXP
ISO

Corticosterone promotes the reaction [Ethanol results in increased expression of CYP1A2 mRNA]
Corticosterone results in increased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 2, subfamily a, polypeptide 2

increases expression

EXP

Corticosterone results in increased expression of CYP2A2 mRNA

NCBI chr 1:91,391,492...91,417,158
Ensembl chr 1:91,391,502...91,417,158

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of CYP2B1 mRNA; Corticosterone results in increased expression of CYP2B1 protein
Corticosterone promotes the reaction [Ethanol results in increased expression of CYP2B1 protein]

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases expression

ISO

Corticosterone promotes the reaction [Ethanol results in increased expression of CYP2B6 mRNA]
Corticosterone results in increased expression of CYP2B6 mRNA; Corticosterone results in increased expression of CYP2B6 protein

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, subfamily 2, polypeptide 11

increases expression

EXP

Corticosterone results in increased expression of CYP2C11 mRNA

NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853

G

cytochrome P450, family 2, subfamily d, polypeptide 2

increases expression

EXP

Corticosterone results in increased expression of CYP2D2 mRNA

NCBI chr 7:115,815,212...115,819,281
Ensembl chr 7:115,815,212...115,819,281

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression
multiple interactions

EXP
ISO

Corticosterone results in increased expression of CYP2D4 mRNA
Corticosterone promotes the reaction [Ethanol results in increased expression of CYP2D6 mRNA]
Corticosterone results in increased expression of CYP2D6 mRNA

PMID:15755911 PMID:35301062

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression
multiple interactions

ISO
EXP

Corticosterone results in increased expression of CYP2E1 mRNA; Corticosterone results in increased expression of CYP2E1 protein
Corticosterone promotes the reaction [Ethanol results in increased expression of CYP2E1 mRNA]

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases expression

ISO

[Corticosterone binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; Corticosterone promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Corticosterone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Corticosterone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Corticosterone results in increased expression of CYP3A4 mRNA]
Corticosterone results in increased expression of CYP3A4 mRNA; Corticosterone results in increased expression of CYP3A4 protein

PMID:11581012 PMID:12072427 PMID:12851153 PMID:35301062

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases expression

EXP

Corticosterone promotes the reaction [Ethanol results in increased expression of CYP3A23-3A1 mRNA]
Corticosterone results in increased expression of CYP3A23-3A1 mRNA; Corticosterone results in increased expression of CYP3A23-3A1 protein

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing

ISO

Corticosterone results in increased metabolism of CYP3A5 protein

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

diazepam binding inhibitor

increases expression

ISO

Corticosterone results in increased expression of DBI mRNA

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450

G

dicarbonyl and L-xylulose reductase

increases expression

EXP

Corticosterone results in increased expression of DCXR mRNA

NCBI chr10:106,504,730...106,506,619

G

DNA-damage inducible transcript 3

decreases expression

EXP

Corticosterone results in decreased expression of DDIT3 mRNA

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

D-dopachrome tautomerase

increases expression

EXP

Corticosterone results in increased expression of DDT mRNA

NCBI chr20:12,883,025...12,886,121

G

dickkopf WNT signaling pathway inhibitor 1

increases expression
multiple interactions

ISO

Corticosterone results in increased expression of DKK1 protein
Mifepristone inhibits the reaction [Corticosterone results in increased expression of DKK1 protein]; NR3C1 protein promotes the reaction [Corticosterone results in increased expression of DKK1 protein]

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

discs large MAGUK scaffold protein 4

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of DLG4 protein
Ascorbic Acid inhibits the reaction [Corticosterone results in decreased expression of DLG4 protein]; Ketamine inhibits the reaction [Corticosterone results in decreased expression of DLG4 protein]

NCBI chr10:55,239,397...55,267,780
Ensembl chr10:55,236,869...55,265,839

G

DNA methyltransferase 3 alpha

decreases expression
increases expression
multiple interactions

EXP

Corticosterone results in decreased expression of DNMT3A mRNA
Corticosterone results in increased expression of DNMT3A mRNA; Corticosterone results in increased expression of DNMT3A protein
Mifepristone inhibits the reaction [Corticosterone results in increased expression of DNMT3A mRNA]

PMID:30423288 PMID:37972751

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

dipeptidase 1

increases expression

EXP

Corticosterone results in increased expression of DPEP1 mRNA

NCBI chr19:68,118,270...68,143,781
Ensembl chr19:68,118,453...68,143,775

G

dermatopontin

decreases expression

EXP

Corticosterone results in decreased expression of DPT mRNA

NCBI chr13:79,656,341...79,684,759
Ensembl chr13:79,655,985...79,684,758

G

dual specificity phosphatase 8

multiple interactions

ISO

[DUSP8 protein affects the susceptibility to Dietary Fats] which affects the abundance of Corticosterone; CRH protein affects the reaction [[DUSP8 protein affects the susceptibility to Dietary Fats] which affects the abundance of Corticosterone]; Dexamethasone affects the reaction [[DUSP8 protein affects the susceptibility to Dietary Fats] which affects the abundance of Corticosterone]

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

ECRG4 augurin precursor

decreases expression

EXP

Corticosterone results in decreased expression of ECRG4 mRNA

NCBI chr 9:53,485,040...53,504,691
Ensembl chr 9:53,485,040...53,504,703

G

endothelin 1

increases secretion

EXP

EDN1 results in increased secretion of Corticosterone

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin 2

increases secretion

EXP

EDN2 results in increased secretion of Corticosterone

NCBI chr 5:139,036,576...139,042,074
Ensembl chr 5:139,036,492...139,043,070

G

endothelin 3

increases secretion

EXP

EDN3 results in increased secretion of Corticosterone

NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:183,980,668...184,005,329

G

eukaryotic elongation factor-2 kinase

increases expression

EXP

Corticosterone results in increased expression of EEF2K mRNA

NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048

G

EGF containing fibulin extracellular matrix protein 1

increases expression

EXP

Corticosterone results in increased expression of EFEMP1 mRNA

NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808

G

egl-9 family hypoxia-inducible factor 3

increases expression

EXP

Corticosterone results in increased expression of EGLN3 mRNA

NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015

G

estrogen receptor 1

multiple interactions

ISO

[Testosterone co-treated with Estradiol co-treated with Corticosterone] promotes the reaction [ESR1 protein binds to TRAF6 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases expression

EXP

Corticosterone results in decreased expression of EZH2 mRNA

NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183

G

fatty acid amide hydrolase

increases activity
multiple interactions

EXP

Corticosterone results in increased activity of FAAH protein
antalarmin inhibits the reaction [Corticosterone results in increased activity of FAAH protein]

NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396

G

fatty acid binding protein 3

decreases expression

EXP

Corticosterone results in decreased expression of FABP3 mRNA

NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881

G

fatty acid binding protein 4

multiple interactions

ISO

[Corticosterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; Corticosterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fatty acid binding protein 7

affects expression

EXP

Corticosterone affects the expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

fatty acid synthase

multiple interactions

EXP

[Corticosterone co-treated with oleoyl-estrone] affects the expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fibulin 2

decreases expression

EXP

Corticosterone results in decreased expression of FBLN2 mRNA

NCBI chr 4:125,261,464...125,321,030
Ensembl chr 4:125,261,607...125,321,029

G

fibrillin 2

increases expression

EXP

Corticosterone results in increased expression of FBN2 mRNA

NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191

G

FKBP prolyl isomerase 5

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of FKBP5 mRNA
Edaravone inhibits the reaction [Corticosterone results in decreased expression of FKBP5 mRNA]

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

Fms related receptor tyrosine kinase 1

increases expression

EXP

Corticosterone results in increased expression of FLT1 mRNA

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750

G

flavin containing dimethylaniline monoxygenase 1

increases expression

EXP

Corticosterone results in increased expression of FMO1 mRNA

NCBI chr13:77,715,405...77,747,666
Ensembl chr13:77,715,402...77,747,874

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Corticosterone results in increased expression of FOS protein

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

forkhead box S1

decreases expression

EXP

Corticosterone results in decreased expression of FOXS1 mRNA

NCBI chr 3:161,857,264...161,858,548
Ensembl chr 3:161,850,782...161,858,662

G

follicle stimulating hormone subunit beta

increases expression

ISO

Corticosterone results in increased expression of FSHB mRNA

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

follistatin like 3

increases expression

EXP

Corticosterone results in increased expression of FSTL3 mRNA

NCBI chr 7:10,574,195...10,579,844
Ensembl chr 7:10,574,186...10,590,509

G

FXYD domain-containing ion transport regulator 6

decreases expression

EXP

Corticosterone results in decreased expression of FXYD6 mRNA

NCBI chr 8:54,575,578...54,602,715
Ensembl chr 8:54,575,591...54,602,715

G

glucose-6-phosphatase catalytic subunit 2

increases expression

ISO

Corticosterone results in increased expression of G6PC2 mRNA

NCBI chr 3:74,404,976...74,413,391

G

glutamate decarboxylase 1

multiple interactions
increases expression

ISO
EXP

GAD1 affects the reaction [2,5-dihydro-2,4,5-trimethylthiazoline results in increased secretion of Corticosterone]
Corticosterone results in increased expression of GAD1 mRNA

PMID:21219938 PMID:32437893

NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:75,777,534...75,818,759

G

galanin and GMAP prepropeptide

increases expression

EXP

Corticosterone results in increased expression of GAL mRNA

NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:210,079,702...210,084,229

G

growth arrest specific 6

increases expression

EXP

Corticosterone results in increased expression of GAS6 mRNA

NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088

G

glycine amidinotransferase

decreases expression

EXP

Corticosterone results in decreased expression of GATM mRNA

NCBI chr 3:130,112,508...130,137,664
Ensembl chr 3:130,112,509...130,129,355

G

glucosaminyl (N-acetyl) transferase 1

increases expression

EXP

Corticosterone results in increased expression of GCNT1 mRNA

NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741

G

glial fibrillary acidic protein

multiple interactions

EXP

[Ethanol co-treated with Corticosterone] results in increased expression of GFAP protein

NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685

G

gap junction protein, alpha 1

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of GJA1 protein
protosappanin A inhibits the reaction [Corticosterone results in decreased expression of GJA1 protein]

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

gap junction protein, alpha 5

increases expression

EXP

Corticosterone results in increased expression of GJA5 mRNA

NCBI chr 2:187,291,227...187,310,770
Ensembl chr 2:187,234,674...187,318,512

G

glycosyltransferase 8 domain containing 1

decreases expression

EXP

Corticosterone results in decreased expression of GLT8D1 mRNA

NCBI chr16:6,198,152...6,213,671
Ensembl chr16:6,204,740...6,213,668

G

glutamate-ammonia ligase

increases expression

EXP

Corticosterone results in increased expression of GLUL mRNA

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

G protein subunit alpha i2

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of GNAI2 mRNA
Fluoxetine inhibits the reaction [Corticosterone results in decreased expression of GNAI2 mRNA]

NCBI chr 8:117,167,045...117,187,652
Ensembl chr 8:117,167,045...117,187,622

G

glutathione peroxidase 3

increases expression

EXP

Corticosterone results in increased expression of GPX3 mRNA

NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405

G

growth regulating estrogen receptor binding 1

increases expression

ISO

Corticosterone results in increased expression of GREB1 mRNA

NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126

G

gremlin 1, DAN family BMP antagonist

decreases expression

EXP

Corticosterone results in decreased expression of GREM1 mRNA

NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089

G

glutamate ionotropic receptor AMPA type subunit 1

decreases expression
multiple interactions

ISO

Corticosterone results in decreased expression of GRIA1 protein
Ketamine inhibits the reaction [Corticosterone results in decreased expression of GRIA1 protein]

NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309

G

G protein-coupled receptor kinase 5

increases expression

EXP

Corticosterone results in increased expression of GRK5 mRNA

NCBI chr 1:270,014,314...270,208,294
Ensembl chr 1:270,014,282...270,204,928

G

glutathione S-transferase alpha 3

increases expression

EXP

Corticosterone results in increased expression of GSTA3 mRNA; Corticosterone results in increased expression of GSTA3 protein

NCBI chr 9:31,154,989...31,180,653
Ensembl chr 9:31,154,989...31,180,654

G

glutathione S-transferase mu 2

increases expression

EXP

Corticosterone results in increased expression of GSTM2 mRNA; Corticosterone results in increased expression of GSTM2 protein

NCBI chr 2:198,312,179...198,316,962

G

H2A.X variant histone

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of H2AX protein
[Ethanol co-treated with Corticosterone] results in increased expression of H2AX protein

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

histone deacetylase 7

multiple interactions
increases expression

EXP

HDAC7 protein affects the reaction [Corticosterone results in decreased expression of KLF4 mRNA]; HDAC7 protein affects the reaction [Corticosterone results in decreased expression of KLF4 protein]; HDAC7 protein affects the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; HDAC7 protein affects the reaction [Corticosterone results in decreased expression of NPHS1 protein]; Mifepristone inhibits the reaction [Corticosterone results in increased expression of HDAC7 mRNA]; Mifepristone inhibits the reaction [Corticosterone results in increased expression of HDAC7 protein]
Corticosterone results in increased expression of HDAC7 mRNA; Corticosterone results in increased expression of HDAC7 protein

NCBI chr 7:130,803,013...130,841,181
Ensembl chr 7:130,803,013...130,841,017

G

high mobility group box 1

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased secretion of HMGB1 protein; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased secretion of HMGB1 protein]

NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327
Ensembl chr12:39,039,050...39,041,327

G

high mobility group box 2

decreases expression

EXP

Corticosterone results in decreased expression of HMGB2 mRNA

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

EXP

Corticosterone results in increased expression of HMGCS2 mRNA

NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242

G

high mobility group nucleosomal binding domain 2

decreases expression

EXP

Corticosterone results in decreased expression of HMGN2 mRNA

NCBI chr 5:151,475,907...151,479,361
Ensembl chr 5:151,475,909...151,479,397

G

heterogeneous nuclear ribonucleoprotein A1

decreases expression

EXP

Corticosterone results in decreased expression of HNRNPA1 mRNA

NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085

G

heparan sulfate-glucosamine 3-sulfotransferase 1

increases expression

EXP

Corticosterone results in increased expression of HS3ST1 mRNA

NCBI chr14:75,398,101...75,429,628
Ensembl chr14:75,398,026...75,436,848

G

hydroxysteroid 11-beta dehydrogenase 1

increases chemical synthesis
multiple interactions
increases oxidation
decreases abundance
increases expression

ISO
EXP

HSD11B1 protein results in increased chemical synthesis of Corticosterone
[[trimethyltin chloride results in increased abundance of trimethyltin] which co-treated with Corticosterone] results in increased expression of HSD11B1 mRNA; Corticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA]; Mifepristone inhibits the reaction [Corticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA]]; Spironolactone inhibits the reaction [Corticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA]]
HSD11B1 protein results in increased oxidation of Corticosterone
HSD11B1 gene mutant form results in decreased abundance of Corticosterone
[HSD11B1 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; [HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] which results in increased chemical synthesis of Corticosterone; resveratrol inhibits the reaction [HSD11B1 protein results in increased chemical synthesis of Corticosterone]; Ziram inhibits the reaction [[HSD11B1 protein results in increased reduction of 11-dehydrocorticosterone] which results in increased chemical synthesis of Corticosterone]
Corticosterone results in increased expression of HSD11B1 mRNA

PMID:15755911 PMID:16751407 PMID:23814014 PMID:25061560 PMID:26859423 More...

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions
increases oxidation
increases metabolic processing
affects metabolic processing

EXP
ISO

[HSD11B2 protein results in increased metabolism of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; [HSD11B2 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone; Betamethasone inhibits the reaction [HSD11B2 protein affects the metabolism of Corticosterone]; Dexamethasone inhibits the reaction [HSD11B2 protein affects the metabolism of Corticosterone]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Corticosterone] which results in increased chemical synthesis of 11-dehydrocorticosterone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Corticosterone]

PMID:19490994 PMID:22796344 PMID:26859423 PMID:32243540

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

heat shock protein family B (small) member 1

increases expression

EXP

Corticosterone results in increased expression of HSPB1 mRNA; Corticosterone results in increased expression of HSPB1 protein

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family B (small) member 6

increases expression

EXP

Corticosterone results in increased expression of HSPB6 mRNA

NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:94,933,543...94,936,512

G

5-hydroxytryptamine receptor 2A

multiple interactions
increases secretion
increases expression

EXP

[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [HTR2A protein results in increased secretion of Corticosterone]; [Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in increased secretion of Corticosterone]
Corticosterone results in increased expression of HTR2A mRNA

PMID:15755911 PMID:18363858 PMID:19304867 PMID:19879056

NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619

G

immediate early response 3

decreases expression

EXP

Corticosterone results in decreased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377

G

insulin-like growth factor 1

decreases expression
multiple interactions
increases expression

EXP

Corticosterone results in decreased expression of IGF1 mRNA; Corticosterone results in decreased expression of IGF1 protein
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of IGF1 mRNA]]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of PCNA mRNA]]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK1 protein]]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK3 protein]]; IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of IGF1 mRNA]; IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of PCNA mRNA]; IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK1 protein]; IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK3 protein]
Corticosterone results in increased expression of IGF1 mRNA

PMID:12807724 PMID:15755911 PMID:29343424 PMID:29966748

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of IGF1R mRNA; Corticosterone results in decreased expression of IGF1R protein
[IGF2R protein co-treated with IGF1R protein] affects the reaction [IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]]

PMID:12807724 PMID:24667322 PMID:29966748

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor 2

multiple interactions

EXP

[IGF2R protein co-treated with IGF1R protein] affects the reaction [IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]]; IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor 2 receptor

multiple interactions

EXP

[IGF2R protein co-treated with IGF1R protein] affects the reaction [IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]]

NCBI chr 1:50,526,878...50,615,265
Ensembl chr 1:50,526,878...50,615,265

G

insulin-like growth factor binding protein 5

decreases expression

EXP

Corticosterone results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

insulin-like growth factor binding protein 6

increases expression

EXP

Corticosterone results in increased expression of IGFBP6 mRNA

NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:135,154,685...135,159,795

G

interleukin 15

increases expression

EXP

Corticosterone results in increased expression of IL15 mRNA

NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348

G

interleukin 1 beta

increases chemical synthesis
increases expression
affects expression
multiple interactions
increases secretion

ISO
EXP

IL1B protein results in increased chemical synthesis of Corticosterone
Corticosterone results in increased expression of IL1B mRNA
Corticosterone affects the expression of IL1B mRNA
Corticosterone results in increased expression of IL1B mRNA; Corticosterone results in increased expression of IL1B protein
[Corticosterone co-treated with Isoflurophate] results in increased expression of IL1B mRNA; [Corticosterone co-treated with O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate] results in increased expression of IL1B mRNA; [Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of and results in increased secretion of IL1B protein; [Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of IL1B mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of and results in increased secretion of IL1B protein]; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of IL1B mRNA]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the reaction [Corticosterone affects the expression of IL1B mRNA]; Physostigmine affects the reaction [Corticosterone affects the expression of IL1B mRNA]
Corticosterone promotes the reaction [Isoflurophate results in increased expression of IL1B mRNA]; Ketorolac inhibits the reaction [IL1B protein results in increased secretion of Corticosterone]; O-1602 compound inhibits the reaction [Corticosterone results in increased expression of IL1B protein]
[Finasteride results in increased susceptibility to IL1B protein] which results in increased secretion of Corticosterone

PMID:10800959 PMID:12773775 PMID:19458216 PMID:28500787 PMID:28782715 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor-like 1

decreases expression

EXP

Corticosterone results in decreased expression of IL1RL1 mRNA

NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891

G

interleukin 6

multiple interactions
decreases expression
increases expression

EXP
ISO

Corticosterone inhibits the reaction [Isoflurophate results in increased expression of IL6 mRNA]
Corticosterone results in decreased expression of IL6 mRNA
[Corticosterone co-treated with Physostigmine] results in decreased expression of IL6 mRNA; [Pyridostigmine Bromide co-treated with Corticosterone] results in decreased expression of IL6 mRNA; Corticosterone inhibits the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in decreased expression of IL6 mRNA]; Corticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of IL6 mRNA]; Isoflurophate inhibits the reaction [Corticosterone results in decreased expression of IL6 mRNA]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate inhibits the reaction [Corticosterone results in decreased expression of IL6 mRNA]; Spironolactone inhibits the reaction [Corticosterone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of IL6 mRNA]]
Corticosterone results in increased expression of IL6 mRNA

PMID:28500787 PMID:28782715 PMID:29846716 PMID:30993381

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 2

multiple interactions

ISO

[Corticosterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein; [Corticosterone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein; Corticosterone inhibits the reaction [[Dexamethasone co-treated with Rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

insulin receptor substrate 3

increases expression

EXP

Corticosterone results in increased expression of IRS3 mRNA

NCBI chr12:24,689,930...24,692,068
Ensembl chr12:24,689,909...24,692,068

G

integrin subunit alpha 1

decreases expression

EXP

Corticosterone results in decreased expression of ITGA1 mRNA

NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:48,386,249...48,545,284

G

integrin subunit alpha 8

increases expression

EXP

Corticosterone results in increased expression of ITGA8 mRNA

NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633

G

integrin subunit beta 1 binding protein 2

increases expression

EXP

Corticosterone results in increased expression of ITGB1BP2 mRNA

NCBI chr X:70,612,118...70,617,158
Ensembl chr X:70,612,521...70,617,158

G

Janus kinase 2

multiple interactions

EXP

[alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide results in decreased activity of JAK2 protein] inhibits the reaction [HTR2A protein results in increased secretion of Corticosterone]

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

EXP

JUN protein affects the reaction [Corticosterone results in increased expression of BCL2L1 mRNA]

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

potassium voltage-gated channel subfamily H member 2

increases expression

EXP

Corticosterone results in increased expression of KCNH2 mRNA

NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421

G

potassium inwardly-rectifying channel, subfamily J, member 5

increases expression

EXP

Corticosterone results in increased expression of KCNJ5 mRNA

NCBI chr 8:38,981,598...39,011,197
Ensembl chr 8:38,983,034...39,011,101

G

kinase insert domain receptor

multiple interactions
decreases expression

ISO

1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Corticosterone results in decreased expression of KDR protein]; Calcium promotes the reaction [Corticosterone results in decreased expression of KDR protein]; Corticosterone inhibits the reaction [KDR protein binds to NR3C1 protein]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of KDR protein]; NR3C1 protein promotes the reaction [Corticosterone results in decreased expression of KDR protein]

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

kinesin family member 15

decreases expression

EXP

Corticosterone results in decreased expression of KIF15 mRNA

NCBI chr 8:131,479,340...131,550,209
Ensembl chr 8:131,479,337...131,550,202

G

kinesin family member C1

decreases expression

EXP

Corticosterone results in decreased expression of KIFC1 mRNA

NCBI chr20:5,000,929...5,018,967
Ensembl chr20:5,000,648...5,018,988

G

KLF transcription factor 4

multiple interactions
decreases expression

EXP

HDAC7 protein affects the reaction [Corticosterone results in decreased expression of KLF4 mRNA]; HDAC7 protein affects the reaction [Corticosterone results in decreased expression of KLF4 protein]; KLF4 protein inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; KLF4 protein inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of KLF4 mRNA]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of KLF4 protein]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of KLF4 mRNA]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of KLF4 protein]
Corticosterone results in decreased expression of KLF4 mRNA; Corticosterone results in decreased expression of KLF4 protein

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

KLF transcription factor 9

increases expression

EXP

Corticosterone results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

leptin

multiple interactions
decreases expression

ISO

1-(3-chlorophenyl)piperazine inhibits the reaction [Corticosterone results in decreased expression of LEP protein]; 8-(5-(5-amino-2,4-dimethoxyphenyl)-5-oxopentyl)-1,3,8-triazaspiro(4.5)decane-2,4-dione inhibits the reaction [1-(3-chlorophenyl)piperazine inhibits the reaction [Corticosterone results in decreased expression of LEP protein]]; [Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased secretion of LEP protein; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased secretion of LEP protein]

PMID:28186389 PMID:29751049

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

LIF, interleukin 6 family cytokine

multiple interactions
decreases expression

EXP
ISO

[Corticosterone co-treated with Isoflurophate] results in increased expression of LIF mRNA
[Corticosterone co-treated with Isoflurophate] results in increased expression of LIF mRNA; [Corticosterone co-treated with O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate] results in increased expression of LIF mRNA; [Corticosterone co-treated with Physostigmine] results in decreased expression of LIF mRNA
Corticosterone results in decreased expression of LIF mRNA

PMID:28500787 PMID:28782715 PMID:29846716

NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053

G

lamin B1

decreases expression

EXP

Corticosterone results in decreased expression of LMNB1 mRNA

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

lysophosphatidic acid receptor 1

increases expression

EXP

Corticosterone results in increased expression of LPAR1 mRNA

NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:78,024,139...78,142,188

G

leucine-rich repeat kinase 2

multiple interactions
increases secretion

ISO

LRRK2 protein mutant form promotes the reaction [Paraquat results in increased secretion of Corticosterone]
LRRK2 protein mutant form results in increased secretion of Corticosterone; LRRK2 protein results in increased secretion of Corticosterone

NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:124,706,080...124,867,239

G

MAGE family member D2

decreases expression

EXP

Corticosterone results in decreased expression of MAGED2 mRNA

NCBI chr X:23,160,928...23,364,994
Ensembl chr X:23,160,931...23,169,104

G

microtubule-associated protein 1 light chain 3 beta

increases lipidation
multiple interactions

EXP

Corticosterone results in increased lipidation of MAP1LC3B protein
3-methyladenine inhibits the reaction [Corticosterone results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Corticosterone results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Corticosterone results in increased lipidation of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase kinase 1

multiple interactions

EXP

astragaloside VI inhibits the reaction [Corticosterone results in decreased expression of and results in decreased phosphorylation of MAP2K1 protein]; Corticosterone results in decreased expression of and results in decreased phosphorylation of MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase kinase kinase 7

multiple interactions
increases phosphorylation

EXP

1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [Estradiol inhibits the reaction [Corticosterone results in increased phosphorylation of MAP3K7 protein]]; Estradiol inhibits the reaction [Corticosterone results in increased phosphorylation of MAP3K7 protein]; Flutamide inhibits the reaction [Estradiol inhibits the reaction [Corticosterone results in increased phosphorylation of MAP3K7 protein]]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in increased phosphorylation of MAP3K7 protein]]

NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012

G

mitogen activated protein kinase 1

increases phosphorylation
decreases phosphorylation
multiple interactions
decreases activity

EXP
ISO

Corticosterone results in increased phosphorylation of MAPK1 protein
Corticosterone results in decreased phosphorylation of MAPK1 protein
2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK1 protein]; KT 5823 inhibits the reaction [2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK1 protein]]
Corticosterone results in decreased activity of MAPK1 protein
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK1 protein]]; astragaloside VI inhibits the reaction [Corticosterone results in decreased expression of and results in decreased phosphorylation of MAPK1 protein]; Corticosterone results in decreased expression of and results in decreased phosphorylation of MAPK1 protein; Curcumin inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK1 protein]; IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK1 protein]

PMID:19175364 PMID:19733225 PMID:22850435 PMID:29343424 PMID:36559001

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation
decreases phosphorylation
multiple interactions
decreases activity

EXP
ISO

Corticosterone results in increased phosphorylation of MAPK3 protein
Corticosterone results in decreased phosphorylation of MAPK3 protein
2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK3 protein]; KT 5823 inhibits the reaction [2-(3,4-dimethoxybenzyl)-7-(1-(1-hydroxyethyl)-4-phenylbutyl)-5-methylimidazo(5,1-f)(1,2,4)triazin-4 (3H)-one inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK3 protein]]
Corticosterone results in decreased activity of MAPK3 protein
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK3 protein]]; astragaloside VI inhibits the reaction [Corticosterone results in decreased expression of and results in decreased phosphorylation of MAPK3 protein]; Corticosterone results in decreased expression of and results in decreased phosphorylation of MAPK3 protein; Curcumin inhibits the reaction [Corticosterone results in increased phosphorylation of MAPK3 protein]; IGF1 protein inhibits the reaction [Corticosterone results in decreased phosphorylation of MAPK3 protein]

PMID:19175364 PMID:19733225 PMID:22850435 PMID:29343424 PMID:36559001

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

myoglobin

decreases expression

EXP

Corticosterone results in decreased expression of MB mRNA

NCBI chr 7:110,640,511...110,647,742
Ensembl chr 7:110,640,512...110,647,958

G

melanocortin 2 receptor

multiple interactions
increases secretion

EXP

MC2R protein promotes the reaction [PRL protein results in increased secretion of Corticosterone]; PRL protein promotes the reaction [MC2R protein results in increased secretion of Corticosterone]

NCBI chr18:64,279,878...64,291,775
Ensembl chr18:64,277,360...64,291,881

G

minichromosome maintenance complex component 3

decreases expression

EXP

Corticosterone results in decreased expression of MCM3 mRNA

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746

G

minichromosome maintenance complex component 4

decreases expression

EXP

Corticosterone results in decreased expression of MCM4 mRNA

NCBI chr11:98,762,599...98,776,300
Ensembl chr11:98,762,634...98,776,536

G

minichromosome maintenance complex component 6

decreases expression

EXP

Corticosterone results in decreased expression of MCM6 mRNA

NCBI chr13:42,379,161...42,404,352
Ensembl chr13:42,379,162...42,465,467

G

minichromosome maintenance complex component 7

decreases expression

EXP

Corticosterone results in decreased expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

malic enzyme 1

decreases expression

EXP

Corticosterone results in decreased expression of ME1 mRNA

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275

G

methyl CpG binding protein 2

multiple interactions

EXP

MECP2 affects the reaction [Lipopolysaccharides promotes the reaction [Ethanol results in increased secretion of Corticosterone]]

NCBI chr X:156,932,481...156,995,981
Ensembl chr X:156,941,234...156,943,560

G

maternal embryonic leucine zipper kinase

decreases expression

EXP

Corticosterone results in decreased expression of MELK mRNA

NCBI chr 5:63,336,151...63,396,254
Ensembl chr 5:63,336,106...63,396,247

G

mitofusin 1

decreases expression

EXP

Corticosterone results in decreased expression of MFN1 mRNA

NCBI chr 2:117,240,525...117,288,017
Ensembl chr 2:117,241,759...117,290,190

G

mitofusin 2

decreases expression

EXP

Corticosterone results in decreased expression of MFN2 mRNA

NCBI chr 5:163,587,463...163,617,363
Ensembl chr 5:163,587,463...163,618,495

G

microsomal glutathione S-transferase 2

increases expression

EXP

Corticosterone results in increased expression of MGST2 mRNA

NCBI chr 2:137,821,787...137,866,664
Ensembl chr 2:137,836,140...137,866,661

G

microRNA 421

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of MIR421 mRNA
MIR421 affects the reaction [Corticosterone results in decreased expression of ACAN protein]; MIR421 affects the reaction [Corticosterone results in decreased expression of and results in decreased phosphorylation of MTOR protein]; MIR421 affects the reaction [Corticosterone results in increased expression of NR3C2 mRNA]

NCBI chr X:72,657,339...72,657,417

G

matrix metallopeptidase 12

decreases expression

EXP

Corticosterone results in decreased expression of MMP12 mRNA

NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478

G

metallothionein 1A

increases expression

EXP

Corticosterone results in increased expression of MT1 mRNA; Corticosterone results in increased expression of MT1A mRNA

PMID:15755911 PMID:31520820

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

mechanistic target of rapamycin kinase

decreases phosphorylation
multiple interactions

ISO
EXP

Corticosterone results in decreased phosphorylation of MTOR protein
Corticosterone results in decreased expression of and results in decreased phosphorylation of MTOR protein; MIR421 affects the reaction [Corticosterone results in decreased expression of and results in decreased phosphorylation of MTOR protein]

PMID:21647420 PMID:38759937

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

musculoskeletal, embryonic nuclear protein 1

increases expression

EXP

Corticosterone results in increased expression of MUSTN1 mRNA

NCBI chr16:6,079,355...6,081,608
Ensembl chr16:6,079,277...6,081,586

G

myosin heavy chain 11

increases expression

EXP

Corticosterone results in increased expression of MYH11 mRNA

NCBI chr10:1,250,554...1,345,681
Ensembl chr10:1,263,194...1,345,678

G

non-SMC condensin I complex, subunit D2

decreases expression

EXP

Corticosterone results in decreased expression of NCAPD2 mRNA

NCBI chr 4:159,655,051...159,677,938
Ensembl chr 4:159,655,051...159,677,938

G

non-SMC condensin II complex, subunit H2

decreases expression

EXP

Corticosterone results in decreased expression of NCAPH2 mRNA

NCBI chr 7:122,302,550...122,319,570
Ensembl chr 7:122,300,252...122,319,569

G

nuclear receptor coactivator 1

multiple interactions

ISO

Corticosterone promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]

NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924

G

neuronal calcium sensor 1

increases expression

ISO

Corticosterone results in increased expression of NCS1 protein

NCBI chr 3:34,920,949...34,966,554
Ensembl chr 3:34,920,971...34,968,711

G

N-myc downstream regulated 1

multiple interactions
increases phosphorylation

ISO

[Corticosterone results in increased phosphorylation of NDRG1 protein] promotes the reaction [NDRG1 protein binds to CTNNB1 protein]; [Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CDH2 protein; [Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CTNNA1 protein; [Corticosterone results in increased phosphorylation of NDRG1 protein] which results in increased expression of and results in increased localization of CTNNB1 protein
[Corticosterone results in increased phosphorylation of SGK1 protein] which results in increased phosphorylation of NDRG1 protein

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

NDRG family member 2

increases expression

EXP

Corticosterone results in increased expression of NDRG2 mRNA

NCBI chr15:27,074,481...27,087,376
Ensembl chr15:27,074,481...27,083,125

G

NFKB inhibitor alpha

increases expression

EXP

Corticosterone results in increased expression of NFKBIA mRNA

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nerve growth factor

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of NGF protein
O-1602 compound inhibits the reaction [Corticosterone results in decreased expression of NGF protein]

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834

G

NPHS1 adhesion molecule, nephrin

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of NPHS1 mRNA; Corticosterone results in decreased expression of NPHS1 protein
HDAC7 protein affects the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; HDAC7 protein affects the reaction [Corticosterone results in decreased expression of NPHS1 protein]; KLF4 protein inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; KLF4 protein inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 mRNA]; trichostatin A inhibits the reaction [Corticosterone results in decreased expression of NPHS1 protein]

NCBI chr 1:94,848,261...94,876,522
Ensembl chr 1:94,848,261...94,876,521

G

natriuretic peptide A

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of NPPA mRNA
Corticosterone promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA]

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

neuropeptide Y

decreases expression

EXP

Corticosterone results in decreased expression of NPY mRNA

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

Corticosterone binds to and results in increased activity of NR1I2 protein; Corticosterone promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Corticosterone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Corticosterone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]

PMID:11581012 PMID:12072427 PMID:16054614

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions

ISO

Corticosterone binds to and results in increased activity of NR1I3 protein; Corticosterone inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein]

NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases expression
affects localization
decreases expression
affects abundance
increases activity
affects binding

ISO
EXP

Corticosterone binds to and results in increased activity of NR3C1 protein
Corticosterone results in increased expression of NR3C1 mRNA; Corticosterone results in increased expression of NR3C1 protein
Corticosterone affects the localization of NR3C1 protein
Corticosterone results in decreased expression of NR3C1 protein
[Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Corticosterone results in increased expression of PTGS2 mRNA]; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Corticosterone results in increased expression of PTGS2 protein]; Corticosterone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]; Corticosterone promotes the reaction [NR3C1 protein binds to PTGS2 promoter]; Lead inhibits the reaction [Corticosterone binds to NR3C1 protein]; Mifepristone inhibits the reaction [Corticosterone promotes the reaction [NR3C1 protein binds to PTGS2 promoter]]
NR3C1 protein affects the abundance of Corticosterone
Corticosterone results in increased activity of NR3C1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Carbamazepine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Lithium inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Valproic Acid inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]]; Carbamazepine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Chlorpromazine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Clozapine inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Corticosterone inhibits the reaction [KDR protein binds to NR3C1 protein]; Lithium inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of NR3C1 protein]; Mifepristone inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; NR3C1 protein promotes the reaction [Corticosterone results in decreased expression of KDR protein]; NR3C1 protein promotes the reaction [Corticosterone results in increased expression of DKK1 protein]; Pregnanolone analog inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; Pregnanolone inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]; pyrazolanthrone inhibits the reaction [Valproic Acid inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]]; Valproic Acid inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]

PMID:10509797 PMID:11861974 PMID:15249158 PMID:15705660 PMID:16049266 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

affects binding
multiple interactions
increases expression

ISO
EXP

Corticosterone binds to NR3C2 protein
MIR421 affects the reaction [Corticosterone results in increased expression of NR3C2 mRNA]

PMID:16061183 PMID:38759937

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

neuregulin 1

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of NRG1 protein
astragaloside VI inhibits the reaction [Corticosterone results in decreased expression of NRG1 protein]

NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849

G

neurotrophic receptor tyrosine kinase 3

increases expression

EXP

Corticosterone results in increased expression of NTRK3 mRNA

NCBI chr 1:141,526,192...141,913,575
Ensembl chr 1:141,542,569...141,913,004

G

occludin

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in decreased expression of OCLN protein; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in decreased expression of OCLN protein]

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

osteomodulin

increases expression

EXP

Corticosterone results in increased expression of OMD mRNA

NCBI chr17:15,266,646...15,274,870
Ensembl chr17:15,266,646...15,274,870

G

5-oxoprolinase (ATP-hydrolysing)

increases expression

EXP

Corticosterone results in increased expression of OPLAH mRNA

NCBI chr 7:109,892,136...109,932,403
Ensembl chr 7:109,891,405...109,915,979

G

orosomucoid 1

increases expression

EXP

Corticosterone results in increased expression of ORM1 mRNA

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667

G

oncostatin M

multiple interactions

EXP
ISO

[Corticosterone co-treated with Isoflurophate] results in increased expression of OSM mRNA
[Corticosterone co-treated with Isoflurophate] results in increased expression of OSM mRNA; [Corticosterone co-treated with Physostigmine] results in increased expression of OSM mRNA; Corticosterone promotes the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased expression of OSM mRNA]

PMID:28500787 PMID:28782715 PMID:29846716

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827

G

prolyl 3-hydroxylase 1

decreases expression

EXP

Corticosterone results in decreased expression of P3H1 mRNA

NCBI chr 5:138,127,240...138,141,974
Ensembl chr 5:138,126,860...138,142,836

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

decreases expression

EXP

Corticosterone results in decreased expression of PCK2 mRNA

NCBI chr15:32,997,853...33,006,691
Ensembl chr15:32,997,834...33,016,864

G

proliferating cell nuclear antigen

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of PCNA mRNA; Corticosterone results in decreased expression of PCNA protein
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluoro-5-bromobenzamide inhibits the reaction [IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of PCNA mRNA]]; IGF1 protein inhibits the reaction [Corticosterone results in decreased expression of PCNA mRNA]

PMID:15755911 PMID:29343424

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphodiesterase 2A

increases expression
multiple interactions

ISO
EXP

Corticosterone results in increased expression of PDE2A mRNA; Corticosterone results in increased expression of PDE2A mRNA alternative form; Corticosterone results in increased expression of PDE2A protein
Mifepristone inhibits the reaction [Corticosterone results in increased expression of PDE2A protein]

NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:165,235,623...165,327,466

G

pyruvate dehydrogenase kinase 1

multiple interactions

ISO

[Corticosterone results in increased phosphorylation of and results in increased activity of PDK1 protein] which results in increased phosphorylation of and results in increased activity of SGK1 protein; Corticosterone results in increased phosphorylation of and results in increased activity of PDK1 protein

NCBI chr 3:77,113,464...77,144,145
Ensembl chr 3:77,113,473...77,144,145

G

PDZ and LIM domain 5

increases expression

EXP

Corticosterone results in increased expression of PDLIM5 mRNA

NCBI chr 2:233,625,478...233,793,582
Ensembl chr 2:233,628,503...233,793,528

G

PDZ and LIM domain 7

increases expression

EXP

Corticosterone results in increased expression of PDLIM7 mRNA

NCBI chr17:9,129,603...9,144,956
Ensembl chr17:9,129,525...9,144,956

G

prodynorphin

multiple interactions

EXP
ISO

Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]
PDYN protein promotes the reaction [Cocaine results in increased abundance of Corticosterone]

PMID:17532787 PMID:18687386

NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:137,354,161...137,366,503

G

proenkephalin

multiple interactions

EXP

Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA]

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705

G

phosphofructokinase, liver type

increases expression

EXP

Corticosterone results in increased expression of PFKL mRNA

NCBI chr20:10,663,907...10,685,967
Ensembl chr20:10,663,955...10,685,966

G

phosphofructokinase, platelet

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PFKP mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PFKP mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PFKP mRNA]

NCBI chr17:68,639,749...68,704,055
Ensembl chr17:68,639,481...68,705,752

G

profilin 2

decreases expression

EXP

Corticosterone results in decreased expression of PFN2 mRNA

NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:144,205,636...144,222,936

G

Pim-3 proto-oncogene, serine/threonine kinase

increases expression

EXP

Corticosterone results in increased expression of PIM3 mRNA

NCBI chr 7:121,822,076...121,836,257
Ensembl chr 7:121,832,742...121,836,259

G

phospholipase A1 member A

increases expression

EXP

Corticosterone results in increased expression of PLA1A mRNA

NCBI chr11:75,825,626...75,863,296
Ensembl chr11:75,825,585...75,878,165

G

polo-like kinase 1

decreases expression

EXP

Corticosterone results in decreased expression of PLK1 mRNA

NCBI chr 1:186,147,658...186,157,637
Ensembl chr 1:186,147,658...186,157,637

G

polo-like kinase 2

decreases expression

EXP

Corticosterone results in decreased expression of PLK2 mRNA

NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296

G

polo-like kinase 4

decreases expression

EXP

Corticosterone results in decreased expression of PLK4 mRNA

NCBI chr 2:125,730,480...125,748,894
Ensembl chr 2:125,730,460...125,748,892

G

podocalyxin-like

increases expression

EXP

Corticosterone results in increased expression of PODXL mRNA

NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789

G

proopiomelanocortin

multiple interactions
increases secretion
increases abundance
decreases abundance
decreases secretion

EXP
ISO

Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone]; Corticosterone inhibits the reaction [Nitroprusside results in increased secretion of POMC protein]; Cromolyn Sodium inhibits the reaction [POMC results in increased secretion of Corticosterone]; Fulvestrant inhibits the reaction [nonylphenol promotes the reaction [POMC protein modified form results in increased secretion of Corticosterone]]; Nitroprusside inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]; nonylphenol inhibits the reaction [Nitroprusside inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]]; nonylphenol promotes the reaction [POMC protein modified form results in increased secretion of Corticosterone]; oxophenylarsine inhibits the reaction [POMC protein results in increased abundance of Corticosterone]; pervanadate inhibits the reaction [POMC protein results in increased abundance of Corticosterone]; SB 203580 inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]
lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]; resveratrol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone]]
POMC protein results in decreased abundance of Corticosterone
POMC protein modified form results in increased secretion of Corticosterone; POMC protein results in increased secretion of Corticosterone; POMC results in increased secretion of Corticosterone
Corticosterone results in decreased secretion of POMC protein; POMC protein results in decreased secretion of Corticosterone

PMID:1659878 PMID:3015567 PMID:7588239 PMID:10518784 PMID:11132610 More...

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PPARA mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PPARA mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PPARA mRNA]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in decreased expression of PPARG mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in decreased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

protein phosphatase 1, regulatory (inhibitor) subunit 1B

multiple interactions

ISO

Cocaine promotes the reaction [PPP1R1B protein results in increased abundance of Corticosterone]

NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,844,036...83,853,063

G

protein phosphatase 2, regulatory subunit B, beta

decreases expression

EXP

Corticosterone results in decreased expression of PPP2R2B mRNA

NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,904,686...35,356,977

G

DNA primase subunit 1

decreases expression

EXP

Corticosterone results in decreased expression of PRIM1 mRNA

NCBI chr 7:1,031,436...1,047,134

G

protein kinase cAMP-dependent type I regulatory subunit alpha

multiple interactions

ISO

[Androgens deficiency affects the activity of PRKAR1A gene mutant form] which results in increased secretion of Corticosterone; [PRKAR1A gene mutant form results in increased susceptibility to Androgens deficiency] which results in increased secretion of Corticosterone; Dexamethasone inhibits the reaction [[PRKAR1A gene mutant form results in increased susceptibility to Androgens deficiency] which results in increased secretion of Corticosterone]; Dexamethasone inhibits the reaction [PRKAR1A gene mutant form results in increased secretion of Corticosterone]; Dihydrotestosterone inhibits the reaction [[Androgens deficiency affects the activity of PRKAR1A gene mutant form] which results in increased secretion of Corticosterone]; Dihydrotestosterone inhibits the reaction [[PRKAR1A gene mutant form results in increased susceptibility to Androgens deficiency] which results in increased secretion of Corticosterone]

NCBI chr10:95,120,537...95,139,028
Ensembl chr10:95,120,487...95,139,025

G

protein kinase C, alpha

multiple interactions

ISO

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione promotes the reaction [Corticosterone results in increased activity of PRKCA protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Corticosterone results in increased activity of PRKCA protein]

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

prolactin

multiple interactions

EXP

MC2R protein promotes the reaction [PRL protein results in increased secretion of Corticosterone]; PRL protein promotes the reaction [MC2R protein results in increased secretion of Corticosterone]

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

phosphatase and tensin homolog

increases phosphorylation

ISO

Corticosterone results in increased phosphorylation of PTEN protein

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin D2 synthase

increases expression

EXP

Corticosterone results in increased expression of PTGDS mRNA

NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978

G

prostaglandin-endoperoxide synthase 1

increases expression

EXP

Corticosterone results in increased expression of PTGS1 mRNA; Corticosterone results in increased expression of PTGS1 protein

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

EXP

[Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Corticosterone results in increased expression of PTGS2 mRNA]; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Corticosterone results in increased expression of PTGS2 protein]; CEBPB protein affects the reaction [Corticosterone results in increased expression of PTGS2 mRNA]; CEBPB protein affects the reaction [Corticosterone results in increased expression of PTGS2 protein]; Corticosterone promotes the reaction [CEBPB protein binds to PTGS2 promoter]; Corticosterone promotes the reaction [NR3C1 protein binds to PTGS2 promoter]; Dactinomycin inhibits the reaction [Corticosterone results in increased expression of PTGS2 mRNA]; Dactinomycin inhibits the reaction [Corticosterone results in increased expression of PTGS2 protein]; Mifepristone inhibits the reaction [Corticosterone promotes the reaction [NR3C1 protein binds to PTGS2 promoter]]
Corticosterone results in increased expression of PTGS2 mRNA; Corticosterone results in increased expression of PTGS2 protein

PMID:15755911 PMID:18650268

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

parathyroid hormone

multiple interactions

EXP

[Corticosterone co-treated with PTH protein] results in decreased expression of TNFRSF11B mRNA; [Corticosterone co-treated with PTH protein] results in decreased expression of TNFSF11 mRNA

NCBI chr 1:176,942,901...176,946,034
Ensembl chr 1:176,943,102...176,946,034

G

protein tyrosine phosphatase, non-receptor type 3

decreases expression

EXP

Corticosterone results in decreased expression of PTPN3 mRNA

NCBI chr 5:76,703,687...76,822,584
Ensembl chr 5:76,703,687...76,860,470

G

PTTG1 regulator of sister chromatid separation, securin

decreases expression

EXP

Corticosterone results in decreased expression of PTTG1 mRNA

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

quiescin sulfhydryl oxidase 1

increases expression

EXP

Corticosterone results in increased expression of QSOX1 mRNA

NCBI chr13:70,500,060...70,537,711
Ensembl chr13:70,500,060...70,537,733

G

Rap guanine nucleotide exchange factor 4

increases expression

EXP

Corticosterone results in increased expression of RAPGEF4 mRNA

NCBI chr 3:77,217,024...77,509,933
Ensembl chr 3:77,217,039...77,509,978

G

retinol binding protein 1

decreases expression

EXP

Corticosterone results in decreased expression of RBP1 mRNA

NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:107,887,417...107,983,847

G

regenerating family member 3 beta

decreases expression

EXP

Corticosterone results in decreased expression of REG3B mRNA

NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:112,419,776...112,423,014

G

resistin

increases expression

ISO

Corticosterone results in increased expression of RETN mRNA

NCBI chr12:6,508,653...6,511,115
Ensembl chr12:6,508,801...6,511,116

G

replication factor C subunit 3

decreases expression

EXP

Corticosterone results in decreased expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

replication factor C subunit 4

decreases expression

EXP

Corticosterone results in decreased expression of RFC4 mRNA

NCBI chr11:91,254,273...91,268,727
Ensembl chr11:91,254,243...91,268,730

G

regulator of cell cycle

increases expression

EXP

Corticosterone results in increased expression of RGCC mRNA

NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408

G

ras homolog family member J

increases expression

EXP

Corticosterone results in increased expression of RHOJ mRNA

NCBI chr 6:99,771,104...99,853,366
Ensembl chr 6:99,771,252...99,853,999

G

replication protein A2

decreases expression

EXP

Corticosterone results in decreased expression of RPA2 mRNA

NCBI chr 5:150,260,668...150,271,329
Ensembl chr 5:150,260,723...150,271,546

G

ribonucleotide reductase catalytic subunit M1

decreases expression

EXP

Corticosterone results in decreased expression of RRM1 mRNA

NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944

G

RUNX family transcription factor 2

multiple interactions
decreases expression

EXP

Enalapril inhibits the reaction [Corticosterone results in decreased expression of RUNX2 mRNA]

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

S100 calcium binding protein B

multiple interactions

EXP

[Ethanol co-treated with Corticosterone] results in increased expression of and affects the localization of S100B protein; Corticosterone results in increased expression of and affects the localization of S100B protein

NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081

G

stearoyl-CoA desaturase

decreases expression

EXP

Corticosterone results in decreased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

syndecan 1

decreases expression

EXP

Corticosterone results in decreased expression of SDC1 mRNA

NCBI chr 6:37,282,041...37,304,503
Ensembl chr 6:37,297,010...37,304,500

G

syndecan 2

decreases expression

EXP

Corticosterone results in decreased expression of SDC2 mRNA

NCBI chr 7:66,012,405...66,125,101
Ensembl chr 7:66,108,853...66,126,294

G

syndecan 4

increases expression

EXP

Corticosterone results in increased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670

G

selenoprotein P

increases expression

EXP

Corticosterone results in increased expression of SELENOP mRNA

NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019

G

serpin family A member 3N

increases expression

EXP

Corticosterone results in increased expression of SERPINA3N mRNA

NCBI chr 6:129,088,392...129,095,950
Ensembl chr 6:129,088,398...129,097,415

G

serum/glucocorticoid regulated kinase 1

increases expression
increases phosphorylation
multiple interactions

EXP
ISO

Corticosterone results in increased expression of SGK1 mRNA
[Corticosterone results in increased phosphorylation of SGK1 protein] which results in increased phosphorylation of NDRG1 protein
[Corticosterone results in increased phosphorylation of and results in increased activity of PDK1 protein] which results in increased phosphorylation of and results in increased activity of SGK1 protein
Corticosterone results in increased expression of SGK1 mRNA; Corticosterone results in increased expression of SGK1 protein

PMID:15755911 PMID:21655274 PMID:31520820

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

sex hormone binding globulin

affects binding

ISO

Corticosterone binds to SHBG protein

NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760

G

solute carrier family 18 member A3

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of SLC18A3 protein
O-1602 compound inhibits the reaction [Corticosterone results in increased expression of SLC18A3 protein]

NCBI chr16:7,719,953...7,722,814

G

solute carrier family 1 member 2

multiple interactions
increases expression

ISO

Corticosterone inhibits the reaction [Hydrogen Peroxide results in decreased expression of SLC1A2 protein]; Vitamin A promotes the reaction [Corticosterone results in increased expression of SLC1A2 protein]

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 22 member 2

multiple interactions

EXP

Corticosterone inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 22 member 3

decreases activity
multiple interactions

EXP
ISO

Corticosterone results in decreased activity of SLC22A3 protein
[Corticosterone results in decreased activity of SLC22A3 protein] inhibits the reaction [Epinephrine results in increased abundance of Epinephrine metabolite]; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased abundance of Epinephrine; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased import of Phenylephrine; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased import of Synephrine; Corticosterone inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased transport of Histamine]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]
Corticosterone inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Corticosterone inhibits the reaction [SLC22A3 protein results in increased uptake of Formoterol Fumarate]

PMID:9830022 PMID:12110607 PMID:12181285 PMID:12411423 PMID:16928864 More...

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353

G

solute carrier family 22 member 8

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of SLC22A8 protein
O-1602 compound inhibits the reaction [Corticosterone results in increased expression of SLC22A8 protein]

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

G

solute carrier family 2 member 1

increases expression
multiple interactions

EXP
ISO

Corticosterone results in increased expression of SLC2A1 mRNA
[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A1 mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A1 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A1 mRNA]

PMID:15755911 PMID:29751049

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 4

increases expression
multiple interactions

EXP
ISO

Corticosterone results in increased expression of SLC2A4 mRNA
[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A4 mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A4 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A4 mRNA]

PMID:15755911 PMID:29751049

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier family 6 member 15

multiple interactions
decreases expression

ISO

Edaravone inhibits the reaction [Corticosterone results in decreased expression of SLC6A15 mRNA]; Paroxetine inhibits the reaction [Corticosterone results in decreased expression of SLC6A15 mRNA]

NCBI chr 7:40,439,607...40,493,788
Ensembl chr 7:40,439,658...40,493,786

G

SMAD family member 2

decreases expression

EXP

Corticosterone results in decreased expression of SMAD2 mRNA; Corticosterone results in decreased expression of SMAD2 protein

PMID:29660438 PMID:32663519

NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388

G

SMAD family member 3

decreases expression

EXP

Corticosterone results in decreased expression of SMAD3 mRNA

PMID:29660438 PMID:32663519

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324

G

SWI/SNF related BAF chromatin remodeling complex subunit D2

increases expression

EXP

Corticosterone results in increased expression of SMARCD2 mRNA

NCBI chr10:91,693,542...91,702,408
Ensembl chr10:91,693,542...91,702,522

G

superoxide dismutase 1

decreases expression

EXP

Corticosterone results in decreased expression of SOD1 mRNA

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

superoxide dismutase 2

multiple interactions
decreases activity
decreases expression

EXP

[IGF2R protein co-treated with IGF1R protein] affects the reaction [IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]]; IGF2 protein inhibits the reaction [Corticosterone results in decreased expression of SOD2 protein]
Corticosterone results in decreased activity of SOD2 protein
Corticosterone results in decreased expression of SOD2 mRNA; Corticosterone results in decreased expression of SOD2 protein

PMID:22244747 PMID:24667322

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

sorbin and SH3 domain containing 2

increases expression

EXP

Corticosterone results in increased expression of SORBS2 mRNA

NCBI chr16:53,167,795...53,481,300
Ensembl chr16:53,167,827...53,358,986

G

SRY-box transcription factor 4

decreases expression

EXP

Corticosterone results in decreased expression of SOX4 mRNA

NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024

G

SRY-box transcription factor 9

decreases expression

EXP

Corticosterone results in decreased expression of SOX9 mRNA; Corticosterone results in decreased expression of SOX9 protein

PMID:29660438 PMID:32663519

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

secreted phosphoprotein 1

multiple interactions
decreases expression

EXP

Enalapril inhibits the reaction [Corticosterone results in decreased expression of SPP1 mRNA]

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

sequestosome 1

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of SQSTM1 protein
3-methyladenine inhibits the reaction [Corticosterone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Corticosterone results in decreased expression of SQSTM1 protein]; Sirolimus promotes the reaction [Corticosterone results in decreased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

multiple interactions

EXP
ISO

[Corticosterone co-treated with oleoyl-estrone] affects the expression of SREBF1 mRNA
[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SREBF1 mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SREBF1 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SREBF1 mRNA]

PMID:19545626 PMID:29751049

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

steroidogenic acute regulatory protein

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of STAR mRNA; Corticosterone results in decreased expression of STAR protein
Mifepristone inhibits the reaction [Corticosterone results in decreased expression of STAR mRNA]; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of STAR protein]

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

signal transducer and activator of transcription 3

multiple interactions

ISO

[Corticosterone co-treated with Isoflurophate] results in increased phosphorylation of STAT3 protein; [Corticosterone co-treated with O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate] results in increased phosphorylation of STAT3 protein

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

stathmin 1

decreases expression

EXP

Corticosterone results in decreased expression of STMN1 mRNA

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842

G

sulfotransferase family 1A member 1

increases expression

EXP

Corticosterone results in increased expression of SULT1A1 mRNA

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

synapsin I

multiple interactions
decreases expression

ISO

Ascorbic Acid inhibits the reaction [Corticosterone results in decreased expression of SYN1 protein]; Ketamine inhibits the reaction [Corticosterone results in decreased expression of SYN1 protein]

NCBI chr X:3,725,745...3,780,940
Ensembl chr X:3,725,714...3,780,938

G

synemin

increases expression

EXP

Corticosterone results in increased expression of SYNM mRNA

NCBI chr 1:130,743,891...130,774,254
Ensembl chr 1:130,743,897...130,773,824

G

tyrosine aminotransferase

multiple interactions

EXP

[Mirex co-treated with Corticosterone] results in increased activity of TAT protein; Corticosterone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]

PMID:2893471 PMID:22465009

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

transcription factor 21

increases expression

EXP

Corticosterone results in increased expression of TCF21 mRNA

NCBI chr 1:24,520,499...24,523,358
Ensembl chr 1:24,520,481...24,523,348

G

t-complex 1

decreases expression

EXP

Corticosterone results in decreased expression of TCP1 mRNA

NCBI chr 1:50,376,848...50,384,527
Ensembl chr 1:50,376,848...50,384,527

G

tryptophan 2,3-dioxygenase

increases activity

EXP

Corticosterone results in increased activity of TDO2 protein

NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586

G

transferrin

increases expression

EXP

Corticosterone results in increased expression of TF mRNA

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transforming growth factor, beta 1

multiple interactions
decreases expression

EXP

Corticosterone inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein]
Corticosterone results in decreased expression of TGFB1 mRNA

PMID:16598785 PMID:29660438 PMID:32663519

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta receptor 1

decreases expression
multiple interactions

EXP

Corticosterone results in decreased expression of TGFBR1 mRNA; Corticosterone results in decreased expression of TGFBR1 protein
Mifepristone inhibits the reaction [Corticosterone results in decreased expression of TGFBR1 mRNA]

PMID:29660438 PMID:32663519

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260

G

transglutaminase 2

increases expression

EXP

Corticosterone results in increased expression of TGM2 mRNA

NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240

G

tyrosine hydroxylase

increases expression

ISO

Corticosterone results in increased expression of TH protein

NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227

G

tubulointerstitial nephritis antigen-like 1

increases expression

EXP

Corticosterone results in increased expression of TINAGL1 mRNA

NCBI chr 5:147,797,884...147,807,925
Ensembl chr 5:147,797,892...147,807,871

G

thymidine kinase 1

decreases expression

EXP

Corticosterone results in decreased expression of TK1 mRNA

NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,533,449...103,556,228

G

toll-like receptor 4

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR4 protein; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR4 protein]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PFKP mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of PPARA mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A1 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SLC2A4 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of SREBF1 mRNA]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR5 protein]

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

toll-like receptor 5

multiple interactions

ISO

[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR5 protein; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR5 protein]; TLR4 gene mutant form inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TLR5 protein]

NCBI chr13:97,166,430...97,190,642
Ensembl chr13:97,166,405...97,192,525

G

tenascin C

decreases expression

EXP

Corticosterone results in decreased expression of TNC mRNA

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131

G

tumor necrosis factor

multiple interactions
increases expression

ISO
EXP

[Corticosterone co-treated with Isoflurophate] results in increased expression of TNF mRNA; [Corticosterone co-treated with O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate] results in increased expression of TNF mRNA; [Corticosterone co-treated with Physostigmine] results in increased expression of TNF mRNA; [Corticosterone co-treated with Pyridostigmine Bromide] results in increased expression of TNF mRNA; [Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TNF mRNA; Butyric Acid inhibits the reaction [[Permethrin co-treated with Pyridostigmine Bromide co-treated with Corticosterone] results in increased expression of TNF mRNA]; Corticosterone promotes the reaction [Isoflurophate results in increased expression of TNF mRNA]; Corticosterone promotes the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate results in increased expression of TNF mRNA]
Corticosterone results in increased expression of TNF protein
Corticosterone results in increased expression of TNF mRNA
[Corticosterone co-treated with Isoflurophate] results in increased expression of TNF mRNA; O-1602 compound inhibits the reaction [Corticosterone results in increased expression of TNF protein]

PMID:28500787 PMID:28782715 PMID:29751049 PMID:29846716 PMID:32733244

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 11B

decreases expression
increases expression
multiple interactions

EXP

Corticosterone results in decreased expression of TNFRSF11B mRNA
Corticosterone results in increased expression of TNFRSF11B mRNA
[Corticosterone co-treated with PTH protein] results in decreased expression of TNFRSF11B mRNA; Mifepristone inhibits the reaction [Corticosterone results in increased expression of TNFRSF11B mRNA]

PMID:17476578 PMID:29981921

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF superfamily member 11

multiple interactions
decreases expression
increases expression

EXP

[Corticosterone co-treated with PTH protein] results in decreased expression of TNFSF11 mRNA; Mifepristone inhibits the reaction [Corticosterone results in decreased expression of TNFSF11 mRNA]
Corticosterone results in increased expression of TNFSF11 mRNA

PMID:17476578 PMID:29981921

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

DNA topoisomerase II alpha

decreases expression

EXP

Corticosterone results in decreased expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

trophoblast glycoprotein

decreases expression

EXP

Corticosterone results in decreased expression of TPBG mRNA

NCBI chr 8:95,673,993...95,677,364
Ensembl chr 8:95,629,267...95,678,394

G

TPD52 like 1

increases expression

EXP

Corticosterone results in increased expression of TPD52L1 mRNA

NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:27,991,131...28,110,158

G

TNF receptor associated factor 6

multiple interactions

ISO
EXP

[Testosterone co-treated with Estradiol co-treated with Corticosterone] promotes the reaction [AR protein binds to TRAF6 protein]; [Testosterone co-treated with Estradiol co-treated with Corticosterone] promotes the reaction [ESR1 protein binds to TRAF6 protein]
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [Estradiol inhibits the reaction [Corticosterone results in increased expression of TRAF6 protein]]; Corticosterone results in increased expression of and results in increased ubiquitination of TRAF6 protein; Estradiol inhibits the reaction [Corticosterone results in increased expression of and results in increased ubiquitination of TRAF6 protein]; Estradiol promotes the reaction [Testosterone inhibits the reaction [Corticosterone results in increased ubiquitination of TRAF6 protein]]; Flutamide inhibits the reaction [Estradiol inhibits the reaction [Corticosterone results in increased expression of TRAF6 protein]]; Testosterone inhibits the reaction [Corticosterone results in increased ubiquitination of TRAF6 protein]; Testosterone promotes the reaction [Estradiol inhibits the reaction [Corticosterone results in increased expression of and results in increased ubiquitination of TRAF6 protein]]

NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328

G

thyrotropin releasing hormone receptor

increases expression

EXP

Corticosterone results in increased expression of TRHR mRNA

NCBI chr 7:77,233,175...77,277,988
Ensembl chr 7:77,233,354...77,277,987

G

tripartite motif-containing 54

increases expression

EXP

Corticosterone results in increased expression of TRIM54 mRNA

NCBI chr 6:30,959,306...30,978,475
Ensembl chr 6:30,959,306...30,978,475

G

TSC22 domain family, member 3

increases expression
multiple interactions

EXP

Corticosterone results in increased expression of TSC22D3 mRNA; Corticosterone results in increased expression of TSC22D3 protein
TSC22D3 protein affects the reaction [Corticosterone results in decreased susceptibility to Doxorubicin]

PMID:24480152 PMID:31520820

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

translocator protein

increases expression
multiple interactions

EXP
ISO

Corticosterone results in increased expression of TSPO mRNA
Corticosterone results in increased expression of TSPO protein
protosappanin A inhibits the reaction [Corticosterone results in increased expression of TSPO protein]

PMID:15755911 PMID:40054743

NCBI chr 7:116,600,214...116,610,461
Ensembl chr 7:116,600,210...116,610,460

G

tubulin, beta 5 class I

decreases expression

EXP

Corticosterone results in decreased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

ubiquitin-conjugating enzyme E2C

decreases expression

EXP

Corticosterone results in decreased expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

versican

decreases expression

EXP

Corticosterone results in decreased expression of VCAN mRNA

NCBI chr 2:22,497,035...22,595,955
Ensembl chr 2:22,497,035...22,595,955

G

vascular endothelial growth factor A

multiple interactions
increases expression
affects expression

EXP
ISO

Corticosterone inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein]
Corticosterone results in increased expression of VEGFA protein
Corticosterone affects the expression of VEGFA protein

PMID:16598785 PMID:21647420

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

tryptophanyl-tRNA synthetase 1

decreases expression

EXP

Corticosterone results in decreased expression of WARS1 mRNA

NCBI chr 6:133,540,463...133,571,645
Ensembl chr 6:133,539,744...133,571,645

G

WT1 transcription factor

decreases expression

EXP

Corticosterone results in decreased expression of WT1 mRNA; Corticosterone results in decreased expression of WT1 protein

NCBI chr 3:112,019,721...112,068,454
Ensembl chr 3:112,021,641...112,068,444

G

exportin 1

decreases expression

EXP

Corticosterone results in decreased expression of XPO1 mRNA

NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714

G

zinc finger protein 36

increases expression

EXP

Corticosterone results in increased expression of ZFP36 mRNA

NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases secretion

ISO

Elacridar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]; valspodar inhibits the reaction [ABCB1 protein results in increased secretion of Hydrocortisone]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily C member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA

NCBI chr10:1,022,041...1,162,431
Ensembl chr10:1,038,947...1,162,404

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
increases activity

ISO

Hydrocortisone promotes the reaction [ABCC3 protein affects the transport of calcein AM]
Hydrocortisone results in increased expression of ABCC3 mRNA
Hydrocortisone results in increased activity of ABCC3 protein

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

acetyl-CoA carboxylase alpha

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of ACACA mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

atypical chemokine receptor 1

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ACKR1 mRNA]

NCBI chr13:88,314,735...88,316,354
Ensembl chr13:88,293,188...88,317,807

G

ATP citrate lyase

increases expression

ISO

Hydrocortisone results in increased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

acyl-CoA synthetase long-chain family member 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

actinin alpha 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

ADAM metallopeptidase domain 12

decreases expression

ISO

Hydrocortisone results in decreased expression of ADAM12 mRNA

NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552

G

adhesion G protein-coupled receptor E5

decreases expression

ISO

Hydrocortisone results in decreased expression of ADGRE5 mRNA

NCBI chr19:41,302,687...41,332,183
Ensembl chr19:41,303,213...41,324,641

G

adhesion G protein-coupled receptor G1

decreases expression

ISO

Hydrocortisone results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

alpha-fetoprotein

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

angiotensinogen

decreases expression
increases secretion

ISO

Hydrocortisone results in decreased expression of AGT protein
AGT protein results in increased secretion of Hydrocortisone

PMID:7473517 PMID:28235592

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

aldo-keto reductase family 1, member D1

increases reduction
multiple interactions

ISO

AKR1D1 protein results in increased reduction of Hydrocortisone
AKR1D1 protein alternative form results in increased reduction of Hydrocortisone; AKR1D1 protein results in increased reduction of Hydrocortisone
[AKR1D1 protein alternative form results in increased reduction of Hydrocortisone] which results in increased chemical synthesis of 5-dihydrocortisol

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

AKT serine/threonine kinase 1

decreases phosphorylation

EXP

Hydrocortisone results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

AKT serine/threonine kinase 2

decreases expression

ISO

Hydrocortisone results in decreased expression of AKT2 mRNA

PMID:31075344 PMID:32535229

NCBI chr 1:92,004,705...92,061,420
Ensembl chr 1:92,014,859...92,061,420

G

albumin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldolase, fructose-bisphosphate A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

anti-Mullerian hormone receptor type 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA

NCBI chr 7:135,454,517...135,470,183
Ensembl chr 7:135,457,922...135,471,104

G

annexin A1

multiple interactions
increases expression

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ANXA1 mRNA]

PMID:25763180 PMID:34480604

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

apolipoprotein A1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein B

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

androgen receptor

affects activity
affects binding
multiple interactions

ISO
EXP

Hydrocortisone affects the activity of AR protein
Hydrocortisone binds to AR protein
Hydrocortisone binds to AR protein mutant form
Hydrocortisone binds to and results in increased activity of AR protein; Hydrocortisone binds to and results in increased activity of AR protein mutant form

PMID:11956172 PMID:12676605 PMID:14565775 PMID:15084347

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginase 1

increases expression
multiple interactions

EXP

Hydrocortisone results in increased expression of ARG1 mRNA
Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of ARG1 mRNA]

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

achaete-scute family bHLH transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA

NCBI chr 7:23,790,642...23,793,509
Ensembl chr 7:23,790,360...23,798,231

G

basic helix-loop-helix ARNT like 1

decreases expression

ISO

Hydrocortisone results in decreased expression of BMAL1 mRNA

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

bone morphogenetic protein 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA

NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189

G

calcium/calmodulin-dependent protein kinase II beta

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA

NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485

G

caspase 3

increases activity
multiple interactions

ISO
EXP

Hydrocortisone results in increased activity of CASP3 protein
Hydrocortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]

PMID:15086553 PMID:15755911

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

decreases expression
multiple interactions

ISO
EXP

Hydrocortisone results in decreased expression of CCL2 protein
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]

PMID:20116850 PMID:25851902

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

ISO

Hydrocortisone results in increased expression of CCL3 protein

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

Hydrocortisone results in increased expression of CCL4 protein

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

CD14 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD14 mRNA

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD40 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD40 protein

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

Cd80 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD80 protein

PMID:15086553 PMID:15241357

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

CD86 molecule

decreases expression

ISO

Hydrocortisone results in decreased expression of CD86 protein

PMID:15086553 PMID:15241357

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

cell division cycle 20

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cadherin 10

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA

NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332

G

cadherin 5

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of CDH5 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CDH5 protein]

NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822

G

CEA cell adhesion molecule 6

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA

NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:89,544,400...89,562,552

G

CCAAT/enhancer binding protein alpha

multiple interactions
increases expression

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of CEBPA mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]
Hydrocortisone results in increased expression of CEBPA mRNA; Hydrocortisone results in increased expression of CEBPA protein

PMID:30528684 PMID:30776459 PMID:32535229 PMID:33476690

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

affects expression
multiple interactions

ISO

Hydrocortisone affects the expression of CEBPB mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of CEBPB mRNA]

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

cell death-inducing DFFA-like effector c

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA

NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806

G

collagen type I alpha 1 chain

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type III alpha 1 chain

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

collagen type VII alpha 1 chain

decreases expression

ISO

Hydrocortisone results in decreased expression of COL7A1 mRNA

NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439

G

carnitine palmitoyltransferase 1A

decreases expression

ISO

Hydrocortisone results in decreased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

corticotropin releasing hormone

increases abundance

ISO

CRH protein results in increased abundance of Hydrocortisone

PMID:8888355 PMID:20570051

NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386

G

cryptochrome circadian regulator 1

increases expression

ISO

Hydrocortisone results in increased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

crystallin, alpha B

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA

NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528

G

citrate synthase

decreases activity
multiple interactions

EXP

Hydrocortisone results in decreased activity of CS protein
Dactinomycin inhibits the reaction [Hydrocortisone results in decreased activity of CS protein]

NCBI chr 7:1,348,389...1,374,624
Ensembl chr 7:1,342,942...1,375,938

G

colony stimulating factor 2

decreases secretion
multiple interactions

ISO

Hydrocortisone results in decreased secretion of CSF2 protein
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]

PMID:10460758 PMID:15086553

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

catenin beta 1

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of CTNNB1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of CTNNB1 protein]

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression
multiple interactions
affects expression

ISO

Hydrocortisone results in decreased expression of CYP11A1 mRNA; Hydrocortisone results in decreased expression of CYP11A1 protein
HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]
Hydrocortisone affects the expression of CYP11A1 mRNA

PMID:30528684 PMID:34454011

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases chemical synthesis
multiple interactions
affects metabolic processing

ISO

CYP11B1 protein results in increased chemical synthesis of Hydrocortisone
3',4'-dimethoxyflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; alpha-naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]; beta-Naphthoflavone promotes the reaction [CYP11B1 protein results in increased chemical synthesis of Hydrocortisone]
CYP11B1 protein affects the metabolism of Hydrocortisone

PMID:16030167 PMID:16054388 PMID:19900470 PMID:22172629

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions
decreases expression

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 mRNA]; Hydrocortisone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]
Hydrocortisone results in decreased expression of CYP1B1 protein

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA

NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 26, subfamily b, polypeptide 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA

NCBI chr 4:118,599,356...118,616,176
Ensembl chr 4:118,599,356...118,616,176

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP2B1 mRNA; Hydrocortisone results in increased expression of CYP2B1 protein

NCBI chr 1:90,646,098...90,669,762

G

cytochrome P450, family 2, subfamily d, polypeptide 4

multiple interactions

ISO

CYP2D6 gene SNP affects the reaction [Ethylenethiourea affects the abundance of Hydrocortisone]

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP2E1 mRNA; Hydrocortisone results in increased expression of CYP2E1 protein

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily s, polypeptide 1

decreases expression

ISO

Hydrocortisone results in decreased expression of CYP2S1 mRNA

NCBI chr 1:90,437,741...90,453,073
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
affects metabolic processing
multiple interactions
affects hydroxylation
increases metabolic processing

EXP
ISO

Hydrocortisone results in increased expression of CYP3A2 mRNA
CYP3A4 protein affects the metabolism of Hydrocortisone
CYP3A4 promoter mutant form inhibits the reaction [Hydrocortisone results in increased expression of CYP3A4 mRNA]; kaempferol inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]; Quercetin inhibits the reaction [CYP3A4 protein results in increased degradation of Hydrocortisone]
CYP3A4 protein affects the hydroxylation of Hydrocortisone
CYP3A4 protein results in increased metabolism of Hydrocortisone

PMID:2271712 PMID:10476907 PMID:11907490 PMID:12505310 PMID:15025748 More...

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP3A23-3A1 mRNA; Hydrocortisone results in increased expression of CYP3A23-3A1 protein

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of CYP3A5 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA

PMID:23223499 PMID:34480604

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 4, subfamily a, polypeptide 1

increases expression

EXP

Hydrocortisone results in increased expression of CYP4A1 mRNA

NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:134,360,111...134,374,231

G

DCC netrin 1 receptor

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA

NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541

G

decorin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

doublecortin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA

NCBI chr X:112,227,455...112,370,291
Ensembl chr X:112,227,455...112,304,161

G

dehydrogenase/reductase 9

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA

NCBI chr 3:74,553,357...74,579,535
Ensembl chr 3:74,555,606...74,581,376

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

desmoglein 1

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of DSG1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of DSG1 mRNA]

NCBI chr18:11,948,098...11,980,455
Ensembl chr18:11,949,488...11,980,451

G

dual specificity phosphatase 1

increases expression

ISO

Hydrocortisone results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

EBF transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA

NCBI chr10:29,597,221...29,990,571
Ensembl chr10:29,601,351...29,988,702

G

EBF transcription factor 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA

NCBI chr 1:201,426,446...201,544,444
Ensembl chr 1:201,426,450...201,544,305

G

endothelial cell surface expressed chemotaxis and apoptosis regulator

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA

NCBI chr18:27,583,791...27,593,184
Ensembl chr18:27,583,195...27,593,195

G

epidermal growth factor

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]

PMID:17805209 PMID:34480604

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

egl-9 family hypoxia-inducible factor 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA

NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015

G

ELAV like RNA binding protein 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA

NCBI chr 8:28,823,120...28,859,395
Ensembl chr 8:28,825,707...28,859,659

G

ELAV like RNA binding protein 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA

NCBI chr 5:130,285,418...130,429,106
Ensembl chr 5:130,285,418...130,429,096

G

empty spiracles homeobox 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA

NCBI chr 1:268,612,663...268,619,671
Ensembl chr 1:268,612,663...268,619,671

G

erythropoietin

increases expression

ISO

Hydrocortisone results in increased expression of EPO protein

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

ERBB receptor feedback inhibitor 1

increases expression

EXP

Hydrocortisone results in increased expression of ERRFI1 mRNA

NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432

G

estrogen receptor 1

multiple interactions

ISO

Hydrocortisone binds to and results in increased activity of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

fatty acid binding protein 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid binding protein 4

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fumarylacetoacetate hydrolase

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA

NCBI chr 1:147,957,931...147,980,708
Ensembl chr 1:147,957,935...147,981,046

G

Fas cell surface death receptor

multiple interactions
increases expression

ISO

[HIV Envelope Protein gp120 co-treated with Hydrocortisone] results in increased expression of FAS mRNA; Hydrocortisone promotes the reaction [Mitoxantrone results in increased expression of FAS]
Hydrocortisone results in increased expression of FAS protein

PMID:9676859 PMID:11075952 PMID:15086553

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

fatty acid synthase

multiple interactions
increases expression

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

F-box protein 32

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA

NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491

G

fibrinogen beta chain

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 7

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA

NCBI chr 3:133,734,557...133,786,678
Ensembl chr 3:133,734,673...133,786,328

G

fibroblast growth factor 9

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ABCC1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ACTN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of AFP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ALDOA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of APOA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CDC20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CIDEC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of CRYAB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ECSCR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of EGLN3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ELAVL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of ESRG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FGB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of H2BC14 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of A2M mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ACSL5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of AMHR2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ANXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ASCL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of BMP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CAMK2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CDH10 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CEACAM6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of COL3A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP24A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP26B1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of CYP3A5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCC mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCN mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DCX mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DHRS9 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of DNAJB1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EBF3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of EMX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FABP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FAH mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FBXO32 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FGF7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGHV3 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KRT6A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA; [4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA

NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926

G

FKBP prolyl isomerase 5

increases expression

ISO

Hydrocortisone results in increased expression of FKBP5 mRNA

NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118

G

filaggrin

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of FLG mRNA
Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of FLG mRNA]

NCBI chr 2:181,583,801...181,596,464
Ensembl chr 2:181,583,808...181,595,968

G

fibronectin leucine rich transmembrane protein 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of FLRT3 mRNA

NCBI chr 3:148,448,115...148,461,458
Ensembl chr 3:148,439,354...148,461,650

G

Fms related receptor tyrosine kinase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FLT1 mRNA

NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750

G

forkhead box D3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXD3 mRNA

NCBI chr 5:119,450,532...119,452,898
Ensembl chr 5:119,450,394...119,452,786

G

forkhead box G1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of FOXG1 mRNA

NCBI chr 6:72,401,582...72,404,392
Ensembl chr 6:72,394,239...72,427,392

G

forkhead box O1

increases expression

ISO

Hydrocortisone results in increased expression of FOXO1 mRNA

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GADD45A mRNA

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

GATA binding protein 6

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GATA6 mRNA

NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,458,253...2,492,322

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

EXP
ISO

Hydrocortisone results in increased expression of GCLC mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GCLC mRNA

PMID:10978506 PMID:34480604

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

growth hormone 1

increases expression

ISO

Hydrocortisone results in increased expression of GH1 protein

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

glyceronephosphate O-acyltransferase

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of GNPAT mRNA]

NCBI chr19:69,719,707...69,746,244
Ensembl chr19:69,719,394...69,746,244

G

G protein-coupled receptor 183

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GPR183 mRNA

NCBI chr15:105,445,129...105,457,192
Ensembl chr15:105,437,561...105,466,977

G

glutathione peroxidase 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GPX2 mRNA

NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862

G

glutamate ionotropic receptor AMPA type subunit 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA2 mRNA

NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:168,247,496...168,367,616

G

glutamate ionotropic receptor AMPA type subunit 3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679

G

glutathione S-transferase alpha 1

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of GSTA1 mRNA
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA1 mRNA; Hydrocortisone results in increased expression of and results in increased activity of GSTA1 protein

PMID:11297599 PMID:34480604

NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528

G

glutathione S-transferase alpha 2

multiple interactions
decreases expression
increases expression

EXP
ISO

Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of GSTA2 mRNA]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTA2 mRNA
Hydrocortisone results in decreased expression of GSTA2 mRNA
Hydrocortisone results in increased expression of GSTA2 mRNA

PMID:10476907 PMID:11502894 PMID:22606287 PMID:34480604

NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092

G

glutathione S-transferase omega 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GSTO1 mRNA

NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167

G

glutathione S-transferase pi 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

guanylate cyclase 1 soluble subunit alpha 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of GUCY1A1 mRNA

NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737

G

hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase)

increases expression

ISO

Hydrocortisone results in increased expression of H6PD mRNA

NCBI chr 5:165,717,456...165,753,158
Ensembl chr 5:165,721,654...165,753,125

G

heart and neural crest derivatives expressed 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAND2 mRNA

NCBI chr16:37,928,145...37,931,488
Ensembl chr16:37,928,145...37,931,488

G

hepatitis A virus cellular receptor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HAVCR1 mRNA

NCBI chr10:31,619,914...31,652,955
Ensembl chr10:31,619,897...31,653,268

G

histone deacetylase 1

multiple interactions
increases expression

ISO

HDAC1 protein affects the reaction [Hydrocortisone results in decreased expression of CYP11A1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

hes family bHLH transcription factor 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HES5 mRNA

NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021

G

hepatocyte growth factor

decreases expression

ISO

Hydrocortisone results in decreased expression of HGF protein

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

homeobox A1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA1 mRNA

NCBI chr 4:82,586,505...82,589,209
Ensembl chr 4:82,586,505...82,589,209

G

homeobox A2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA2 mRNA

NCBI chr 4:82,593,389...82,597,589
Ensembl chr 4:82,593,389...82,595,692

G

homeo box A5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXA5 mRNA

NCBI chr 4:82,632,958...82,636,851
Ensembl chr 4:82,632,306...82,639,038

G

homeo box B3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXB3 mRNA

NCBI chr10:81,786,001...81,810,655
Ensembl chr10:81,795,882...81,809,628

G

homeo box D4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD4 mRNA

NCBI chr 3:80,021,886...80,041,462
Ensembl chr 3:80,036,900...80,038,948

G

homeobox D8

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of HOXD8 mRNA

NCBI chr 3:80,015,223...80,017,789
Ensembl chr 3:80,014,735...80,018,765

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
affects expression
increases oxidation
affects response to substance
increases chemical synthesis
increases expression
increases activity
affects oxidation

ISO
EXP

[HSD11B1 protein results in increased metabolism of Ketosteroids] which results in increased chemical synthesis of Hydrocortisone; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; Mifepristone affects the reaction [Hydrocortisone affects the expression of HSD11B1 mRNA]; perfluorooctane sulfonic acid inhibits the reaction [Hydrocortisone results in increased expression of HSD11B1]
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein
HSD11B1 protein results in increased chemical synthesis of Hydrocortisone
Hydrocortisone results in increased expression of HSD11B1; Hydrocortisone results in increased expression of HSD11B1 mRNA; Hydrocortisone results in increased expression of HSD11B1 protein
Hydrocortisone results in increased activity of HSD11B1 protein

PMID:16054388 PMID:16751407 PMID:17761898 PMID:20410225 PMID:22178014 More...

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

affects binding
decreases expression
increases oxidation
multiple interactions
increases metabolic processing

ISO

HSD11B2 protein binds to Hydrocortisone
Hydrocortisone results in decreased expression of HSD11B2 mRNA; Hydrocortisone results in decreased expression of HSD11B2 protein
HSD11B2 protein results in increased oxidation of Hydrocortisone
[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of HSD11B2 mRNA]; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]; Ziram inhibits the reaction [HSD11B2 protein results in increased oxidation of Hydrocortisone]
HSD11B2 protein results in increased metabolism of Hydrocortisone

PMID:22273746 PMID:22796344 PMID:26859423 PMID:30528684

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

affects binding

ISO

Hydrocortisone binds to HSD3B1 protein

NCBI chr 2:188,858,574...188,864,694

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

multiple interactions

ISO

[galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Hydrocortisone

NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]
Hydrocortisone results in decreased expression of ICAM1 protein

PMID:9150321 PMID:15086553 PMID:15358673

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon-induced protein 44

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IFI44 mRNA

NCBI chr 2:243,286,050...243,303,869
Ensembl chr 2:243,286,052...243,306,877

G

interferon beta 1

multiple interactions
decreases secretion

ISO

IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]; Mitotane promotes the reaction [IFNB1 protein results in decreased secretion of Hydrocortisone]

NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487

G

interferon gamma

multiple interactions

ISO

[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA; Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IFNG protein]

PMID:15663561 PMID:29594315

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

insulin-like growth factor 1

multiple interactions
decreases expression

ISO

IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of APOB mRNA]; IGF1 protein inhibits the reaction [Hydrocortisone results in decreased expression of HMGCR mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]
Hydrocortisone results in decreased expression of IGF1 mRNA; Hydrocortisone results in decreased expression of IGF1 protein

PMID:30528684 PMID:31075344 PMID:32535229

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

affects expression
multiple interactions

ISO

Hydrocortisone affects the expression of IGF1R mRNA
Mifepristone affects the reaction [Hydrocortisone affects the expression of IGF1R mRNA]

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor 2

multiple interactions
increases secretion

ISO

IFNB1 protein inhibits the reaction [IGF2 protein results in increased secretion of Hydrocortisone]

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor binding protein 1

multiple interactions

ISO

Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]

NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344

G

insulin-like growth factor binding protein 5

decreases expression

ISO

Hydrocortisone results in decreased expression of IGFBP5 mRNA

NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390

G

insulin-like growth factor binding protein 7

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IGFBP7 mRNA

NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620

G

interleukin 10

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]

PMID:29777833 PMID:33476690

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 17A

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 1 alpha

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of IL1A mRNA
Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]

PMID:18722610 PMID:21980503

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases abundance
decreases expression
multiple interactions

ISO
EXP

IL1B protein results in increased abundance of Hydrocortisone
Hydrocortisone results in decreased expression of IL1B mRNA
Hydrocortisone inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]]; Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]

PMID:10460758 PMID:12548226 PMID:25851902 PMID:29594315 PMID:33476690

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 2

multiple interactions

ISO

[Hydrocortisone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA; Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]

PMID:29594315 PMID:29777833

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 2 receptor subunit alpha

decreases expression

ISO

Hydrocortisone results in decreased expression of IL2RA protein

NCBI chr17:71,759,802...71,808,475
Ensembl chr17:71,759,802...71,808,507

G

interleukin 4

decreases expression

ISO

Hydrocortisone results in decreased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [nickel sulfate results in increased secretion of IL5 protein]
Hydrocortisone results in decreased expression of IL5 protein

PMID:7988651 PMID:15663561

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

decreases secretion
decreases expression

ISO

Hydrocortisone results in decreased secretion of IL6 protein
Hydrocortisone results in decreased expression of IL6 protein

PMID:12682474 PMID:16255036

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

insulin 1

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Colforsin promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions
increases expression

ISO

[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Octreotide inhibits the reaction [Hydrocortisone results in increased expression of INS protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:7473517 PMID:7792821 PMID:7917157 PMID:33476690

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

ISL LIM homeobox 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ISL1 mRNA

NCBI chr 2:49,813,618...49,823,442
Ensembl chr 2:49,813,618...49,823,442

G

integrin subunit alpha 10

increases expression

ISO

Hydrocortisone results in increased expression of ITGA10 mRNA

NCBI chr 2:186,871,711...186,891,012
Ensembl chr 2:186,871,711...186,891,012

G

integrin subunit alpha 5

increases expression

ISO

Hydrocortisone results in increased expression of ITGA5 mRNA

NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:136,358,097...136,381,305

G

involucrin

decreases expression

ISO

Hydrocortisone results in decreased expression of IVL mRNA

NCBI chr 2:180,842,307...180,854,646
Ensembl chr 2:180,842,307...180,846,578

G

Kelch-like ECH-associated protein 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of KEAP1 mRNA

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

kallikrein 1

increases export

ISO

Hydrocortisone results in increased export of KLK1 protein

NCBI chr 1:103,779,152...103,783,270
Ensembl chr 1:103,779,164...103,783,270

G

kallikrein 1-related peptidase C10

increases expression

ISO

Hydrocortisone results in increased expression of KLK3 protein

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin 1

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT1 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT1 mRNA]

NCBI chr 7:134,855,311...134,860,537
Ensembl chr 7:134,855,313...134,860,537

G

keratin 10

multiple interactions

ISO

Hydrocortisone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of antimonite] which results in decreased expression of KRT10 mRNA]; Hydrocortisone inhibits the reaction [[sodium arsenite results in increased abundance of arsenite] which results in decreased expression of KRT10 mRNA]

NCBI chr10:84,834,865...84,839,160
Ensembl chr10:84,834,840...84,839,160

G

LCK proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of LCK mRNA

NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267

G

low density lipoprotein receptor

multiple interactions
decreases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of LDLR mRNA]

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

lymphoid enhancer binding factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LEF1 mRNA

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929

G

loricrin cornified envelope precursor protein

decreases expression

ISO

Hydrocortisone results in decreased expression of LORICRIN mRNA

NCBI chr 2:180,253,674...180,256,572
Ensembl chr 2:180,253,674...180,256,572

G

lipoprotein lipase

multiple interactions

ISO

Hydrocortisone results in decreased activity of and results in decreased expression of LPL protein

NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107

G

lumican

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of LUM mRNA

NCBI chr 7:34,245,323...34,252,510
Ensembl chr 7:34,245,360...34,252,508

G

lymphocyte antigen 75

decreases expression

ISO

Hydrocortisone results in decreased expression of LY75 protein

NCBI chr 3:65,173,395...65,260,878
Ensembl chr 3:65,173,395...65,260,878

G

MAF bZIP transcription factor G

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MAFG mRNA

NCBI chr10:106,401,633...106,410,159

G

monoamine oxidase A

increases expression

ISO

Hydrocortisone results in increased expression of MAOA mRNA

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631

G

mitogen activated protein kinase kinase kinase 7

decreases expression

ISO

Hydrocortisone results in decreased expression of MAP3K7 mRNA

NCBI chr 5:51,149,524...51,212,012
Ensembl chr 5:51,154,352...51,212,012

G

muscular LMNA-interacting protein

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MLIP mRNA

NCBI chr 8:86,815,491...87,085,117
Ensembl chr 8:86,814,798...87,082,408

G

matrix metallopeptidase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MMP1 mRNA

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 9

multiple interactions

ISO

Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]; Hydrocortisone inhibits the reaction [IL1A protein results in increased expression of MMP9 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

myelin protein zero-like 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of MPZL1 mRNA

NCBI chr13:80,385,454...80,422,315
Ensembl chr13:80,385,456...80,422,390

G

metallothionein 1A

increases expression

EXP

Hydrocortisone results in increased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

myosin, light chain 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of MYL4 mRNA

NCBI chr10:89,949,733...89,985,308
Ensembl chr10:89,949,404...89,985,308

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO
EXP

[Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA
[HSD11B1 protein affects the susceptibility to Hydrocortisone] which results in decreased activity of NFE2L2 protein; Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NFE2L2 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]

PMID:22606287 PMID:33476690

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NFKB inhibitor alpha

multiple interactions
increases expression

ISO

[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of NFKBIA mRNA]

PMID:25763180 PMID:33476690

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nitric oxide synthase 2

multiple interactions

EXP

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

natriuretic peptide A

increases expression
decreases secretion

ISO

Hydrocortisone results in increased expression of NPPA protein
NPPA protein results in decreased secretion of Hydrocortisone

PMID:2434734 PMID:2931268 PMID:7473517

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

neuropeptide Y

affects expression

ISO

Hydrocortisone affects the expression of NPY protein

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

EXP
ISO

Hydrocortisone inhibits the reaction [Hydrogen Peroxide promotes the reaction [sulforaphane results in increased expression of NQO1 protein]]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 mRNA]; Hydrocortisone inhibits the reaction [sulforaphane results in increased expression of NQO1 protein]
[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of NQO1 mRNA

PMID:22606287 PMID:34480604

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 2, group F, member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F1 mRNA

NCBI chr 2:9,776,179...9,785,924
Ensembl chr 2:9,776,179...9,785,924

G

nuclear receptor subfamily 2, group F, member 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of NR2F2 mRNA

NCBI chr 1:133,419,161...133,434,290
Ensembl chr 1:133,420,227...133,431,975

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
affects localization
increases activity
affects binding
increases phosphorylation
decreases expression
affects abundance
increases expression

ISO
EXP

2,2',4,4',5-brominated diphenyl ether inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; 3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; [Hydrocortisone co-treated with Progesterone] results in increased expression of NR3C1 mRNA; [Hydrocortisone results in increased activity of NR3C1 protein] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; Atrazine inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bifenthrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A analog inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol A inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol AF inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol AF inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol B inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; bisphenol Z inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; bisphenol Z inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; croneton inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Hydrocortisone binds to and affects the activity of NR3C1 protein; Hydrocortisone binds to and results in increased activity of NR3C1 protein; Hydrocortisone results in increased expression of and affects the localization of NR3C1 protein; Methoxychlor inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone affects the localization of NR3C1 protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of IGF1 protein]; NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of FASN mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein alternative form inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein alternative form]; NR3C1 protein promotes the reaction [Hydrocortisone inhibits the reaction [IL1A protein results in increased activity of MMP9 protein]]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Pesticides inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Polybrominated Biphenyls metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; resmethrin inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; Soil Pollutants inhibits the reaction [Hydrocortisone results in increased expression of NR3C1 mRNA]; Thiram inhibits the reaction [Hydrocortisone binds to NR3C1 protein]; tributyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; triphenyl phosphate metabolite inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]; tris(1,3-dichloro-2-propyl)phosphate inhibits the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
NR3C1 protein binds to Hydrocortisone
Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]
Hydrocortisone results in increased phosphorylation of NR3C1 protein
Hydrocortisone results in decreased expression of NR3C1 mRNA; Hydrocortisone results in decreased expression of NR3C1 protein
Fluoxetine promotes the reaction [Hydrocortisone results in increased activity of NR3C1 protein]
Hydrocortisone analog binds to NR3C1 protein
NR3C1 gene polymorphism affects the abundance of Hydrocortisone
Hydrocortisone results in increased expression of NR3C1; Hydrocortisone results in increased expression of NR3C1 mRNA

PMID:926113 PMID:1597467 PMID:11956172 PMID:12871829 PMID:15362971 More...

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions
increases activity

ISO

[Fludrocortisone binds to and results in increased activity of NR3C2 protein] which results in decreased abundance of Hydrocortisone
Hydrocortisone results in increased activity of NR3C2 protein

PMID:15362971 PMID:15780662 PMID:16566900

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

nuclear receptor subfamily 6, group A, member 1

decreases expression

ISO

Hydrocortisone results in decreased expression of NR6A1 mRNA

NCBI chr 3:42,904,832...43,094,622
Ensembl chr 3:42,904,832...43,092,951

G

occludin

increases expression

ISO

Hydrocortisone results in increased expression of OCLN mRNA

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

oxytocin/neurophysin I prepropeptide

affects abundance

ISO

OXT protein affects the abundance of Hydrocortisone

NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594

G

progestagen associated endometrial protein

increases metabolic processing

ISO

PAEP protein modified form results in increased metabolism of Hydrocortisone

NCBI chr 3:28,929,252...28,932,592

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
increases activity
increases expression

EXP

3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; bifenthrin inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dactinomycin inhibits the reaction [Hydrocortisone results in increased activity of PCK1 protein]; DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of PCK1 mRNA]

PMID:6476976 PMID:26647222

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

proliferating cell nuclear antigen

decreases expression

ISO

Hydrocortisone results in decreased expression of PCNA protein

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphodiesterase 1A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of PDE1A mRNA

NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212

G

period circadian regulator 1

increases expression

ISO

Hydrocortisone results in increased expression of PER1 mRNA

NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211

G

phospholamban

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of PLN mRNA

NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241

G

patatin-like phospholipase domain containing 2

decreases expression

ISO

Hydrocortisone results in decreased expression of PNPLA2 mRNA

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

proopiomelanocortin

increases response to substance
multiple interactions
increases abundance
increases secretion

ISO

POMC protein results in increased susceptibility to Hydrocortisone
Lead inhibits the reaction [POMC protein modified form results in increased secretion of Hydrocortisone]; Melatonin inhibits the reaction [POMC protein results in increased abundance of Hydrocortisone]
POMC protein results in increased secretion of Hydrocortisone

PMID:1321309 PMID:3015460 PMID:9881897 PMID:11082157 PMID:21332028 More...

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

POU class 5 homeobox 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of POU5F1 mRNA

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

peroxisome proliferator activated receptor alpha

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor delta

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

prolactin

multiple interactions

EXP

[Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

prune homolog 2 with BCH domain

decreases expression

ISO

Hydrocortisone results in decreased expression of PRUNE2 mRNA

NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO
EXP

Hydrocortisone inhibits the reaction [EGF protein results in increased expression of PTGS2 mRNA]
Hydrocortisone results in increased expression of PTGS2 protein
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of PTGS2 protein]

PMID:17805209 PMID:18650268

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RAP1A, member of RAS oncogene family

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of RAP1A mRNA
Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAP1A mRNA]

NCBI chr 2:195,896,967...195,974,851
Ensembl chr 2:195,896,971...195,974,808

G

Rap guanine nucleotide exchange factor 3

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of RAPGEF3 mRNA]

NCBI chr 7:130,754,883...130,777,303
Ensembl chr 7:130,754,871...130,777,668

G

retinoic acid receptor, alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RARA mRNA

NCBI chr10:84,379,780...84,424,371
Ensembl chr10:84,389,622...84,425,160

G

RB binding protein 7, chromatin remodeling factor

affects response to substance

ISO

RBBP7 protein affects the susceptibility to Hydrocortisone

NCBI chr X:35,544,873...35,563,030
Ensembl chr X:35,544,873...35,563,030

G

RNA binding motif protein 20

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RBM20 mRNA

NCBI chr 1:262,671,311...262,912,551
Ensembl chr 1:262,688,978...262,891,364

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ISO

Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

decreases expression

ISO

Hydrocortisone results in decreased expression of REN protein

PMID:7473517 PMID:15743397

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

RAR-related orphan receptor A

increases expression

ISO

Hydrocortisone results in increased expression of RORA mRNA

NCBI chr 8:78,182,710...78,915,730
Ensembl chr 8:78,182,620...78,915,730

G

RRAD, Ras related glycolysis inhibitor and calcium channel regulator

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of RRAD mRNA

NCBI chr19:360,581...363,874
Ensembl chr19:360,973...363,871

G

scavenger receptor class B, member 1

multiple interactions
decreases expression

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SCARB1 mRNA; Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SCARB1 mRNA]

PMID:31075344 PMID:34480604

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

sodium channel epithelial 1 subunit alpha

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1A mRNA

NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405

G

sodium channel epithelial 1 subunit beta

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1B mRNA

NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049

G

sodium channel epithelial 1 subunit gamma

increases expression

ISO

Hydrocortisone results in increased expression of SCNN1G mRNA

NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097

G

semaphorin 3C

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SEMA3C mRNA

NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740

G

serpin family A member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SERPINA1 mRNA

NCBI chr 6:128,631,101...128,653,125
Ensembl chr 6:128,619,382...128,660,703

G

serpin family B member 1A

multiple interactions

EXP
ISO

Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1A protein modified form
Hydrocortisone results in increased cleavage of and results in increased activity of and affects the localization of SERPINB1 protein modified form

NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,799,415...31,808,166

G

serpin family C member 1

increases expression

ISO

Hydrocortisone results in increased expression of SERPINC1 protein

NCBI chr13:75,790,558...75,804,826
Ensembl chr13:75,790,546...75,817,643

G

splicing factor 1

multiple interactions
decreases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of SF1 mRNA]; SF1 protein inhibits the reaction [Hydrocortisone results in increased expression of HDAC1 mRNA]

NCBI chr 1:213,090,256...213,112,688
Ensembl chr 1:213,099,260...213,113,590

G

secreted frizzled-related protein 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SFRP2 mRNA

NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079

G

surfactant protein B

increases expression

ISO

Hydrocortisone results in increased expression of SFTPB mRNA

NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646

G

surfactant protein C

increases expression

ISO

Hydrocortisone results in increased expression of SFTPC mRNA

NCBI chr15:52,006,274...52,009,324
Ensembl chr15:52,006,283...52,009,475

G

SH3-domain binding protein 5

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SH3BP5 mRNA

NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,589,877...6,655,211

G

sirtuin 1

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of SIRT1 mRNA
NR3C1 protein affects the reaction [Hydrocortisone results in decreased expression of SIRT1 mRNA]

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

solute carrier family 22 member 2

multiple interactions

ISO

Hydrocortisone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 23 member 2

multiple interactions

ISO

Hydrocortisone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid]

NCBI chr 3:139,755,583...139,913,304
Ensembl chr 3:139,755,584...139,847,343

G

solute carrier family 5 member 5

multiple interactions

ISO

1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] affects the localization of SLC5A5 protein]; 1-Methyl-3-isobutylxanthine promotes the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased expression of SLC5A5 protein]; Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin affects the localization of SLC5A5 protein]; Hydrocortisone promotes the reaction [Tretinoin results in increased expression of SLC5A5 protein]

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

SRY-box transcription factor 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX1 mRNA

NCBI chr16:83,837,689...83,841,703
Ensembl chr16:83,802,160...83,841,775

G

SRY-box transcription factor 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SOX2 mRNA

NCBI chr 2:119,465,131...119,467,542
Ensembl chr 2:119,454,541...119,496,350

G

serine palmitoyltransferase, small subunit B

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SPTSSB mRNA

NCBI chr 2:156,432,509...156,461,936
Ensembl chr 2:156,432,512...156,460,909

G

sequestosome 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of SQSTM1 mRNA

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

sterol regulatory element binding transcription factor 1

increases expression
multiple interactions

ISO

Hydrocortisone results in increased expression of SREBF1 mRNA
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; CEBPA protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; NR3C1 protein affects the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Resveratrol inhibits the reaction [Hydrocortisone results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]

PMID:30776459 PMID:33476690

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

sulfiredoxin 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of SRXN1 mRNA

NCBI chr 3:161,064,812...161,070,372
Ensembl chr 3:161,059,931...161,088,765

G

steroidogenic acute regulatory protein

decreases expression
multiple interactions

ISO

Hydrocortisone results in decreased expression of STAR mRNA; Hydrocortisone results in decreased expression of STAR protein
Mifepristone inhibits the reaction [Hydrocortisone results in decreased expression of STAR mRNA]

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

stathmin 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of STMN2 mRNA

NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335

G

tyrosine aminotransferase

multiple interactions
increases expression
increases activity

ISO
EXP

Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; o-Aminoazotoluene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]
Hydrocortisone results in increased expression of TAT mRNA
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein]; cypermethrin inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Diethylnitrosamine inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Hydrocortisone promotes the reaction [[NR3C1 protein binds to TAT promoter] which results in increased expression of TAT mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; Methyldimethylaminoazobenzene inhibits the reaction [Hydrocortisone results in increased activity of TAT protein]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TAT mRNA]

PMID:6120038 PMID:16267830 PMID:22465009 PMID:26647222

NCBI chr19:54,856,604...54,867,168
Ensembl chr19:54,856,563...54,867,482

G

T-box transcription factor 19

decreases abundance

ISO

TBX19 gene mutant form results in decreased abundance of Hydrocortisone

NCBI chr13:79,983,935...80,016,219
Ensembl chr13:79,983,935...80,007,023

G

T-box transcription factor 2

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TBX2 mRNA

NCBI chr10:71,177,082...71,186,275
Ensembl chr10:71,177,082...71,186,275

G

transferrin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TF mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA; [Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Orlistat promotes the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

PMID:33476690 PMID:34480604

NCBI chr 8:112,668,667...112,695,376
Ensembl chr 8:112,647,642...112,695,400

G

transcription factor AP-2 alpha

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2A mRNA

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transcription factor AP-2 beta

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TFAP2B mRNA

NCBI chr 9:29,282,703...29,312,568
Ensembl chr 9:29,282,825...29,312,568

G

transforming growth factor, beta 1

multiple interactions

EXP
ISO

Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Hydrocortisone inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]
[Orlistat co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA

PMID:17434272 PMID:33476690

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transglutaminase 1

multiple interactions
increases expression

ISO

[Hydrocortisone co-treated with sodium arsenate] results in increased expression of TGM1 mRNA; [Hydrocortisone co-treated with sodium arsenite] results in increased expression of TGM1 mRNA; sodium arsenate inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]; sodium arsenite inhibits the reaction [Hydrocortisone results in increased expression of TGM1 mRNA]

NCBI chr15:33,160,985...33,175,632
Ensembl chr15:33,160,987...33,174,463

G

tight junction protein 1

increases localization
multiple interactions

ISO

Hydrocortisone results in increased localization of TJP1 protein
GGTI 298 inhibits the reaction [Hydrocortisone results in increased localization of TJP1 protein]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

toll-like receptor 2

increases expression

ISO

Hydrocortisone results in increased expression of TLR2 mRNA

NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194

G

toll-like receptor 4

decreases expression

ISO

Hydrocortisone results in decreased expression of TLR4 mRNA

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

transmembrane 4 L six family member 4

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TM4SF4 mRNA

NCBI chr 2:143,720,220...143,771,283
Ensembl chr 2:143,720,267...143,771,227

G

tumor necrosis factor

decreases secretion
multiple interactions
decreases expression

ISO

Hydrocortisone results in decreased secretion of TNF protein
Hydrocortisone affects the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein]; Hydrocortisone inhibits the reaction [Lipopolysaccharides affects the expression of TNF mRNA]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
Hydrocortisone results in decreased expression of TNF mRNA

PMID:9150321 PMID:10100995 PMID:15086553 PMID:21980503 PMID:26481333 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

trehalase

decreases activity

ISO

Hydrocortisone results in decreased activity of TREH protein

NCBI chr 8:53,886,946...53,901,113
Ensembl chr 8:53,886,946...53,900,335

G

TSC22 domain family, member 3

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]
3-phenoxybenzoic acid inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cobaltous chloride results in increased abundance of Cobalt] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [cupric chloride results in increased abundance of Copper] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [lead nitrate results in increased abundance of Lead] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [Lithium Chloride results in increased abundance of Lithium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [stannous chloride results in increased abundance of Tin] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; [zinc chloride results in increased abundance of Zinc] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; cyhalothrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Methoxychlor inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; N-dichlorofluoromethylthio-N',N'-dimethyl-N-p-tolylsulfamide inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; o,p'-DDT inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]; resmethrin inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA]

PMID:25763180 PMID:26647222 PMID:29957541

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

transthyretin

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of TTR mRNA

NCBI chr18:12,216,684...12,225,972
Ensembl chr18:12,216,732...12,225,969

G

thioredoxin reductase 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of TXNRD1 mRNA

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

urocortin 2

increases abundance

ISO

UCN2 protein results in increased abundance of Hydrocortisone

NCBI chr 8:118,516,111...118,517,660
Ensembl chr 8:118,483,364...118,517,439

G

uncoupling protein 1

multiple interactions

ISO

[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA; Orlistat inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA]

NCBI chr19:41,713,350...41,721,421
Ensembl chr19:41,713,351...41,721,420

G

UDP glucuronosyltransferase family 2 member A3

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in decreased expression of UGT2A3 mRNA

NCBI chr14:20,851,970...20,869,974
Ensembl chr14:20,851,969...20,869,973

G

UDP glucuronosyltransferase 2 family, polypeptide B1

increases expression

EXP

Hydrocortisone results in increased expression of UGT2B1 mRNA

NCBI chr14:21,378,882...21,390,631
Ensembl chr14:21,378,853...21,392,331

G

vascular cell adhesion molecule 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VCAM1 mRNA; Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]; Hydrocortisone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Medroxyprogesterone Acetate inhibits the reaction [Hydrocortisone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]

PMID:10100995 PMID:15358673 PMID:34480604

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

multiple interactions
decreases expression

ISO

Hydrocortisone inhibits the reaction [Nickel results in increased expression of VEGFA protein]
Hydrocortisone results in decreased expression of VEGFA protein

PMID:9390328 PMID:17549480 PMID:20116850

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vestigial-like family member 1

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of VGLL1 mRNA

NCBI chr X:140,016,938...140,036,348

G

von Willebrand factor

multiple interactions
increases expression

ISO

Mifepristone inhibits the reaction [Hydrocortisone results in increased expression of VWF mRNA]

NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757

G

zinc finger AN1-type containing 2A

multiple interactions

ISO

[4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid co-treated with Chir 99021 co-treated with 3-(4-pyridyl)-1H-indole co-treated with Hydrocortisone co-treated with EGF protein co-treated with FGF9 protein] results in increased expression of ZFAND2A mRNA

NCBI chr12:20,275,435...20,286,513
Ensembl chr12:20,275,450...20,286,513

G

zinc finger protein 36

increases expression

ISO

Hydrocortisone results in increased expression of ZFP36 mRNA

NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adiponectin, C1Q and collagen domain containing

multiple interactions

ISO

[Calcitriol co-treated with Cortisone] results in decreased expression of ADIPOQ mRNA

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

aldo-keto reductase family 1, member D1

multiple interactions

ISO

[AKR1D1 protein co-treated with NADP] results in increased reduction of Cortisone

NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540

G

caspase 3

multiple interactions

EXP

Cortisone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

C-C motif chemokine ligand 2

increases expression

ISO

Cortisone results in increased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

dehydrogenase/reductase 7

increases reduction

ISO

DHRS7 protein results in increased reduction of Cortisone

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744

G

fatty acid binding protein 4

increases expression
multiple interactions

ISO

Cortisone results in increased expression of FABP4 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of FABP4 mRNA]

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

glutamate-ammonia ligase

increases activity

EXP

Cortisone results in increased activity of GLUL protein

NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions
increases expression
increases reduction
affects response to substance
increases metabolic processing
affects metabolic processing

ISO
EXP

[Calcitriol co-treated with Cortisone] results in increased expression of HSD11B1 mRNA; [HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [HSD11B1 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; [HSD11B1 protein results in increased reduction of Cortisone] which results in increased chemical synthesis of Hydrocortisone; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
Cortisone results in increased expression of HSD11B1 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of and results in increased activity of HSD11B1 protein]; Cortisone results in increased expression of and results in increased activity of HSD11B1 protein
[HSD11B1 protein affects the susceptibility to Cortisone] which results in decreased activity of NFE2L2 protein; [HSD11B1 protein co-treated with Cortisone] results in decreased expression of NQO1 mRNA; Cortisone promotes the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA]
HSD11B1 protein results in increased metabolism of Cortisone
HSD11B1 protein affects the metabolism of Cortisone

PMID:16054388 PMID:16751407 PMID:19918113 PMID:21315688 PMID:22606287 More...

NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

increases chemical synthesis
multiple interactions

ISO

HSD11B2 protein results in increased chemical synthesis of Cortisone
[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone; Ziram inhibits the reaction [[HSD11B2 protein results in increased oxidation of Hydrocortisone] which results in increased chemical synthesis of Cortisone]

PMID:22796344 PMID:26859423

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

interleukin 1 beta

multiple interactions
decreases expression

ISO

perfluorooctane sulfonic acid inhibits the reaction [Cortisone results in decreased expression of IL1B]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases expression
multiple interactions

ISO

Cortisone results in decreased expression of IL6
perfluorooctane sulfonic acid inhibits the reaction [Cortisone results in decreased expression of IL6]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO
EXP

[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]; [Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
[HSD11B1 protein affects the susceptibility to Cortisone] which results in decreased activity of NFE2L2 protein

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nitric oxide synthase 2

increases expression

ISO

Cortisone results in increased expression of NOS2 protein

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

EXP

[HSD11B1 protein co-treated with Cortisone] results in decreased expression of NQO1 mRNA

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 3, group C, member 1

affects binding
multiple interactions
increases activity

ISO

Cortisone binds to NR3C1 protein
[Mifepristone binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [[HSD11B1 protein results in increased activity of Cortisone] inhibits the reaction [sulforaphane results in increased activity of NFE2L2 protein]]
Cortisone results in increased activity of NR3C1 protein

PMID:15705660 PMID:15780662 PMID:22606287

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 3, group C, member 2

increases activity

ISO

Cortisone results in increased activity of NR3C2 protein

NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078

G

peroxisome proliferator-activated receptor gamma

multiple interactions
increases expression

ISO

2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

PPARG coactivator 1 alpha

increases expression

ISO

Cortisone results in increased expression of PPARGC1A mRNA

NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation

ISO

Cortisone results in increased phosphorylation of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

serum/glucocorticoid regulated kinase 1

increases expression
multiple interactions

EXP

Cortisone results in increased expression of SGK1 mRNA
Phenylephrine promotes the reaction [Cortisone results in increased expression of SGK1 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cortisone results in increased expression of SGK1 mRNA]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

solute carrier family 22 member 2

multiple interactions

ISO

Cortisone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 2 member 4

increases expression
multiple interactions

ISO

Cortisone results in increased expression of SLC2A4 mRNA
2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone inhibits the reaction [Cortisone results in increased expression of SLC2A4 mRNA]

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

tumor necrosis factor

increases expression

ISO

Cortisone results in increased expression of TNF mRNA

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

adiponectin, C1Q and collagen domain containing

decreases expression

ISO

cucurbitacin B results in decreased expression of ADIPOQ mRNA

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

BCL2-associated agonist of cell death

increases expression
multiple interactions

ISO

cucurbitacin B results in increased expression of BAD mRNA
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAD mRNA

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BCL2-antagonist/killer 1

multiple interactions
increases expression

ISO

[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 protein
cucurbitacin B results in increased expression of BAK1 mRNA; cucurbitacin B results in increased expression of BAK1 protein

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of BAX mRNA]
cucurbitacin B results in increased expression of BAX mRNA; cucurbitacin B results in increased expression of BAX protein
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX protein

PMID:26183715 PMID:29250925

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of BCL2 mRNA]
[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 protein
cucurbitacin B results in decreased expression of BCL2 mRNA; cucurbitacin B results in decreased expression of BCL2 protein

PMID:26183715 PMID:29250925

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

multiple interactions
decreases expression

ISO

[cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2L1 mRNA
cucurbitacin B results in decreased expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 11

increases expression
multiple interactions

ISO

cucurbitacin B results in increased expression of BCL2L11 mRNA
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BCL2L11 mRNA

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

caspase 3

increases cleavage
multiple interactions

ISO

cucurbitacin B results in increased cleavage of CASP3 protein
[cucurbitacin B co-treated with Gefitinib] results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

catalase

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

C-C motif chemokine ligand 2

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

cyclin D1

decreases expression
multiple interactions

ISO

cucurbitacin B results in decreased expression of CCND1
[cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 protein
cucurbitacin B results in decreased expression of CCND1 mRNA; cucurbitacin B results in decreased expression of CCND1 protein

PMID:24316209 PMID:26183715

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

CD36 molecule

decreases expression

ISO

cucurbitacin B results in decreased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

ISO

[cucurbitacin B co-treated with Gefitinib] results in increased expression of CDKN1B protein
cucurbitacin B results in increased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

CCAAT/enhancer binding protein alpha

decreases expression
multiple interactions

ISO

cucurbitacin B results in decreased expression of CEBPA mRNA
STAT3 protein affects the reaction [cucurbitacin B results in decreased expression of CEBPA mRNA]

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein delta

decreases expression

ISO

cucurbitacin B results in decreased expression of CEBPD

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

collagen type I alpha 1 chain

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

epidermal growth factor receptor

multiple interactions

ISO

[cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

fatty acid binding protein 4

decreases expression

ISO

cucurbitacin B results in decreased expression of FABP4 mRNA

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

glutamic-oxaloacetic transaminase 1

multiple interactions

ISO

cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GOT1 protein]
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of GOT1 protein]

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glutamic--pyruvic transaminase

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of GPT protein]
cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of GPT protein]

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of HIF1A mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of HIF1A protein]
cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of HIF1A mRNA]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of HIF1A protein]

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

interleukin 1 beta

multiple interactions

ISO

cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of IL1B protein]; cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL1B mRNA]

PMID:29250925 PMID:38104874

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL6 mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of IL6 protein]
cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 mRNA]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of IL6 protein]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

KLF transcription factor 5

increases expression

ISO

cucurbitacin B results in increased expression of KLF5

NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262

G

matrix metallopeptidase 2

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of MMP2 mRNA]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases expression

ISO

STAT3 protein affects the reaction [cucurbitacin B results in decreased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

signal transducer and activator of transcription 3

multiple interactions
decreases phosphorylation
affects response to substance

ISO

[WP1066 results in decreased activity of STAT3 protein] which results in decreased susceptibility to cucurbitacin B; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of STAT3 mRNA]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of STAT3 protein]; cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT3 protein]; cucurbitacin B results in decreased phosphorylation of and results in decreased activity of STAT3 protein; STAT3 protein affects the reaction [cucurbitacin B results in decreased expression of CEBPA mRNA]; STAT3 protein affects the reaction [cucurbitacin B results in decreased expression of PPARG mRNA]
cucurbitacin B results in decreased phosphorylation of STAT3 protein
[cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of STAT3 protein; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of and results in increased phosphorylation of STAT3 mRNA]
STAT3 protein affects the susceptibility to cucurbitacin B

PMID:24316209 PMID:26183715 PMID:29250925 PMID:38104874

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transforming growth factor, beta 1

multiple interactions

ISO

cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

tumor necrosis factor

multiple interactions

ISO

cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF mRNA]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased expression of TNF protein]; cucurbitacin B inhibits the reaction [3,5-diethoxycarbonyl-1,4-dihydrocollidine results in increased secretion of TNF protein]; cucurbitacin B inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]
cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of TNF mRNA]; cucurbitacin B inhibits the reaction [Lithocholic Acid results in increased expression of TNF protein]

PMID:29250925 PMID:38104874

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

EXP
ISO

cucurbitacin E results in decreased expression of ACTA2 mRNA; cucurbitacin E results in decreased expression of ACTA2 protein
cucurbitacin E inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein]

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

AKT serine/threonine kinase 1

multiple interactions
affects phosphorylation

ISO

Acetylcysteine inhibits the reaction [cucurbitacin E affects the phosphorylation of AKT1 protein]

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

BCL2 associated X, apoptosis regulator

increases expression

ISO
EXP

cucurbitacin E results in increased expression of BAX protein

PMID:27106530 PMID:27363783

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

decreases expression

ISO
EXP

cucurbitacin E results in decreased expression of BCL2 protein

PMID:27106530 PMID:27363783

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

ISO

cucurbitacin E results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

beclin 1

multiple interactions

ISO

Acetylcysteine inhibits the reaction [cucurbitacin E results in increased expression of and results in increased phosphorylation of BECN1 protein]; cucurbitacin E results in increased expression of and results in increased phosphorylation of BECN1 protein

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

caspase 3

multiple interactions
increases cleavage

ISO
EXP

acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [cucurbitacin E results in increased cleavage of CASP3 protein]; Acetylcysteine inhibits the reaction [cucurbitacin E results in increased cleavage of CASP3 protein]

PMID:27106530 PMID:27363783

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 7

multiple interactions
increases cleavage

ISO

acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [cucurbitacin E results in increased cleavage of CASP7 protein]; Acetylcysteine inhibits the reaction [cucurbitacin E results in increased cleavage of CASP7 protein]

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 9

increases cleavage

ISO

cucurbitacin E results in increased cleavage of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

collagen type I alpha 1 chain

decreases expression

EXP

cucurbitacin E results in decreased expression of COL1A1 mRNA

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

mitogen activated protein kinase 1

decreases phosphorylation

EXP

cucurbitacin E results in decreased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 3

decreases phosphorylation

EXP

cucurbitacin E results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mechanistic target of rapamycin kinase

multiple interactions
decreases phosphorylation

ISO
EXP

Acetylcysteine inhibits the reaction [cucurbitacin E results in decreased phosphorylation of MTOR protein]
cucurbitacin E inhibits the reaction [Thioacetamide results in increased phosphorylation of MTOR protein]

PMID:27106530 PMID:27363783

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO
EXP

acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [cucurbitacin E results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [cucurbitacin E results in increased cleavage of PARP1 protein]

PMID:27106530 PMID:27363783

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

phosphatase and tensin homolog

multiple interactions

ISO

cucurbitacin E results in increased expression of and results in increased phosphorylation of PTEN protein

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

ribosomal protein S6 kinase B1

multiple interactions
decreases phosphorylation

ISO
EXP

cucurbitacin E inhibits the reaction [Thioacetamide results in increased phosphorylation of RPS6KB1 protein]
cucurbitacin E results in decreased phosphorylation of RPS6KB1 protein

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

sequestosome 1

multiple interactions
increases expression

ISO

Acetylcysteine inhibits the reaction [cucurbitacin E results in increased expression of SQSTM1 protein]

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

TIMP metallopeptidase inhibitor 1

multiple interactions
decreases expression

ISO
EXP

cucurbitacin E inhibits the reaction [Thioacetamide results in increased expression of TIMP1 protein]
cucurbitacin E results in decreased expression of TIMP1 mRNA; cucurbitacin E results in decreased expression of TIMP1 protein

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

unc-51 like autophagy activating kinase 1

multiple interactions

ISO

Acetylcysteine inhibits the reaction [cucurbitacin E results in decreased expression of and results in decreased phosphorylation of ULK1 protein]; cucurbitacin E results in decreased expression of and results in decreased phosphorylation of ULK1 protein

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

cucurbitacin I inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

adiponectin, C1Q and collagen domain containing

multiple interactions

EXP

cucurbitacin I inhibits the reaction [ADIPOQ protein results in increased expression of HMOX1 mRNA]

NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169

G

caspase 3

increases cleavage

ISO

cucurbitacin I results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 7

increases cleavage

ISO

cucurbitacin I results in increased cleavage of CASP7 protein

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

increases cleavage

ISO

cucurbitacin I results in increased cleavage of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases cleavage

ISO

cucurbitacin I results in increased cleavage of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

cyclin A2

decreases expression

ISO

cucurbitacin I results in decreased expression of CCNA2 protein

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

decreases expression

ISO

cucurbitacin I results in decreased expression of CCNB1 protein

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

decreases expression

ISO

cucurbitacin I results in decreased expression of CCND1

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

CD36 molecule

decreases expression

ISO

cucurbitacin I results in decreased expression of CD36 mRNA

NCBI chr 4:18,209,088...18,302,142

G

cell division cycle 25C

decreases expression

ISO

cucurbitacin I results in decreased expression of CDC25C protein

NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,609,959...26,630,292

G

cyclin-dependent kinase 1

decreases expression

ISO

cucurbitacin I results in decreased expression of CDK1 protein

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

CCAAT/enhancer binding protein alpha

decreases expression

ISO

cucurbitacin I results in decreased expression of CEBPA mRNA

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

fatty acid binding protein 4

decreases expression

ISO

cucurbitacin I results in decreased expression of FABP4 mRNA

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

heme oxygenase 1

multiple interactions

EXP

cucurbitacin I inhibits the reaction [ADIPOQ protein results in increased expression of HMOX1 mRNA]

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

interleukin 21

multiple interactions

ISO

cucurbitacin I inhibits the reaction [IL21 protein promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of IL22 mRNA]]

NCBI chr 2:122,045,240...122,055,142
Ensembl chr 2:122,045,240...122,055,142

G

Janus kinase 2

multiple interactions

ISO

cucurbitacin I inhibits the reaction [glycine-extended gastrin 17 results in increased phosphorylation of and results in increased activity of JAK2 protein]

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

KLF transcription factor 5

increases expression

ISO

cucurbitacin I results in increased expression of KLF5

NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262

G

natriuretic peptide A

increases expression

EXP

cucurbitacin I results in increased expression of NPPA mRNA

NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493

G

natriuretic peptide B

increases expression

EXP

cucurbitacin I results in increased expression of NPPB mRNA

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

poly (ADP-ribose) polymerase 1

increases cleavage

ISO

cucurbitacin I results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

peroxisome proliferator-activated receptor gamma

decreases expression

ISO

cucurbitacin I results in decreased expression of PPARG mRNA

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

signal transducer and activator of transcription 3

multiple interactions
affects response to substance
decreases activity

ISO

cucurbitacin I inhibits the reaction [glycine-extended gastrin 17 results in increased phosphorylation of and results in increased activity of STAT3 protein]
[WP1066 results in decreased activity of STAT3 protein] which results in decreased susceptibility to cucurbitacin I
STAT3 protein affects the susceptibility to cucurbitacin I
cucurbitacin I results in decreased activity of STAT3 protein

PMID:19153190 PMID:24316209

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

vascular endothelial growth factor A

multiple interactions

ISO

cucurbitacin I inhibits the reaction [Arsenic results in increased expression of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

ISO

[Cyproterone co-treated with Albuterol] results in decreased expression of CYP19A1

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

Cyproterone results in increased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

growth regulating estrogen receptor binding 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of GREB1 mRNA]

NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126

G

MYB proto-oncogene like 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of MYBL1 mRNA]

NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588

G

serum/glucocorticoid regulated kinase 1

multiple interactions
increases expression

ISO

Fulvestrant inhibits the reaction [Cyproterone results in increased expression of SGK1 mRNA]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

multiple interactions
increases phosphorylation

ISO

EGF protein inhibits the reaction [Cytochalasin D results in increased phosphorylation of ABL1 protein]

NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846

G

actin alpha 2, smooth muscle

multiple interactions
increases expression

ISO
EXP

Cytochalasin D inhibits the reaction [Oxygen results in increased expression of ACTA2 mRNA]; Cytochalasin D inhibits the reaction [Oxygen results in increased expression of ACTA2 protein]
Cytochalasin D results in increased expression of ACTA2 mRNA

PMID:11035001 PMID:23517783

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actin, gamma 1

multiple interactions

ISO

Cytochalasin D inhibits the reaction [UPF1 protein binds to ACTG1 protein]; Cytochalasin D inhibits the reaction [UPF2 protein binds to ACTG1 protein]; Cytochalasin D inhibits the reaction [UPF3B protein binds to ACTG1 protein]

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

cadherin 1

multiple interactions
increases expression

ISO

[Cytochalasin D results in increased expression of CDH1 protein] which results in decreased activity of RHOA protein; RHOA protein mutant form affects the reaction [Cytochalasin D results in increased expression of CDH1 protein]
Cytochalasin D results in increased expression of CDH1 mRNA; Cytochalasin D results in increased expression of CDH1 protein

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

collagen type I alpha 1 chain

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Oxygen results in increased expression of COL1A1 mRNA]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Oxygen results in increased expression of COL1A2 mRNA]

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

colony stimulating factor 2

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cytochalasin D inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein]

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

C-X-C motif chemokine receptor 1

multiple interactions

ISO

Cytochalasin D promotes the reaction [CXCL8 protein results in decreased expression of CXCR1 protein]

NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872

G

C-X-C motif chemokine receptor 2

multiple interactions

ISO

Cytochalasin D promotes the reaction [CXCL8 protein results in decreased expression of CXCR2 protein]

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

epidermal growth factor

multiple interactions

ISO

EGF protein inhibits the reaction [Cytochalasin D results in increased phosphorylation of ABL1 protein]

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of EGFR protein]

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

coagulation factor III, tissue factor

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Particulate Matter results in increased expression of F3 mRNA]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

glutathione peroxidase 1

affects localization

ISO

Cytochalasin D affects the localization of GPX1 mRNA mutant form

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

intercellular adhesion molecule 1

multiple interactions

ISO

Cytochalasin D inhibits the reaction [TNF protein affects the localization of ICAM1 protein]

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon gamma

multiple interactions

ISO

Cytochalasin D promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

inhibitor of nuclear factor kappa B kinase subunit beta

increases phosphorylation
multiple interactions

ISO

Cytochalasin D results in increased phosphorylation of IKBKB protein
Cytochalasin D results in decreased localization of [IKBKB protein binds to NFKBIA protein]

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

interleukin 1 alpha

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Quartz results in increased import of IL1A protein]; Cytochalasin D promotes the reaction [Quartz results in increased secretion of IL1A protein]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

ISO

Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of and results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [Nanotubes, Carbon results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [titanium dioxide results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Cytochalasin D promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]
Cytochalasin D inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of IL1B mRNA]; Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Silicon Dioxide] results in increased cleavage of and results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [[Lipopolysaccharides co-treated with Uric Acid] results in increased cleavage of and results in increased secretion of IL1B protein]; Cytochalasin D inhibits the reaction [Coal Ash results in increased secretion of IL1B protein]

PMID:12799187 PMID:18403674 PMID:18604214 PMID:24158569 PMID:24760326 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

decreases chemical synthesis
increases stability

ISO

Cytochalasin D results in decreased chemical synthesis of IL6 protein
Cytochalasin D results in increased stability of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

influenza virus NS1A binding protein

increases response to substance

ISO

IVNS1ABP gene mutant form results in increased susceptibility to Cytochalasin D

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547

G

lactate dehydrogenase A

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Quartz results in increased activity of and results in increased secretion of LDHA protein]

NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521

G

matrix metallopeptidase 9

multiple interactions

ISO

Cytochalasin D promotes the reaction [TNF results in increased expression of MMP9 mRNA]

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

myocardin related transcription factor A

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Oxygen affects the localization of MRTFA protein]

NCBI chr 7:114,424,481...114,594,594
Ensembl chr 7:114,424,481...114,594,594

G

nuclear factor of activated T-cells 4

decreases localization

ISO

Cytochalasin D results in decreased localization of NFATC4 protein

NCBI chr15:33,256,912...33,284,522
Ensembl chr15:33,274,153...33,285,582

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

ISO

Cytochalasin D results in increased phosphorylation of NFKBIA protein
Cytochalasin D results in decreased localization of [IKBKB protein binds to NFKBIA protein]

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

NLR family, pyrin domain containing 3

decreases expression
multiple interactions

ISO

Cytochalasin D results in decreased expression of NLRP3 mRNA
Cytochalasin D inhibits the reaction [[Air Pollutants results in increased abundance of Particulate Matter] which results in increased expression of NLRP3 mRNA]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nitric oxide synthase 2

multiple interactions

ISO

Cytochalasin D promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

purinergic receptor P2X 1

decreases activity

ISO

Cytochalasin D results in decreased activity of P2RX1 protein

NCBI chr10:58,117,107...58,132,167
Ensembl chr10:58,117,088...58,132,164

G

pancreatic and duodenal homeobox 1

decreases uptake

ISO

Cytochalasin D results in decreased uptake of PDX1 protein

NCBI chr12:12,793,957...12,799,156
Ensembl chr12:12,793,957...12,799,156

G

plasminogen activator, tissue type

increases expression

ISO

Cytochalasin D results in increased expression of PLAT

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

ras homolog family member A

multiple interactions

ISO

[Cytochalasin D results in increased expression of CDH1 protein] which results in decreased activity of RHOA protein; RHOA protein mutant form affects the reaction [Cytochalasin D results in increased expression of CDH1 protein]

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302

G

retinoschisin 1

decreases secretion

ISO

Cytochalasin D results in decreased secretion of RS1 protein

NCBI chr X:37,771,135...37,800,894
Ensembl chr X:37,771,135...37,800,894

G

solute carrier family 31 member 1

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Cisplatin results in increased degradation of SLC31A1 protein]

NCBI chr 5:80,830,574...80,859,810
Ensembl chr 5:80,830,389...80,859,809

G

SMAD family member 1

affects localization

ISO

Cytochalasin D affects the localization of SMAD1 protein

NCBI chr19:45,417,430...45,477,962
Ensembl chr19:45,417,433...45,477,957

G

SMAD family member 2

affects localization

ISO

Cytochalasin D affects the localization of SMAD2 protein

NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388

G

SMAD family member 3

affects localization

ISO

Cytochalasin D affects the localization of SMAD3 protein

NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324

G

snail family transcriptional repressor 1

affects localization

ISO

Cytochalasin D affects the localization of SNAI1 protein

NCBI chr 3:176,667,476...176,671,965

G

signal transducer and activator of transcription 1

multiple interactions

ISO

Cytochalasin D deficiency results in decreased activity of and affects the localization of STAT1 protein

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 3

multiple interactions

ISO

Cytochalasin D deficiency results in decreased activity of and affects the localization of STAT3 protein

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

transgelin

increases expression

EXP

Cytochalasin D results in increased expression of TAGLN mRNA

NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:55,121,301...55,127,563

G

tumor necrosis factor

multiple interactions

ISO

Cytochalasin D inhibits the reaction [TNF protein affects the localization of ICAM1 protein]; Cytochalasin D inhibits the reaction [TNF protein affects the localization of VCAM1 protein]; Cytochalasin D inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; Cytochalasin D promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; Cytochalasin D promotes the reaction [TNF results in increased expression of MMP9 mRNA]
Cytochalasin D inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Cytochalasin D inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]

PMID:8409756 PMID:12799187 PMID:15034928 PMID:17560598

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

thioredoxin 1

multiple interactions

ISO

Cytochalasin D inhibits the reaction [Cadmium Chloride affects the localization of TXN protein]

NCBI chr 5:77,507,455...77,519,685
Ensembl chr 5:77,507,321...77,520,307

G

UPF1, RNA helicase and ATPase

affects localization
multiple interactions

ISO

Cytochalasin D affects the localization of UPF1 protein
Cytochalasin D inhibits the reaction [UPF1 protein binds to ACTG1 protein]

NCBI chr16:19,110,531...19,131,327
Ensembl chr16:19,110,538...19,131,327

G

UPF2, regulator of nonsense mediated mRNA decay

multiple interactions

ISO

Cytochalasin D inhibits the reaction [UPF2 protein binds to ACTG1 protein]

NCBI chr17:77,133,975...77,245,266
Ensembl chr17:77,134,716...77,245,704

G

UPF3B, regulator of nonsense mediated mRNA decay

multiple interactions

ISO

Cytochalasin D inhibits the reaction [UPF3B protein binds to ACTG1 protein]

NCBI chr X:121,200,993...121,219,059
Ensembl chr X:121,200,993...121,218,921

G

vascular cell adhesion molecule 1

multiple interactions

ISO

Cytochalasin D inhibits the reaction [TNF protein affects the localization of VCAM1 protein]; Cytochalasin D inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

decreases expression

ISO

deoxynivalenol results in decreased expression of A2M protein

NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868

G

alanyl-tRNA synthetase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of AARS1 protein

NCBI chr19:55,906,694...55,930,499
Ensembl chr19:55,906,702...55,930,497

G

aminoadipate-semialdehyde synthase

decreases expression

ISO

deoxynivalenol results in decreased expression of AASS protein

NCBI chr 4:52,572,146...52,628,811
Ensembl chr 4:52,572,147...52,657,600

G

4-aminobutyrate aminotransferase

decreases expression

ISO

deoxynivalenol results in decreased expression of ABAT protein

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474

G

ATP binding cassette subfamily B member 1A

decreases response to substance
multiple interactions

ISO

ABCB1 protein results in decreased susceptibility to deoxynivalenol
deoxynivalenol inhibits the reaction [valspodar inhibits the reaction [ABCB1 protein results in increased export of calcein AM]]

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 6

decreases expression

ISO

deoxynivalenol results in decreased expression of ABCB6 protein

NCBI chr 9:84,117,222...84,125,939
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ABCC2 protein

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily C member 3

decreases expression

ISO

deoxynivalenol results in decreased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily F member 1

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of ABCF1 protein

PMID:23352502 PMID:23811945

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

ATP binding cassette subfamily F member 2

increases expression

ISO

deoxynivalenol results in increased expression of ABCF2 protein

NCBI chr 4:11,485,865...11,500,067
Ensembl chr 4:11,487,395...11,500,053

G

abl-interactor 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of ABI1 protein

NCBI chr17:90,006,917...90,088,002
Ensembl chr17:90,006,925...90,087,827

G

actin-binding LIM protein 1

increases expression

ISO

deoxynivalenol results in increased expression of ABLIM1 protein

NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:266,088,870...266,377,098

G

abraxas 2, BRISC complex subunit

increases expression

ISO

deoxynivalenol results in increased expression of ABRAXAS2 mRNA

NCBI chr 1:197,077,177...197,102,753
Ensembl chr 1:197,077,158...197,102,757

G

acetyl-CoA acyltransferase 1A

decreases expression

ISO

deoxynivalenol results in decreased expression of ACAA1 protein

NCBI chr 8:127,956,126...127,966,348
Ensembl chr 8:127,956,129...127,966,241

G

acyl-CoA dehydrogenase, short/branched chain

decreases expression

ISO

deoxynivalenol results in decreased expression of ACADSB protein

NCBI chr 1:195,619,088...195,660,564
Ensembl chr 1:195,619,038...195,660,561

G

aggrecan

decreases expression

ISO

deoxynivalenol results in decreased expression of ACAN mRNA

NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779

G

apoptotic chromatin condensation inducer 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of ACIN1 protein

NCBI chr15:32,072,121...32,117,004
Ensembl chr15:32,072,123...32,117,166

G

ATP citrate lyase

decreases expression

ISO

deoxynivalenol results in decreased expression of ACLY protein

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

acyl-CoA thioesterase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ACOT1 protein

NCBI chr 6:109,367,274...109,375,268
Ensembl chr 6:109,367,268...109,380,749

G

acyl-CoA thioesterase 9

increases expression

ISO

deoxynivalenol results in increased expression of ACOT9 protein

NCBI chr X:43,922,943...43,973,311
Ensembl chr X:43,914,923...43,973,205

G

acyl-CoA synthetase family member 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ACSF2 protein

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase long-chain family member 4

decreases expression
increases expression

ISO

deoxynivalenol results in decreased expression of ACSL4 protein
deoxynivalenol results in increased expression of ACSL4 mRNA; deoxynivalenol results in increased expression of ACSL4 protein

PMID:33890134 PMID:39638853 PMID:39983889

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase long-chain family member 5

decreases expression

ISO

deoxynivalenol results in decreased expression of ACSL5 protein

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

acyl-CoA synthetase short-chain family member 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ACSS1 protein

NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:159,910,809...159,960,748

G

acyl-CoA synthetase short-chain family member 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ACSS2 protein

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actin, alpha 1, skeletal muscle

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of ACTA1 protein

NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178

G

actin, beta-like 2

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of ACTBL2 protein

NCBI chr 2:44,591,391...44,594,138
Ensembl chr 2:44,591,391...44,594,138

G

ADAM metallopeptidase domain 10

decreases expression

ISO

deoxynivalenol results in decreased expression of ADAM10 protein

NCBI chr 8:80,226,862...80,358,728
Ensembl chr 8:80,226,674...80,361,600

G

AFG2 AAA ATPase homolog B

increases expression

ISO

deoxynivalenol results in increased expression of AFG2B mRNA

NCBI chr 3:130,148,061...130,162,458
Ensembl chr 3:130,148,301...130,162,112

G

alpha-fetoprotein

decreases expression

ISO

deoxynivalenol results in decreased expression of AFP protein

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

ArfGAP with FG repeats 1

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of AGFG1 protein
deoxynivalenol results in increased expression of AGFG1 mRNA

PMID:23811945 PMID:31863870

NCBI chr 9:91,572,962...91,630,688
Ensembl chr 9:91,573,157...91,626,910

G

agrin

decreases expression

ISO

deoxynivalenol results in decreased expression of AGRN protein

NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539

G

angiotensinogen

decreases expression

ISO

deoxynivalenol results in decreased expression of AGT protein

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

alanine--glyoxylate aminotransferase

decreases expression

ISO

deoxynivalenol results in decreased expression of AGXT protein

NCBI chr 9:101,122,793...101,132,746
Ensembl chr 9:101,122,793...101,132,745

G

AHNAK nucleoprotein

affects phosphorylation
decreases expression

ISO

deoxynivalenol affects the phosphorylation of AHNAK protein
deoxynivalenol results in decreased expression of AHNAK protein

PMID:23352502 PMID:23811945 PMID:39638853

NCBI chr 1:215,311,289...215,400,010
Ensembl chr 1:215,321,931...215,400,675

G

aryl hydrocarbon receptor

multiple interactions
increases expression

ISO

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR protein]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of AHR protein]
deoxynivalenol results in increased expression of AHR mRNA; deoxynivalenol results in increased expression of AHR protein

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

alpha-2-HS-glycoprotein

decreases expression

ISO

deoxynivalenol results in decreased expression of AHSG protein

NCBI chr11:91,625,975...91,632,583
Ensembl chr11:91,625,975...91,634,039

G

ajuba LIM protein

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of AJUBA protein

NCBI chr15:31,989,796...32,000,042
Ensembl chr15:31,989,799...32,000,042

G

adenylate kinase 7

decreases expression

ISO

deoxynivalenol results in decreased expression of AK7 mRNA

NCBI chr 6:130,376,499...130,444,674
Ensembl chr 6:130,376,550...130,444,677

G

A-kinase anchoring protein 8 like

increases expression

ISO

deoxynivalenol results in increased expression of AKAP8L mRNA

NCBI chr 7:11,983,215...12,012,843
Ensembl chr 7:11,982,721...12,012,811

G

aldo-keto reductase family 1, member B7

multiple interactions

ISO

[Selenomethionine co-treated with deoxynivalenol] results in increased expression of AKR1B7 mRNA

NCBI chr 4:64,043,901...64,083,751
Ensembl chr 4:64,020,686...64,064,909

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation
decreases phosphorylation

ISO

AKT1 protein affects the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; AKT1 protein affects the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; deoxynivalenol results in increased phosphorylation of and results in increased activity of AKT1 protein; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of AKT1 protein]; lauric acid inhibits the reaction [deoxynivalenol results in decreased phosphorylation of AKT1 protein]
[Zearalenone co-treated with deoxynivalenol] results in decreased phosphorylation of AKT1 protein

PMID:15976193 PMID:16424113 PMID:24937323 PMID:34506767 PMID:35090964 More...

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

albumin

decreases expression
multiple interactions
increases expression

ISO

deoxynivalenol results in decreased expression of ALB protein
[deoxynivalenol co-treated with Zearalenone] affects the expression of ALB mRNA; [deoxynivalenol co-treated with Zearalenone] results in decreased expression of ALB protein; [deoxynivalenol co-treated with Zearalenone] results in increased expression of ALB mRNA
deoxynivalenol results in decreased expression of ALB mRNA; deoxynivalenol results in decreased expression of ALB protein
deoxynivalenol results in increased expression of ALB mRNA

PMID:25445755 PMID:28865950 PMID:28935499

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldehyde dehydrogenase 1 family, member A1

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDH1A1 protein

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 2 family member

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDH2 protein

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

aldehyde dehydrogenase 3 family, member B1

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDH3B1 mRNA

NCBI chr 1:210,574,545...210,605,188
Ensembl chr 1:210,573,661...210,610,538

G

aldehyde dehydrogenase 6 family, member A1

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDH6A1 protein

NCBI chr 6:109,809,092...109,829,725
Ensembl chr 6:109,809,122...109,829,743

G

aldehyde dehydrogenase 7 family, member A1

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDH7A1 protein

NCBI chr18:52,208,035...52,240,293
Ensembl chr18:52,204,161...52,240,467

G

aldolase, fructose-bisphosphate A

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDOA protein

NCBI chr 1:190,832,820...190,838,021
Ensembl chr 1:190,832,820...190,838,211

G

aldolase, fructose-bisphosphate B

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of ALDOB mRNA
[deoxynivalenol co-treated with Zearalenone] affects the expression of ALDOB mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of ALDOB mRNA

PMID:28865950 PMID:28935499

NCBI chr 5:68,684,541...68,697,582
Ensembl chr 5:68,684,542...68,716,740

G

aldolase, fructose-bisphosphate C

decreases expression

ISO

deoxynivalenol results in decreased expression of ALDOC protein

NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133

G

alkB homolog 1, histone H2A dioxygenase

increases expression

ISO

deoxynivalenol results in increased expression of ALKBH1 mRNA

NCBI chr 6:112,799,234...112,819,708
Ensembl chr 6:112,799,234...112,819,708

G

arachidonate 12-lipoxygenase, 12S type

decreases expression

ISO

deoxynivalenol results in decreased expression of ALOX12 mRNA

NCBI chr10:55,456,923...55,469,239
Ensembl chr10:55,456,928...55,469,199

G

alkaline phosphatase, intestinal

multiple interactions

ISO

deoxynivalenol results in decreased expression of and results in decreased activity of ALPI protein

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

alpha-kinase 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ALPK2 mRNA

NCBI chr18:61,045,717...61,161,703
Ensembl chr18:61,045,380...61,175,985

G

alpha-1-microglobulin/bikunin precursor

decreases expression

ISO

deoxynivalenol results in decreased expression of AMBP protein

NCBI chr 5:81,583,621...81,593,938
Ensembl chr 5:81,583,622...81,593,850

G

adhesion molecule with Ig like domain 2

decreases expression

ISO

deoxynivalenol results in decreased expression of AMIGO2 mRNA

NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218

G

angiopoietin like 7

decreases expression

ISO

deoxynivalenol results in decreased expression of ANGPTL7 mRNA

NCBI chr 5:164,215,223...164,220,408
Ensembl chr 5:164,215,223...164,220,584

G

ankyrin repeat domain 13C

increases expression

ISO

deoxynivalenol results in increased expression of ANKRD13C mRNA

NCBI chr 2:249,679,752...249,729,272
Ensembl chr 2:249,681,872...249,729,272

G

ankyrin repeat domain 37

decreases expression

ISO

deoxynivalenol results in decreased expression of ANKRD37 mRNA

NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545

G

anillin, actin binding protein

increases expression

ISO

deoxynivalenol results in increased expression of ANLN mRNA

NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513

G

alanyl aminopeptidase, membrane

decreases expression

ISO

deoxynivalenol results in decreased expression of ANPEP mRNA; deoxynivalenol results in decreased expression of ANPEP protein

PMID:31863870 PMID:39638853

NCBI chr 1:143,176,645...143,219,447
Ensembl chr 1:143,176,645...143,195,101

G

annexin A6

decreases expression

ISO

deoxynivalenol results in decreased expression of ANXA6 protein

NCBI chr10:39,602,106...39,657,183
Ensembl chr10:39,602,106...39,657,359

G

amine oxidase, copper containing 1

increases activity
multiple interactions

ISO

deoxynivalenol results in increased activity of AOC1 protein
Curcumin inhibits the reaction [deoxynivalenol results in increased activity of AOC1 protein]

NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:79,143,126...79,162,704

G

amyloid beta precursor like protein 2

decreases expression

ISO

deoxynivalenol results in decreased expression of APLP2 protein

NCBI chr 8:37,857,407...37,920,487
Ensembl chr 8:37,857,407...37,920,031

G

apolipoprotein A1

decreases expression

ISO

deoxynivalenol results in decreased expression of APOA1 protein

NCBI chr 8:55,423,945...55,425,729
Ensembl chr 8:55,423,825...55,425,729

G

apolipoprotein B

decreases expression

ISO

deoxynivalenol results in decreased expression of APOB protein

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

apolipoprotein C3

decreases expression

ISO

deoxynivalenol results in decreased expression of APOC3 protein

NCBI chr 8:55,428,172...55,430,352
Ensembl chr 8:55,428,024...55,458,679

G

apolipoprotein E

decreases expression

ISO

deoxynivalenol results in decreased expression of APOE protein

NCBI chr 1:88,481,889...88,485,816
Ensembl chr 1:88,481,385...88,485,855

G

apolipoprotein H

decreases expression

ISO

deoxynivalenol results in decreased expression of APOH protein

NCBI chr10:93,841,992...93,855,897
Ensembl chr10:93,841,966...93,857,127

G

androgen receptor

decreases activity
multiple interactions

ISO

deoxynivalenol results in decreased activity of AR protein
[15-acetyldeoxynivalenol co-treated with 3-acetyldeoxynivalenol co-treated with deoxynivalenol co-treated with zearalenol co-treated with Zearalenone] results in decreased activity of AR protein; [15-acetyldeoxynivalenol co-treated with 3-acetyldeoxynivalenol co-treated with deoxynivalenol] results in decreased activity of AR protein

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginine and glutamate rich 1

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of ARGLU1 protein

NCBI chr16:87,455,097...87,479,148
Ensembl chr16:87,455,113...87,479,148

G

Rho GTPase activating protein 45

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of ARHGAP45 protein

NCBI chr 7:10,325,515...10,340,955
Ensembl chr 7:10,325,539...10,341,890

G

arkadia (RNF111) N-terminal like PKA signaling regulator 2N

increases expression

ISO

deoxynivalenol results in increased expression of ARK2N mRNA

NCBI chr18:73,431,104...73,520,759
Ensembl chr18:73,431,104...73,518,144

G

armadillo repeat containing 10

affects phosphorylation
increases phosphorylation

ISO

deoxynivalenol affects the phosphorylation of ARMC10 protein
deoxynivalenol results in increased phosphorylation of ARMC10 protein

PMID:23352502 PMID:23811945

NCBI chr 4:14,291,211...14,306,799
Ensembl chr 4:14,291,211...14,306,817

G

activating signal cointegrator 1 complex subunit 3

increases expression

ISO

deoxynivalenol results in increased expression of ASCC3 mRNA

NCBI chr20:55,089,430...55,372,374
Ensembl chr20:55,255,503...55,372,374

G

achaete-scute family bHLH transcription factor 2

increases expression

ISO

deoxynivalenol results in increased expression of ASCL2 mRNA

NCBI chr 1:207,578,447...207,665,126
Ensembl chr 1:207,578,449...207,580,856

G

achaete-scute family bHLH transcription factor 4

increases expression

ISO

deoxynivalenol results in increased expression of ASCL4 mRNA

NCBI chr 7:19,828,710...19,830,952
Ensembl chr 7:19,828,710...19,830,952

G

asialoglycoprotein receptor 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ASGR1 protein

NCBI chr10:55,274,299...55,278,323
Ensembl chr10:55,274,706...55,278,322

G

asialoglycoprotein receptor 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ASGR2 protein

NCBI chr10:55,320,082...55,333,294
Ensembl chr10:55,320,091...55,333,263

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

deoxynivalenol results in decreased expression of ASNS mRNA; deoxynivalenol results in decreased expression of ASNS protein

PMID:31863870 PMID:39638853

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

ATPase family, AAA domain containing 2

increases expression

ISO

deoxynivalenol results in increased expression of ATAD2 protein

NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238

G

activating transcription factor 1

multiple interactions
increases phosphorylation
increases expression

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF1 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF1 protein]
deoxynivalenol results in increased expression of ATF1 mRNA

PMID:16424113 PMID:22846391

NCBI chr 7:133,240,774...133,283,488
Ensembl chr 7:133,241,197...133,283,485

G

activating transcription factor 2

increases expression
multiple interactions
increases phosphorylation
affects localization

ISO

deoxynivalenol results in increased expression of ATF2 mRNA
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF2 protein]
deoxynivalenol affects the localization of ATF2 protein

PMID:12604842 PMID:15772366 PMID:22846391

NCBI chr 3:79,125,814...79,202,896
Ensembl chr 3:79,126,705...79,202,745

G

activating transcription factor 3

multiple interactions
decreases expression
increases expression
increases response to substance
decreases degradation

ISO

[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of ATF3 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of ATF3 mRNA]; ATF3 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the phosphorylation of RELA protein]; ATF3 protein affects the reaction [deoxynivalenol results in increased expression of EGR1 protein]; EP300 protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]; KAT2A protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]; KAT2B protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]; N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 protein]
deoxynivalenol results in decreased expression of ATF3 mRNA
deoxynivalenol results in increased expression of ATF3 mRNA; deoxynivalenol results in increased expression of ATF3 protein; deoxynivalenol results in increased expression of ATF3 protein alternative form
ATF3 protein results in increased susceptibility to deoxynivalenol
deoxynivalenol results in decreased degradation of ATF3 mRNA; deoxynivalenol results in decreased degradation of ATF3 protein

PMID:19101521 PMID:19360757 PMID:21074547 PMID:22003189 PMID:22846391 More...

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 6

multiple interactions
increases expression

ISO

ATF6 protein affects the reaction [deoxynivalenol results in increased expression of IL6 mRNA]
deoxynivalenol results in increased expression of ATF6 protein
deoxynivalenol results in increased expression of ATF6 mRNA

PMID:19336499 PMID:20682335 PMID:22846391

NCBI chr13:85,460,312...85,639,959
Ensembl chr13:85,462,840...85,640,033

G

autophagy related 14

increases expression

ISO

deoxynivalenol results in increased expression of ATG14 mRNA

NCBI chr15:23,275,457...23,306,817
Ensembl chr15:23,275,457...23,306,815

G

autophagy related 4B, cysteine peptidase

increases expression

ISO

deoxynivalenol results in increased expression of ATG4B mRNA

NCBI chr 9:101,729,772...101,761,456
Ensembl chr 9:101,726,782...101,761,622

G

autophagy related 5

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of ATG5 mRNA; deoxynivalenol results in increased expression of ATG5 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of ATG5 protein]

NCBI chr20:49,380,835...49,471,826
Ensembl chr20:49,380,813...49,471,821

G

atlastin GTPase 2

increases expression

ISO

deoxynivalenol results in increased expression of ATL2 protein

NCBI chr 6:20,891,220...20,932,644
Ensembl chr 6:20,891,227...20,933,320

G

ATPase phospholipid transporting 10A (putative)

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP10A mRNA

NCBI chr 1:118,692,456...118,866,117
Ensembl chr 1:118,692,478...118,866,114

G

ATPase Na+/K+ transporting subunit alpha 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP1A1 protein

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATP synthase F1 subunit gamma

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP5F1C protein

NCBI chr17:73,333,584...73,355,872
Ensembl chr17:73,333,588...73,383,073

G

ATP synthase peripheral stalk subunit d

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP5PD protein

NCBI chr10:101,156,673...101,161,926
Ensembl chr10:101,156,673...101,162,954

G

ATPase H+ transporting accessory protein 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6AP2 protein

NCBI chr X:12,856,708...12,883,670
Ensembl chr X:12,855,859...12,905,875

G

ATPase H+ transporting V1 subunit A

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6V1A protein

NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603

G

ATPase H+ transporting V1 subunit B2

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6V1B2 protein

NCBI chr16:25,384,254...25,408,388
Ensembl chr16:25,384,257...25,408,839

G

ATPase H+ transporting V1 subunit D

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6V1D protein

NCBI chr 6:103,389,778...103,405,346
Ensembl chr 6:103,389,783...103,405,346

G

ATPase H+ transporting V1 subunit G1

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6V1G1 protein

NCBI chr 5:81,976,959...81,983,139
Ensembl chr 5:81,977,015...81,985,930

G

ATPase H+ transporting V1 subunit H

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP6V1H protein

NCBI chr 5:19,176,849...19,282,516
Ensembl chr 5:19,176,849...19,282,516

G

ATPase phospholipid transporting 8B2

decreases expression

ISO

deoxynivalenol results in decreased expression of ATP8B2 mRNA

NCBI chr 2:177,676,205...177,699,575
Ensembl chr 2:177,676,208...177,699,575

G

attractin

decreases expression

ISO

deoxynivalenol results in decreased expression of ATRN protein

NCBI chr 3:138,563,271...138,697,360
Ensembl chr 3:138,563,312...138,697,360

G

ATRX, chromatin remodeler

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of ATRX protein

NCBI chr X:74,916,548...75,062,880
Ensembl chr X:74,916,548...75,062,880

G

ataxin 10

decreases expression

ISO

deoxynivalenol results in decreased expression of ATXN10 protein

NCBI chr 7:118,321,516...118,444,967
Ensembl chr 7:118,319,490...118,445,636

G

ataxin 2-like

increases expression

ISO

deoxynivalenol results in increased expression of ATXN2L protein

NCBI chr 1:190,508,878...190,526,263
Ensembl chr 1:190,508,878...190,520,579

G

aurora kinase A

increases expression

ISO

deoxynivalenol results in increased expression of AURKA protein

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

beta-2 microglobulin

decreases expression

ISO

deoxynivalenol results in decreased expression of B2M protein

NCBI chr 3:129,549,236...129,555,354
Ensembl chr 3:129,549,318...129,555,356

G

Beta-1,3-galactosyltransferase 4

decreases expression

ISO

deoxynivalenol results in decreased expression of B3GALT4 mRNA

NCBI chr20:4,937,974...4,939,549
Ensembl chr20:4,937,674...4,939,885

G

beta-1,4-glucuronyltransferase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of B4GAT1 protein

NCBI chr 1:211,772,644...211,774,866
Ensembl chr 1:211,772,606...211,775,442

G

BTB domain and CNC homolog 2

increases expression

ISO

deoxynivalenol results in increased expression of BACH2 mRNA

NCBI chr 5:51,428,802...51,779,030
Ensembl chr 5:51,434,870...51,774,234

G

BCL2-associated agonist of cell death

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of BAD protein

NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034

G

BAG cochaperone 3

increases expression

ISO

deoxynivalenol results in increased expression of BAG3 mRNA

NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280

G

BCL2-antagonist/killer 1

increases expression

ISO

deoxynivalenol results in increased expression of BAK1 mRNA

NCBI chr20:5,102,334...5,111,615
Ensembl chr20:5,102,335...5,110,974

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
affects localization
decreases expression

ISO

[Zearalenone co-treated with deoxynivalenol] results in increased expression of BAX mRNA; [Zearalenone co-treated with deoxynivalenol] results in increased expression of BAX protein; Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of BAX protein]
[deoxynivalenol co-treated with Aflatoxin B1] results in increased expression of BAX protein; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of BAX protein]; deoxynivalenol promotes the reaction [Zearalenone results in increased expression of BAX mRNA]
deoxynivalenol results in increased expression of BAX mRNA; deoxynivalenol results in increased expression of BAX protein
deoxynivalenol affects the localization of BAX protein
deoxynivalenol results in decreased expression of BAX mRNA

PMID:15976193 PMID:17166419 PMID:19410639 PMID:22269384 PMID:25445755 More...

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

bromodomain adjacent to zinc finger domain, 1B

increases expression

ISO

deoxynivalenol results in increased expression of BAZ1B protein

NCBI chr12:27,068,541...27,126,511
Ensembl chr12:27,068,541...27,126,511

G

Bcl-2 binding component 3

increases expression

ISO

deoxynivalenol results in increased expression of BBC3 mRNA

NCBI chr 1:86,141,450...86,150,666
Ensembl chr 1:86,141,603...86,150,666

G

basal cell adhesion molecule (Lutheran blood group)

decreases expression

ISO

deoxynivalenol results in decreased expression of BCAM protein

NCBI chr 1:88,542,971...88,557,358
Ensembl chr 1:88,542,972...88,557,888

G

BCAS2, pre-mRNA processing factor

increases expression

ISO

deoxynivalenol results in increased expression of BCAS2 protein

NCBI chr 2:193,381,000...193,388,881
Ensembl chr 2:193,380,982...193,388,878

G

BCL10, immune signaling adaptor

increases expression

ISO

deoxynivalenol results in increased expression of BCL10 mRNA

NCBI chr 2:237,501,181...237,510,821
Ensembl chr 2:237,501,134...237,511,829

G

BCL2, apoptosis regulator

multiple interactions
decreases expression
increases expression

ISO

Ascorbic Acid inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]
deoxynivalenol results in decreased expression of BCL2 mRNA; deoxynivalenol results in decreased expression of BCL2 protein
[deoxynivalenol co-treated with Aflatoxin B1] results in decreased expression of BCL2 protein; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; deoxynivalenol promotes the reaction [Aflatoxin B1 results in decreased expression of BCL2 mRNA]; Selenomethionine inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]
deoxynivalenol results in increased expression of BCL2 mRNA

PMID:17166419 PMID:22269384 PMID:25445755 PMID:35817260 PMID:37705238 More...

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

ISO

deoxynivalenol results in decreased expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 13

increases expression

ISO

deoxynivalenol results in increased expression of BCL2L13 mRNA

NCBI chr 4:155,728,284...155,785,058
Ensembl chr 4:155,728,284...155,781,158

G

BCL6, transcription repressor

increases expression

ISO

deoxynivalenol results in increased expression of BCL6 mRNA

PMID:22968694 PMID:31863870

NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047

G

BCL2-associated transcription factor 1

increases expression
affects phosphorylation

ISO

deoxynivalenol results in increased expression of BCLAF1 mRNA
deoxynivalenol affects the phosphorylation of BCLAF1 protein

PMID:22846391 PMID:23352502 PMID:23811945

NCBI chr 1:16,904,572...16,937,106
Ensembl chr 1:16,914,118...16,936,801

G

beclin 1

increases expression
decreases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of BECN1 mRNA
deoxynivalenol results in decreased expression of BECN1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]]; Selenomethionine inhibits the reaction [deoxynivalenol results in decreased expression of BECN1 protein]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of BECN1 mRNA]

PMID:34677630 PMID:35381244 PMID:38040082

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

BEN domain containing 7

increases expression

ISO

deoxynivalenol results in increased expression of BEND7 mRNA

NCBI chr17:78,392,489...78,475,459
Ensembl chr17:78,393,601...78,475,223

G

BH3 interacting domain death agonist

decreases expression

ISO

deoxynivalenol results in decreased expression of BID mRNA

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

bridging integrator 1

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of BIN1 protein

NCBI chr18:24,282,840...24,341,461
Ensembl chr18:24,283,801...24,341,458

G

basic helix-loop-helix ARNT like 1

multiple interactions

ISO

BMAL1 protein inhibits the reaction [deoxynivalenol results in increased activity of GOT1 protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased activity of GPT protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL1B protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased expression of TNF protein]; BMAL1 protein promotes the reaction [deoxynivalenol results in decreased expression of CLOCK protein]; BMAL1 protein promotes the reaction [deoxynivalenol results in decreased expression of NR1D1 protein]; BMAL1 protein promotes the reaction [deoxynivalenol results in decreased expression of PER2 protein]; BMAL1 protein promotes the reaction [deoxynivalenol results in decreased expression of PER3 protein]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CLOCK mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY1 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY1 protein]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY2 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY2 protein]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of NR1D1 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of NR1D2 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of PER1 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of PER1 protein]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of PER3 mRNA]

NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739

G

bone morphogenetic protein 2

increases expression

ISO

deoxynivalenol results in increased expression of BMP2 mRNA

NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760

G

BMS1 ribosome biogenesis factor

increases expression

ISO

deoxynivalenol results in increased expression of BMS1 protein

NCBI chr 4:153,230,471...153,267,437
Ensembl chr 4:153,230,471...153,267,429

G

BCL2 interacting protein 1

increases expression

ISO

deoxynivalenol results in increased expression of BNIP1 mRNA

NCBI chr10:16,891,317...16,903,561
Ensembl chr10:16,891,317...16,903,561

G

BCL2 interacting protein 2

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of BNIP2 protein

NCBI chr 8:79,521,375...79,539,148
Ensembl chr 8:79,521,363...79,547,368

G

BOP1 ribosomal biogenesis factor

increases expression

ISO

deoxynivalenol results in increased expression of BOP1 protein

NCBI chr 7:110,052,716...110,076,529
Ensembl chr 7:110,052,720...110,076,529

G

bromodomain PHD finger transcription factor

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of BPTF protein

NCBI chr10:92,480,007...92,582,485
Ensembl chr10:92,480,007...92,582,413

G

bromodomain containing 3

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of BRD3 protein

NCBI chr 3:31,173,332...31,227,749
Ensembl chr 3:31,173,332...31,227,629

G

bone marrow stromal cell antigen 1

decreases expression

ISO

deoxynivalenol results in decreased expression of BST1 mRNA

NCBI chr14:71,466,179...71,482,671
Ensembl chr14:71,466,180...71,482,647

G

BUB1 mitotic checkpoint serine/threonine kinase B

increases expression

ISO

deoxynivalenol results in increased expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

BUB3 mitotic checkpoint protein

increases expression

ISO

deoxynivalenol results in increased expression of BUB3 mRNA; deoxynivalenol results in increased expression of BUB3 protein

PMID:31863870 PMID:39638853

NCBI chr 1:195,760,532...195,771,140
Ensembl chr 1:195,758,105...195,791,028

G

bystin-like

increases expression

ISO

deoxynivalenol results in increased expression of BYSL protein

NCBI chr 9:20,880,341...20,890,092
Ensembl chr 9:20,880,026...20,890,900

G

complement C3

increases expression
decreases expression

ISO

deoxynivalenol results in increased expression of C3 mRNA
deoxynivalenol results in decreased expression of C3 protein

PMID:22968694 PMID:39638853

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

complement C3a receptor 1

increases expression

ISO

deoxynivalenol results in increased expression of C3AR1 mRNA

PMID:12604170 PMID:22968694

NCBI chr 4:157,747,419...157,756,609
Ensembl chr 4:157,746,089...157,776,323

G

complement C4A (Rodgers blood group)

decreases expression

ISO

deoxynivalenol results in decreased expression of C4A protein

NCBI chr20:4,010,306...4,024,707

G

complement C4B

increases expression

ISO

deoxynivalenol results in increased expression of C4B mRNA

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289

G

calcium voltage-gated channel subunit alpha1 D

increases expression

ISO

deoxynivalenol results in increased expression of CACNA1D mRNA

NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,233,690...5,674,692

G

calcium voltage-gated channel auxiliary subunit gamma 6

decreases expression

ISO

deoxynivalenol results in decreased expression of CACNG6 mRNA

NCBI chr 1:74,648,342...74,663,351
Ensembl chr 1:74,648,063...74,662,753

G

cell adhesion molecule 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CADM1 protein

NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:56,744,372...57,080,192

G

calnexin

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of CANX protein

NCBI chr10:35,124,941...35,157,954
Ensembl chr10:35,124,941...35,157,857

G

caspase recruitment domain family, member 11

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of CARD11 protein

NCBI chr12:18,735,088...18,872,045
Ensembl chr12:18,735,088...18,872,045

G

CASC3 exon junction complex subunit

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of CASC3 protein

NCBI chr10:84,264,157...84,286,639
Ensembl chr10:84,265,033...84,286,637

G

calcium/calmodulin dependent serine protein kinase

increases expression

ISO

deoxynivalenol results in increased expression of CASK protein

NCBI chr X:11,572,328...11,915,831
Ensembl chr X:11,572,636...11,911,948

G

caspase 1

increases expression
increases cleavage
multiple interactions

ISO

deoxynivalenol results in increased expression of CASP1 mRNA
deoxynivalenol results in increased cleavage of CASP1 protein
deoxynivalenol promotes the reaction [fumonisin B1 results in increased cleavage of CASP1 protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased cleavage of CASP1 protein]

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

increases activity
increases cleavage
increases expression
multiple interactions
decreases expression

ISO
EXP

deoxynivalenol results in increased activity of CASP3 protein
deoxynivalenol results in increased cleavage of CASP3 protein
deoxynivalenol results in increased expression of CASP3 mRNA; deoxynivalenol results in increased expression of CASP3 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [deoxynivalenol results in increased activity of CASP3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; [deoxynivalenol co-treated with Aflatoxin B1] results in increased expression of CASP3 protein; acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased expression of and results in increased cleavage of CASP3 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of and results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; deoxynivalenol promotes the reaction [Aflatoxin B1 results in increased expression of CASP3 mRNA]; deoxynivalenol results in increased activity of and results in increased cleavage of CASP3 protein; deoxynivalenol results in increased expression of and results in increased cleavage of CASP3 protein; HCK protein affects the reaction [deoxynivalenol results in increased activity of CASP3 protein]; lauric acid inhibits the reaction [deoxynivalenol results in increased cleavage of CASP3 protein]; pifithrin inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; Zearalenone promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]
deoxynivalenol results in decreased expression of CASP3 protein
[Zearalenone co-treated with Aflatoxin B1] promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]; [Zearalenone co-treated with deoxynivalenol] results in increased expression of CASP3 protein; Aflatoxin B1 promotes the reaction [deoxynivalenol results in increased expression of CASP3 mRNA]; Ascorbic Acid inhibits the reaction [deoxynivalenol results in increased expression of CASP3 protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in decreased expression of and results in increased cleavage of CASP3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in decreased expression of and results in increased cleavage of CASP3 protein]; deoxynivalenol results in decreased expression of and results in increased cleavage of CASP3 protein

PMID:15772366 PMID:15976193 PMID:17166419 PMID:19410639 PMID:19664677 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 7

increases activity

ISO

deoxynivalenol results in increased activity of CASP7 protein

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

increases expression
multiple interactions

ISO
EXP

deoxynivalenol results in increased expression of CASP8 mRNA
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of CASP8 mRNA]
[Aflatoxin B1 co-treated with deoxynivalenol] promotes the reaction [Zearalenone results in increased expression of CASP8 mRNA]; [Aflatoxin B1 co-treated with deoxynivalenol] results in increased expression of CASP8 mRNA; [Zearalenone co-treated with Aflatoxin B1] promotes the reaction [deoxynivalenol results in increased expression of CASP8 mRNA]; [Zearalenone co-treated with deoxynivalenol] promotes the reaction [Aflatoxin B1 results in increased expression of CASP8 mRNA]; Zearalenone promotes the reaction [[Aflatoxin B1 co-treated with deoxynivalenol] results in increased expression of CASP8 mRNA]
deoxynivalenol results in increased activity of and results in increased cleavage of CASP8 protein

PMID:22491426 PMID:22846391 PMID:30668976 PMID:34673182

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

decreases expression
multiple interactions
increases expression
increases activity

ISO
EXP

deoxynivalenol results in decreased expression of CASP9 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of CASP9 mRNA]
Zearalenone promotes the reaction [[Aflatoxin B1 co-treated with deoxynivalenol] results in increased expression of CASP9 mRNA]
[deoxynivalenol co-treated with Aflatoxin B1] results in increased expression of CASP9 protein; deoxynivalenol results in increased activity of and results in increased cleavage of CASP9 protein
deoxynivalenol results in increased expression of CASP9 mRNA; deoxynivalenol results in increased expression of CASP9 protein
deoxynivalenol results in increased activity of CASP9 protein

PMID:22269384 PMID:22491426 PMID:30668976 PMID:34673182 PMID:35314294 More...

Ensembl chr 5:159,391,188...159,409,648

G

calcium-sensing receptor

multiple interactions

ISO

CASR affects the reaction [deoxynivalenol results in increased secretion of CCK protein]

NCBI chr11:77,738,398...77,813,639
Ensembl chr11:77,740,614...77,810,167

G

catalase

increases expression
decreases activity
multiple interactions
decreases expression
increases activity

ISO
EXP

deoxynivalenol results in increased expression of CAT mRNA; deoxynivalenol results in increased expression of CAT protein
deoxynivalenol results in decreased activity of CAT protein
Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CAT mRNA]
deoxynivalenol results in increased activity of CAT protein
Lutein inhibits the reaction [deoxynivalenol results in increased expression of CAT protein]

PMID:20347963 PMID:34400200 PMID:34673182 PMID:35314294 PMID:35817260 More...

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

Cbl proto-oncogene like 1

increases expression

ISO

deoxynivalenol results in increased expression of CBLL1 mRNA

NCBI chr 6:53,798,712...53,812,890
Ensembl chr 6:53,798,712...53,813,880

G

cystathionine beta synthase

decreases expression

ISO

deoxynivalenol results in decreased expression of CBS mRNA

NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066

G

chromobox 5

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of CBX5 protein

NCBI chr 7:136,203,827...136,254,575
Ensembl chr 7:136,211,649...136,229,118

G

coiled-coil domain containing 112

increases expression

ISO

deoxynivalenol results in increased expression of CCDC112 mRNA

NCBI chr18:41,184,769...41,218,958
Ensembl chr18:41,184,769...41,218,958

G

coiled-coil domain containing 137

increases expression

ISO

deoxynivalenol results in increased expression of CCDC137 protein

NCBI chr10:106,229,099...106,235,502
Ensembl chr10:106,229,099...106,235,502

G

coiled-coil domain containing 86

increases expression

ISO

deoxynivalenol results in increased expression of CCDC86 protein

NCBI chr 1:217,015,059...217,021,439
Ensembl chr 1:217,014,848...217,021,468

G

cholecystokinin

increases secretion
multiple interactions
increases expression

ISO

deoxynivalenol results in increased secretion of CCK protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [deoxynivalenol results in increased secretion of CCK protein]; 2-aminoethyl diphenylborinate inhibits the reaction [deoxynivalenol results in increased secretion of CCK protein]; [N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine co-treated with Ruthenium Red] inhibits the reaction [deoxynivalenol results in increased expression of CCK protein]; CASR affects the reaction [deoxynivalenol results in increased secretion of CCK protein]; Egtazic Acid inhibits the reaction [deoxynivalenol results in increased secretion of CCK protein]; N-(2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl)-1,1-dimethyl-2-(2-nephthyl)ethylamine inhibits the reaction [deoxynivalenol results in increased expression of CCK protein]; Nitrendipine inhibits the reaction [deoxynivalenol results in increased secretion of CCK protein]; Ruthenium Red inhibits the reaction [deoxynivalenol results in increased expression of CCK protein]; triphenylphosphine oxide inhibits the reaction [deoxynivalenol results in increased secretion of CCK protein]; TRPA1 affects the reaction [deoxynivalenol results in increased secretion of CCK protein]

PMID:22903826 PMID:24385417 PMID:25787141 PMID:26979077

NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:130,031,013...130,037,686

G

C-C motif chemokine ligand 1

increases expression

ISO

deoxynivalenol results in increased expression of CCL1 mRNA

NCBI chr10:67,625,962...67,628,740
Ensembl chr10:67,625,962...67,628,790

G

C-C motif chemokine ligand 11

increases expression

ISO

deoxynivalenol results in increased expression of CCL11 mRNA

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 12

increases expression

ISO

deoxynivalenol results in increased expression of CCL12 mRNA

NCBI chr10:67,567,876...67,569,426
Ensembl chr10:67,567,876...67,569,426

G

C-C motif chemokine ligand 17

increases expression

ISO

deoxynivalenol results in increased expression of CCL17 mRNA

NCBI chr19:10,208,120...10,218,340
Ensembl chr19:10,208,120...10,209,895

G

C-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CCL2 mRNA; deoxynivalenol results in increased expression of CCL2 protein
Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of CCL2 mRNA]

PMID:15371230 PMID:15681167 PMID:17090620 PMID:22846391 PMID:22968694 More...

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 20

increases expression

ISO

deoxynivalenol results in increased expression of CCL20 mRNA

PMID:27757495 PMID:35314294

NCBI chr 9:91,837,139...91,839,736
Ensembl chr 9:91,836,946...91,839,736

G

C-C motif chemokine ligand 22

increases expression

ISO

deoxynivalenol results in increased expression of CCL22 mRNA

NCBI chr19:10,263,589...10,270,359
Ensembl chr19:10,263,589...10,270,359

G

C-C motif chemokine ligand 24

increases expression

ISO

deoxynivalenol results in increased expression of CCL24 mRNA

NCBI chr12:26,737,423...26,741,420
Ensembl chr12:26,737,439...26,750,924

G

C-C motif chemokine ligand 25

decreases expression

ISO

deoxynivalenol results in decreased expression of CCL25 mRNA

NCBI chr12:7,505,231...7,514,402
Ensembl chr12:7,505,235...7,514,385

G

C-C motif chemokine ligand 3

increases expression

ISO

deoxynivalenol results in increased expression of CCL3 mRNA

PMID:22846391 PMID:22968694

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

C-C motif chemokine ligand 4

increases expression

ISO

deoxynivalenol results in increased expression of CCL4 mRNA

PMID:21074547 PMID:22846391 PMID:22968694 PMID:27757495

NCBI chr10:68,963,893...68,965,728
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CCL5 mRNA
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of CCL5 mRNA]

PMID:22968694 PMID:27757495 PMID:35925383

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

C-C motif chemokine ligand 7

multiple interactions
increases expression

ISO

Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of CCL7 mRNA]

PMID:15371230 PMID:15681167 PMID:22968694 PMID:24793808

NCBI chr10:67,514,095...67,515,945
Ensembl chr10:67,514,091...67,515,947

G

cellular communication network factor 1

increases expression

ISO

deoxynivalenol results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression

ISO

deoxynivalenol results in increased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cyclin B1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CCNB1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of CCNB1 mRNA]

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CCND1 mRNA; deoxynivalenol results in increased expression of CCND1 protein
Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of CCND1 protein]

PMID:22454431 PMID:24937323 PMID:32416088

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin E1

decreases expression

ISO

deoxynivalenol results in decreased expression of CCNE1 mRNA

NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822

G

cyclin G2

increases expression

ISO

deoxynivalenol results in increased expression of CCNG2 mRNA

NCBI chr14:15,088,694...15,097,190
Ensembl chr14:15,088,695...15,096,206

G

cyclin Y

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of CCNY protein

NCBI chr17:62,079,925...62,207,780
Ensembl chr17:62,079,925...62,207,979

G

C-C motif chemokine receptor 1

increases expression

ISO

deoxynivalenol results in increased expression of CCR1 mRNA

NCBI chr 8:132,433,711...132,439,266
Ensembl chr 8:132,431,592...132,439,374

G

C-C motif chemokine receptor 2

increases expression

ISO

deoxynivalenol results in increased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059

G

C-C motif chemokine receptor 3

increases expression

ISO

deoxynivalenol results in increased expression of CCR3 mRNA

NCBI chr 8:132,463,533...132,511,601
Ensembl chr 8:132,463,788...132,511,593

G

C-C motif chemokine receptor 4

increases expression

ISO

deoxynivalenol results in increased expression of CCR4 mRNA

NCBI chr 8:123,054,505...123,060,244
Ensembl chr 8:123,054,324...123,077,642

G

C-C motif chemokine receptor 7

increases expression

ISO

deoxynivalenol results in increased expression of CCR7 mRNA

NCBI chr10:84,594,399...84,604,514
Ensembl chr10:84,593,594...84,604,501

G

CD14 molecule

multiple interactions

ISO

deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of CD14 protein]

NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292

G

CD248 molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CD248 mRNA

NCBI chr 1:211,803,052...211,805,616
Ensembl chr 1:211,801,934...211,805,776

G

Cd276 molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CD276 protein

NCBI chr 8:67,833,587...67,863,918
Ensembl chr 8:67,829,048...67,864,505

G

CD40 molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CD40 mRNA

NCBI chr 3:174,209,113...174,224,592
Ensembl chr 3:174,209,719...174,224,847

G

CD46 molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CD46 protein

NCBI chr13:109,104,122...109,134,903

G

CD55 molecule (Cromer blood group)

increases expression

ISO

deoxynivalenol results in increased expression of CD55 mRNA

PMID:22846391 PMID:24247028

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

Cd68 molecule

increases expression

ISO

deoxynivalenol results in increased expression of CD68 mRNA

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

Cd69 molecule

increases expression

ISO

deoxynivalenol results in increased expression of CD69 mRNA

PMID:22846391 PMID:24247028

NCBI chr 4:164,411,485...164,419,403
Ensembl chr 4:164,411,485...164,419,509

G

CD74 molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CD74 protein

NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410

G

Cd80 molecule

increases expression

ISO

deoxynivalenol results in increased expression of CD80 mRNA

NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540

G

CD86 molecule

increases expression

ISO

deoxynivalenol results in increased expression of CD86 mRNA

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

codanin 1

increases expression

ISO

deoxynivalenol results in increased expression of CDAN1 mRNA

NCBI chr 3:128,129,664...128,143,520
Ensembl chr 3:128,129,301...128,143,549

G

cell division cycle 5-like

increases expression

ISO

deoxynivalenol results in increased expression of CDC5L protein

NCBI chr 9:23,062,397...23,100,901
Ensembl chr 9:23,062,205...23,100,899

G

cadherin 13

decreases expression

ISO

deoxynivalenol results in decreased expression of CDH13 mRNA

NCBI chr19:63,258,251...64,296,122
Ensembl chr19:63,258,122...64,296,119

G

cadherin 2

decreases expression

ISO

deoxynivalenol results in decreased expression of CDH2 protein

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cyclin-dependent kinase 1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CDK1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of CDK1 mRNA]

PMID:31863870 PMID:34677630

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions
decreases degradation

ISO

deoxynivalenol results in increased expression of CDKN1A mRNA; deoxynivalenol results in increased expression of CDKN1A protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of CDKN1A mRNA]; EGR1 protein affects the reaction [deoxynivalenol results in increased expression of CDKN1A protein]; U 0126 inhibits the reaction [deoxynivalenol results in decreased degradation of CDKN1A mRNA]

PMID:18006205 PMID:22454431 PMID:30169763 PMID:30286430 PMID:31863870 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 3

increases expression

ISO

deoxynivalenol results in increased expression of CDKN3 mRNA

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

carnitine deficiency-associated gene expressed in ventricle 3

increases expression

ISO

deoxynivalenol results in increased expression of CDV3 protein

NCBI chr 8:112,812,898...112,826,073
Ensembl chr 8:112,813,952...112,826,056

G

CCAAT/enhancer binding protein alpha

multiple interactions
decreases expression

ISO

[deoxynivalenol co-treated with Zearalenone] results in decreased expression of CEBPA mRNA
deoxynivalenol results in decreased expression of CEBPA mRNA

PMID:28865950 PMID:28935499

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein beta

multiple interactions
increases activity
affects localization

ISO

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased activity of CEBPB protein]
deoxynivalenol affects the localization of CEBPB protein

PMID:12604842 PMID:15772366

NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072

G

cell migration inducing hyaluronidase 2

increases expression

ISO

deoxynivalenol results in increased expression of CEMIP2 protein

NCBI chr 1:228,756,826...228,834,313
Ensembl chr 1:228,757,466...228,832,906

G

centromere protein W

increases expression

ISO

deoxynivalenol results in increased expression of CENPW mRNA

NCBI chr 1:29,353,939...29,359,109
Ensembl chr 1:29,353,970...29,359,109

G

cerebral endothelial cell adhesion molecule

decreases expression

ISO

deoxynivalenol results in decreased expression of CERCAM mRNA

NCBI chr 3:33,515,513...33,553,817
Ensembl chr 3:33,486,664...33,553,813

G

ceramide synthase 2

increases expression

ISO

deoxynivalenol results in increased expression of CERS2 protein

NCBI chr 2:185,579,511...185,587,789
Ensembl chr 2:185,579,119...185,588,839

G

carboxylesterase 2H

decreases expression

ISO

deoxynivalenol results in decreased expression of CES2 protein

NCBI chr19:49,884,164...49,898,764
Ensembl chr19:49,884,164...49,898,752

G

cell growth regulator with EF hand domain 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CGREF1 mRNA

NCBI chr 6:31,151,795...31,163,801
Ensembl chr 6:31,151,795...31,163,800

G

ChaC glutathione-specific gamma-glutamylcyclotransferase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CHAC1 mRNA

NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361

G

chromosome alignment maintaining phosphoprotein 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of CHAMP1 protein

NCBI chr16:82,436,172...82,447,144
Ensembl chr16:82,434,823...82,458,984

G

calcium homeostasis endoplasmic reticulum protein

increases expression

ISO

deoxynivalenol results in increased expression of CHERP protein

NCBI chr16:17,401,497...17,414,549
Ensembl chr16:17,401,497...17,414,549

G

choline kinase alpha

increases expression

ISO

deoxynivalenol results in increased expression of CHKA mRNA

NCBI chr 1:210,506,069...210,554,753
Ensembl chr 1:210,506,056...210,554,752

G

cholesin

increases expression

ISO

deoxynivalenol results in increased expression of C7ORF50 protein

NCBI chr12:20,298,968...20,402,890
Ensembl chr12:20,388,520...20,402,922

G

chimerin 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CHN1 mRNA

NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:78,917,329...79,084,197

G

cysteine and histidine rich domain containing 1

increases expression

ISO

deoxynivalenol results in increased expression of CHORDC1 mRNA; deoxynivalenol results in increased expression of CHORDC1 protein

PMID:31863870 PMID:39638853

NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696

G

chromatin target of PRMT1

increases expression

ISO

deoxynivalenol results in increased expression of CHTOP protein

NCBI chr 2:178,278,848...178,291,142
Ensembl chr 2:178,278,848...178,290,348

G

component of inhibitor of nuclear factor kappa B kinase complex

increases phosphorylation
increases expression

ISO

deoxynivalenol results in increased phosphorylation of CHUK protein
deoxynivalenol results in increased expression of CHUK mRNA

PMID:20633634 PMID:34400200

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

cytokine inducible SH2-containing protein

increases expression

ISO

deoxynivalenol results in increased expression of CISH mRNA

NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986

G

cytoskeleton associated protein 2

increases expression

ISO

deoxynivalenol results in increased expression of CKAP2 mRNA

NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352

G

cytoskeleton associated protein 5

increases expression

ISO

deoxynivalenol results in increased expression of CKAP5 mRNA

NCBI chr 3:97,946,966...98,049,050
Ensembl chr 3:97,947,031...98,049,049

G

CDC28 protein kinase regulatory subunit 1B

increases expression

ISO

deoxynivalenol results in increased expression of CKS1B mRNA

NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365

G

claudin 1

increases expression
decreases expression
multiple interactions
affects expression

ISO

deoxynivalenol results in increased expression of CLDN1 mRNA
deoxynivalenol results in decreased expression of CLDN1 mRNA; deoxynivalenol results in decreased expression of CLDN1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]; lauric acid inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]
[deoxynivalenol co-treated with Zearalenone] results in decreased expression of CLDN1 mRNA; [deoxynivalenol co-treated with Zearalenone] results in decreased expression of CLDN1 protein; deoxynivalenol results in decreased expression of and affects the localization of CLDN1 protein
deoxynivalenol affects the expression of CLDN1 protein

PMID:24568843 PMID:28865950 PMID:28935499 PMID:34506767 PMID:35381244 More...

NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529

G

claudin 2

affects expression
increases expression

ISO

deoxynivalenol affects the expression of CLDN2 protein
deoxynivalenol results in increased expression of CLDN2 mRNA

NCBI chr X:108,248,383...108,258,847
Ensembl chr X:108,237,676...108,262,377

G

claudin 3

multiple interactions
increases expression
affects expression

ISO

deoxynivalenol results in decreased expression of and affects the localization of CLDN3 protein
[deoxynivalenol results in increased susceptibility to Antigens] which results in decreased expression of CLDN3 mRNA
deoxynivalenol results in increased expression of CLDN3 mRNA
deoxynivalenol affects the expression of CLDN3 protein

PMID:24568843 PMID:28935500

NCBI chr12:27,345,075...27,346,547
Ensembl chr12:27,345,076...27,348,841

G

claudin 4

decreases expression
increases expression
multiple interactions

ISO

deoxynivalenol results in decreased expression of CLDN4 protein
deoxynivalenol results in increased expression of CLDN4 mRNA
deoxynivalenol results in decreased expression of and affects the localization of CLDN4 protein

PMID:19289138 PMID:20362602 PMID:24568843

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958

G

chloride intracellular channel 3

decreases expression

ISO

deoxynivalenol results in decreased expression of CLIC3 mRNA

NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723

G

clock circadian regulator

multiple interactions
decreases expression

ISO

BMAL1 protein promotes the reaction [deoxynivalenol results in decreased expression of CLOCK protein]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CLOCK mRNA]

NCBI chr14:32,262,747...32,346,872
Ensembl chr14:32,262,750...32,346,872

G

CLPTM1 regulator of GABA type A receptor forward trafficking

decreases expression

ISO

deoxynivalenol results in decreased expression of CLPTM1 protein

NCBI chr 1:88,417,447...88,449,047
Ensembl chr 1:88,417,447...88,449,446

G

clusterin

decreases expression

ISO

deoxynivalenol results in decreased expression of CLU protein

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

cornichon family member 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CNIH1 protein

NCBI chr15:22,517,755...22,529,651
Ensembl chr15:22,497,340...22,529,578

G

canopy FGF signaling regulator 2

decreases expression

ISO

deoxynivalenol results in decreased expression of CNPY2 mRNA

NCBI chr 7:1,332,293...1,338,081
Ensembl chr 7:1,334,335...1,340,333

G

collagen type XV alpha 1 chain

decreases expression

ISO

deoxynivalenol results in decreased expression of COL15A1 mRNA

NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170

G

collagen type XVIII alpha 1 chain

decreases expression

ISO

deoxynivalenol results in decreased expression of COL18A1 protein

NCBI chr20:11,473,645...11,582,111
Ensembl chr20:11,473,645...11,582,112

G

collagen type IV alpha 1 chain

decreases expression

ISO

deoxynivalenol results in decreased expression of COL4A1 mRNA

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

collagen type V alpha 1 chain

decreases expression

ISO

deoxynivalenol results in decreased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type VI alpha 2 chain

decreases expression

ISO

deoxynivalenol results in decreased expression of COL6A2 mRNA

NCBI chr20:12,021,182...12,048,932
Ensembl chr20:12,021,265...12,057,042

G

catechol-O-methyltransferase

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of COMT protein

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

COPI coat complex subunit beta 2

decreases expression

ISO

deoxynivalenol results in decreased expression of COPB2 protein

NCBI chr 8:108,040,687...108,062,810
Ensembl chr 8:108,040,693...108,064,550

G

coenzyme Q8A

decreases expression

ISO

deoxynivalenol results in decreased expression of COQ8A protein

NCBI chr13:94,436,680...94,465,535
Ensembl chr13:94,436,546...94,463,378

G

coronin 1A

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of CORO1A protein

NCBI chr 1:190,726,129...190,731,133
Ensembl chr 1:190,726,130...190,731,102

G

coronin 2A

decreases expression

ISO

deoxynivalenol results in decreased expression of CORO2A protein

NCBI chr 5:65,623,820...65,677,483
Ensembl chr 5:65,623,823...65,654,602

G

coronin 2B

decreases expression

ISO

deoxynivalenol results in decreased expression of CORO2B mRNA

NCBI chr 8:71,802,329...71,912,739
Ensembl chr 8:71,802,329...71,912,739

G

cytochrome c oxidase subunit 5B

decreases expression

ISO

deoxynivalenol results in decreased expression of COX5B protein

NCBI chr 9:46,417,735...46,419,664
Ensembl chr 9:46,417,838...46,420,403

G

carboxypeptidase D

decreases expression

ISO

deoxynivalenol results in decreased expression of CPD protein

NCBI chr10:62,121,681...62,185,638
Ensembl chr10:62,121,679...62,185,638

G

cleavage and polyadenylation specific factor 2

increases expression

ISO

deoxynivalenol results in increased expression of CPSF2 mRNA

NCBI chr 6:126,885,417...126,917,634
Ensembl chr 6:126,885,476...126,917,632

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation
increases activity
affects localization

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; AKT1 protein affects the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; deoxynivalenol promotes the reaction [CREB1 protein modified form binds to IL6 promoter]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol promotes the reaction [CREB1 protein modified form binds to IL6 promoter]]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased activity of CREB1 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]
deoxynivalenol affects the localization of CREB1 protein

PMID:12604842 PMID:16424113 PMID:32416088

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

cAMP responsive element binding protein 5

increases expression

ISO

deoxynivalenol results in increased expression of CREB5 mRNA

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793

G

CREB binding protein

increases expression

ISO

deoxynivalenol results in increased expression of CREBBP mRNA

NCBI chr10:11,842,307...11,968,266
Ensembl chr10:11,822,620...11,968,266

G

cysteine-rich with EGF-like domains 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CRELD1 mRNA

NCBI chr 4:148,187,510...148,197,120
Ensembl chr 4:148,187,265...148,197,116

G

C-reactive protein

increases expression

ISO

deoxynivalenol results in increased expression of CRP mRNA

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

cryptochrome circadian regulator 1

multiple interactions

ISO

deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY1 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY1 protein]

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

cryptochrome circadian regulator 2

multiple interactions

ISO

deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY2 mRNA]; deoxynivalenol inhibits the reaction [BMAL1 protein results in increased expression of CRY2 protein]

NCBI chr 3:98,830,479...98,860,437
Ensembl chr 3:98,830,483...98,860,447

G

crystallin, lambda 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CRYL1 protein

NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563

G

cold shock domain containing E1

increases expression

ISO

deoxynivalenol results in increased expression of CSDE1 protein

NCBI chr 2:193,234,546...193,271,301
Ensembl chr 2:193,243,526...193,271,301

G

colony stimulating factor 3

increases expression

ISO

deoxynivalenol results in increased expression of CSF3 mRNA

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

collagen triple helix repeat containing 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CTHRC1 mRNA

NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654

G

catenin alpha 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CTNNA1 protein

NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,999,820...27,135,007

G

catenin beta 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of CTNNB1 protein

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin D

decreases expression

ISO

deoxynivalenol results in decreased expression of CTSD protein

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

cathepsin O

decreases expression

ISO

deoxynivalenol results in decreased expression of CTSO mRNA

NCBI chr 2:169,528,468...169,551,975
Ensembl chr 2:169,528,511...169,554,995

G

CWF19 like cell cycle control factor 2

increases expression

ISO

deoxynivalenol results in increased expression of CWF19L2 mRNA

NCBI chr 6:6,036,158...6,102,686
Ensembl chr 6:6,026,861...6,102,635

G

C-X3-C motif chemokine ligand 1

increases expression

ISO

deoxynivalenol results in increased expression of CX3CL1 mRNA

NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999

G

C-X-C motif chemokine ligand 1

multiple interactions
increases expression

ISO

[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]

PMID:22003189 PMID:27757495

NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811

G

C-X-C motif chemokine ligand 10

decreases expression
increases expression

ISO

deoxynivalenol results in decreased expression of CXCL10 mRNA
deoxynivalenol results in increased expression of CXCL10 mRNA; deoxynivalenol results in increased expression of CXCL10 protein

PMID:15371230 PMID:22968694 PMID:34400200

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine ligand 11

decreases expression
increases expression

ISO

deoxynivalenol results in decreased expression of CXCL11 mRNA
deoxynivalenol results in increased expression of CXCL11 mRNA

PMID:22968694 PMID:27757495

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567

G

C-X-C motif chemokine ligand 2

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CXCL2 mRNA; deoxynivalenol results in increased expression of CXCL2 protein
deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]; Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of CXCL2 mRNA]

PMID:12604170 PMID:15371230 PMID:15681167 PMID:22968694 PMID:24793808 More...

NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255

G

C-X-C motif chemokine ligand 3

multiple interactions
increases expression

ISO

[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA; [Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] promotes the reaction [deoxynivalenol results in increased expression of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]
deoxynivalenol results in increased expression of CXCL1 mRNA; deoxynivalenol results in increased expression of CXCL3 mRNA

PMID:15371230 PMID:15681167 PMID:22003189 PMID:22968694 PMID:27757495

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine ligand 9

increases expression

ISO

deoxynivalenol results in increased expression of CXCL9 mRNA

NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299

G

C-X-C motif chemokine receptor 1

increases expression

ISO

deoxynivalenol results in increased expression of CXCR1 mRNA

NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872

G

C-X-C motif chemokine receptor 2

increases expression

ISO

deoxynivalenol results in increased expression of CXCR2 mRNA

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

C-X-C motif chemokine receptor 4

increases expression

ISO

deoxynivalenol results in increased expression of CXCR4 mRNA

PMID:22846391 PMID:27757495

NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459

G

cytochrome c-1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYC1 protein

NCBI chr 7:109,947,750...109,950,142
Ensembl chr 7:109,947,766...109,950,657

G

cytochrome c, somatic

affects localization
multiple interactions
increases expression
decreases expression
increases activity

ISO

deoxynivalenol affects the localization of CYCS protein
[deoxynivalenol co-treated with Aflatoxin B1] results in increased expression of CYCS protein
deoxynivalenol results in increased expression of CYCS mRNA; deoxynivalenol results in increased expression of CYCS protein
deoxynivalenol results in decreased expression of CYCS protein
deoxynivalenol results in increased activity of CYCS protein

PMID:15976193 PMID:22269384 PMID:22846391 PMID:38763499

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily b, polypeptide 2

increases expression

ISO

deoxynivalenol results in increased expression of CYP11B1 mRNA

NCBI chr 7:108,719,349...108,726,024
Ensembl chr 7:108,719,349...108,725,763

G

cytochrome P450, family 11, subfamily b, polypeptide 3

increases expression

ISO

deoxynivalenol results in increased expression of CYP11B2 mRNA

NCBI chr 7:108,689,319...108,694,808
Ensembl chr 7:108,689,165...108,694,921

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression

ISO

deoxynivalenol results in increased expression of CYP17A1 mRNA

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP19A1 mRNA

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of CYP1A1 mRNA
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of CYP1A1 mRNA]

PMID:22982764 PMID:35381244

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP27A1 protein

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases expression

ISO

deoxynivalenol results in increased expression of CYP2E1 mRNA; deoxynivalenol results in increased expression of CYP2E1 protein

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily w, polypeptide 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP2W1 protein

NCBI chr12:20,405,400...20,410,282
Ensembl chr12:20,405,400...20,410,282

G

cytochrome P450, family 3, subfamily a, polypeptide 2

affects expression
multiple interactions

ISO

deoxynivalenol affects the expression of CYP3A4 mRNA
[deoxynivalenol co-treated with Zearalenone] affects the expression of CYP3A4 mRNA; [deoxynivalenol co-treated with Zearalenone] results in decreased expression of CYP3A4 protein; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CYP3A4 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CYP3A4 protein

PMID:28865950 PMID:28935499

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 4, subfamily f, polypeptide 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP4F12 protein

NCBI chr 7:12,661,357...12,672,952
Ensembl chr 7:12,661,359...12,672,612

G

cytochrome P450, family 4, subfamily f, polypeptide 18

multiple interactions

ISO

[deoxynivalenol co-treated with Zearalenone] results in decreased expression of CYP4F3 mRNA; [deoxynivalenol co-treated with Zearalenone] results in increased expression of CYP4F3 mRNA

PMID:28865950 PMID:28935499

NCBI chr16:17,797,558...17,838,958
Ensembl chr16:17,740,001...17,838,958

G

cytochrome P450, family 51

decreases expression

ISO

deoxynivalenol results in decreased expression of CYP51A1 protein

NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450

G

cytokine like 1

decreases expression

ISO

deoxynivalenol results in decreased expression of CYTL1 mRNA

NCBI chr14:77,278,635...77,283,645
Ensembl chr14:77,278,636...77,283,645

G

dystroglycan 1

decreases expression

ISO

deoxynivalenol results in decreased expression of DAG1 protein

NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199

G

diazepam binding inhibitor

decreases expression

ISO

deoxynivalenol results in decreased expression of DBI protein

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450

G

DDB1 and CUL4 associated factor 13

increases expression

ISO

deoxynivalenol results in increased expression of DCAF13 protein

NCBI chr 7:72,045,828...72,081,039
Ensembl chr 7:72,045,872...72,083,629

G

damage specific DNA binding protein 2

increases expression

ISO

deoxynivalenol results in increased expression of DDB2 mRNA

NCBI chr 3:97,640,923...97,667,617
Ensembl chr 3:97,640,579...97,664,066

G

DNA-damage inducible transcript 3

increases expression
decreases expression

ISO

deoxynivalenol results in increased expression of DDIT3 mRNA
deoxynivalenol results in decreased expression of DDIT3 mRNA

PMID:22846391 PMID:23253260 PMID:30169763

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DNA-damage-inducible transcript 4

decreases expression

ISO

deoxynivalenol results in decreased expression of DDIT4 mRNA

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

DDRGK domain containing 1

increases expression

ISO

deoxynivalenol results in increased expression of DDRGK1 protein

NCBI chr 3:138,315,006...138,336,691
Ensembl chr 3:138,315,282...138,335,766

G

DEAD-box helicase 17

increases expression

ISO

deoxynivalenol results in increased expression of DDX17 protein

NCBI chr 7:112,971,522...112,989,747
Ensembl chr 7:112,971,523...112,989,747

G

DEAD-box helicase 18

increases expression

ISO

deoxynivalenol results in increased expression of DDX18 protein

NCBI chr13:35,282,391...35,296,038
Ensembl chr13:35,282,467...35,295,972

G

DExD-box helicase 21

decreases phosphorylation
increases expression

ISO

deoxynivalenol results in decreased phosphorylation of DDX21 protein
deoxynivalenol results in increased expression of DDX21 protein

PMID:23352502 PMID:23811945 PMID:39638853

NCBI chr20:31,077,044...31,097,238
Ensembl chr20:31,077,045...31,097,238

G

DEAD-box helicase 24

increases expression

ISO

deoxynivalenol results in increased expression of DDX24 protein

NCBI chr 6:128,329,554...128,346,818
Ensembl chr 6:128,329,554...128,349,625

G

DEAD-box helicase 27

increases expression

ISO

deoxynivalenol results in increased expression of DDX27 protein

NCBI chr 3:176,163,220...176,182,418
Ensembl chr 3:176,163,203...176,182,410

G

DExD-box helicase 39A

increases expression

ISO

deoxynivalenol results in increased expression of DDX39A mRNA

NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306

G

DEAD-box helicase 42

increases expression

ISO

deoxynivalenol results in increased expression of DDX42 protein

NCBI chr10:91,648,719...91,680,730
Ensembl chr10:91,648,248...91,680,729

G

DEAD-box helicase 46

increases expression

ISO

deoxynivalenol results in increased expression of DDX46 protein

NCBI chr17:8,947,237...8,993,705
Ensembl chr17:8,947,237...8,990,247

G

DEAD-box helicase 5

increases expression

ISO

deoxynivalenol results in increased expression of DDX5 protein

NCBI chr10:92,224,393...92,231,928
Ensembl chr10:92,224,395...92,231,300

G

DExD-box helicase 50

increases expression

ISO

deoxynivalenol results in increased expression of DDX50 protein

NCBI chr20:31,104,354...31,133,652
Ensembl chr20:31,104,354...31,133,652

G

DExD-box helicase 52

increases expression

ISO

deoxynivalenol results in increased expression of DDX52 mRNA

NCBI chr10:69,322,062...69,344,856
Ensembl chr10:69,322,114...69,428,714

G

DEAD-box helicase 54

increases expression

ISO

deoxynivalenol results in increased expression of DDX54 protein

NCBI chr12:41,595,298...41,610,560
Ensembl chr12:41,595,555...41,611,053

G

DEAD-box helicase 56

increases expression

ISO

deoxynivalenol results in increased expression of DDX56 protein

NCBI chr14:85,325,942...85,336,262
Ensembl chr14:85,325,942...85,336,262

G

DEP domain containing MTOR-interacting protein

decreases expression

ISO

deoxynivalenol results in decreased expression of DEPTOR mRNA

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

DNA fragmentation factor subunit alpha

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of DFFA protein

NCBI chr 5:164,823,807...164,836,729
Ensembl chr 5:164,823,807...164,836,728

G

diacylglycerol kinase, gamma

multiple interactions

ISO

[Selenomethionine co-treated with deoxynivalenol] results in increased expression of DGKG mRNA

NCBI chr11:91,888,957...92,083,715
Ensembl chr11:91,888,782...92,082,105

G

diacylglycerol kinase, iota

multiple interactions

ISO

[Selenomethionine co-treated with deoxynivalenol] results in increased expression of DGKI mRNA

NCBI chr 4:66,377,897...66,839,790
Ensembl chr 4:66,387,126...66,990,832

G

dehydrogenase/reductase 2

decreases expression

ISO

deoxynivalenol results in decreased expression of DHRS2 protein

NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588

G

DEAH-box helicase 33

increases expression

ISO

deoxynivalenol results in increased expression of DHX33 protein

NCBI chr10:56,206,680...56,223,189
Ensembl chr10:56,206,680...56,223,143

G

DEAH-box helicase 37

increases expression

ISO

deoxynivalenol results in increased expression of DHX37 protein

NCBI chr12:36,856,119...36,876,245
Ensembl chr12:36,849,701...36,876,240

G

diablo, IAP-binding mitochondrial protein

increases expression

ISO

deoxynivalenol results in increased expression of DIABLO protein

NCBI chr12:38,716,668...38,731,285
Ensembl chr12:38,716,668...38,731,265

G

DIM1 rRNA methyltransferase and ribosome maturation factor

increases expression

ISO

deoxynivalenol results in increased expression of DIMT1 protein

NCBI chr 2:40,076,622...40,101,792
Ensembl chr 2:40,076,570...40,101,787

G

dyskerin pseudouridine synthase 1

decreases phosphorylation
increases expression

ISO

deoxynivalenol results in decreased phosphorylation of DKC1 protein
deoxynivalenol results in increased expression of DKC1 protein

PMID:23811945 PMID:39638853

NCBI chr  X:157,751,651...157,757,796
Ensembl chr  Y:380,743...385,405
Ensembl chr  X:380,743...385,405

G

dynein, axonemal, heavy chain 10

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of DNAH10 protein

NCBI chr12:37,484,444...37,607,810
Ensembl chr12:37,472,813...37,640,860

G

DnaJ heat shock protein family (Hsp40) member A1

increases expression
decreases expression

ISO

deoxynivalenol results in increased expression of DNAJA1 mRNA
deoxynivalenol results in decreased expression of DNAJA1 protein

PMID:15371230 PMID:33890134

NCBI chr 5:60,638,404...60,649,315
Ensembl chr 5:60,638,410...60,650,160

G

DnaJ heat shock protein family (Hsp40) member C1

increases expression

ISO

deoxynivalenol results in increased expression of DNAJC1 mRNA

NCBI chr17:85,863,651...86,020,954
Ensembl chr17:85,863,651...86,020,432

G

DnaJ heat shock protein family (Hsp40) member C3

multiple interactions
decreases expression

ISO

deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DNAJC3 mRNA]
deoxynivalenol results in decreased expression of DNAJC3 mRNA

NCBI chr15:102,432,667...102,475,643
Ensembl chr15:102,432,663...102,475,643

G

DnaJ heat shock protein family (Hsp40) member C5

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of DNAJC5 protein

NCBI chr 3:188,999,508...189,033,455
Ensembl chr 3:188,999,470...189,034,089

G

DnaJ heat shock protein family (Hsp40) member C7

increases expression

ISO

deoxynivalenol results in increased expression of DNAJC7 protein

NCBI chr10:86,018,977...86,055,419
Ensembl chr10:86,018,961...86,055,489

G

DNA methyltransferase 1

affects phosphorylation
increases expression

ISO
EXP

deoxynivalenol affects the phosphorylation of DNMT1 protein
deoxynivalenol results in increased expression of DNMT1 mRNA; deoxynivalenol results in increased expression of DNMT1 protein

PMID:23352502 PMID:23811945 PMID:32738333

NCBI chr 8:27,716,797...27,763,405
Ensembl chr 8:27,716,797...27,763,119

G

DNA methyltransferase 3 alpha

increases expression

EXP

deoxynivalenol results in increased expression of DNMT3A mRNA; deoxynivalenol results in increased expression of DNMT3A protein

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

deoxynucleotidyltransferase, terminal, interacting protein 2

increases expression

ISO

deoxynivalenol results in increased expression of DNTTIP2 mRNA; deoxynivalenol results in increased expression of DNTTIP2 protein

PMID:31863870 PMID:39638853

NCBI chr 2:213,058,975...213,071,020
Ensembl chr 2:213,058,962...213,071,016

G

dipeptidase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of DPEP1 protein

NCBI chr19:68,118,270...68,143,781
Ensembl chr19:68,118,453...68,143,775

G

dihydropyrimidinase-like 2

decreases expression

ISO

deoxynivalenol results in decreased expression of DPYSL2 protein

NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065

G

desmocollin 1

increases expression

ISO

deoxynivalenol results in increased expression of DSC1 protein

NCBI chr18:11,774,711...11,831,868
Ensembl chr18:11,775,010...11,803,522

G

dual specificity phosphatase 1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of DUSP1 mRNA; deoxynivalenol results in increased expression of DUSP1 protein
Fatty Acids, Omega-3 promotes the reaction [deoxynivalenol results in increased expression of DUSP1 mRNA]
[deoxynivalenol results in increased expression of DUSP1 protein] which results in decreased activity of MAPK8 protein; [deoxynivalenol results in increased expression of DUSP1 protein] which results in decreased activity of MAPK9 protein

PMID:15371230 PMID:15681167 PMID:20708668

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 6

decreases expression

ISO

deoxynivalenol results in decreased expression of DUSP6 mRNA

NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833

G

dual specificity phosphatase 8

increases expression

ISO

deoxynivalenol results in increased expression of DUSP8 mRNA

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

dual specificity phosphatase 9

decreases expression

ISO

deoxynivalenol results in decreased expression of DUSP9 protein

NCBI chr X:156,503,237...156,507,162
Ensembl chr X:156,503,190...156,507,161

G

dynein cytoplasmic 1 light intermediate chain 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of DYNC1LI1 protein

NCBI chr 8:123,254,823...123,288,496
Ensembl chr 8:123,254,859...123,289,167

G

EBNA1 binding protein 2

increases expression

ISO

deoxynivalenol results in increased expression of EBNA1BP2 protein

NCBI chr 5:137,433,534...137,438,100
Ensembl chr 5:137,433,226...137,438,637

G

endothelin converting enzyme 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ECE1 protein

NCBI chr 5:155,361,031...155,462,723
Ensembl chr 5:155,360,639...155,462,719

G

enoyl-CoA delta isomerase 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ECI2 protein

NCBI chr17:30,056,274...30,092,169
Ensembl chr17:30,076,524...30,092,161

G

extracellular matrix protein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ECM1 mRNA

NCBI chr 2:185,976,439...185,981,656
Ensembl chr 2:185,976,440...185,981,606

G

epithelial cell transforming 2

increases expression

ISO

deoxynivalenol results in increased expression of ECT2 mRNA

NCBI chr 2:111,904,522...111,966,786
Ensembl chr 2:111,904,522...111,966,626

G

endothelial differentiation-related factor 1

increases expression

ISO

deoxynivalenol results in increased expression of EDF1 protein

NCBI chr 3:28,764,906...28,779,499

G

early endosome antigen 1

increases expression

ISO

deoxynivalenol results in increased expression of EEA1 protein

NCBI chr 7:32,441,281...32,608,808
Ensembl chr 7:32,441,272...32,608,476

G

eukaryotic translation elongation factor 1 beta 2

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of EEF1B2 protein

NCBI chr 9:72,074,091...72,076,591
Ensembl chr 9:72,073,802...72,076,589

G

eukaryotic translation elongation factor 1 delta

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of EEF1D protein

NCBI chr 7:109,462,645...109,478,021
Ensembl chr 7:109,462,646...109,489,531

G

epidermal growth factor

increases expression

ISO

deoxynivalenol results in increased expression of EGF mRNA

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

decreases expression

ISO

deoxynivalenol results in decreased expression of EGFR protein

PMID:33890134 PMID:39638853

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

increases expression
multiple interactions

ISO

[deoxynivalenol results in increased expression of EGR1 protein] which results in increased expression of CXCL8 protein; deoxynivalenol results in increased expression of EGR1 mRNA; deoxynivalenol results in increased expression of EGR1 protein
ATF3 protein affects the reaction [deoxynivalenol results in increased expression of EGR1 protein]; deoxynivalenol results in increased expression of and results in increased phosphorylation of EGR1 protein; EGR1 protein affects the reaction [deoxynivalenol results in increased expression of CDKN1A protein]; EGR1 protein promotes the reaction [deoxynivalenol results in increased expression of PPARG mRNA]

PMID:17707346 PMID:18485432 PMID:19360757 PMID:30286430 PMID:33890134

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

EH-domain containing 1

decreases expression

ISO

deoxynivalenol results in decreased expression of EHD1 protein

NCBI chr 1:213,009,113...213,031,488
Ensembl chr 1:213,008,049...213,031,485

G

EP300 interacting inhibitor of differentiation 2

increases expression

ISO

deoxynivalenol results in increased expression of EID2 mRNA

NCBI chr 1:92,665,837...92,667,162
Ensembl chr 1:92,665,481...92,675,307

G

eukaryotic translation initiation factor 1

increases expression

ISO

deoxynivalenol results in increased expression of EIF1 protein

NCBI chr10:85,747,064...85,749,447
Ensembl chr 5:25,895,968...25,896,654
Ensembl chr10:25,895,968...25,896,654

G

eukaryotic translation initiation factor 2A

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of EIF2A protein

NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:144,911,153...144,945,201

G

eukaryotic translation initiation factor 2-alpha kinase 2

decreases expression
affects response to substance
multiple interactions

ISO

deoxynivalenol results in decreased expression of EIF2AK2 mRNA
EIF2AK2 protein affects the susceptibility to deoxynivalenol
EIF2AK2 protein affects the reaction [deoxynivalenol results in increased activity of RELA protein]; EIF2AK2 protein affects the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]

PMID:17090620 PMID:18599499 PMID:22491426

NCBI chr 6:21,941,147...21,977,115
Ensembl chr 6:21,952,631...21,977,116

G

eukaryotic translation initiation factor 2B subunit delta

increases expression

ISO

deoxynivalenol results in increased expression of EIF2B4 mRNA

NCBI chr 6:30,903,148...30,908,803
Ensembl chr 6:30,903,219...30,908,800

G

eukaryotic translation initiation factor 2 subunit beta

affects expression

ISO

deoxynivalenol affects the expression of EIF2S2 mRNA

NCBI chr 3:163,834,846...163,855,733
Ensembl chr 3:163,834,851...163,855,570

G

eukaryotic translation initiation factor 3, subunit A

increases expression

ISO

deoxynivalenol results in increased expression of EIF3A protein

NCBI chr 1:269,888,730...269,925,785
Ensembl chr 1:269,888,615...269,919,025

G

eukaryotic translation initiation factor 3, subunit B

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of EIF3B protein
deoxynivalenol results in increased expression of EIF3B protein

PMID:23811945 PMID:39638853

NCBI chr12:19,310,308...19,334,768
Ensembl chr12:19,310,311...19,334,939

G

eukaryotic translation initiation factor 3, subunit C

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of EIF3C protein

NCBI chr 1:190,565,183...190,583,067
Ensembl chr 1:190,565,184...190,583,067

G

eukaryotic translation initiation factor 3, subunit D

increases expression

ISO

deoxynivalenol results in increased expression of EIF3D protein

NCBI chr 7:111,420,351...111,432,761
Ensembl chr 7:111,420,351...111,432,740

G

eukaryotic translation initiation factor 3 subunit E

increases expression

ISO

deoxynivalenol results in increased expression of EIF3E protein

NCBI chr 7:76,224,567...76,257,346
Ensembl chr 7:76,224,568...76,257,785

G

eukaryotic translation initiation factor 3, subunit F

increases expression

ISO

deoxynivalenol results in increased expression of EIF3F protein

NCBI chr 1:172,369,062...172,378,043
Ensembl chr 1:172,369,062...172,378,041

G

eukaryotic translation initiation factor 3, subunit I

increases expression

ISO

deoxynivalenol results in increased expression of EIF3I protein

NCBI chr 5:147,219,457...147,226,910
Ensembl chr 5:147,219,366...147,241,232

G

eukaryotic translation initiation factor 3, subunit J

increases expression

ISO

deoxynivalenol results in increased expression of EIF3J protein

NCBI chr 3:129,438,715...129,460,953
Ensembl chr 3:129,438,722...129,462,246

G

eukaryotic translation initiation factor 4A3

increases expression

ISO

deoxynivalenol results in increased expression of EIF4A3 protein

NCBI chr10:105,047,567...105,057,561
Ensembl chr10:105,047,568...105,058,207

G

eukaryotic translation initiation factor 4E binding protein 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of EIF4EBP1 protein

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 4 gamma 1

increases phosphorylation
increases expression

ISO

deoxynivalenol results in increased phosphorylation of EIF4G1 protein
deoxynivalenol results in increased expression of EIF4G1 protein

PMID:23352502 PMID:39638853

NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367

G

eukaryotic translation initiation factor 4, gamma 2

increases expression

ISO

deoxynivalenol results in increased expression of EIF4G2 protein

NCBI chr 1:174,616,102...174,628,252
Ensembl chr 1:174,616,103...174,628,252

G

eukaryotic translation initiation factor 5B

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of EIF5B protein
deoxynivalenol results in increased expression of EIF5B protein

PMID:23811945 PMID:39638853

NCBI chr 9:47,718,706...47,773,289
Ensembl chr 9:47,718,706...47,778,583

G

eukaryotic translation initiation factor 6

increases expression

ISO

deoxynivalenol results in increased expression of EIF6 protein

NCBI chr 3:164,785,162...164,791,410
Ensembl chr 3:164,785,163...164,791,525

G

ELAV like RNA binding protein 1

multiple interactions

ISO

[[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which affects the localization of ELAVL1 protein] which co-treated with deoxynivalenol] promotes the reaction [[ELAVL1 protein binds to ATF3 3' UTR] which results in increased stability of ATF3 mRNA]; [[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] affects the localization of ELAVL1 protein; [deoxynivalenol results in increased expression of ELAVL1 protein] which results in decreased degradation of CXCL8 mRNA; deoxynivalenol results in increased expression of and results in increased localization of ELAVL1 protein; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL1 mRNA]; ELAVL1 protein affects the reaction [[[Acetylmuramyl-Alanyl-Isoglutamine binds to and results in increased activity of NOD2 protein] which co-treated with deoxynivalenol] results in increased stability of CXCL8 mRNA]; ELAVL1 protein affects the reaction [deoxynivalenol results in increased expression of CXCL8 mRNA]; ELAVL1 protein affects the reaction [deoxynivalenol results in increased expression of CXCL8 protein]

PMID:19591856 PMID:22003189

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

ETS transcription factor ELK1

increases expression

ISO

deoxynivalenol results in increased expression of ELK1 protein

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

ER membrane protein complex subunit 10

decreases expression

ISO

deoxynivalenol results in decreased expression of EMC10 mRNA

NCBI chr 1:104,119,040...104,125,409
Ensembl chr 1:104,119,040...104,125,368

G

EMG1 N1-specific pseudouridine methyltransferase

increases expression

ISO

deoxynivalenol results in increased expression of EMG1 protein

NCBI chr 4:159,195,545...159,203,826
Ensembl chr 4:159,195,564...159,203,826

G

elastin microfibril interfacer 1

decreases expression

ISO

deoxynivalenol results in decreased expression of EMILIN1 mRNA

NCBI chr 6:31,175,919...31,183,657
Ensembl chr 6:31,175,919...31,183,657

G

endoglin

decreases expression

ISO

deoxynivalenol results in decreased expression of ENG mRNA

NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933

G

endo-beta-N-acetylglucosaminidase

increases expression

ISO

deoxynivalenol results in increased expression of ENGASE mRNA

NCBI chr10:104,205,753...104,218,416
Ensembl chr10:104,205,752...104,218,411

G

enolase 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ENO2 protein

NCBI chr 4:159,258,371...159,267,220
Ensembl chr 4:159,258,371...159,267,220

G

E1A binding protein p300

multiple interactions
increases expression

ISO

EP300 protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]
deoxynivalenol results in increased expression of EP300 protein

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

E1A binding protein p400

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of EP400 protein

NCBI chr12:51,551,665...51,658,635
Ensembl chr12:51,551,695...51,658,634

G

erythrocyte membrane protein band 4.1-like 2

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of EPB41L2 protein

NCBI chr 1:21,682,336...21,857,106
Ensembl chr 1:21,682,335...21,857,105

G

Eph receptor A2

increases expression

ISO

deoxynivalenol results in increased expression of EPHA2 protein

NCBI chr 5:158,888,629...158,917,100
Ensembl chr 5:158,888,629...158,917,234

G

epoxide hydrolase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of EPHX1 mRNA
deoxynivalenol results in decreased expression of EPHX1 protein

PMID:15371230 PMID:39638853

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

epiplakin 1

decreases expression

ISO

deoxynivalenol results in decreased expression of EPPK1 protein

NCBI chr 7:109,697,607...109,718,468
Ensembl chr 7:109,697,607...109,718,468

G

endoplasmic reticulum to nucleus signaling 1

decreases expression
increases expression

ISO

deoxynivalenol results in decreased expression of ERN1 mRNA
deoxynivalenol results in increased expression of ERN1 protein

PMID:19336499 PMID:20682335

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

ESF1 nucleolar pre-rRNA processing protein homolog

increases expression

ISO

deoxynivalenol results in increased expression of ESF1 protein

NCBI chr 3:147,908,405...147,961,567
Ensembl chr 3:147,908,405...147,961,485

G

estrogen receptor 1

multiple interactions
increases phosphorylation

ISO

ESR1 promotes the reaction [deoxynivalenol results in increased expression of PGR mRNA]; ESR1 promotes the reaction [deoxynivalenol results in increased expression of TFF1 mRNA]
deoxynivalenol results in increased phosphorylation of ESR1 protein

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

ethanolamine kinase 1

increases expression

ISO

deoxynivalenol results in increased expression of ETNK1 mRNA

NCBI chr 4:177,857,001...177,901,278
Ensembl chr 4:177,856,960...177,924,721

G

ecotropic viral integration site 2A

increases expression

ISO

deoxynivalenol results in increased expression of EVI2A mRNA

NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516

G

Enah/Vasp-like

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of EVL protein

NCBI chr 6:133,238,547...133,358,730
Ensembl chr 6:133,238,547...133,358,729

G

exosome component 1

increases expression

ISO

deoxynivalenol results in increased expression of EXOSC1 protein

NCBI chr 1:250,684,746...250,694,748
Ensembl chr 1:250,684,750...250,694,748

G

exosome component 10

increases expression

ISO

deoxynivalenol results in increased expression of EXOSC10 protein

NCBI chr 5:164,278,414...164,302,067
Ensembl chr 5:164,278,440...164,302,067

G

exosome component 2

increases expression

ISO

deoxynivalenol results in increased expression of EXOSC2 mRNA; deoxynivalenol results in increased expression of EXOSC2 protein

PMID:24247028 PMID:39638853

NCBI chr 3:35,360,652...35,370,948
Ensembl chr 3:35,360,666...35,371,373

G

exosome component 4

increases expression

ISO

deoxynivalenol results in increased expression of EXOSC4 protein

NCBI chr 7:109,928,491...109,931,233
Ensembl chr 7:109,928,498...109,931,820

G

exosome component 7

increases expression

ISO

deoxynivalenol results in increased expression of EXOSC7 protein

NCBI chr 8:131,650,988...131,676,399
Ensembl chr 8:131,651,050...131,696,825

G

F11 receptor

decreases expression

ISO

deoxynivalenol results in decreased expression of F11R protein

NCBI chr13:86,406,229...86,429,819
Ensembl chr13:86,406,218...86,429,816

G

coagulation factor II, thrombin

decreases expression

ISO

deoxynivalenol results in decreased expression of F2 protein

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor III, tissue factor

decreases expression

ISO

deoxynivalenol results in decreased expression of F3 mRNA

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

fatty acid binding protein 3

decreases expression

ISO

deoxynivalenol results in decreased expression of FABP3 mRNA

NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881

G

fatty acid binding protein 4

decreases expression

ISO

deoxynivalenol results in decreased expression of FABP4 mRNA

NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972

G

fatty acid binding protein 6

decreases expression

ISO

deoxynivalenol results in decreased expression of FABP6 mRNA

NCBI chr10:28,565,054...28,569,727
Ensembl chr10:28,565,054...28,573,058

G

fatty acid desaturase 2

decreases expression

ISO

deoxynivalenol results in decreased expression of FADS2 protein

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

family with sequence similarity 169, member A

decreases expression

ISO

deoxynivalenol results in decreased expression of FAM169A protein

NCBI chr 2:30,115,307...30,175,972
Ensembl chr 2:30,119,381...30,175,962

G

family with sequence similarity 83, member D

increases expression

ISO

deoxynivalenol results in increased expression of FAM83D mRNA

NCBI chr 3:167,841,748...167,861,062
Ensembl chr 3:167,841,791...167,861,061

G

Fas cell surface death receptor

multiple interactions
increases expression

EXP

Bentonite inhibits the reaction [deoxynivalenol results in increased expression of FAS protein]; Charcoal inhibits the reaction [deoxynivalenol results in increased expression of FAS protein]
deoxynivalenol results in increased expression of FAS mRNA

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

increases expression

ISO

deoxynivalenol results in increased expression of FASL mRNA

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fatty acid synthase

decreases expression

ISO

deoxynivalenol results in decreased expression of FASN protein

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAST kinase domains 2

increases expression

ISO

deoxynivalenol results in increased expression of FASTKD2 mRNA; deoxynivalenol results in increased expression of FASTKD2 protein

PMID:31863870 PMID:39638853

NCBI chr 9:72,659,961...72,681,986
Ensembl chr 9:72,661,764...72,721,338

G

fibrillarin

increases expression

ISO

deoxynivalenol results in increased expression of FBL protein

NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506

G

F-box protein 2

decreases expression

ISO

deoxynivalenol results in decreased expression of FBXO2 protein

NCBI chr 5:163,876,079...163,881,508
Ensembl chr 5:163,875,757...163,881,508

G

F-box protein 22

increases expression

ISO

deoxynivalenol results in increased expression of FBXO22 mRNA

NCBI chr 8:64,476,034...64,492,063
Ensembl chr 8:64,475,957...64,492,062

G

F-box protein 28

increases expression

ISO

deoxynivalenol results in increased expression of FBXO28 mRNA

NCBI chr13:96,527,667...96,553,138
Ensembl chr13:96,527,670...96,553,138

G

Fc gamma receptor and transporter

decreases expression

ISO

deoxynivalenol results in decreased expression of FCGRT protein

NCBI chr 1:104,710,902...104,720,685
Ensembl chr 1:104,710,909...104,720,532

G

farnesyl diphosphate farnesyl transferase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FDFT1 protein

PMID:33890134 PMID:39638853

NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168

G

farnesyl diphosphate synthase

decreases expression

ISO

deoxynivalenol results in decreased expression of FDPS protein

PMID:33890134 PMID:39638853

NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136

G

fibroblast growth factor receptor 4

decreases expression

ISO

deoxynivalenol results in decreased expression of FGFR4 protein

NCBI chr17:9,466,686...9,481,423
Ensembl chr17:9,466,692...9,481,389

G

filamin A

decreases phosphorylation
increases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of FLNA protein
deoxynivalenol results in increased phosphorylation of FLNA protein

NCBI chr X:157,159,051...157,185,559
Ensembl chr X:157,159,051...157,182,343

G

formin-like 1

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of FMNL1 protein

NCBI chr10:88,615,290...88,643,411
Ensembl chr10:88,615,869...88,643,411

G

fibromodulin

decreases expression

ISO

deoxynivalenol results in decreased expression of FMOD mRNA

NCBI chr13:48,045,567...48,056,184
Ensembl chr13:47,990,774...48,056,183

G

fibronectin 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FN1 mRNA; deoxynivalenol results in decreased expression of FN1 protein

PMID:31863870 PMID:39638853

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

fructosamine 3 kinase

decreases expression

ISO

deoxynivalenol results in decreased expression of FN3K protein

NCBI chr10:107,198,566...107,214,176
Ensembl chr10:107,198,892...107,214,175

G

formin binding protein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FNBP1 mRNA

NCBI chr 3:34,706,814...34,826,770
Ensembl chr 3:34,706,814...34,822,117

G

fibronectin type III domain containing 3B

increases expression

ISO

deoxynivalenol results in increased expression of FNDC3B protein

NCBI chr 2:112,240,108...112,546,113
Ensembl chr 2:112,243,202...112,546,306

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression
multiple interactions
affects activity

ISO

deoxynivalenol results in increased expression of FOS mRNA
deoxynivalenol inhibits the reaction [Cadmium Chloride results in decreased expression of FOS mRNA]
Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of FOS protein]
deoxynivalenol affects the activity of FOS protein
deoxynivalenol results in increased expression of FOS mRNA; deoxynivalenol results in increased expression of FOS protein

PMID:10662601 PMID:15371230 PMID:15681167 PMID:19360757 PMID:21873375 More...

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

affects activity
multiple interactions
increases expression

ISO

deoxynivalenol affects the activity of FOSB protein
[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of FOSB mRNA
deoxynivalenol results in increased expression of FOSB mRNA

PMID:10662601 PMID:33309878

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions

ISO

[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of FOSL1 mRNA

NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391

G

FOS like 2, AP-1 transcription factor subunit

multiple interactions
increases expression
affects activity

ISO

Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of FOSL2 mRNA]
deoxynivalenol results in increased expression of FOSL2 mRNA; deoxynivalenol results in increased expression of FOSL2 protein
[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of FOSL2 mRNA
deoxynivalenol affects the activity of FOSL2 protein

PMID:10662601 PMID:15371230 PMID:15681167 PMID:33309878 PMID:33890134

NCBI chr 6:30,017,952...30,039,269
Ensembl chr 6:30,021,916...30,039,406

G

forkhead box O1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of FOXO1 protein

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

forkhead box O3

affects response to substance
increases expression
multiple interactions

ISO

FOXO3A affects the susceptibility to deoxynivalenol
deoxynivalenol results in increased expression of FOXO3A mRNA
Acetylcysteine inhibits the reaction [deoxynivalenol affects the localization of and results in increased activity of FOXO3A protein]; deoxynivalenol affects the localization of and results in increased activity of FOXO3A protein; pyrazolanthrone inhibits the reaction [deoxynivalenol affects the localization of FOXO3A protein]

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

forkhead box P3

increases expression

ISO

deoxynivalenol results in increased expression of FOXP3 mRNA

NCBI chr X:17,580,380...17,601,181
Ensembl chr X:17,580,380...17,595,894

G

Fraser extracellular matrix complex subunit 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FRAS1 protein

NCBI chr14:13,095,370...13,506,895
Ensembl chr14:13,095,370...13,504,664

G

FtsJ RNA 2'-O-methyltransferase 3

increases expression

ISO

deoxynivalenol results in increased expression of FTSJ3 protein

NCBI chr10:91,680,735...91,687,475
Ensembl chr10:91,680,753...91,687,179

G

far upstream element binding protein 1

increases expression

ISO

deoxynivalenol results in increased expression of FUBP1 protein

NCBI chr 2:243,819,529...243,846,544
Ensembl chr 2:243,819,218...243,846,428

G

alpha-L-fucosidase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FUCA1 mRNA

NCBI chr 5:153,436,262...153,453,512
Ensembl chr 5:153,436,248...153,453,511

G

Fus RNA binding protein

increases expression

ISO

deoxynivalenol results in increased expression of FUS protein

NCBI chr 1:192,007,011...192,020,887
Ensembl chr 1:192,007,006...192,020,884

G

fucosyltransferase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of FUT1 mRNA

NCBI chr 1:105,223,399...105,226,817
Ensembl chr 1:105,223,390...105,227,513

G

G3BP stress granule assembly factor 1

decreases phosphorylation
increases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of G3BP1 protein
deoxynivalenol results in increased phosphorylation of G3BP1 protein

PMID:23352502 PMID:23811945

NCBI chr10:40,087,533...40,120,931
Ensembl chr10:40,087,533...40,120,931

G

G3BP stress granule assembly factor 2

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of G3BP2 protein

NCBI chr14:16,216,684...16,304,828
Ensembl chr14:16,248,744...16,304,823

G

GA binding protein transcription factor subunit alpha

decreases expression

ISO

deoxynivalenol results in decreased expression of GABPA protein

NCBI chr11:37,375,040...37,404,060
Ensembl chr11:37,375,084...37,404,059

G

growth arrest and DNA-damage-inducible, alpha

increases expression

ISO

deoxynivalenol results in increased expression of GADD45A mRNA

PMID:30169763 PMID:31863870

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

galactokinase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of GALK1 protein

NCBI chr10:101,742,067...101,746,244
Ensembl chr10:101,735,061...101,746,258

G

galactose mutarotase

decreases expression

ISO

deoxynivalenol results in decreased expression of GALM protein

NCBI chr 6:20,589,775...20,641,516
Ensembl chr 6:20,589,776...20,644,417

G

polypeptide N-acetylgalactosaminyltransferase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588

G

galanin-like peptide

multiple interactions
increases expression

EXP

GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL11 protein]; GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL1B protein]; GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL6 protein]
deoxynivalenol results in increased expression of GALP mRNA; deoxynivalenol results in increased expression of GALP protein

NCBI chr 1:76,717,110...76,741,056
Ensembl chr 1:76,717,110...76,735,354

G

galanin receptor 2

increases expression

EXP

deoxynivalenol results in increased expression of GALR2 mRNA

NCBI chr10:102,012,086...102,016,057
Ensembl chr10:102,013,370...102,016,055

G

galanin receptor 3

increases expression

EXP

deoxynivalenol results in increased expression of GALR3 mRNA

NCBI chr 7:112,483,183...112,496,359
Ensembl chr 7:112,485,672...112,488,136

G

glucosidase II alpha subunit

decreases expression

ISO

deoxynivalenol results in decreased expression of GANAB protein

NCBI chr 1:215,222,918...215,242,808
Ensembl chr 1:215,222,995...215,243,036

G

GATA zinc finger domain containing 2A

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of GATAD2A protein
deoxynivalenol results in increased expression of GATAD2A protein

PMID:23352502 PMID:39638853

NCBI chr16:19,463,500...19,553,497
Ensembl chr16:19,463,500...19,553,497

G

glucagon

multiple interactions
increases expression
increases secretion

ISO

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [deoxynivalenol results in increased secretion of GCG protein alternative form]; 2-aminoethyl diphenylborinate inhibits the reaction [deoxynivalenol results in increased secretion of GCG protein alternative form]; Egtazic Acid inhibits the reaction [deoxynivalenol results in increased secretion of GCG protein alternative form]; Nitrendipine inhibits the reaction [deoxynivalenol results in increased secretion of GCG protein alternative form]; triphenylphosphine oxide inhibits the reaction [deoxynivalenol results in increased secretion of GCG protein alternative form]
deoxynivalenol results in increased expression of GCG protein

PMID:25787141 PMID:28633506

NCBI chr 3:67,522,489...67,531,533
Ensembl chr 3:67,522,489...67,531,533

G

GTP cyclohydrolase I feedback regulator

decreases expression

ISO

deoxynivalenol results in decreased expression of GCHFR protein

NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926

G

glutamate-cysteine ligase, catalytic subunit

decreases expression
multiple interactions

ISO

deoxynivalenol results in decreased expression of GCLC mRNA
NNMT protein promotes the reaction [deoxynivalenol results in decreased expression of GCLC protein]; Resveratrol inhibits the reaction [deoxynivalenol results in decreased expression of GCLC protein]
deoxynivalenol results in decreased expression of GCLC mRNA; deoxynivalenol results in decreased expression of GCLC protein
Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of GCLC mRNA]

PMID:35817260 PMID:37419272 PMID:39147090 PMID:39983889

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

increases expression

ISO

deoxynivalenol results in increased expression of GCLM mRNA

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

growth differentiation factor 15

increases expression

ISO

deoxynivalenol results in increased expression of GDF15 protein

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

growth differentiation factor 5

increases expression

ISO

deoxynivalenol results in increased expression of GDF5 mRNA

NCBI chr 3:164,914,401...164,918,593
Ensembl chr 3:164,914,401...164,918,593

G

growth hormone 1

multiple interactions
decreases secretion
decreases expression

EXP

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; deoxynivalenol results in decreased expression of and results in decreased secretion of GH1 protein; farnesylthiosalicylic acid inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; farnesylthiosalicylic acid inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]; pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]
deoxynivalenol results in decreased secretion of GH1 protein

PMID:26141394 PMID:32738333 PMID:34673182

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

growth hormone receptor

affects expression

EXP

deoxynivalenol affects the expression of GHR mRNA

NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331

G

growth hormone releasing hormone

increases expression

EXP

deoxynivalenol results in increased expression of GHRH mRNA

NCBI chr 3:166,412,763...166,432,519
Ensembl chr 3:166,412,764...166,431,880

G

gastric inhibitory polypeptide

increases expression

ISO

deoxynivalenol results in increased expression of GIP protein

NCBI chr10:81,465,070...81,473,216
Ensembl chr10:81,465,062...81,473,216

G

G kinase anchoring protein 1

increases expression

ISO

deoxynivalenol results in increased expression of GKAP1 mRNA

NCBI chr17:6,389,377...6,429,091
Ensembl chr17:6,389,377...6,438,279

G

galactosidase, beta 1

decreases expression

ISO

deoxynivalenol results in decreased expression of GLB1 protein

NCBI chr 8:122,963,718...123,036,326
Ensembl chr 8:122,963,718...123,036,326

G

glycine decarboxylase

decreases expression

ISO

deoxynivalenol results in decreased expression of GLDC protein

NCBI chr 1:237,296,753...237,375,620
Ensembl chr 1:237,296,753...237,375,604

G

gliomedin

decreases expression

ISO

deoxynivalenol results in decreased expression of GLDN mRNA

NCBI chr 8:63,575,270...63,619,346
Ensembl chr 8:63,575,270...63,619,346

G

golgi glycoprotein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of GLG1 protein

NCBI chr19:56,034,248...56,133,538
Ensembl chr19:56,006,459...56,133,528

G

glutaminase

increases expression

ISO

deoxynivalenol results in increased expression of GLS protein

NCBI chr 9:56,836,584...56,908,861
Ensembl chr 9:56,836,584...56,908,861

G

glycosyltransferase 8 domain containing 1

decreases expression

ISO

deoxynivalenol results in decreased expression of GLT8D1 protein

NCBI chr16:6,198,152...6,213,671
Ensembl chr16:6,204,740...6,213,668

G

glyoxylate reductase 1 homolog

decreases expression

ISO

deoxynivalenol results in decreased expression of GLYR1 protein

NCBI chr10:11,038,577...11,074,093
Ensembl chr10:11,038,568...11,074,090

G

G protein nucleolar 2

increases expression

ISO

deoxynivalenol results in increased expression of GNL2 protein

NCBI chr 5:142,577,798...142,603,185
Ensembl chr 5:142,577,731...142,603,178

G

G protein nucleolar 3

increases expression

ISO

deoxynivalenol results in increased expression of GNL3 protein

NCBI chr16:6,213,844...6,220,029
Ensembl chr16:6,213,871...6,219,845

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

ISO

BMAL1 protein inhibits the reaction [deoxynivalenol results in increased activity of GOT1 protein]

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glycoprotein Ib platelet subunit beta

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of GP1BB protein

NCBI chr11:95,882,561...95,883,738

G

glypican 3

decreases expression

ISO

deoxynivalenol results in decreased expression of GPC3 protein

NCBI chr X:136,789,770...137,157,598
Ensembl chr X:136,789,770...137,157,639

G

glucose-6-phosphate isomerase

decreases expression

ISO

deoxynivalenol results in decreased expression of GPI protein

NCBI chr 1:95,965,389...95,996,932
Ensembl chr 1:95,965,396...95,993,261

G

G patch domain and KOW motifs

increases expression

ISO

deoxynivalenol results in increased expression of GPKOW mRNA

NCBI chr X:17,463,521...17,478,298
Ensembl chr X:17,463,525...17,478,298

G

GPN-loop GTPase 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of GPN1 protein

NCBI chr 6:30,667,337...30,685,011
Ensembl chr 6:30,666,868...30,685,011

G

G protein-coupled receptor, class C, group 5, member C

decreases expression

ISO

deoxynivalenol results in decreased expression of GPRC5C protein

NCBI chr10:100,385,682...100,407,953
Ensembl chr10:100,383,631...100,426,962

G

glutamic--pyruvic transaminase

multiple interactions
increases expression
increases activity

ISO
EXP

acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased activity of GPT protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased activity of GPT protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased activity of GPT protein]; deoxynivalenol promotes the reaction [Aflatoxin B1 results in increased activity of GPT protein]
Bentonite inhibits the reaction [deoxynivalenol results in increased expression of GPT protein]; Charcoal inhibits the reaction [deoxynivalenol results in increased expression of GPT protein]

PMID:25445755 PMID:26115597 PMID:34400200 PMID:35925383 PMID:36602574

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

glutathione peroxidase 1

increases phosphorylation
increases expression

ISO

deoxynivalenol results in increased phosphorylation of GPX1 protein
deoxynivalenol results in increased expression of GPX1 mRNA

PMID:23811945 PMID:34400200

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 4

multiple interactions
decreases expression

ISO

NNMT protein promotes the reaction [deoxynivalenol results in decreased expression of GPX4 protein]; Resveratrol inhibits the reaction [deoxynivalenol results in decreased expression of GPX4 protein]
Selenomethionine inhibits the reaction [deoxynivalenol results in decreased expression of GPX4 protein]
deoxynivalenol results in decreased expression of GPX4 mRNA; deoxynivalenol results in decreased expression of GPX4 protein

PMID:37419272 PMID:38040082 PMID:39147090 PMID:39983889

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

gremlin 1, DAN family BMP antagonist

decreases expression

ISO

deoxynivalenol results in decreased expression of GREM1 mRNA

NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089

G

granulin precursor

decreases expression

ISO

deoxynivalenol results in decreased expression of GRN protein

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936

G

glutamate-rich WD repeat containing 1

increases expression

ISO

deoxynivalenol results in increased expression of GRWD1 protein

NCBI chr 1:105,437,708...105,443,410
Ensembl chr 1:105,437,709...105,443,825

G

gasdermin D

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of GSDMD mRNA; deoxynivalenol results in increased expression of GSDMD protein
deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of GSDMD mRNA]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of GSDMD protein]; deoxynivalenol results in increased expression of and results in increased cleavage of GSDMD protein; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of GSDMD mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of GSDMD protein]

PMID:35925383 PMID:36309173

NCBI chr 7:109,423,209...109,427,771
Ensembl chr 7:109,422,910...109,430,722

G

gasdermin E

multiple interactions

ISO

acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased expression of and results in increased cleavage of GSDME protein]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of and results in increased cleavage of GSDME protein]; deoxynivalenol results in increased expression of and results in increased cleavage of GSDME protein
[GSDME protein co-treated with deoxynivalenol] results in increased secretion of IL1B protein; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased cleavage of GSDME protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased cleavage of GSDME protein]; deoxynivalenol results in decreased expression of and results in increased cleavage of GSDME protein; GSDME protein inhibits the reaction [deoxynivalenol results in increased cleavage of PARP1 protein]; GSDME protein promotes the reaction [deoxynivalenol results in increased secretion of IL6 protein]

NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525

G

glycogen synthase kinase 3 beta

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of GSK3B protein

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione synthetase

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of GSS mRNA; deoxynivalenol results in increased expression of GSS protein
Resveratrol inhibits the reaction [deoxynivalenol results in decreased expression of GSS protein]; Resveratrol promotes the reaction [deoxynivalenol results in increased expression of GSS protein]

PMID:37419272 PMID:39983889

NCBI chr 3:164,508,005...164,538,343
Ensembl chr 3:164,508,005...164,538,306

G

GTP binding protein 10

increases expression

ISO

deoxynivalenol results in increased expression of GTPBP10 protein

NCBI chr 4:29,431,683...29,449,201
Ensembl chr 4:29,431,692...29,449,212

G

GTP binding protein 4

increases expression

ISO

deoxynivalenol results in increased expression of GTPBP4 protein

NCBI chr17:65,997,472...66,019,530
Ensembl chr17:66,276,566...66,289,637

G

GTP binding elongation factor GUF1

increases expression

ISO

deoxynivalenol results in increased expression of GUF1 protein

NCBI chr14:38,891,905...38,911,283
Ensembl chr14:38,891,905...38,911,283

G

H1.0 linker histone

increases expression

ISO

deoxynivalenol results in increased expression of H1-0 mRNA; deoxynivalenol results in increased expression of H1-0 protein

PMID:31863870 PMID:39638853

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H1.10 linker histone

increases expression

ISO

deoxynivalenol results in increased expression of H1-10 mRNA; deoxynivalenol results in increased expression of H1-10 protein

PMID:31863870 PMID:39638853

NCBI chr 4:121,997,834...121,998,897
Ensembl chr 4:121,997,831...121,998,966

G

H1.2 linker histone, cluster member

increases expression

ISO

deoxynivalenol results in increased expression of H1-2 mRNA

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317

G

H1.4 linker histone, cluster member

increases expression

ISO

deoxynivalenol results in increased expression of H1-4 protein

NCBI chr17:41,914,425...41,915,206
Ensembl chr17:41,914,431...41,916,129

G

H1.5 linker histone, cluster member

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of H1F5 protein

NCBI chr17:47,421,875...47,422,905
Ensembl chr17:47,421,843...47,477,387

G

H2B clustered histone 14

increases expression

ISO

deoxynivalenol results in increased expression of H2BC5 mRNA

NCBI chr17:47,488,627...47,489,008

G

H3.7 histone like

increases expression

ISO

deoxynivalenol results in increased expression of H3-7 protein

NCBI chr 7:102,145,916...102,146,683

G

hyaluronan and proteoglycan link protein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of HAPLN1 mRNA

NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098

G

HAUS augmin like complex subunit 2

increases expression

ISO

deoxynivalenol results in increased expression of HAUS2 mRNA

NCBI chr 3:128,006,894...128,019,730
Ensembl chr 3:128,006,932...128,019,729

G

hemoglobin alpha, adult chain 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of HBA protein

NCBI chr10:15,841,724...15,842,580
Ensembl chr10:15,841,763...15,842,603

G

hemoglobin subunit beta

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of HBB-B1 protein

NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873

G

HCK proto-oncogene, Src family tyrosine kinase

increases phosphorylation
affects response to substance
multiple interactions

ISO

deoxynivalenol results in increased phosphorylation of HCK protein
HCK protein affects the susceptibility to deoxynivalenol
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of and results in increased activity of HCK protein]; deoxynivalenol results in increased phosphorylation of and results in increased activity of HCK protein; HCK protein affects the reaction [deoxynivalenol results in increased activity of CASP3 protein]; HCK protein affects the reaction [deoxynivalenol results in increased expression of TNF protein]

PMID:15772366 PMID:20181660 PMID:22491426

NCBI chr 3:162,031,833...162,074,933
Ensembl chr 3:162,031,817...162,074,935

G

histone deacetylase 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of HDAC1 protein

NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387

G

histone deacetylase 2

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of HDAC2 protein
deoxynivalenol results in increased expression of HDAC2 protein

PMID:23352502 PMID:39638853

NCBI chr20:42,101,815...42,126,486
Ensembl chr20:42,102,861...42,126,311

G

heparin binding growth factor

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of HDGF protein

NCBI chr 2:175,668,290...175,677,614
Ensembl chr 2:175,668,324...175,677,225

G

HEAT repeat containing 1

increases expression

ISO

deoxynivalenol results in increased expression of HEATR1 protein

NCBI chr17:62,745,008...62,785,609
Ensembl chr17:62,745,008...62,785,186

G

helicase, lymphoid specific

increases expression

ISO

deoxynivalenol results in increased expression of HELLS protein

NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:246,114,096...246,159,228

G

hemogen

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of HEMGN protein

NCBI chr 5:65,475,228...65,495,384
Ensembl chr 5:65,475,228...65,494,375

G

hypoxia inducible factor 1 subunit alpha

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of HIF1A mRNA
Selenomethionine inhibits the reaction [deoxynivalenol results in increased expression of HIF1A protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of HIF1A mRNA]

PMID:34677630 PMID:38040082

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

histone H4 transcription factor

increases expression

ISO

deoxynivalenol results in increased expression of HINFP protein

NCBI chr 8:53,525,576...53,541,101
Ensembl chr 8:53,527,236...53,540,555

G

histidine triad nucleotide binding protein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of HINT1 mRNA

NCBI chr10:39,490,225...39,493,970
Ensembl chr 4:93,430,926...93,431,642
Ensembl chr10:93,430,926...93,431,642

G

H2.0-like homeobox

increases expression

ISO

deoxynivalenol results in increased expression of HLX mRNA

NCBI chr13:98,811,852...98,817,264
Ensembl chr13:98,811,856...98,817,264

G

3-hydroxy-3-methylglutaryl-CoA reductase

decreases expression

ISO

deoxynivalenol results in decreased expression of HMGCR mRNA

NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533

G

heme oxygenase 1

decreases expression
multiple interactions
increases expression
decreases response to substance

ISO

deoxynivalenol results in decreased expression of HMOX1 mRNA; deoxynivalenol results in decreased expression of HMOX1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of HMOX1 mRNA]
deoxynivalenol results in increased expression of HMOX1 mRNA; deoxynivalenol results in increased expression of HMOX1 protein
Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of HMOX1 mRNA]; HMOX1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL1B protein]; HMOX1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; HMOX1 protein inhibits the reaction [deoxynivalenol results in increased expression of TNF protein]; Selenomethionine inhibits the reaction [deoxynivalenol results in increased expression of HMOX1 protein]
HMOX1 protein results in decreased susceptibility to deoxynivalenol

PMID:24355168 PMID:26763390 PMID:31034930 PMID:31863870 PMID:34400200 More...

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heme oxygenase 2

increases expression

ISO

deoxynivalenol results in increased expression of HMOX2 protein

NCBI chr10:11,303,512...11,337,640
Ensembl chr10:11,303,512...11,318,800

G

hepatocyte nuclear factor 4, alpha

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of HNF4 mRNA; deoxynivalenol results in increased expression of HNF4A mRNA
[deoxynivalenol co-treated with Zearalenone] affects the expression of HNF4A mRNA

PMID:28865950 PMID:35314294

NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758

G

heterogeneous nuclear ribonucleoprotein F

increases expression

ISO

deoxynivalenol results in increased expression of HNRNPF protein

NCBI chr 4:152,755,668...152,776,867
Ensembl chr 4:152,722,617...152,815,769

G

heterogeneous nuclear ribonucleoprotein H1

increases expression

ISO

deoxynivalenol results in increased expression of HNRNPH1 protein

NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906

G

heterogeneous nuclear ribonucleoprotein U-like 1

increases expression

ISO

deoxynivalenol results in increased expression of HNRNPUL1 protein

NCBI chr 1:90,356,182...90,391,923
Ensembl chr 1:90,356,182...90,390,370

G

homeobox A7

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of HOXA7 mRNA
AG 1879 inhibits the reaction [deoxynivalenol results in increased expression of HOXA7 mRNA]

NCBI chr 4:82,646,342...82,652,449
Ensembl chr 4:82,646,364...82,648,241

G

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2

increases expression

ISO

deoxynivalenol results in increased expression of HSD3B2 mRNA

NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569

G

heat shock protein 90 alpha family class B member 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of HSP90AB1 protein

NCBI chr 9:22,930,249...22,935,929
Ensembl chr 9:22,931,070...22,935,926

G

heat shock protein family A (Hsp70) member 1 like

decreases expression

ISO

deoxynivalenol results in decreased expression of HSPA1L protein

NCBI chr20:3,853,496...3,860,223
Ensembl chr20:3,853,331...3,876,877

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases phosphorylation
decreases expression

ISO

calpain inhibitor III inhibits the reaction [deoxynivalenol results in increased degradation of HSPA5 protein]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 mRNA]; deoxynivalenol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA5 protein]; deoxynivalenol results in increased degradation of and results in decreased expression of HSPA5 protein; phenylalanyl-glycyl-NHO-Bz inhibits the reaction [deoxynivalenol results in increased degradation of HSPA5 protein]
deoxynivalenol results in increased phosphorylation of HSPA5 protein
deoxynivalenol results in decreased expression of HSPA5 mRNA

PMID:10652249 PMID:19336499 PMID:20682335 PMID:23811945 PMID:24356939

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

heat shock protein family A (Hsp70) member 8

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of HSPA8 protein

NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372

G

heparan sulfate proteoglycan 2

decreases expression

ISO

deoxynivalenol results in decreased expression of HSPG2 protein

NCBI chr 5:154,960,818...155,061,971
Ensembl chr 5:154,960,846...155,061,971

G

heat shock protein family H (Hsp110) member 1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of HSPH1 protein

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

HYLS1, centriolar and ciliogenesis associated

increases expression

ISO

deoxynivalenol results in increased expression of HYLS1 mRNA

NCBI chr 8:42,170,505...42,179,573
Ensembl chr 8:42,168,546...42,179,725

G

intercellular adhesion molecule 1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of ICAM1 mRNA; deoxynivalenol results in increased expression of ICAM1 protein
deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]

PMID:19549553 PMID:21074547 PMID:34400200 PMID:39638853

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

inhibitor of DNA binding 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

isocitrate dehydrogenase (NADP(+)) 1

decreases expression

ISO

deoxynivalenol results in decreased expression of IDH1 protein

NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:74,027,892...74,049,555

G

interferon induced transmembrane protein 3

decreases expression

ISO

deoxynivalenol results in decreased expression of IFITM3 protein

NCBI chr 1:205,540,649...205,541,758
Ensembl chr 1:205,481,168...205,547,920

G

interferon, alpha 1

decreases expression

ISO

deoxynivalenol results in decreased expression of IFNA1 mRNA

NCBI chr 5:108,143,240...108,143,809
Ensembl chr 5:108,143,240...108,143,809

G

interferon alpha and beta receptor subunit 1

decreases expression

ISO

deoxynivalenol results in decreased expression of IFNAR1 mRNA

NCBI chr11:44,211,769...44,238,206
Ensembl chr11:44,211,845...44,238,205

G

interferon beta 1

multiple interactions
increases expression

ISO

deoxynivalenol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IFNB1 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]
deoxynivalenol results in increased expression of IFNB1 mRNA

PMID:14644621 PMID:17090620 PMID:19857559

NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487

G

interferon gamma

affects expression
multiple interactions
increases expression

ISO

deoxynivalenol affects the expression of IFNG mRNA
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; Adenine inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]; deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of CD14 protein]; deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of IFNGR1 protein]; lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; pyrrolidine dithiocarbamic acid inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]
deoxynivalenol results in increased expression of IFNG mRNA; deoxynivalenol results in increased expression of IFNG protein
[deoxynivalenol co-treated with Aflatoxin B1] results in decreased expression of IFNG mRNA; [deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IFNG protein; Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of IFNG protein]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IFNG mRNA]

PMID:9194413 PMID:9707511 PMID:14644621 PMID:17090620 PMID:17166736 More...

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon gamma receptor 1

multiple interactions
decreases expression

ISO

deoxynivalenol inhibits the reaction [IFNG protein results in increased expression of IFNGR1 protein]
deoxynivalenol results in decreased expression of IFNGR1 mRNA

PMID:17090620 PMID:19549553

NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:16,152,879...16,171,437

G

insulin-like growth factor 1

multiple interactions
increases expression
decreases expression

ISO
EXP

deoxynivalenol promotes the reaction [Glutathione results in increased expression of IGF1 mRNA]
deoxynivalenol results in increased expression of IGF1 mRNA
deoxynivalenol results in decreased expression of IGF1 protein

PMID:19805407 PMID:32738333

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 2

decreases expression

ISO

deoxynivalenol results in decreased expression of IGF2 protein

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor binding protein, acid labile subunit

decreases expression
increases expression
multiple interactions

ISO
EXP

deoxynivalenol results in decreased expression of IGFALS mRNA; deoxynivalenol results in decreased expression of IGFALS protein
deoxynivalenol results in increased expression of IGFALS mRNA
deoxynivalenol inhibits the reaction [Glutathione results in increased expression of IGFALS mRNA]

PMID:19625342 PMID:19805407 PMID:23298694 PMID:32738333

NCBI chr10:14,397,076...14,408,439
Ensembl chr10:14,403,399...14,407,138

G

insulin-like growth factor binding protein 3

multiple interactions

ISO

deoxynivalenol promotes the reaction [Glutathione results in increased expression of IGFBP3 mRNA]

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

insulin-like growth factor binding protein 6

decreases expression

ISO

deoxynivalenol results in decreased expression of IGFBP6 mRNA

NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:135,154,685...135,159,795

G

immunoglobulin superfamily, member 1

decreases expression

ISO

deoxynivalenol results in decreased expression of IGSF1 protein

NCBI chr X:133,947,717...133,963,154
Ensembl chr X:133,947,429...133,962,962

G

interleukin 10

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of IL10 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased expression of IL1B mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased expression of TNF mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 protein]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of STAT3 mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of STAT3 protein]]; deoxynivalenol promotes the reaction [IL10 protein results in increased expression of IL1B mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased expression of SOCS3 mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased expression of SOCS3 protein]; deoxynivalenol promotes the reaction [IL10 protein results in increased expression of TNF mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 protein]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of STAT3 mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of STAT3 protein]

PMID:9194413 PMID:9707511 PMID:22968694 PMID:38432439

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 10 receptor subunit beta

increases expression

ISO

deoxynivalenol results in increased expression of IL10RB mRNA

NCBI chr11:44,132,471...44,154,062
Ensembl chr11:44,132,189...44,154,053

G

interleukin 11

increases expression
affects expression
multiple interactions

ISO
EXP

deoxynivalenol results in increased expression of IL11 mRNA
deoxynivalenol affects the expression of IL11 mRNA
deoxynivalenol results in increased expression of IL11 mRNA; deoxynivalenol results in increased expression of IL11 protein
GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL11 protein]
Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of IL11 mRNA]

PMID:15371230 PMID:15681167 PMID:32738333 PMID:34673182

NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915

G

interleukin 12A

increases expression

ISO

deoxynivalenol results in increased expression of IL12A mRNA

PMID:9707511 PMID:27757495

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

interleukin 12B

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of IL12B mRNA
[Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of IL12B protein

PMID:9194413 PMID:9707511 PMID:28935500

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 13

multiple interactions

ISO

deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of and results in increased secretion of IL13 protein]

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 15

increases expression

ISO

deoxynivalenol results in increased expression of IL15 mRNA

NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348

G

interleukin 17A

multiple interactions
increases expression

ISO

[deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL17A protein; Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of IL17A protein]

PMID:28935500 PMID:32416088

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 18

decreases expression
increases secretion
increases expression
multiple interactions

ISO

deoxynivalenol results in decreased expression of IL18 mRNA
deoxynivalenol results in increased secretion of IL18 protein
deoxynivalenol results in increased expression of IL18 mRNA; deoxynivalenol results in increased expression of IL18 protein
acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased expression of IL18 mRNA]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of IL18 mRNA]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL18 protein]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of IL18 mRNA]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of IL18 protein]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased secretion of IL18 protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of IL18 mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of IL18 protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased secretion of IL18 protein]

PMID:22968694 PMID:35925383 PMID:36309173

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 18 receptor accessory protein

decreases expression

ISO

deoxynivalenol results in decreased expression of IL18RAP mRNA

NCBI chr 9:50,263,723...50,296,583
Ensembl chr 9:50,263,733...50,296,583

G

interleukin 1 alpha

increases expression
multiple interactions

ISO
EXP

deoxynivalenol results in increased expression of IL1A mRNA
Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of IL1A mRNA]; Lipopolysaccharides promotes the reaction [deoxynivalenol results in increased expression of IL1A mRNA]

PMID:15371230 PMID:15681167 PMID:16009389 PMID:32738333

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases expression
increases secretion
multiple interactions
decreases expression

ISO
EXP

deoxynivalenol results in increased expression of IL1B mRNA; deoxynivalenol results in increased expression of IL1B protein
deoxynivalenol results in increased secretion of IL1B protein
GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL1B protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; [GSDME protein co-treated with deoxynivalenol] results in increased secretion of IL1B protein; [Zearalenone co-treated with deoxynivalenol] results in increased expression of IL1B mRNA; Adenine inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL1B protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL1B protein]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased abundance of Nitric Oxide]; deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]; deoxynivalenol inhibits the reaction [IL1B protein results in increased expression of CXCL8 protein]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; lactacystin inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; pyrrolidine dithiocarbamic acid inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]]; [deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of IL1B protein; acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased expression of IL1B mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL1B protein]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of IL1B protein]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of IL1B mRNA]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of IL1B protein]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased secretion of IL1B protein]; deoxynivalenol promotes the reaction [IL10 protein results in increased expression of IL1B mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of IL1B protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased secretion of IL1B protein]; HMOX1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL1B protein]; Lipopolysaccharides promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; Lipopolysaccharides promotes the reaction [deoxynivalenol results in increased expression of IL1B protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; resiquimod promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; stattic inhibits the reaction [deoxynivalenol results in increased expression of IL1B mRNA]; Zymosan promotes the reaction [deoxynivalenol results in increased expression of IL1B mRNA]
deoxynivalenol results in decreased expression of IL1B mRNA

PMID:9194413 PMID:9707511 PMID:10344227 PMID:12604842 PMID:12773775 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 family member 10

increases expression

ISO

deoxynivalenol results in increased expression of IL1F10 mRNA

NCBI chr 3:27,470,798...27,473,726
Ensembl chr 3:27,470,798...27,473,726

G

interleukin 1 receptor type 1

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of IL1R1 mRNA
IL1R1 protein affects the susceptibility to [Lipopolysaccharides co-treated with deoxynivalenol]

PMID:12773775 PMID:22968694

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor-like 1

increases expression

ISO

deoxynivalenol results in increased expression of IL1RL1 mRNA

NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891

G

interleukin 1 receptor antagonist

increases expression

ISO

deoxynivalenol results in increased expression of IL1RN mRNA

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

affects secretion
increases expression
increases stability
multiple interactions
affects expression

ISO

deoxynivalenol affects the secretion of IL2 protein
deoxynivalenol results in increased expression of IL2 mRNA
deoxynivalenol results in increased stability of IL2 mRNA
[deoxynivalenol co-treated with Aflatoxin B1] results in decreased expression of IL2 mRNA; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]
deoxynivalenol affects the expression of IL2 mRNA

PMID:8560498 PMID:8658534 PMID:9194413 PMID:9439728 PMID:9707511 More...

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 22 receptor subunit alpha 2

increases expression

ISO

deoxynivalenol results in increased expression of IL22RA2 mRNA

NCBI chr 1:16,172,238...16,228,009
Ensembl chr 1:16,184,113...16,197,950

G

interleukin 23 subunit alpha

increases expression

ISO

deoxynivalenol results in increased expression of IL23A mRNA

NCBI chr 7:1,306,320...1,308,434
Ensembl chr 7:1,306,320...1,308,434

G

interleukin 33

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of IL33 mRNA; deoxynivalenol results in increased expression of IL33 protein
deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of IL33 protein]; Oligosaccharides analog inhibits the reaction [deoxynivalenol results in increased expression of IL33 mRNA]; Oligosaccharides analog inhibits the reaction [deoxynivalenol results in increased expression of IL33 protein]

PMID:26304032 PMID:33170220

NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901

G

interleukin 36, gamma

increases expression

ISO

deoxynivalenol results in increased expression of IL36G protein

NCBI chr 3:27,346,675...27,352,839
Ensembl chr 3:27,346,670...27,352,834

G

interleukin 4

increases expression
multiple interactions
affects secretion

ISO

deoxynivalenol results in increased expression of IL4 mRNA
deoxynivalenol results in increased expression of IL4 mRNA; deoxynivalenol results in increased expression of IL4 protein
deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein]; deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of and results in increased secretion of IL4 protein]
deoxynivalenol affects the secretion of IL4 protein

PMID:8560498 PMID:8658534 PMID:9194413 PMID:9707511 PMID:22846391 More...

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 5

affects secretion
increases expression
multiple interactions

ISO

deoxynivalenol affects the secretion of IL5 protein
deoxynivalenol results in increased expression of IL5 mRNA
deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 mRNA]; deoxynivalenol promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein]; deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of and results in increased secretion of IL5 protein]

PMID:8560498 PMID:8658534 PMID:33170220

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

decreases expression
increases secretion
multiple interactions
increases expression
increases stability

ISO
EXP

deoxynivalenol results in decreased expression of IL6 mRNA
deoxynivalenol results in increased secretion of IL6 protein
[Zearalenone co-treated with deoxynivalenol] results in increased expression of IL6 mRNA; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL6 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL6 protein]; GSDME protein promotes the reaction [deoxynivalenol results in increased secretion of IL6 protein]
deoxynivalenol results in increased expression of IL6 mRNA; deoxynivalenol results in increased expression of IL6 protein
GALP protein promotes the reaction [deoxynivalenol results in increased expression of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]]; [deoxynivalenol co-treated with Aflatoxin B1] results in decreased expression of IL6 mRNA; [deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL6 protein; [Docosahexaenoic Acids co-treated with Eicosapentaenoic Acid] inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; [Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of IL6 protein; acetyl-aspartyl-glutamyl-valyl-aspartal inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; AKT1 protein affects the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; ATF6 protein affects the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [deoxynivalenol results in increased secretion of IL6 protein]; BMAL1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; deoxynivalenol promotes the reaction [CREB1 protein modified form binds to IL6 promoter]; deoxynivalenol promotes the reaction [fumonisin B1 results in increased expression of IL6 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol promotes the reaction [CREB1 protein modified form binds to IL6 promoter]]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased expression of IL6]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased expression of IL6]; Fatty Acids, Omega-3 inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Fish Oils inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; fumonisin B1 promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; HMOX1 protein inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Indomethacin inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; Indomethacin inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Indomethacin inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Lipopolysaccharides promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Lipopolysaccharides promotes the reaction [deoxynivalenol results in increased expression of IL6 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein]; Poly I-C promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; PTGS2 protein affects the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; PTGS2 protein affects the reaction [deoxynivalenol results in increased expression of IL6 protein]; resiquimod promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; stattic inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; Zymosan promotes the reaction [deoxynivalenol results in increased expression of IL6 mRNA]
deoxynivalenol results in increased stability of IL6 mRNA

PMID:9194413 PMID:9707511 PMID:10344227 PMID:11295263 PMID:11922776 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 7

decreases expression

ISO

deoxynivalenol results in decreased expression of IL7 mRNA

NCBI chr 2:96,142,523...96,186,282
Ensembl chr 2:96,142,092...96,187,389

G

interleukin 9

multiple interactions

ISO

deoxynivalenol promotes the reaction [Antigens, Dermatophagoides results in increased expression of and results in increased secretion of IL9 protein]

NCBI chr17:8,117,028...8,120,151
Ensembl chr17:8,117,028...8,120,151

G

interleukin enhancer binding factor 3

increases expression

ISO

deoxynivalenol results in increased expression of ILF3 protein

NCBI chr 8:28,198,454...28,236,634
Ensembl chr 8:28,198,543...28,236,612

G

inositol polyphosphate-5-phosphatase D

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of INPP5D protein

NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589

G

integrator complex subunit 11

increases expression

ISO

deoxynivalenol results in increased expression of INTS11 protein

NCBI chr 5:171,761,370...171,779,883
Ensembl chr 5:171,761,371...171,779,883

G

interleukin-1 receptor-associated kinase 1

multiple interactions

ISO

deoxynivalenol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of IRAK1 protein]

NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825

G

interferon regulatory factor 2 binding protein 2

increases expression

ISO

deoxynivalenol results in increased expression of IRF2BP2 mRNA

NCBI chr19:71,456,689...71,462,368
Ensembl chr19:71,456,689...71,462,368

G

IST1 factor associated with ESCRT-III

increases expression

ISO

deoxynivalenol results in increased expression of IST1 mRNA

NCBI chr19:54,558,353...54,580,551
Ensembl chr19:54,558,353...54,580,491

G

integrin subunit alpha 10

decreases expression

ISO

deoxynivalenol results in decreased expression of ITGA10 mRNA

NCBI chr 2:186,871,711...186,891,012
Ensembl chr 2:186,871,711...186,891,012

G

integrin subunit alpha 6

decreases expression

ISO

deoxynivalenol results in decreased expression of ITGA6 protein

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

integrin subunit beta 2

increases expression

ISO

deoxynivalenol results in increased expression of ITGB2 mRNA

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182

G

integrin subunit beta like 1

decreases expression

ISO

deoxynivalenol results in decreased expression of ITGBL1 mRNA

NCBI chr15:107,186,792...107,448,335
Ensembl chr15:107,186,689...107,451,098

G

inter-alpha-trypsin inhibitor heavy chain 2

decreases expression

ISO

deoxynivalenol results in decreased expression of ITIH2 protein

NCBI chr17:73,285,281...73,321,555
Ensembl chr17:73,285,270...73,321,547

G

inter-alpha-trypsin inhibitor heavy chain 5

decreases expression

ISO

deoxynivalenol results in decreased expression of ITIH5 mRNA

NCBI chr17:73,161,886...73,261,930
Ensembl chr17:73,161,611...73,262,496

G

integral membrane protein 2B

decreases expression

ISO

deoxynivalenol results in decreased expression of ITM2B protein

NCBI chr15:54,955,549...54,978,455
Ensembl chr15:54,955,552...54,978,455

G

Janus kinase 1

increases expression
increases phosphorylation

ISO

deoxynivalenol results in increased expression of JAK1 mRNA
deoxynivalenol results in increased phosphorylation of JAK1 protein

PMID:22454431 PMID:36602574

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

Janus kinase 2

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of JAK2 mRNA
alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 mRNA]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 protein]]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [deoxynivalenol results in increased expression of JAK2 mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 mRNA]; deoxynivalenol promotes the reaction [IL10 protein results in increased phosphorylation of JAK2 protein]; stattic inhibits the reaction [deoxynivalenol results in increased expression of JAK2 mRNA]

PMID:22454431 PMID:38432439

NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762

G

Jupiter microtubule associated homolog 1

increases expression

ISO

deoxynivalenol results in increased expression of JPT1 protein

NCBI chr10:101,243,428...101,261,464
Ensembl chr10:101,243,424...101,261,469

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases phosphorylation
increases activity
increases expression
affects localization
affects activity

ISO

[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of JUN mRNA; deoxynivalenol results in increased expression of and results in increased phosphorylation of JUN protein
deoxynivalenol results in increased phosphorylation of JUN protein
deoxynivalenol results in increased activity of JUN protein
deoxynivalenol results in increased expression of JUN mRNA; deoxynivalenol results in increased expression of JUN protein
deoxynivalenol affects the localization of JUN protein
deoxynivalenol affects the activity of JUN protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased activity of JUN protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of JUN protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of JUN protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of JUN protein]

PMID:10662601 PMID:12604842 PMID:15371230 PMID:15681167 PMID:15772366 More...

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression
increases activity
affects activity

ISO

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased activity of JUNB protein]
deoxynivalenol results in increased expression of JUNB mRNA
[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of JUNB mRNA
deoxynivalenol affects the activity of JUNB protein

PMID:10662601 PMID:15371230 PMID:15681167 PMID:15772366 PMID:33309878

NCBI chr19:40,081,126...40,082,910
Ensembl chr19:40,073,541...40,085,218

G

JunD proto-oncogene, AP-1 transcription factor subunit

affects activity
multiple interactions
affects localization
increases activity
increases expression

ISO

deoxynivalenol affects the activity of JUND protein
[Cadmium Chloride co-treated with deoxynivalenol] results in increased expression of JUND mRNA
deoxynivalenol affects the localization of JUND protein
deoxynivalenol results in increased activity of JUND protein
deoxynivalenol results in increased expression of JUND mRNA; deoxynivalenol results in increased expression of JUND protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased activity of JUND protein]

PMID:10662601 PMID:12604842 PMID:15772366 PMID:22846391 PMID:33309878 More...

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148

G

junction plakoglobin

decreases expression

ISO

deoxynivalenol results in decreased expression of JUP protein

NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,800,814...85,827,429

G

lysine acetyltransferase 2A

multiple interactions

ISO

KAT2A protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]

NCBI chr10:86,132,535...86,140,877
Ensembl chr10:86,132,535...86,140,485

G

lysine acetyltransferase 2B

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of KAT2B protein
KAT2B protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form]

NCBI chr 9:6,799,101...6,903,616
Ensembl chr 9:6,799,145...6,903,616

G

kelch repeat and BTB domain containing 11

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of KBTBD11 protein

NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390

G

potassium calcium-activated channel subfamily M regulatory beta subunit 4

decreases expression

ISO

deoxynivalenol results in decreased expression of KCNMB4 mRNA

NCBI chr 7:53,952,150...54,005,101
Ensembl chr 7:53,949,881...54,005,281

G

KDEL endoplasmic reticulum protein retention receptor 1

decreases expression

ISO

deoxynivalenol results in decreased expression of KDELR1 protein

NCBI chr 1:105,483,598...105,494,587
Ensembl chr 1:105,480,967...105,494,600

G

KDEL endoplasmic reticulum protein retention receptor 3

decreases expression

ISO

deoxynivalenol results in decreased expression of KDELR3 mRNA

NCBI chr 7:112,959,632...112,969,858
Ensembl chr 7:112,959,718...112,969,858

G

lysine demethylase 4B

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of KDM4B protein

NCBI chr 9:1,245,885...1,324,384
Ensembl chr 9:1,245,899...1,324,384

G

Kelch-like ECH-associated protein 1

decreases expression
multiple interactions
increases expression

ISO

deoxynivalenol results in decreased expression of KEAP1 mRNA
Selenomethionine inhibits the reaction [deoxynivalenol results in increased expression of KEAP1 protein]

PMID:34400200 PMID:38040082

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KH domain containing 4, pre-mRNA splicing factor

increases expression

ISO

deoxynivalenol results in increased expression of KHDC4 mRNA

NCBI chr 2:176,446,895...176,475,405
Ensembl chr 2:176,446,910...176,475,392

G

KH RNA binding domain containing, signal transduction associated 3

increases expression

ISO

deoxynivalenol results in increased expression of KHDRBS3 mRNA

NCBI chr 7:102,726,628...102,884,545
Ensembl chr 7:102,726,843...102,884,541

G

kinesin family member 11

increases expression

ISO

deoxynivalenol results in increased expression of KIF11 mRNA

NCBI chr 1:244,494,916...244,589,250
Ensembl chr 1:244,494,875...244,589,250

G

kinesin family member 2C

increases expression

ISO

deoxynivalenol results in increased expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

KIT ligand

increases expression

ISO

deoxynivalenol results in increased expression of KITLG mRNA

PMID:27757495 PMID:31863870

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793

G

KLF transcription factor 4

affects localization
affects expression

ISO

deoxynivalenol affects the localization of KLF4 protein
deoxynivalenol affects the expression of KLF4 protein

NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592

G

kelch-like family member 30

decreases expression

ISO

deoxynivalenol results in decreased expression of KLHL30 mRNA

NCBI chr 9:99,389,982...99,400,295
Ensembl chr 9:99,390,014...99,400,295

G

lysine methyltransferase 2A

multiple interactions
increases expression

ISO

AG 1879 inhibits the reaction [deoxynivalenol results in increased expression of KMT2A mRNA]; deoxynivalenol promotes the reaction [SP1 protein binds to KMT2A promoter]; SP1 protein promotes the reaction [deoxynivalenol results in increased expression of KMT2A mRNA]

NCBI chr 8:54,013,547...54,089,219
Ensembl chr 8:54,013,547...54,089,317

G

karyopherin subunit alpha 4

increases expression

ISO

deoxynivalenol results in increased expression of KPNA4 protein

NCBI chr 2:155,635,679...155,691,056
Ensembl chr 2:155,634,247...155,691,053

G

KRR1, small subunit processome component homolog

increases expression

ISO

deoxynivalenol results in increased expression of KRR1 protein

NCBI chr 7:49,361,794...49,374,222
Ensembl chr 7:49,361,901...49,374,216

G

keratin 18

increases expression

ISO

deoxynivalenol results in increased expression of KRT18 protein

PMID:33890134 PMID:39638853

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848

G

keratin 20

multiple interactions
decreases expression

ISO

lauric acid inhibits the reaction [deoxynivalenol results in decreased expression of KRT20 protein]

NCBI chr10:84,880,952...84,890,285
Ensembl chr10:84,880,952...84,890,285

G

kinectin 1

increases expression

ISO

deoxynivalenol results in increased expression of KTN1 protein

NCBI chr15:23,392,570...23,485,061
Ensembl chr15:23,394,315...23,482,263

G

ladinin 1

increases expression

ISO

deoxynivalenol results in increased expression of LAD1 protein

NCBI chr13:49,801,347...49,815,709
Ensembl chr13:49,800,472...49,815,709

G

laminin subunit alpha 5

decreases expression

ISO

deoxynivalenol results in decreased expression of LAMA5 protein

NCBI chr 3:187,647,904...187,695,974
Ensembl chr 3:187,647,904...187,696,173

G

laminin subunit beta 1

decreases expression

ISO

deoxynivalenol results in decreased expression of LAMB1 mRNA

NCBI chr 6:53,562,849...53,630,118
Ensembl chr 6:53,563,073...53,630,760

G

laminin subunit gamma 1

decreases expression

ISO

deoxynivalenol results in decreased expression of LAMC1 protein

NCBI chr13:67,924,872...68,051,986
Ensembl chr13:67,924,872...68,051,986

G

lysosomal protein transmembrane 4 alpha

decreases expression

ISO

deoxynivalenol results in decreased expression of LAPTM4A protein

NCBI chr 6:37,438,503...37,456,238
Ensembl chr 6:37,438,121...37,456,223

G

La ribonucleoprotein 4

increases expression

ISO

deoxynivalenol results in increased expression of LARP4 protein

NCBI chr 7:132,983,276...133,031,514
Ensembl chr 7:132,980,385...133,029,633

G

La ribonucleoprotein 7, transcriptional regulator

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of LARP7 protein

NCBI chr 2:218,672,145...218,687,332
Ensembl chr 2:218,672,208...218,687,308

G

lipocalin 1

increases expression

ISO

deoxynivalenol results in increased expression of LCN1 protein

NCBI chr 3:29,930,943...29,935,418

G

lymphocyte cytosolic protein 1

increases phosphorylation
affects phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of LCP1 protein
deoxynivalenol affects the phosphorylation of LCP1 protein

PMID:23352502 PMID:23811945

NCBI chr15:56,846,375...56,954,090
Ensembl chr15:56,847,433...56,954,092

G

galectin 3 binding protein

decreases expression

ISO

deoxynivalenol results in decreased expression of LGALS3BP protein

PMID:33890134 PMID:39638853

NCBI chr10:104,118,510...104,127,848
Ensembl chr10:104,118,510...104,127,848

G

leucine rich repeat containing G protein coupled receptor 5

multiple interactions
decreases expression

ISO

lauric acid inhibits the reaction [deoxynivalenol results in decreased expression of LGR5 protein]

NCBI chr 7:52,973,151...53,107,964
Ensembl chr 7:52,974,332...53,108,163

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

ISO

[Colforsin co-treated with deoxynivalenol] results in increased expression of LHCGR mRNA

NCBI chr 6:11,415,361...11,480,834
Ensembl chr 6:11,415,415...11,478,061

G

DNA ligase 1

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of LIG1 protein

NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:83,219,545...83,281,708

G

lin-28 homolog B

increases expression

ISO

deoxynivalenol results in increased expression of LIN28B protein

NCBI chr20:50,447,700...50,547,135
Ensembl chr20:50,450,971...50,541,968

G

lipase A, lysosomal acid type

decreases expression

ISO

deoxynivalenol results in decreased expression of LIPA protein

PMID:33890134 PMID:39638853

NCBI chr 1:241,437,524...241,470,936
Ensembl chr 1:241,437,524...241,470,740

G

LLP homolog, long-term synaptic facilitation factor

increases expression

ISO

deoxynivalenol results in increased expression of LLPH protein

NCBI chr 7:57,620,925...57,625,924
Ensembl chr 7:57,620,993...57,625,925

G

lamin A/C

affects phosphorylation
decreases phosphorylation

ISO

deoxynivalenol affects the phosphorylation of LMNA protein
deoxynivalenol results in decreased phosphorylation of LMNA protein

PMID:23352502 PMID:23811945

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072

G

lamin B1

increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of LMNB1 protein

NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283

G

LIM domain only 2

decreases expression

ISO

deoxynivalenol results in decreased expression of LMO2 mRNA

NCBI chr 3:110,810,162...110,832,895
Ensembl chr 3:110,809,912...110,833,075

G

lysyl oxidase-like 3

decreases expression

ISO

deoxynivalenol results in decreased expression of LOXL3 mRNA

NCBI chr 4:117,098,358...117,114,673
Ensembl chr 4:117,099,635...117,115,046

G

lysophosphatidylcholine acyltransferase 3

multiple interactions
decreases expression

ISO

Selenomethionine inhibits the reaction [deoxynivalenol results in decreased expression of LPCAT3 protein]

NCBI chr 4:159,154,690...159,196,176
Ensembl chr 4:159,154,158...159,196,358

G

leupaxin

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of LPXN protein

NCBI chr 1:219,353,319...219,387,743
Ensembl chr 1:219,353,708...219,387,742

G

LDL receptor related protein 1

decreases expression

ISO

deoxynivalenol results in decreased expression of LRP1 protein

NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196

G

leucine rich repeat containing 59

increases expression

ISO

deoxynivalenol results in increased expression of LRRC59 protein

NCBI chr10:80,069,162...80,083,820
Ensembl chr10:80,069,120...80,084,079

G

LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated

increases expression

ISO

deoxynivalenol results in increased expression of LSM3 protein

NCBI chr 4:125,578,185...125,584,429
Ensembl chr 4:125,578,185...125,584,429

G

lymphocyte-specific protein 1

affects phosphorylation
decreases expression
increases phosphorylation

ISO

deoxynivalenol affects the phosphorylation of LSP1 protein
deoxynivalenol results in decreased expression of LSP1 mRNA
deoxynivalenol results in increased phosphorylation of LSP1 protein

PMID:23352502 PMID:23811945 PMID:31863870

NCBI chr 1:207,044,157...207,077,891
Ensembl chr 1:207,044,159...207,077,893

G

lanosterol synthase

decreases expression

ISO

deoxynivalenol results in decreased expression of LSS protein

NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253

G

lymphotoxin alpha

increases expression

ISO

deoxynivalenol results in increased expression of LTA mRNA

NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,623,527...3,625,533

G

lymphotoxin beta

decreases expression

ISO

deoxynivalenol results in decreased expression of LTB mRNA

NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054

G

latent transforming growth factor beta binding protein 2

decreases expression

ISO

deoxynivalenol results in decreased expression of LTBP2 mRNA

NCBI chr 6:110,161,029...110,261,586
Ensembl chr 6:110,161,029...110,257,298

G

LUC7 pre-mRNA splicing factor like 1

increases expression

ISO

deoxynivalenol results in increased expression of LUC7L protein

NCBI chr10:15,777,837...15,811,586
Ensembl chr10:15,777,829...15,817,940

G

LUC7 pre-mRNA splicing factor like 3

increases expression

ISO

deoxynivalenol results in increased expression of LUC7L3 protein

NCBI chr10:79,737,457...79,773,478
Ensembl chr10:79,736,853...79,773,429

G

Ly1 antibody reactive

increases expression

ISO

deoxynivalenol results in increased expression of LYAR protein

NCBI chr14:76,789,193...76,802,973
Ensembl chr14:76,789,200...76,802,765

G

lysozyme 2

multiple interactions
decreases expression

ISO

lauric acid inhibits the reaction [deoxynivalenol results in decreased expression of LYZ protein]

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

macroH2A.1 histone

increases expression

ISO

deoxynivalenol results in increased expression of MACROH2A1 protein

NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257

G

MAF bZIP transcription factor F

increases expression

ISO

deoxynivalenol results in increased expression of MAFF mRNA

NCBI chr 7:112,792,787...112,804,139
Ensembl chr 7:112,791,416...112,804,147

G

mal, T-cell differentiation protein-like

decreases expression

ISO

deoxynivalenol results in decreased expression of MALL mRNA

NCBI chr 3:135,381,180...135,404,136
Ensembl chr 3:135,377,410...135,404,066

G

monoamine oxidase A

decreases expression

ISO

deoxynivalenol results in decreased expression of MAOA protein

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631

G

microtubule-associated protein 1 light chain 3 beta

increases expression
decreases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of MAP1LC3B mRNA
deoxynivalenol results in decreased expression of MAP1LC3B protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3B mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3B mRNA]]; Selenomethionine inhibits the reaction [deoxynivalenol results in decreased expression of MAP1LC3B protein]; sodium arsenite promotes the reaction [deoxynivalenol results in increased expression of MAP1LC3B mRNA]

PMID:34677630 PMID:35381244 PMID:38040082

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase kinase 4

increases phosphorylation
multiple interactions

ISO

deoxynivalenol results in increased phosphorylation of MAP2K4 protein
Celecoxib inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAP2K4 protein]

NCBI chr10:50,842,348...50,947,063
Ensembl chr10:50,844,034...50,947,185

G

mitogen-activated protein kinase kinase 6

multiple interactions
increases phosphorylation

ISO

AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAP2K6 protein]

NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions
increases phosphorylation

ISO

AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAP3K5 protein]

NCBI chr 1:16,505,387...16,723,899
Ensembl chr 1:16,505,596...16,723,898

G

microtubule-associated protein 4

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of MAP4 protein

NCBI chr 8:118,800,393...118,942,805
Ensembl chr 8:118,804,022...118,942,805

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ISO

4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; Fish Oils inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]; Lipopolysaccharides inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK1 protein]
[deoxynivalenol results in increased phosphorylation of MAPK1 protein] which results in increased expression of CXCL8 protein; deoxynivalenol results in increased phosphorylation of and results in increased activity of MAPK1 protein; MAPK1 protein promotes the reaction [deoxynivalenol results in increased expression of PPARG mRNA]

PMID:12377986 PMID:12604842 PMID:14644621 PMID:14690764 PMID:15570035 More...

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen-activated protein kinase 12

decreases expression

ISO

deoxynivalenol results in decreased expression of MAPK12 mRNA

NCBI chr 7:122,085,647...122,096,307
Ensembl chr 7:122,085,913...122,096,307

G

mitogen activated protein kinase 14

multiple interactions
increases expression
increases phosphorylation

ISO

deoxynivalenol results in increased phosphorylation of and results in increased activity of MAPK14 protein
deoxynivalenol results in increased expression of MAPK14 mRNA
deoxynivalenol results in increased phosphorylation of MAPK14 protein

PMID:15976193 PMID:16364386 PMID:20702593

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ISO

[deoxynivalenol results in increased phosphorylation of MAPK3 protein] which results in increased expression of CXCL8 protein; deoxynivalenol results in increased phosphorylation of and results in increased activity of MAPK3 protein; MAPK3 protein promotes the reaction [deoxynivalenol results in increased expression of PPARG mRNA]
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; Fish Oils inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]; Lipopolysaccharides inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK3 protein]

PMID:12377986 PMID:12604842 PMID:14644621 PMID:14690764 PMID:15570035 More...

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 8

decreases activity
increases phosphorylation
multiple interactions

ISO

deoxynivalenol results in decreased activity of MAPK8 protein
deoxynivalenol results in increased phosphorylation of MAPK8 protein
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]; AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]; Celecoxib inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]; Fish Oils inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK8 protein]
[deoxynivalenol results in increased expression of DUSP1 protein] which results in decreased activity of MAPK8 protein; deoxynivalenol results in increased phosphorylation of and results in increased activity of MAPK8 protein

PMID:12377986 PMID:12604842 PMID:14644621 PMID:14690764 PMID:15570035 More...

NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427

G

mitogen-activated protein kinase 9

decreases activity
increases phosphorylation
decreases phosphorylation
decreases expression
multiple interactions

ISO

deoxynivalenol results in decreased activity of MAPK9 protein
deoxynivalenol results in increased phosphorylation of MAPK9 protein
deoxynivalenol results in decreased phosphorylation of MAPK9 protein
deoxynivalenol results in decreased expression of MAPK9 mRNA
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK9 protein]; AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK9 protein]; deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]; Docosahexaenoic Acids inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK9 protein]; Eicosapentaenoic Acid inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK9 protein]; Fish Oils inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAPK9 protein]
[deoxynivalenol results in increased expression of DUSP1 protein] which results in decreased activity of MAPK9 protein; deoxynivalenol results in increased phosphorylation of and results in increased activity of MAPK9 protein

PMID:12377986 PMID:12604842 PMID:14644621 PMID:14690764 PMID:15371230 More...

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

myristoylated alanine rich protein kinase C substrate

increases phosphorylation
decreases expression

ISO

deoxynivalenol results in increased phosphorylation of MARCKS protein
deoxynivalenol results in decreased expression of MARCKS protein

PMID:23811945 PMID:39638853

NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882

G

multiple coagulation factor deficiency 2, ER cargo receptor complex subunit

decreases expression

ISO

deoxynivalenol results in decreased expression of MCFD2 protein

NCBI chr 6:13,028,036...13,039,388
Ensembl chr 6:13,016,104...13,039,379

G

MDM2 proto-oncogene

increases expression

ISO

deoxynivalenol results in increased expression of MDM2 mRNA

NCBI chr 7:55,176,558...55,201,757
Ensembl chr 7:55,176,560...55,200,791

G

MDM4 regulator of p53

increases expression

ISO

deoxynivalenol results in increased expression of MDM4 mRNA

NCBI chr13:46,922,236...47,068,241
Ensembl chr13:46,958,298...47,026,372

G

Meis homeobox 3

decreases response to substance
decreases expression

ISO

MEIS3 protein results in decreased susceptibility to deoxynivalenol
deoxynivalenol results in decreased expression of MEIS3 mRNA

NCBI chr 1:85,986,602...86,000,873
Ensembl chr 1:85,990,050...86,000,873

G

MET proto-oncogene, receptor tyrosine kinase

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of MET protein

NCBI chr 4:46,756,823...46,864,041
Ensembl chr 4:46,756,506...46,870,821

G

methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit

increases expression

ISO

deoxynivalenol results in increased expression of METTL14 mRNA

NCBI chr 2:214,215,165...214,231,412
Ensembl chr 2:214,215,165...214,231,412

G

MICAL-like 1

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of MICALL1 protein

NCBI chr 7:112,557,192...112,587,618
Ensembl chr 7:112,557,192...112,587,618

G

multiple inositol-polyphosphate phosphatase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of MINPP1 protein

NCBI chr 1:239,766,809...239,793,023
Ensembl chr 1:239,767,286...239,793,015

G

microRNA 221

multiple interactions

ISO

[Zearalenone co-treated with deoxynivalenol] results in decreased expression of MIR221 mRNA

NCBI chr X:6,023,182...6,023,290
Ensembl chr X:6,023,182...6,023,290

G

marker of proliferation Ki-67

increases phosphorylation
multiple interactions
increases expression

ISO

deoxynivalenol results in increased phosphorylation of MKI67 protein
Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of MKI67 protein]
deoxynivalenol results in increased expression of MKI67 mRNA; deoxynivalenol results in increased expression of MKI67 protein

PMID:23352502 PMID:23811945 PMID:31863870 PMID:32416088 PMID:39638853

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

MAPK interacting serine/threonine kinase 2

affects phosphorylation
decreases expression

ISO

deoxynivalenol affects the phosphorylation of MKNK2 protein
deoxynivalenol results in decreased expression of MKNK2 mRNA

PMID:23811945 PMID:31863870

NCBI chr 7:9,690,385...9,701,527
Ensembl chr 7:9,690,421...9,701,529

G

methylmalonyl-CoA mutase

decreases expression

ISO

deoxynivalenol results in decreased expression of MMUT protein

PMID:33890134 PMID:39638853

NCBI chr 9:27,425,935...27,454,202
Ensembl chr 9:27,425,935...27,454,342

G

myeloperoxidase

increases activity

ISO

deoxynivalenol results in increased activity of MPO protein

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

melanocortin 2 receptor accessory protein 2

decreases expression

ISO

deoxynivalenol results in decreased expression of MRAP2 mRNA

NCBI chr 8:96,968,239...97,024,581
Ensembl chr 8:96,988,079...97,024,579

G

mitochondrial rRNA methyltransferase 1

increases expression

ISO

deoxynivalenol results in increased expression of MRM1 protein

NCBI chr10:70,187,842...70,194,785
Ensembl chr10:70,188,748...70,194,131

G

mitochondrial ribosomal protein L12

increases expression

ISO

deoxynivalenol results in increased expression of MRPL12 protein

NCBI chr10:106,256,746...106,261,249
Ensembl chr10:106,256,547...106,263,088

G

mitochondrial ribosomal protein L28

increases expression

ISO

deoxynivalenol results in increased expression of MRPL28 protein

NCBI chr10:15,653,006...15,656,062
Ensembl chr10:15,653,179...15,666,971

G

mitochondrial ribosomal protein L39

increases expression

ISO

deoxynivalenol results in increased expression of MRPL39 mRNA

NCBI chr11:37,266,116...37,281,612
Ensembl chr11:37,257,696...37,281,544

G

mitochondrial ribosomal protein S18B

increases expression

ISO

deoxynivalenol results in increased expression of MRPS18B mRNA

NCBI chr20:2,842,978...2,849,065
Ensembl chr20:2,842,528...2,849,065

G

mitochondrial ribosomal protein S22

increases expression

ISO

deoxynivalenol results in increased expression of MRPS22 mRNA

NCBI chr 8:108,063,468...108,076,638
Ensembl chr 8:108,063,471...108,076,638

G

mitochondrial ribosomal protein S30

increases expression

ISO

deoxynivalenol results in increased expression of MRPS30 mRNA

PMID:24247028 PMID:31863870

NCBI chr 2:52,189,049...52,196,136
Ensembl chr 2:52,189,058...52,195,904

G

mitochondrial ribosomal protein S31

increases expression

ISO

deoxynivalenol results in increased expression of MRPS31 mRNA

NCBI chr16:76,303,807...76,332,970
Ensembl chr16:76,301,645...76,333,065

G

MRT4 homolog, ribosome maturation factor

increases expression

ISO

deoxynivalenol results in increased expression of MRTO4 protein

NCBI chr 5:156,884,985...156,891,738
Ensembl chr 5:156,884,985...156,891,738

G

mutS homolog 6

decreases expression

ISO

deoxynivalenol results in decreased expression of MSH6 protein

NCBI chr 6:12,316,190...12,333,505
Ensembl chr 6:12,316,198...12,333,844

G

msh homeobox 2

increases expression

ISO

deoxynivalenol results in increased expression of MSX2 mRNA

NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945

G

metastasis associated 1

increases expression

ISO

deoxynivalenol results in increased expression of MTA1 protein

NCBI chr 6:137,999,845...138,038,696
Ensembl chr 6:137,999,915...138,038,696

G

metastasis associated 1 family, member 2

increases expression

ISO

deoxynivalenol results in increased expression of MTA2 protein

NCBI chr 1:215,267,286...215,276,008
Ensembl chr 1:215,267,046...215,276,062

G

metastasis associated 1 family, member 3

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of MTA3 protein

NCBI chr 6:16,619,575...16,739,732
Ensembl chr 6:16,621,998...16,739,485

G

metadherin

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of LYRIC protein

NCBI chr 7:67,192,592...67,250,819
Ensembl chr 7:67,192,393...67,249,584

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

decreases expression

ISO

deoxynivalenol results in decreased expression of MTHFD2 mRNA

NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350

G

mechanistic target of rapamycin kinase

multiple interactions
decreases phosphorylation

ISO

lauric acid inhibits the reaction [deoxynivalenol results in decreased phosphorylation of MTOR protein]

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

Mtr4 exosome RNA helicase

increases expression

ISO

deoxynivalenol results in increased expression of MTREX mRNA; deoxynivalenol results in increased expression of MTREX protein

PMID:31863870 PMID:39638853

NCBI chr 2:46,233,528...46,293,827
Ensembl chr 2:46,194,647...46,293,827

G

microsomal triglyceride transfer protein

decreases expression

ISO

deoxynivalenol results in decreased expression of MTTP protein

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

mucin 16, cell surface associated

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of MUC16 protein

NCBI chr 8:24,440,840...24,644,494

G

mucin 2, oligomeric mucus/gel-forming

multiple interactions
decreases expression

ISO

lauric acid inhibits the reaction [deoxynivalenol results in decreased expression of MUC2 protein]

NCBI chr 1:206,225,775...206,261,280
Ensembl chr 1:206,229,035...206,261,280

G

mucin 5AC, oligomeric mucus/gel-forming

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of MUC5AC mRNA
deoxynivalenol results in increased expression of and results in increased secretion of MUC5AC protein

NCBI chr 1:206,293,717...206,326,006
Ensembl chr 1:206,293,869...206,326,006

G

mucin 5B, oligomeric mucus/gel-forming

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of MUC5B mRNA
deoxynivalenol results in increased expression of and results in increased secretion of MUC5B protein

NCBI chr 1:206,346,400...206,378,367
Ensembl chr 1:206,346,400...206,378,367

G

mevalonate kinase

decreases expression

ISO

deoxynivalenol results in decreased expression of MVK protein

NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503

G

MYB binding protein 1a

decreases phosphorylation
increases expression

ISO

deoxynivalenol results in decreased phosphorylation of MYBBP1A protein
deoxynivalenol results in increased expression of MYBBP1A protein

PMID:23352502 PMID:39638853

NCBI chr10:57,555,458...57,565,819
Ensembl chr10:57,555,452...57,566,041

G

MYC proto-oncogene, bHLH transcription factor

increases expression

ISO

deoxynivalenol results in increased expression of MYC mRNA

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

MYCN proto-oncogene, bHLH transcription factor

affects phosphorylation

ISO

deoxynivalenol affects the phosphorylation of MYCN protein

NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508

G

MYD88, innate immune signal transduction adaptor

multiple interactions
increases expression

ISO

deoxynivalenol inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MYD88 protein]
deoxynivalenol results in increased expression of MYD88 mRNA; deoxynivalenol results in increased expression of MYD88 protein

PMID:26961612 PMID:34400200

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 11

decreases phosphorylation

ISO

deoxynivalenol results in decreased phosphorylation of MYH11 protein

NCBI chr10:1,250,554...1,345,681
Ensembl chr10:1,263,194...1,345,678

G

myosin, heavy chain 9

affects phosphorylation
increases phosphorylation

ISO

deoxynivalenol affects the phosphorylation of MYH9 protein
deoxynivalenol results in increased phosphorylation of MYH9 protein

PMID:23352502 PMID:23811945

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

myosin light chain 9

multiple interactions
increases expression

ISO

Curcumin inhibits the reaction [deoxynivalenol results in increased expression of MYL9 protein modified form]

NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:165,742,046...165,748,410

G

myosin light chain kinase

increases expression
multiple interactions

ISO

deoxynivalenol results in increased expression of MYLK mRNA; deoxynivalenol results in increased expression of MYLK protein
Curcumin inhibits the reaction [deoxynivalenol results in increased expression of MYLK mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of MYLK protein]

NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659

G

myosin VC

decreases expression

ISO

deoxynivalenol results in decreased expression of MYO5C mRNA

NCBI chr 8:84,870,031...84,946,996
Ensembl chr 8:84,870,043...84,946,996

G

myeloid zinc finger 1

decreases expression

ISO

deoxynivalenol results in decreased expression of MZF1 protein

NCBI chr 1:82,742,709...82,755,069
Ensembl chr 1:82,742,726...82,753,820

G

N-acetyl-alpha-glucosaminidase

decreases expression

ISO

deoxynivalenol results in decreased expression of NAGLU mRNA

NCBI chr10:86,501,864...86,509,333
Ensembl chr10:86,501,836...86,509,315

G

nicotinamide phosphoribosyltransferase

increases expression

ISO

deoxynivalenol results in increased expression of NAMPT mRNA

NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544

G

nanos C2HC-type zinc finger 1

decreases expression

ISO

deoxynivalenol results in decreased expression of NANOS1 mRNA

NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417

G

nucleolin

affects phosphorylation
increases expression

ISO

deoxynivalenol affects the phosphorylation of NCL protein
deoxynivalenol results in increased expression of NCL protein

PMID:23352502 PMID:39638853

NCBI chr 9:94,447,559...94,456,083
Ensembl chr 9:94,446,682...94,456,083

G

nuclear receptor coactivator 4

decreases expression

ISO

deoxynivalenol results in decreased expression of NCOA4 mRNA

NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,401,802...7,415,840

G

nuclear receptor coactivator 5

increases expression

ISO

deoxynivalenol results in increased expression of NCOA5 protein

NCBI chr 3:174,155,731...174,188,862
Ensembl chr 3:174,155,741...174,188,862

G

NDC80 kinetochore complex component

increases expression

ISO

deoxynivalenol results in increased expression of NDC80 mRNA

NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568

G

NADH:ubiquinone oxidoreductase subunit B7

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFB7 protein

NCBI chr19:41,472,953...41,477,291
Ensembl chr19:41,472,953...41,477,291

G

NADH:ubiquinone oxidoreductase subunit B8

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFB8 protein

NCBI chr 1:253,357,878...253,362,936
Ensembl chr 1:253,357,841...253,362,936

G

NADH:ubiquinone oxidoreductase subunit B9

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFB9 protein

NCBI chr 7:92,370,423...92,376,841
Ensembl chr 7:92,370,467...92,379,955

G

NADH:ubiquinone oxidoreductase subunit S4

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFS4 protein

NCBI chr 2:47,684,420...47,794,914
Ensembl chr 2:47,684,406...47,794,931

G

NADH:ubiquinone oxidoreductase subunit S5

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFS5 protein

NCBI chr 5:141,258,828...141,264,552
Ensembl chr 2:184,849,197...185,028,909
Ensembl chr 5:184,849,197...185,028,909
Ensembl chr14:184,849,197...185,028,909

G

NADH:ubiquinone oxidoreductase core subunit S7

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFS7 protein

NCBI chr 7:10,103,226...10,110,862
Ensembl chr 7:10,103,227...10,110,691

G

NADH:ubiquinone oxidoreductase subunit V3

decreases expression

ISO

deoxynivalenol results in decreased expression of NDUFV3 protein

NCBI chr20:9,613,786...9,622,941
Ensembl chr13:48,468,224...48,488,847
Ensembl chr20:48,468,224...48,488,847

G

NEDD4 like E3 ubiquitin protein ligase

increases expression

ISO

deoxynivalenol results in increased expression of NEDD4L mRNA

NCBI chr18:60,663,918...60,996,824
Ensembl chr18:60,663,970...60,996,824

G

neuraminidase 1

decreases expression

ISO

deoxynivalenol results in decreased expression of NEU1 protein

NCBI chr20:3,902,120...3,906,383
Ensembl chr20:3,902,120...3,906,383

G

nuclear factor of activated T-cells 1

affects localization

ISO

deoxynivalenol affects the localization of NFATC1 protein

PMID:21074547 PMID:22846391